0001193125-16-481909.txt : 20160226 0001193125-16-481909.hdr.sgml : 20160226 20160226160313 ACCESSION NUMBER: 0001193125-16-481909 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 93 CONFORMED PERIOD OF REPORT: 20151231 FILED AS OF DATE: 20160226 DATE AS OF CHANGE: 20160226 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEALTHSTREAM INC CENTRAL INDEX KEY: 0001095565 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROGRAMMING, DATA PROCESSING, ETC. [7370] IRS NUMBER: 621443555 STATE OF INCORPORATION: TN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-27701 FILM NUMBER: 161461609 BUSINESS ADDRESS: STREET 1: 209 10TH AVE SOUTH STE 450 CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 6153013100 MAIL ADDRESS: STREET 1: 209 10TH AVE SOUTH STE 450 CITY: NASHVILLE STATE: TN ZIP: 37203 10-K 1 d111635d10k.htm FORM 10-K Form 10-K
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 10-K

 

 

 

x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE FISCAL YEAR ENDED DECEMBER 31, 2015

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM                      TO                     

Commission File Number 000-27701

 

 

HEALTHSTREAM, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Tennessee   62-1443555

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

209 10th Avenue South, Suite 450

Nashville, Tennessee

  37203
(Address of principal executive offices)   (Zip Code)

(615) 301-3100

(Registrant’s telephone number, including area code)

Securities Registered Pursuant To Section 12(b) Of The Act:

 

Title of each class

 

Name of each Exchange on which registered

Common Stock, No Par Value   NASDAQ Global Select Market

Securities Registered Pursuant To Section 12(g) Of The Act: None

 

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ¨    No  x

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 of 15(d) of the Act.    Yes  ¨    No  x

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   x    Accelerated filer   ¨
Non-accelerated filer   ¨    Smaller reporting company   ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  ¨    No  x

The aggregate market value of the Common Stock issued and outstanding and held by non-affiliates of the Registrant, based upon the closing sales price for the Common Stock on the NASDAQ Global Select Market on June 30, 2015 was approximately $768.8 million. All executive officers and directors of the registrant have been deemed, solely for the purpose of the foregoing calculation, to be “affiliates” of the registrant.

As of February 23, 2016, there were 31,651,860 shares of the Registrant’s common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Registrant’s definitive Proxy Statement for its 2016 Annual Meeting of Shareholders are incorporated by reference into Part III hereof.

 

 

 


Table of Contents

HEALTHSTREAM, INC.

TABLE OF CONTENTS

ANNUAL REPORT ON FORM 10-K

 

          Page  

PART I

     

Item 1.

  

Business

     1   

Item 1A.

  

Risk Factors

     10   

Item 1B.

  

Unresolved Staff Comments

     18   

Item 2.

  

Properties

     18   

Item 3.

  

Legal Proceedings

     18   

Item 4.

  

Mine Safety Disclosures

     18   

PART II

     

Item 5.

  

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

     19   

Item 6.

  

Selected Financial Data.

     21   

Item 7.

  

Management’s Discussion and Analysis of Financial Condition and Results of Operations

     21   

Item 7A.

  

Quantitative and Qualitative Disclosures About Market Risk.

     32   

Item 8.

  

Financial Statements and Supplementary Data.

     33   

Item 9.

  

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

     58   

Item 9A.

  

Controls and Procedures

     58   

Item 9B.

  

Other Information

     58   

PART III

     

Item 10.

  

Directors, Executive Officers and Corporate Governance

     59   

Item 11.

  

Executive Compensation

     59   

Item 12.

  

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

     59   

Item 13.

  

Certain Relationships and Related Transactions, and Director Independence

     59   

Item 14.

  

Principal Accounting Fees and Services

     59   

PART IV

     

Item 15.

  

Exhibits, Financial Statement Schedules

     60   
  

Signatures

     61   


Table of Contents

PART I

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements include, among others, those statements including the words “expects,” “anticipates,” “intends,” “believes,” “may,” “will,” “should,” “continue” and similar language or the negative of such terms or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements are reasonable, HealthStream’s actual results may differ significantly from those projected in the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in the section “Risk Factors” in Item 1A of this Annual Report on Form 10-K and elsewhere in this document. In addition, factors that we are not currently aware of could harm our future operating results. You should carefully review the risks described in other documents HealthStream files from time to time with the Securities and Exchange Commission. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this Annual Report on Form 10-K. HealthStream undertakes no obligation to publicly release any revisions to the forward-looking statements or reflect events or circumstances after the date of this document.

Item 1. Business

OVERVIEW AND HISTORY

HealthStream, Inc. (HealthStream or the Company) provides workforce, patient experience, and provider solutions for healthcare organizations—all designed to support the people that deliver patient care which, in turn, supports the improvement of business and clinical outcomes. Delivered primarily as Software-as-a-Service (“SaaS”), our solutions focus on some of the most significant challenges facing the healthcare workforce and healthcare organizations today, including the need to effectively manage, retain, engage, and develop healthcare workforce talent; meet rigorous compliance requirements; efficiently manage ongoing medical staff credentialing and privileging processes; and deliver optimal patient experiences of care in healthcare organizations.

With 26 years of experience, HealthStream is recognized as a leading innovator and thought leader in the healthcare industry for its healthcare workforce solutions. Using technology to enhance learning and productivity, HealthStream pioneered the delivery of online learning for hospitals’ required regulatory training as Internet-based training was first introduced. Stemming from that early success, demand for expanded learning solutions led the Company to build what is now a full eco-system of diverse HR and clinical-focused applications, courseware, assessments, and talent management programs. At year-end 2015—with over 4.6 million healthcare professionals subscribing to HealthStream’s platform through their respective organizations, HealthStream is a leading provider in workforce development in the healthcare industry.

With its singular healthcare focus, HealthStream understands that healthcare organizations want to provide their patients with an engaged, confident, and competent workforce that delivers optimal patient experiences. HealthStream’s solutions offer organizations a robust array of products and services that provide targeted insights to take actions that produce sustainable performance improvements. Moreover, HealthStream’s vast database of healthcare workforce benchmarks offer organizations a powerful tool to compare, assess, and fine-tune their strategies for managing initiatives to success.

HealthStream believes that the key to quality patient care is—and always has been—a result of the people who deliver care. To that end, the Company’s solutions support the recruiting, retaining, engaging, assessing, and developing the healthcare workforce, including medical staff who provide patient care in our customers’ organizations.

Headquartered in Nashville, Tennessee, the Company was incorporated in 1990 and began providing its SaaS-based workforce solutions in 1999, its survey and research solutions in 2005, and its provider solutions in 2012. Including additional offices in Laurel, Maryland; Nashville, Tennessee; Jericho, New York; Brentwood, Tennessee; San Diego, California; Boulder, Colorado; and Pensacola, Florida, HealthStream had 833 full-time and 139 part-time employees as of December 31, 2015. Our business has evolved from an initial focus on technology-based training to a company providing workforce development, patient experience, and provider solutions to the nation’s healthcare providers.

INDUSTRY BACKGROUND

According to the deputy director of the National Health Statistics Group at the Centers for Medicare and Medicaid Services (CMS), spending in the healthcare industry reached approximately $3.0 trillion in 2014, or 17.5% of the U.S. gross domestic product. Hospital care expenditures accounted for approximately 32.4% of the $3.0 trillion industry. According to the Bureau of Labor Statistics, approximately 18.9 million professionals are employed in the healthcare segment of the domestic economy, with approximately 4.8 million employed in acute-care hospitals and approximately 3.3 million employed in post-acute-care organizations, our primary target markets for our products. As of December 31, 2015, approximately 4.62 million healthcare professionals were subscribers to our SaaS-based solutions, which include 4.48 million subscribers already implemented and 142,000 subscribers in the process of implementation.

All of the 4.8 million hospital-based healthcare professionals that work in the nation’s approximately 5,000 acute-care hospitals are required by federal mandates and accrediting bodies to complete training in a number of areas. This training includes safety training mandated by both the Occupational Safety and Health Administration (OSHA) and The Joint Commission (an independent, not-for-profit organization that accredits and certifies healthcare organizations and programs in the United States), as well as training on patient information confidentiality required under the Health Insurance Portability and Accountability Act (HIPAA).

 

1


Table of Contents

In hospitals, staffing issues and personnel shortages have also contributed to the need for facility based workforce development as well as additional assessment and competency based training. An ongoing nursing shortage, for example, is resulting in skill gaps and rising costs. The U.S. Bureau of Labor Statistics projects the need for 525,000 replacement nurses over the next several years, bringing the total number of openings for nurses due to growth and replacements to 1.05 million by 2022. We believe that offering training and education for hospital personnel is increasingly being utilized as a retention and recruitment incentive.

Many healthcare professionals use continuing education to keep abreast of the latest developments and meet licensing and certification requirements. Continuing education is required for nurses, emergency medical services personnel, first responder personnel, radiologic personnel, and physicians. Pharmaceutical and medical device companies must also provide their medical industry sales representatives with training mandated for the healthcare industry and training for new products. Such companies also provide support and content for education and training of audiences that use their products in healthcare organizations.

A large portion of the nation’s hospitals utilize research and survey tools to gain insight about patients’ experiences, to assess workforce competency and engagement, to determine the status of physician relations, and to measure the perceptions about the hospitals in the communities they serve. Industry-wide interest is increasing in research due in part, to the CAHPS® (Consumer Assessment of Healthcare Providers and Systems) Hospital Survey launched by CMS in partnership with the Agency for Healthcare Research and Quality (AHRQ). Hospitals must submit data to CMS for certain required quality measures—which for inpatients includes the CAHPS® Hospital Survey—in order to receive the full market basket increase to their reimbursement payment rates from CMS. Hospitals that fail to submit this survey data will incur a reduction in the inpatient market basket update amount for the following federal fiscal year. We are designated as a certified vendor for and offer CAHPS® Hospital Survey services.

The healthcare education and training industry is highly fragmented, varies significantly in delivery methods (i.e., online products, live events, written materials, and manikins for simulation-based training), and is composed of a wide variety of entities competing for customers. The sheer volume of healthcare information available to satisfy continuing education needs, rapid advances in medical developments, and the time constraints that healthcare professionals face make it difficult to quickly and efficiently access the continuing education content most relevant to an individual’s practice or profession. Historically, healthcare professionals have received continuing education and training through offline publications, such as medical journals or by attending conferences and seminars. In addition, other healthcare workers and pharmaceutical and medical device manufacturers’ sales and internal regulatory personnel usually fulfill their training from external vendors or internal training departments. While these approaches satisfy the ongoing education and training requirements, they are typically costly and inconvenient. In addition, live courses are often limited in the breadth of offerings and do not provide a method for tracking training completion. The results of these traditional methods, both from a business and compliance standpoint, are difficult to track and measure. While hospitals and health systems occasionally survey their patients, physicians, and employees using their own internal resources, the practice is limited since they do not typically possess the valuable comparative benchmarking data that is available from independent survey research vendors.

Provider data management has become more complex and arduous for healthcare organizations. Spurred by the Joint Commission Medical Staff standards and other regulatory requirements, credentialing and privileging has been transformed from a periodic review to continuous, evidence-driven analysis of professional competency and provider performance. This transformation requires ongoing, automatic monitoring of licenses, sanctions, and exclusions, as well as expanding the area to review at initial and re-credentialing. In addition, provider enrollment processes have compounded in difficulty. For example, a single provider may need to enroll annually with some 30-40 payers, with each payer application often taking two to four hours to complete.

Finally, the hospital industry continues to operate under intense pressure to reduce costs as a result of reductions in government reimbursement rates and increased focus on cost containment consistent with participation of patients in managed care programs. In addition, hospitals, as well as pharmaceutical and medical device companies, continue to experience rising operating costs, coupled with increased pressure to measure and report on the outcomes of the dollars spent on training. Our products and services are designed to meet these needs by reducing healthcare organizations’ costs of training while improving learning outcomes, enhancing reporting capabilities, and supporting customers’ business objectives.

HEALTHSTREAM’S SOLUTIONS

HealthStream’s products and services are organized into three segments—Workforce Solutions, Patient Experience Solutions, and Provider Solutions—that collectively help healthcare organizations meet their ongoing talent management, training, education, assessment, competency management, compliance, provider credentialing & privileging management, and provider enrollment needs. HealthStream’s solutions are provided to a wide range of customers within the healthcare industry across the continuum of care.

HealthStream Workforce Solutions— Our workforce development solutions, which are comprised primarily of SaaS, subscription-based products, are used by healthcare organizations to meet a broad range of their talent management, training, certification, competency assessment, performance appraisal, and development needs. Our numerous content libraries allow our customers to subscribe to a wide array of additional courseware, which includes content from leading healthcare and nursing associations, medical and healthcare publishers, and other content providers. Additionally, medical device companies and other industry partners offer online training support through HealthStream’s platform for their products and they sponsor continuing education directly to healthcare workers.

 

2


Table of Contents

At December 31, 2015, HealthStream had approximately 4.62 million “total subscribers” to its subscription-based solutions. Each individual end-user who utilizes at least one HealthStream subscription-based solution is counted as one subscriber, regardless of the number of subscriptions contracted by or for that end-user. Our subscription-based solutions include any one or a combination of our many platform applications, plus courseware, or content. For example, we deliver courseware to our customers primarily through our learning application, the HealthStream Learning Center™ (HLC), while we deliver competency management and performance appraisal tools through our applications known as the HealthStream Competency Center (HCC) and HealthStream Performance Center (HPC), respectively, which are all on our SaaS-based platform, along with a series of other applications.

Pricing for the HLC, HCC, and HPC are subscription based, with fees based on the number of subscribers, courseware provided, and other factors. We offer training, implementation, and account management services to facilitate adoption of our subscription-based solutions. Fees for training are based on the time and efforts of the personnel involved. Implementation fees vary based on the size, scope, and complexity of the project. Our SaaS-based platform and subscription-based solutions are hosted in a central data center that allows authorized subscribers Internet access to our services, thereby eliminating the need for onsite local implementations of installed workforce development products. During 2015, 2014, and 2013, our subscription-based solutions accounted for approximately 74%, 76%, and 72% of consolidated revenues, respectively.

Other Applications on our Platform — HealthStream offers an array of other applications on our platform, each serving a unique function for hospitals and health systems. Each application on our platform has its own value proposition and revenue stream. Examples of individual applications that are offered on our platform include applications for recruiting and applicant tracking; learning; performance appraisal; compensation management; succession planning; competency management; credentialing and privileging; provider enrollment; disclosure management; clinical development; simulation-based education; and industry-sponsored training.

HealthStream Patient Experience Solutions — Our patient experience solutions complement HealthStream’s workforce solutions’ product and service offerings by providing customers with Patient Insights™, Employee Insights™, Physician Insights™, and Community Insights™ surveys, data analyses of survey results, and other research-based measurement tools. Our services are designed to provide thorough analyses with insightful recommendations for change; benchmarking capability using our comprehensive databases; and consulting services to identify solutions for our customers based on their survey results. Clients are able to access and analyze their survey results data through Insights Online™, our secure web-based reporting platform.

As a CMS-approved vendor, HealthStream offers its customers full services to meet their Consumer Assessment of Healthcare Providers and Systems, or CAHPS, program requirements. Along with the mandatory-for-hospitals CAHPS (HCAHPS), the Company offers a range of solutions for other mandated CAHPS reporting, including those for accountable care organizations, medical groups, and home health organizations. Other CAHPS survey services are offered for fulfilling voluntary reporting needs for pediatrics, emergency departments, hospice, in-center hemodialysis, and outpatient surgery.

All of our survey and research solutions focus on providing statistically valid data to assist our customers with their decision making related to their organization’s performance improvement objectives. In addition to collecting and reporting data, we provide analysis and consulting to help customers understand and improve their survey results and patient experiences and the underlying impact on their business. Pricing for these services is based on the survey type, delivery method, size of the survey instrument, sample size, frequency of survey cycles, and other factors. During 2015, 2014, and 2013, our Patient Insights™ survey product accounted for approximately 13%, 14%, and 17% of consolidated revenues, respectively.

HealthStream Provider Solutions – Our provider solutions are offered through our business segment that is branded in the marketplace as “Echo, a HealthStream Company.” Echo solutions enable healthcare organizations to launch paperless credentialing processes, reduce provider enrollment timelines, accelerate the provider onboarding process, and drive improvement through validated provider profiles. Together, more than 2,000 healthcare organizations in the U.S. use one or more Echo products.

EchoCredentialing™ is a comprehensive platform that manages medical staff credentialing and privileging processes. Healthcare organizations leverage EchoCredentialing to support enterprise-wide or regional Credentialing Verification Organizations (CVOs), unified privileging, peer review, one-click integration with CVO services, and the move to paperless processes. EchoOneApp™is a provider enrollment platform, which includes automatic form population directly from a continuously updated library of 3,500+ preformatted payer form templates as well as online form integration with CAQH, CMS, PECOS, and state-based payer enrollment sites. EchoAccess™is our enterprise class platform to support hospital call centers with physician referral, call triage, provider directories, class enrollment, and discharge planning functionalities. EchoAnalytics™ offers a wide array of validation tools and EchoOnboarding™ consists of an onboarding dashboard with a workflow functionality, along with onboarding navigator tools to facilitate coordination of the provider onboarding process.

BUSINESS COMBINATIONS

We acquired substantially all of the assets of Baptist Leadership Group (BLG) in September 2013, acquired Health Care Compliance Strategies, Inc. (HCCS) in March 2014 and acquired HealthLine Systems, LLC (HLS) in March 2015. For additional information regarding acquisitions, please see Note 5 of the Consolidated Financial Statements and Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included elsewhere in this report.

 

3


Table of Contents

CUSTOMERS

We provide our solutions to customers across a broad range of entities within the healthcare industry, including private, not for profit, and government entities, as well as pharmaceutical and medical device companies. We derive a substantial portion of our revenues from a relatively small number of customers, although no single customer represented more than 10 percent of our revenues during 2015, 2014, or 2013. Examples of customers that have purchased or contracted for products and services from HealthStream include: Ardent Health Services; Saint Luke’s Health System; HCA Holdings, Inc.; Community Health Systems, Inc.; McLaren Health Care Corporation; Sutter Health; and Tenet Healthcare Corporation.

SALES AND MARKETING

We market our products and services primarily through our direct sales teams, who are based at our corporate headquarters in Nashville, Tennessee and in our additional offices located in Laurel, Maryland; Jericho, New York; Brentwood, Tennessee; San Diego, California and Pensacola, Florida as well as remote home office sales locations. As of December 31, 2015, our HealthStream Workforce Development Solutions sales personnel consisted of 105 employees who carried sales quotas; our HealthStream Patient Experience Solutions sales personnel consisted of 15 employees who carried sales quotas; and our Provider Solutions sales personnel consisted of 17 employees who carried sales quotas. We also have nine employees who support our sales teams with sales force productivity and optimization, onboarding, training, and administration services.

We conduct a variety of marketing programs to promote our products and services, including product catalogs, user groups—including our annual customer Summit, trade shows, internet promotion and demonstrations, telemarketing campaigns, public relations, distribution of product-specific literature, direct mail, and advertising.

Over most of the last fourteen years, we have hosted an annual conference in Nashville, Tennessee for our customers known as the “Summit.” We have utilized this client conference to reach out to existing and potential customers and business partners, provide training and educational services, and to demonstrate our new and existing product offerings. We have marketing teams that are responsible for these initiatives and for working with and supporting our product management and sales teams. At December 31, 2015, our marketing personnel consisted of 29 employees.

OPERATIONS AND TECHNOLOGY

We believe our ability to establish and maintain long-term customer relationships, adoption of our products and services, recurring sales, and development and maintenance of new and existing products are dependent on the strength of our operations, customer service, product development and maintenance, training, and other support teams. As of December 31, 2015, our Workforce Development Solutions operations team consisted of 302 employees associated with customer support, implementation services, product development and maintenance, training, and project management; our Patient Experience Solutions operations team consisted of 352 employees (of which 205 employees worked in our interviewing centers) associated with phone interviewing, distributing and processing paper-based survey instruments, patient experience coaching and consulting, data analysis and reporting of survey results, and project management; and our Provider Solutions operations team consisted of 69 employees associated with implementation services, data integration, product development and quality assurance, credentials verification, consulting, and other services.

Our services are designed to be reliable, secure, and scalable. Our software is a combination of proprietary and commercially available software and operating systems. Our software solutions support hosting and management of content, publication of our web sites, execution of courseware, registration and tracking of users, collection, sampling, and analysis of survey data, tracking and reporting of physician credentialing and provider enrollment information, and reporting of information for both internal and external use. We designed the platforms that provide our services to allow each component to be independently scaled by adding commercially available hardware and a combination of commercially available and proprietary software components.

Our software applications, servers, and network infrastructure that deliver our services are hosted by a combination of third-party data center providers and HealthStream owned data centers. We maintain fully redundant disaster recovery data centers which are located in geographically separate locations. Our technology equipment is maintained in secure, limited access environments, supported by redundant power, environmental conditioning, and network connectivity, and we follow industry best practices for backup and disaster recovery. Company personnel monitor all servers, networks, and systems on a continuous basis, and we employ enterprise firewall systems and data abstraction to protect our databases, customer information, and courseware library from unauthorized access.

 

4


Table of Contents

COMPETITION

In addition to the competing healthcare education delivery methods in the industry, we also have direct competitors. In our workforce solutions business segment, a number of companies offer competitive learning management products and talent management modules to the healthcare industry. We compete with companies such as Cornerstone OnDemand, Healthcare Source, Oracle, SABA, SAP, and SumTotal Systems that provide their services to multiple industries, including healthcare. We also compete with large medical publishers that have operating units that offer learning management systems that focus on healthcare, such as Reed Elsevier Group’s MC Strategies. In our patient experience business segment, we face competition from large nationally recognized research firms such as Avatar International, Gallup, National Research Corporation, Press Ganey Associates, Studer Group, Professional Research Consultants, Inc., and others. Our patient experience business also experiences direct competition from vendors who provide research services to other industries including Kenexa, which is now owned by IBM, and Foresight, which is now owned by TNS Global. In our provider solutions business segment, we see competition primarily from several large companies, such as MD-Staff, Morissey & Associates, and Cactus Software.

We believe our workforce solutions, which include both products and services that facilitate training, assessment, and development for healthcare professionals, a wide assortment of courseware, a mechanism for measuring satisfaction and/or other results, and the ability to provide all our services on a single platform over the Internet, provide us with a competitive advantage. In our patient experience business segment, we believe our large proprietary database of survey results, technology infrastructure designed to automate the processing of survey results, proprietary core survey instruments and action plan development methodology, and our ability to quickly deliver relevant online courseware targeted at addressing survey related findings provide us with a competitive advantage. In our provider solutions business segment, we believe the scope and quality of our products, capability to connect medical staff credentialing with provider enrollment, and innovative new predictive analytics provide us with a competitive advantage. We believe that the principal competitive factors affecting the marketing of our workforce, patient experience, and provider solutions to the healthcare industry include:

 

    features of our SaaS-based platform and applications, including reporting, management functionality, ability to manage a variety of events or modalities, courseware assignment, curriculum management, documenting competency assessments and performance appraisals, scalability, and the ability to track utilization and results;

 

    scope and variety of Internet-based learning courseware available, including mandated content for OSHA, The Joint Commission, patient safety, and HIPAA requirements, ICD-10 training, competency-based content, courseware scenarios that drive simulators, courseware that provides CPR certification, as well as the ability of our customers to create and host their own web-enabled courseware;

 

    our singular focus on the healthcare industry and our deep healthcare expertise;

 

    scope and quality of professional services offered, including survey execution, implementation, benchmarking, training and the expertise and technical knowledge of the customers’ employees;

 

    competitive pricing, which supports a return on investment to customers when compared to other alternative delivery methods;

 

    customer service and support;

 

    effectiveness of sales and marketing efforts; and

 

    company reputation.

Collectively, we believe these capabilities provide us with the ability to improve the quality of healthcare by assessing and developing the people who deliver care.

GOVERNMENT REGULATION OF THE INTERNET AND THE HEALTHCARE INDUSTRY

Regulation of the Internet and the Privacy and Security of Personal Information

The laws and regulations that govern our business change rapidly. The following are some of the evolving areas of law that are relevant to our business:

 

    Privacy and Security Laws. Federal, state and foreign privacy and security regulations and other laws restricting the collection, use, security and disclosure of personal information limit our ability to collect information or use and disclose the information in our databases or derived from other sources to generate revenues. It may be costly to implement security or other measures designed to comply with any new legislation.

 

    Content Regulation. Both foreign and domestic governments have adopted and proposed laws governing the content of material transmitted over the Internet. These include laws relating to obscenity, indecency, libel and defamation. We could be liable if content delivered by us violates these regulations.

 

5


Table of Contents
    Information Security Accountability Regulation. As a business associate of our customers, we are required to report certain breaches of protected health information to our customers, which must in turn notify affected individuals, the U.S. Department of Health and Human Services (HHS) and, in certain situations involving large breaches, the media. All non-permitted uses or disclosures of unsecured, protected health information are presumed to be breaches unless the covered entity or business associate establishes that there is a low probability the information has been compromised. In addition, we are subject to certain state laws that relate to privacy or the reporting of security breaches. For example, California law requires notification of security breaches involving personal information and medical information. We may incur costs to comply with these privacy and security requirements. Because many of these laws are new and there is little guidance related to many of these laws, it is difficult to estimate the cost of our compliance with these laws. Further, Congress has considered bills that would require companies to engage independent third parties to audit the companies’ computer information security. If the Company is required to report a breach of security or if one of the Company’s customers is required to report a breach of security by the Company, the Company’s business could be negatively impacted.

 

    Sales and Use Tax. Through December 31, 2015, we collected sales, use or other taxes on taxable transactions in states in which we have employees or have a significant level of sales activity. While HealthStream expects that this approach is appropriate, other states or foreign jurisdictions may seek to impose tax collection obligations on companies like us that engage in online commerce. If they do, these obligations could limit the growth of electronic commerce in general and limit our ability to profit from the sale of our services over the Internet.

Laws and regulations directly applicable to content regulation, e-commerce, Internet communications, and the privacy and security of personal information are becoming more prevalent. Congress continues considering laws regarding Internet taxation. The dynamic nature of this regulatory environment increases the uncertainty regarding the marketplace impact of such regulation. The enactment of any additional laws or regulations may increase our cost of conducting business or otherwise harm our business, financial condition and operating results.

Regulation of Education, Training and Other Services for Healthcare Professionals

Occupational Safety and Health Administration (OSHA). OSHA regulations require employers to provide training to employees to minimize the risk of injury from various potential workplace hazards. Employers in the healthcare industry are required to provide training with respect to various topics, including blood borne pathogens exposure control, laboratory safety and tuberculosis infection control. OSHA regulations require employers to keep records of their employees’ completion of training with respect to these workplace hazards.

The Joint Commission. The Joint Commission mandates that employers in the healthcare industry provide certain workplace safety and patient interaction training to employees. Training required by The Joint Commission may include programs on infection control, patient bill of rights, radiation safety, and incident reporting. Healthcare organizations are required to provide and document training on these topics to receive accreditation from The Joint Commission. In addition, The Joint Commission imposes continuing education requirements on physicians that relate to each physician’s specific staff appointments.

Health Insurance Portability and Accountability Act (HIPAA). HIPAA regulations require certain organizations (known as covered entities), including most healthcare providers and health plans, to adopt safeguards regarding the use and disclosure of health-related information. HIPAA regulations also require these organizations to provide reasonable and appropriate safeguards to protect the privacy, integrity and confidentiality of individually identifiable healthcare information. Covered entities are required to establish, maintain and provide training with regard to their policies and procedures for protecting the integrity and confidentiality of individually identifiable healthcare information and must document training on these topics to support their compliance. Certain HIPAA privacy and security requirements apply to (entities known as business associates that handle individually identifiable healthcare information on behalf of covered entities) companies and business associates and their subcontractors may be directly subject to criminal and civil sanctions for violations of HIPAA privacy and security standards.

The American Nurses Credentialing Center (ANCC). ANCC, a subsidiary of the American Nurses Association (ANA), provides individuals and organizations throughout the nursing profession with the resources they need to achieve practice excellence. ANCC’s internationally renowned credentialing programs certify nurses in specialty practice areas; recognize healthcare organizations for promoting safe, positive work environments through the Magnet Recognition Program® and the Pathway to Excellence® Program; and accredit providers of continuing nursing education. In addition, ANCC’s Institute for Credentialing Innovation® offers an array of informational and educational services and products to support its core credentialing programs. ANCC certification exams validate nurses’ skills, knowledge, and abilities. More than a quarter million nurses have been certified by ANCC since 1990. More than 80,000 advanced practice nurses are currently certified by ANCC. The ANCC Magnet Recognition Program® recognizes healthcare organizations that provide the very best in nursing care and professionalism in nursing practice. The program also provides a vehicle for disseminating best practices and strategies among nursing systems. The ANCC Magnet Recognition Program is a highly recognized standard for nursing excellence. The Pathway to Excellence® Program recognizes the essential elements of a high standard nursing practice environment. The designation is earned by healthcare organizations that create work environments where nurses can develop professionally. The award substantiates the professional satisfaction of nurses and identifies best places to work.

 

6


Table of Contents

Continuing Nursing Education (CNE). State nurse practice laws are usually the source of authority for establishing the state board of nursing requirements. The state board of nursing establishes the state’s CNE requirements for professional nurses. CNE credits are provided through accredited providers that have been approved by the ANCC Commission on Accreditation and/or the state board of nursing. CNE requirements vary widely from state to state. Thirty-four states require registered nurses to certify that they have accumulated a minimum number of CNE credits in order to maintain their licenses. In some states, the CNE requirement only applies to re-licensure of advance practice nurses, or additional CNEs may be required of this category of nurses. Required CNE ranges from 12 to 45 credits annually, with reporting generally on a bi-annual basis. Board certifications (e.g., CNOR – certification of perioperative nursing) also require CNE credits, with certain percentages required in specific categories based on the certification type. We are an accredited provider of CNE by the ANCC.

Continuing Medical Education (CME). State licensing boards, professional organizations and employers require physicians to certify that they have accumulated a minimum number of continuing medical education hours to maintain their licenses. Generally, each state’s medical practice laws authorize the state’s board of medicine to establish and track CME requirements. Forty-eight state medical licensing boards currently have CME requirements, as well as Puerto Rico, Guam, and the U.S. Virgin Islands. The number of CME hours required by each state ranges from 15 to 50 hours per year. Other sources of CME requirements are state medical societies and practice specialty boards. The failure to obtain the requisite amount and type of CME could result in non-renewal of the physician’s license to practice medicine and/or membership in a medical or practice specialty society. American Medical Association (AMA) classifies continuing medical education activities as either Category 1, which includes formal CME activities, or Category 2, which includes most informal activities. Sponsors can only designate CME activities for AMA PRA Category 1 Credit™. Most agencies nationwide that require CME participation specify AMA PRA Category 1 Credit™. Only institutions and organizations accredited to provide CME can designate an activity for AMA PRA Category 1 Credit™. The Accreditation Council for Continuing Medical Education (ACCME) is responsible for awarding accreditation status to state medical societies, medical schools, and other institutions and organizations that provide CME activities for a national audience of physicians. Only institutions and organizations are accredited. State medical societies, operating under the aegis of the ACCME, accredit institutions and organizations that provide CME activities primarily for physicians within the state or bordering states. We are an accredited provider of CME by the ACCME.

Centers for Medicare & Medicaid Services (CMS). CMS has articulated a vision for health care quality—the right care for every person every time. To achieve this vision, CMS is committed to care that is safe, effective, timely, patient-centered, efficient, and equitable. Value-based purchasing (VBP), which links payment more directly to the quality of care provided, is a strategy that can help to transform the current payment system by rewarding providers for delivering high quality, efficient clinical care. Through a number of public reporting programs, demonstration projects, pilot programs, and voluntary efforts, CMS has launched VBP initiatives in hospitals, physician offices, nursing homes, home health services, and dialysis facilities. Further, pursuant to the Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Reconciliation Act of 2010 (collectively, ACA), CMS is implementing a number of initiatives designed to link payments to quality and efficiency, including a VBP program for inpatient hospital services.

Consumer Assessment of Healthcare Providers and Systems (CAHPS). CMS has partnered with AHRQ to develop a standardized survey instrument and data collection methodology for measuring patients’ perspectives on hospital care. The intent of the survey is to produce comparable data on the patients’ perspectives to allow consumer-based comparisons between hospitals, align incentives to drive hospitals to improve their quality of care, and increase the transparency of hospital reporting. Hospitals must submit data for certain required quality measures—which for inpatients includes the CAHPS® Hospital Survey—in order to receive the full market basket increase to their reimbursement payment rates from CMS. While hospital participation is voluntary, hospitals that fail to submit this survey data will incur a reduction of two percentage points in the inpatient market basket update amount for the following federal fiscal year. We have received certified vendor designation and will continue to offer CAHPS® Hospital Survey services. In addition, we are a certified vendor approved to offer CAHPS® Home Health Care Survey used to measure the experiences of people receiving home health care from Medicare-certified home health agencies. We also offer CAHPS® Clinician and Group Survey used to measure patient experiences with health care providers and staff in doctor’s offices.

Medicare and Medicaid Electronic Health Records (EHR) Incentive Programs. The Medicare and Medicaid EHR Incentive Programs provide incentive payments to eligible professionals, eligible hospitals and critical access hospitals (CAHs) as they adopt, implement, upgrade or demonstrate meaningful use of certified EHR technology. By putting into action and meaningfully using an EHR system, providers will reap benefits beyond financial incentives–such as reduction in errors, availability of records and data, reminders and alerts, clinical decision support, and e-prescribing/refill automation.

Allied Disciplines. Various allied health professionals are required to obtain continuing education to maintain their licenses. For example, emergency medical services personnel may be required to acquire up to 20 continuing education hours per year, all or a portion of which can be fulfilled online. These requirements vary by state and depend on the classification of the employee.

Other Continuing Education. We are also an accredited provider of continuing education and continuing pharmacy education by the Association of Surgical Technologists, Inc. (AST) and the Accreditation Council for Pharmacy Education (ACPE), respectively.

 

7


Table of Contents

Regulation of Educational Program Sponsorship and Support

There are a variety of laws and regulations that affect the relationships between our medical device and pharmaceutical customers and the users of our products and services, including the sponsorship and support of educational programs. For example, the Physician Payment Sunshine Act (“Sunshine Act”) requires manufacturers of drugs, biological devices and medical devices covered by Medicare, Medicaid, or the Children’s Health Insurance Program to report annually to CMS payments and other transfers of value, including educational programs, given by such manufacturers to physicians and teaching hospitals, with limited exceptions. CMS has issued a final rule implementing the Sunshine Act. Manufacturers are required to report the physician’s name, business address and national provider identifier as well as other information including the value, date, form and nature of what is offered. CMS publishes the information on its website. Manufacturers that do not meet the reporting obligations will be subject to significant monetary penalties.

Further, the Office of Inspector General (OIG) has issued Compliance Program Guidance for Pharmaceutical Manufacturers and for the Durable Medical Equipment, Prosthetics, Orthotics, and Supply Industry (collectively, the Guidelines). The Guidelines address compliance risks raised by the support of continuing educational activities by pharmaceutical and medical device companies. The Guidelines have affected and may continue to affect the type and extent of commercial support we receive for our continuing education activities. The trade associations for the pharmaceutical and medical device industries (PhRMA and AdvaMed, respectively) have also promulgated their own codes of ethics that further restrict the interactions between industry and health care professionals. In addition, the AMA has established its own code of ethics regarding Gifts to Physicians from Industry to provide standards of conduct for the medical profession. The Company follows the rules and guidelines provided by ACCME, ANCC, and other continuing education accrediting bodies to ensure that its continuing education programming is free from commercial bias and consistent with the Guidelines.

The U.S. Food and Drug Administration (FDA) and the Federal Trade Commission (FTC)

Current FDA and FTC rules and enforcement actions and regulatory policies or those that the FDA or the FTC may develop in the future could have a material adverse effect on our ability to provide existing or future applications or services to our end users or obtain the necessary corporate sponsorship to do so. The FDA and the FTC regulate the form, content and dissemination of labeling, advertising and promotional materials, including direct-to-consumer prescription drug and medical device advertising, prepared by, or for, pharmaceutical, biotechnology or medical device companies. The FTC regulates over-the-counter drug advertising and, in some cases, medical device advertising. Generally, regulated companies must limit their advertising and promotional materials to discussions of the FDA-approved indications and, in limited circumstances, to a limited number of indications not approved by the FDA. Therefore, any truthful or untruthful information that promotes the use of pharmaceutical or medical device products that is presented with our services is subject to the FDA and FTC requirements and regulatory oversight including criminal, civil and administrative actions. We believe that banner advertisements, sponsorship links and any educational programs that lack independent editorial control that we may present with our services could be subject to FDA or FTC regulation. While the FDA and the FTC place the principal burden of compliance with advertising and promotional regulations on the advertiser, if the FDA or FTC finds that any regulated information presented with our services violates FDA or FTC regulations, they may take regulatory action against us or the advertiser or sponsor of that information. In addition, the FDA may adopt new regulatory policies that more tightly regulate the format and content of promotional information on the Internet.

INTELLECTUAL PROPERTY AND OTHER PROPRIETARY RIGHTS

To protect our proprietary rights, we rely generally on copyright, trademark and trade secret laws; confidentiality agreements and procedures with employees, consultants and other third parties; contractual provisions in license agreements with consultants, vendors and customers; and use measures designed to control access to our software, documentation and other proprietary information. We own federal trademark and service mark registrations for several marks, including without limitation “EXCELLENCE THROUGH INSIGHT’, “HEALTHSTREAM”, “HOSPITAL DIRECT”, “OR PROTOCOL”, “PATIENT INSIGHTS”, “PHYSICIAN INSIGHTS”, “INSIGHTS ONLINE”, “INSIGHT INTO ACTION”, “QUALITY CHECK”, “SIMCENTER”, “SIMMANAGER”, and “SIMSTORE.” We also have obtained registration of the “HEALTHSTREAM” mark in certain other countries. Applications for several trademarks are currently pending. However, there can be no assurance that we will be successful in obtaining registration of other trademarks for which we have applied.

The courseware that we license to our customers is developed through a combination of license agreements with publishers and authors, assignments and work-for-hire arrangements with third parties, and development by employees. We require publishers, authors and other third parties to represent and warrant that their content does not infringe on or misappropriate any third-party intellectual property rights and that they have the right to provide their content and have obtained all third-party consents necessary to do so. Our publishers, authors and other third parties also agree to indemnify us against certain liability we might sustain due to the content they provide.

If a third party asserts a claim that we have infringed its patents or other intellectual property right, we may be required to redesign our products or enter into royalty or licensing agreements. In addition, we license technologies from third parties for incorporation into our services. Royalty and licensing agreements with these third parties may not be available on terms acceptable to us, if at all. Additionally, despite the steps we have taken to protect our intellectual property and proprietary rights, our efforts may not be adequate. Third parties may infringe or misappropriate our intellectual property, and such violations of our intellectual property are difficult to detect and police. Competitors may also independently develop technologies that are substantially equivalent or superior to the technologies we employ in our products or services. If we fail to protect our proprietary rights adequately, our competitors could offer similar services, potentially significantly harming our competitive position and decreasing our revenues.

 

8


Table of Contents

AVAILABLE INFORMATION

The Company files reports with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and other reports from time to time. The public may read and copy any materials we file with the SEC at the SEC’s Public Reference Room at 100 F Street, NE, Washington, DC 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The Company is an electronic filer and the SEC maintains an Internet site at http://www.sec.gov that contains the reports, proxy and information statements, and other information filed electronically. Our website address is www.healthstream.com. Please note that our website address is provided as an inactive textual reference only. We make available free of charge through our website, our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with or furnished to the SEC. The information provided on our website is not part of this report, and is therefore not incorporated by reference unless such information is otherwise specifically referenced elsewhere in this report.

OUR EMPLOYEES

As of December 31, 2015, we employed 833 full-time and 139 part-time persons, of which 205 persons are employed in our interviewing centers. Our success will depend in large part upon our ability to attract and retain qualified employees. We face competition in this regard from other companies, but we believe that we maintain good relations with our employees. We are not subject to any collective bargaining agreements.

EXECUTIVE OFFICERS OF THE REGISTRANT

The following is a brief summary of the business experience of each of the executive officers of the Company. Executive Officers of the Company are elected by the Board of Directors and serve at the pleasure of the Board of Directors. The following table sets forth certain information regarding the executive officers of the Company:

 

Name

   Age     

Position

Robert A. Frist, Jr.

     48       Chief Executive Officer, President and Chairman of the Board of Directors

Jeffrey S. Doster

     51       Senior Vice President and Chief Technology Officer

Gerard M. Hayden, Jr.

     61       Senior Vice President and Chief Financial Officer

J. Edward Pearson

     53       Senior Vice President and Chief Operating Officer

Thomas Schultz

     49       Senior Vice President, Sales

Michael Sousa

     47       Senior Vice President and President, Echo, Inc.

Robert A. Frist, Jr., one of our co-founders, has served as our chief executive officer and chairman of the board of directors since 1990 and president since 2001. Mr. Frist is the company’s chief operating decision maker. He graduated with a Bachelor of Science in business with concentrations in finance, economics and marketing from Trinity University.

Jeffrey S. Doster joined the Company in May 2008 as senior vice president and chief technology officer. He earned undergraduate degrees in both Economics and Business Administration from Towson University, as well as a Master of Business Administration from Loyola College, in Maryland.

Gerard M. Hayden, Jr. joined the Company as senior vice president and chief financial officer in May 2008. He earned a Bachelor of Arts from the University of Notre Dame and a Master of Science from Northeastern University.

J. Edward Pearson joined the Company in June 2006 as senior vice president and was promoted to Chief Operating Officer in 2011. He earned a Bachelor of Business Administration in accounting from Middle Tennessee State University.

Thomas Schultz joined the Company in June 2014 as senior vice president of sales. He worked for Lawson Software, a subsidiary of Infor, Inc., in various sales leadership roles for sixteen years prior to joining the Company. He earned a Bachelor of Arts from St. Mary’s University of Minnesota.

Michael Sousa joined the Company in October 2004, and served as senior vice president of sales from January 2010 to June 2014. In June 2014, he was promoted to senior vice president of business development. In September 2015, he was named president of Echo, Inc., HealthStream’s Provider Solutions business segment, while continuing to serve as a senior vice president of the Company. He earned a Bachelor of Science degree from Boston College and a Master of Business Administration from Boston University.

 

9


Table of Contents

Item 1A. Risk Factors

We believe that the risks and uncertainties described below and elsewhere in this document are the principal material risks facing the Company as of the date of this report. In the future, we may become subject to additional risks that are not currently known to us. Our business, financial condition or results of operations could be materially adversely affected by any of the following risks and by any unknown risks. The trading price of our common stock could decline due to any of the following risks or any unknown risks.

Risks Related to Our Business Model

We may be unable to effectively execute our growth strategy which could have an adverse effect on our business and competitive position in the industry.

Our business strategy includes increasing our market share and presence through sales to new customers, additional sales to existing customers, introductions of new products and services, and maintaining strong relationships with our existing customers. Some of the risks that we may encounter in executing our growth strategy include:

 

  expenses, delays and difficulties of identifying and developing new products or services and integrating such new products or services into our existing organization;

 

  inability to leverage our operational and financial systems sufficiently to support our growth;

 

  inability to generate sufficient revenue from new products to offset investment costs;

 

  inability to effectively identify, manage and exploit existing and emerging market opportunities;

 

  inability to maintain our existing customer relationships;

 

  increased competition from new and existing competitors;

 

  lengthy sales cycles, or customers delaying purchasing decisions due to economic conditions;

 

  reduced spending within the training, information and education departments of hospitals within our target market; and

 

  failure of the market for training, information and education in the healthcare industry to grow to a sufficient size or at a sufficient rate.

If any of these risks are realized, our business, and our competitive position in the industry, could suffer.

We may be unable to effectively identify, complete or integrate the operations of future acquisitions, joint ventures, collaborative arrangements or other strategic investments.

As part of our growth strategy, we actively review possible acquisitions, joint ventures, collaborative arrangements or strategic investments that complement or enhance our business. We may not be able to identify, complete or integrate the operations of future acquisitions, joint ventures, collaborative arrangements or other strategic investments. In addition, if we finance acquisitions, joint ventures, collaborative arrangements or other strategic initiatives by issuing equity securities, our existing shareholders may be diluted which could affect the market price of our stock. As a result, if we fail to properly evaluate and execute acquisitions and investments, our business prospects may be seriously harmed. Some of the risks that we may encounter in implementing our acquisition, joint venture, collaborative arrangement or strategic investment strategies include:

 

  expenses, delays or difficulties in identifying and integrating acquired companies or joint venture operations, collaborative arrangements or other strategic investments into our organization;

 

  inability to retain personnel associated with acquisitions, joint ventures, collaborative arrangements or other strategic investments;

 

  diversion of management’s attention from other initiatives and/or day-to-day operations to effectively execute our growth strategy; and

 

  inability to generate sufficient revenue, profit, and cash flow from acquisitions, joint ventures, collaborative arrangements or other strategic investments to offset our investment costs.

 

10


Table of Contents

Our ability to accurately forecast revenue for certain products and services may be hindered by customer scheduling.

As revenues from our subscription business continue to increase, a larger portion of our revenues will be predictable; however, quarterly performance may be more subject to fluctuations. Our HealthStream Patient Experience Solutions products and services are typically contracted by healthcare organizations for multi-year terms, but the frequency, sample size, and timing of survey cycles can vary from quarter to quarter and year to year. The contract structure for some Patient Experience Solutions products gives customers latitude about when to initiate a survey, which can affect quarterly or annual revenue forecasts. Also, other project-based products, such as certain content development and professional services, are subject to the customers’ involvement in the provision of the product or service. The timing and magnitude of these project-based product and service contracts may vary widely from quarter to quarter and year to year, and thus may affect our ability to accurately forecast quarterly and annual financial performance.

Our ability to accurately forecast revenue may be affected by lengthy and widely varying sales cycles.

The period from our initial contact with a potential customer and their first purchase of our solution typically ranges from three to nine months, and in some cases has extended much further. The range in the sales cycle can be impacted by multiple factors, including an increasing trend towards more formal request for proposal processes and more competition within our industry, as well as formal budget timelines which impact timing of purchases by target customers. New products tend to have a longer and more unpredictable revenue ramp period. As a result of these factors, we have only limited ability to forecast the timing and type of initial sales. This, in turn, makes it more difficult to forecast quarterly and annual financial performance.

We may not be able to maintain our competitive position against current and potential competitors, especially those with significantly greater financial, technical, marketing, or other resources.

Several of our competitors and many potential competitors have longer operating histories and significantly greater financial, technical, marketing, or other resources than we do. We encounter direct competition from both large and small companies and other companies focused on workforce development management in the healthcare industry. We also face competition from larger survey and research companies. Given the profile and growth of the healthcare industry and the growing need for education, training, simulation, research, and information, it is likely that additional competitors will emerge. We believe we maintain a competitive advantage against our competitors by offering a comprehensive array of products and services; however, our lack of market diversification resulting from our concentration on the healthcare industry may make us susceptible to losing market share to our competitors who also offer a more robust talent management suite to a cross-section of industries. These companies may be able to respond more quickly than we can to new or changing opportunities, technologies, standards or customer requirements. Further, most of our customer agreements are for terms ranging from one to four or five years, with no obligation to renew. The short terms of these agreements may enable customers to more easily shift to one of our competitors.

The failure to maintain and strengthen our relationships with strategic partners or significant changes in the terms of the agreements we have with them may have an adverse impact on our ability to successfully market our products and services.

We have entered into contracts with strategic partners, including content, technology, and retail channel vendors. Our ability to increase the sales of our products and services depends in part upon maintaining and strengthening relationships with these current and future strategic partners. Most of these contracts are on a non-exclusive basis. Certain strategic partners may offer products and services from multiple distinct companies, including, in some instances, products or services which may compete with our products and services. Moreover, under contracts with some of our strategic partners, we may be bound by provisions that restrict our ability to market and sell our products and services to certain potential customers. The success of these contractual arrangements will depend in part upon the strategic partners’ own competitive, marketing, and strategic considerations, including the relative advantages for such strategic partners in using alternative products being developed and marketed by them or our competitors, rather than our products and services.

We cannot guarantee that we will be able to maintain and strengthen our relationships with strategic partners, that we will be successful in effectively integrating such partners’ products and technology into our own, or that such relationships will be successful in generating additional revenue. If any of these strategic partners have negative experiences with our products and services, or seek to amend the financial or other terms of the contracts we have with them, we may need to increase our organizational focus on the types of services and solutions they sell and alter our development, integration, and/or distribution strategies, which may divert our planned efforts and resources from other projects.

Lastly, we could be subject to claims and liability, as a result of the activities, products, or services of these strategic partners, and/or our acts or omissions with regard to these strategic partners. Even if these claims do not result in liability to us, investigating and defending these claims could be expensive, time-consuming and result in suspension of or interference with certain offerings to our clients and/or adverse publicity that could harm our business.

 

11


Table of Contents

We may not be able to retain distribution rights from our content partners, and this could affect projected growth in courseware subscription revenue.

Most of our agreements with content providers are for initial terms of two to three years. The content partners may choose not to renew their agreements with us or may terminate the agreements early if we do not fulfill our contractual obligations. If a significant number of our content providers terminate or fail to renew their agreements with us on acceptable terms, it could result in a reduction in the number of courses we are able to distribute, causing decreased revenues. Most of our agreements with our content partners are non-exclusive, and our competitors offer, or could offer, training, development and continuing education content that is similar to or the same as ours. If publishers and authors, including our current content partners offer information to users or our competitors on more favorable terms than those offered to us, or increase our license fees, our competitive position and our profit margins and prospects could be harmed. In addition, the failure by our content partners to deliver high-quality content and to revise their content in response to user demand and evolving healthcare advances and trends could result in customer dissatisfaction and inhibit our ability to attract and retain subscribers of our courseware offerings.

We may not be able to develop new products and services, or enhancements to our existing products and services, or be able to achieve widespread acceptance of new products, services or features, or keep pace with technological developments.

Our growth strategy depends in part on our ability to generate revenue growth through sales to new customers as well as increasing sales of additional courseware subscriptions and other products and services to existing customers. Our identification of additional features, content, products and services may not result in timely development of complementary products. In addition, the success of certain new products and services may be dependent on continued growth in our customer base. We are not able to accurately predict the volume or speed with which existing and new customers will adopt such new products and services. Because healthcare training continues to change and evolve, we may be unable to accurately predict and develop new products, features, content and other products to address the needs of the healthcare industry. Further, the new products, services and enhancements we develop may introduce significant defects into or otherwise negatively impact our core software platform. While all new products and services are subject to testing and quality control, all software and software-based services are subject to errors and malfunctions. If we release new products, services and/or enhancements with bugs, defects or errors or that cause bugs, defects or errors in existing products, it could result in lost revenues, reduced ability to meet contractual obligations and would be detrimental to our business and reputation. If new products, features, or content are not accepted or integrated by new or existing customers, we may not be able to recover the cost of this development and our financial performance will be harmed. Continued growth of our customer population is dependent on our ability to continue to provide relevant products and services in a timely manner. The success of our business will depend on our ability to continue providing our products and services as well as enhancing our courseware, product and service offerings that address the needs of healthcare organizations.

We may be unable to continue to license our third party software, on which a portion of our product and service offerings rely, or we may experience errors in this software, which could increase our costs and decrease our revenue.

We use technology components in some of our products that have been licensed from third parties. Future licenses to these technologies may not be available to us on commercially reasonable terms, or at all. The loss of or inability to obtain or maintain any of these licenses could result in delays in the introduction of new products and services or could force us to discontinue offering portions of our workforce development or patient experience solutions until equivalent technology, if available, is identified, licensed and integrated. The operation of our products would be impaired if errors occur in third party technology or content that we incorporate, and we may incur additional costs to repair or replace the defective technology or content. It may be difficult for us to correct any errors in third party products because the products are not within our control. Accordingly, our revenue could decrease and our costs could increase in the event of any errors in this technology. Furthermore, we may become subject to legal claims related to licensed technology based on product liability, infringement of intellectual property or other legal theories. Even if these claims do not result in liability to us, investigating and defending these claims could be expensive, time-consuming and result in suspension of or interference with certain offerings to our clients and/or adverse publicity that could harm our business.

Financial Risks

A significant portion of our revenue is generated from a relatively small number of customers.

We derive a substantial portion of our revenues from a relatively small number of customers. A termination of our agreements with any of our significant customers or a failure of these customers to renew their contracts on favorable terms, or at all, could have a material adverse effect on our business.

 

12


Table of Contents

A significant portion of our business is subject to renewal each year. Therefore, renewals have a significant impact on our revenue and operating results.

For the year ended December 31, 2015, approximately 74% of our net revenue was derived from our subscription-based solution products. Our subscription-based customers have no obligation to renew their subscriptions for our products or services after the expiration of the subscription agreement, and in fact, some customers have elected not to renew their subscription. In addition, our customers may renew at a lower pricing or activity level. Our customers’ renewals may decline or fluctuate as a result of a number of factors, including but not limited to their dissatisfaction with our service, a dissipation or cessation of their need for one or more of our products or services, pricing or competitive product offerings. If we are unable to renew a substantial portion of the contracts that are up for renewal or maintain our pricing, our revenue could be adversely affected, which would have a material adverse effect on our results of operations and financial position. For example, the requirement mandated by CMS for healthcare organizations to transition to the ICD-10 coding system, effective in October 2015, generated significant demand for our ICD-10 readiness training courseware from 2012 through 2015, when subscriptions for that product positively influenced the Company’s revenue and operating income. However, sales of that product have ceased and revenue and operating income from that product will significantly decline during 2016 compared to the previous year since there will not be renewals of that product. HealthStream Patient Experience Solutions product and service contracts typically range from one to three years in length, and customers are not obligated to renew their contract with us after their contract expires. If our customers do not renew their arrangements for our services, or if their activity levels decline, our revenue may decline and our business will suffer.

We may be unable to accurately predict the timing of revenue recognition from sales activity as it is often dependent on achieving certain events or performance milestones, and this inability could impact our operating results.

Our ability to recognize revenue is dependent upon several factors including the transfer of customer-specific information such as unique subscriber IDs, which are required for us to implement customers on our subscription-based platform and certain platform applications. Accordingly, if customers do not provide us with the specified information in a timely manner, our ability to recognize revenue will be delayed, which could adversely impact our operating results. In addition, implementation completion and acceptance of our subscription-based platform and certain platform applications by our customers must be achieved, survey responses must be received and tabulated, and delivery of courseware is required in connection with subscription-based products for us to recognize revenue.

Because we recognize revenue from subscriptions for our products and services over the term of the subscription period, downturns or upturns in sales may not be immediately reflected in our operating results.

During the year ended December 31, 2015, we recognized approximately 74% of our revenue from customers monthly over the terms of their subscription agreements, which have initial contract terms ranging from one to five years. As a result, much of the revenue we report in each quarter is related to subscription agreements entered into during previous quarters. Consequently, a decline in new or renewed subscription agreements in any one quarter will not necessarily be fully reflected in the revenue in that quarter and will negatively affect our revenue in future quarters. In addition, we may be unable to adjust our cost structure to reflect this reduced revenue. Accordingly, the effect of significant downturns in sales and market acceptance of our products and services may not be fully reflected in our results of operations until future periods. Additionally, our subscription model also makes it difficult for us to rapidly increase our revenue through additional sales in any period, as revenue from new customers must be recognized over the applicable subscription term. Finally, the majority of costs associated with our sales cycles are incurred up front before revenue recognition commences, and therefore periods of strong sales performance may increase our costs in the near term negatively affecting our financial performance.

We may not be able to meet our strategic business objectives unless we obtain additional financing, which may not be available to us on favorable terms, or at all.

We believe that our existing cash and cash equivalents, marketable securities, cash generated from operations, and available borrowings under our revolving credit facility will be sufficient to meet anticipated working capital needs, new product development and capital expenditures for at least the next 12 months. However, we may need to raise additional funds in order to:

 

    develop new, or enhance existing, services or products;

 

    respond to competitive pressures;

 

    finance working capital requirements;

 

    acquire or invest in complementary businesses, technologies, content or products; or

 

    otherwise effectively execute our growth strategy.

At December 31, 2015, we had approximately $149.0 million in cash, cash equivalents, and marketable securities. We also have up to $50.0 million of availability under our Revolving Credit Facility, subject to certain covenants, which expires in November 2017. We expect to incur between $14.0 and $16.0 million of capital expenditures, software development and content purchases during 2016. We actively review possible business acquisitions to complement or enhance our products and services. We may not have adequate cash and investments or availability under our Revolving Credit Facility to consummate one or more of these acquisitions. We cannot assure you that if we

 

13


Table of Contents

need additional financing that it will be available on terms favorable to us, or at all. If adequate funds are not available or are not available on acceptable terms, our ability to fund expansion, take advantage of available opportunities, develop or enhance services or products or otherwise respond to competitive pressures would be significantly limited. If we raise additional funds by issuing equity or convertible debt securities, the percentage ownership of our existing shareholders may be reduced.

We have significant goodwill and identifiable intangible assets recorded on our balance sheet that may be subject to impairment losses that would reduce our reported assets and earnings.

As of December 31, 2015, our balance sheet included goodwill of $83.1 million and identifiable intangible assets of $56.0 million. There are inherent uncertainties in the estimates, judgments and assumptions used in assessing recoverability of goodwill and intangible assets. Economic, legal, regulatory, competitive, reputational, contractual, and other factors could result in future declines in the operating results of our business units or market value declines that do not support the carrying value of goodwill and identifiable intangible assets. If the value of our goodwill and/or intangible assets is impaired, accounting rules require us to reduce their carrying value and report an impairment charge, which would reduce our reported assets and earnings for the period in which an impairment is recognized.

The current uncertain economic environment may have a negative impact on our customers and us which could have a significant impact on our revenue, operating results and financial condition.

It is difficult to predict the full magnitude and duration of the current uncertain economic environment and its related impact on our customers, suppliers and our company. For example, our customers may experience fluctuations or declines in their business and as a consequence, some customers may choose to invest less in information technology assets for their business which, in turn, could have an impact on us. The potential negative effects on us include, but are not limited to, reductions in our renewal and revenue growth rates, shorter contract terms, pricing pressures, and delays in payments from customers that increase our accounts receivable resulting in a deterioration of our cash flow and working capital position. We continue to monitor general economic conditions, however, and depending on the severity and/or duration of any economic downturn, these circumstances could have a material adverse effect on our revenue, results from operations and financial condition. In addition, because our clients are concentrated in the healthcare industry, our revenue and operating results may be adversely affected by changes in regulations, a business downturn in the healthcare industry, or consolidation with respect to the healthcare industry.

We may not be able to demonstrate compliance with Sarbanes-Oxley Section 404 in a timely manner, and the correction of any deficiencies identified during annual audits may be costly and could harm our business.

Sarbanes-Oxley Section 404 requires our management to report on, and requires our independent public accounting firm to attest to, the effectiveness of our internal controls over financial reporting. The rules governing the standards to be met are complex and will require significant process review, documentation and testing, as well as possible remediation efforts for any identified deficiencies. This process of review, documentation, testing and remediation will result in increased expenses and require significant attention from management and other internal and external resources. Any material weaknesses identified during this process may preclude us from asserting the effectiveness of our internal controls. This may negatively affect our stock price if we cannot effectively remediate the issues identified in a timely manner.

Changes in generally accepted accounting principles (GAAP) and other accounting regulations and interpretations could require us to delay recognition of revenue and/or accelerate the recognition of expenses, resulting in lower earnings.

While we believe we correctly account for and recognize revenue and expenses, any changes in GAAP or other accounting regulations and interpretations concerning revenue and expense recognition could decrease our revenue or increase our expenses. Changes to regulations concerning revenue recognition could require us to alter our current revenue accounting practices and cause us to either defer revenue into a future period, or to recognize lower revenue in a current period. Likewise, changes to regulations concerning expense recognition could require us to alter our current expense accounting practices and cause us to defer recognition of expense into a future period, or to recognize increased expenses in a current period. Changes to either revenue recognition or expense recognition accounting practices could affect our financial performance.

Risks Related to Sales, Marketing and Competition

Our operating margins could be affected if our ongoing refinement to pricing models for our products and services is not accepted by our customers and the market.

We continue to make changes in our pricing and our product and service offerings to increase revenue and to meet the needs of our customers. We cannot predict whether our current pricing and products and services, or any ongoing refinements we make will be accepted by our existing customer base or by prospective customers. If our customers and potential customers decide not to accept our current or future pricing or product and service offerings, it could have a material adverse effect on our business.

 

14


Table of Contents

Risks Related to Operations

We may be unable to adequately develop our systems, processes and support in a manner that will enable us to meet the demand for our services.

We have provided our online products and services for over 16 years and continue to develop our ability to provide our solutions on both a subscription and transactional basis over the Internet. Our future success will depend on our ability to effectively develop and maintain the infrastructure, including procurement of additional hardware and software, and to implement the services, including customer support, necessary to meet the demand for our products and services. Our inability from time to time to successfully develop the necessary systems and implement the necessary services on a timely basis has resulted in our customers experiencing some delays, interruptions and/or errors in their service. Such delays or interruptions may cause customers to become dissatisfied with our service and move to competing providers of traditional and online training and education services. If this happens, our revenue and reputation could be adversely affected, which would have a material adverse effect on our financial condition.

Our business operations could be significantly disrupted if we lose members of, or fail to integrate, our management team.

Our future performance is substantially dependent on the continued services of our management team and our ability to retain and motivate them. The loss of the services of any of our officers or senior managers could harm our business, as we may not be able to find suitable replacements. We do not have employment agreements with any of our key personnel, other than our chief executive officer, and we do not maintain any “key person” life insurance policies.

We may not be able to hire and retain a sufficient number of qualified employees and, as a result, we may not be able to effectively execute our growth strategy or maintain the quality of our services.

Our future success will depend on our ability to attract, train, motivate, and retain other highly skilled technical, managerial, marketing, customer support, and survey personnel. Competition for certain personnel is intense, especially for developers, web designers and sales personnel, and we may be unable to successfully attract sufficiently qualified personnel. We have experienced in the past, and continue to experience, difficulty hiring qualified personnel in a timely manner for these positions. The pool of qualified technical personnel, in particular, is limited in Nashville, Tennessee, where our headquarters are located. We operate interviewing centers located in Laurel, Maryland, and Nashville, Tennessee. We may experience difficulty in maintaining and recruiting qualified individuals to perform interviewing services. We will also need to maintain or increase the size of our staff to support our anticipated growth, without compromising the quality of our offerings or customer service. Our inability to locate, attract, hire, integrate and retain qualified personnel in sufficient numbers may reduce the quality of our services and impair our ability to grow.

We may not be able to upgrade our hardware and software technology infrastructure quickly enough to effectively meet demand for our services or our operational needs.

We must continue to obtain reasonably priced, commercially available hardware and operating software as well as continue to enhance our software and systems to accommodate the increased use of our platform, the increased courseware and content in our library and the resulting increase in operational demands on our business. Decisions about hardware and software enhancements are based in part on estimated forecasts of the growth in demand for our services. This growth in demand for our services is difficult to forecast and the potential audience for our services is widespread and dynamic. If we are unable to increase the data storage and processing capacity of our systems at least as fast as the growth in demand, our customers may encounter delays or disruptions in their service. Unscheduled downtime could harm our business and also could discourage current and potential customers from using or continuing to use our services and reduce future revenue. If we are unable to acquire, update, or enhance our technology infrastructure and systems quickly enough to effectively meet increased operational demands on our business, that may also have a material adverse effect on our financial condition.

Our network infrastructure and computer systems and software may fail.

An unexpected event (including but not limited to a cyber-security incident, telecommunications failure, fire, earthquake, or other catastrophic loss) at our Internet service providers’ facilities or at our on-site data facilities could cause the loss of critical data and prevent us from offering our products and services for an unknown period of time. System downtime could negatively affect our reputation and ability to sell our products and services and may expose us to significant third-party claims. Our business interruption insurance may not adequately compensate us for losses that may occur. In addition, we rely on third parties to securely store our archived data, house our web server and network systems and connect us to the Internet. While our service providers have planned for certain contingencies, the failure by any of these third parties to provide these services satisfactorily and our inability to find suitable replacements would impair our ability to access archives and operate our systems and software, and our customers may encounter delays. Such disruptions could harm our reputation and cause customers to become dissatisfied and possibly take their business to a competing provider, which would adversely affect our revenues.

 

15


Table of Contents

We may lose users and lose revenue if our security measures fail.

If the security measures that we use to protect customer or personal information are ineffective, we may lose users of our services, which could reduce our revenue, tarnish our reputation, and subject us to significant liability. We rely on security and authentication technology licensed from third parties. With this technology, we perform real-time credit card authorization and verification, as well as the encryption of other selected secure customer data. We cannot predict whether these security measures could be circumvented by new technological developments. Further, the audit processes and controls used within our production platforms may not be sufficient to identify and prevent errors or deliberate misuse. In addition, our software, databases and servers may be vulnerable to computer viruses, physical or electronic attacks and similar disruptions. We may need to spend significant resources to protect against security breaches or to alleviate problems caused by any breaches. We cannot assure that we can prevent all security breaches.

A security incident could result in a loss of confidential data, give rise to remediation and other expenses, expose us to liability under the Health Insurance Portability and Accountability Act (HIPAA), the Health Information Technology for Economic and Clinical Health Act (HITECH), state privacy laws, consumer protection laws, common law theories or other laws, subject us to litigation and federal and state governmental inquiries, damage our reputation, and otherwise be disruptive to our business.

We collect and store sensitive information, including intellectual property and protected health information (“PHI”) and other personally identifiable information, on our networks. The secure maintenance of this information is critical to our business operations. We have implemented multiple layers of security measures to protect this confidential data through technology, processes, and our people; we utilize current security technologies; and our defenses are monitored and routinely tested internally and by external parties. Despite these efforts, a security breach or failure could result from a variety of circumstances and events, including third-party action, system errors, employee negligence or error, malfeasance, computer viruses, failures during the process of upgrading or replacing software, databases, or components thereof, power outages, hardware failures, telecommunication failures, user errors, catastrophic events, or threats from malicious persons and groups, new vulnerabilities, and advanced new attacks against information systems create risk of security incidents. Like many other organizations, we have experienced data incidents from time to time in the course of our business and handled these incidents in accordance with our understanding of the applicable laws.

In addition, we may experience data incidents again in the future, including incidents more significant than we have experienced to date, which could expose us and our customers to penalties under HIPAA or applicable state laws, damage our reputation, and result in plaintiff or state Attorney General litigation, especially if a large number of patients are affected or if the compromised information is highly sensitive.

We may experience errors or omissions in our software products or processes that (i) deliver provider credentialing, privileging and payer enrollment services for our hospitals and medical practice customers and (ii) administer and report on hospital performance, and these errors could result in action taken against us that could harm our business.

Hospitals and medical practices use our credentialing, privileging, and payer enrollment software to manage, validate and maintain their providers’ credentials and authorization to practice in a particular facility, and to maintain authorization to perform care covered by insurance providers. In some instances, we also rely on information from sources outside the Company that we then use in our credentialing and privileging products. If errors or omissions occur that inaccurately validate or invalidate the credentials of a provider, or improperly deny or authorize a provider to practice in a hospital or medical practice, these errors or omissions could result in litigation brought against us either by our hospital and medical practice customers, or by the provider. For example, an important element in a malpractice case brought against a hospital or other provider would often be the validation of proper credentialing for the provider, and any errors or omissions in our products that provide these services could subject us to claims. Further, a list of providers’ privileges are made available to the general public by hospitals and medical practices, and errors in credentialing and privileging may result in damage to that hospital’s or medical practice’s reputation.

Certain survey data collected and reported by us, such as the survey data included as part of our CAHPS® Hospital survey is used by CMS to determine, in part, the amount of reimbursement payments to hospitals, and any errors in data collection, survey sampling, or statistical reporting could result in reduced reimbursements to our hospital customers if we are unable to correct these errors, and this could, in turn, result in litigation against us. Further, this survey data reported to CMS is then published by CMS to the general public, and any errors we experience that result in incorrect scoring on our hospital customer may result in damage to that hospital’s reputation, and the hospital may in turn bring litigation against us.

We may be required to indemnify against such claims, and defending against any such claims could be costly, time consuming and could negatively affect our business.

 

16


Table of Contents

Risks Related to Government Regulation, Content and Intellectual Property

Government regulation may subject us to investigation, litigation, or liability or require us to change the way we do business.

The laws and regulations that govern our business change rapidly. Evolving areas of law that are relevant to our business include privacy and security laws, proposed encryption laws, content regulation, information security accountability regulation, sales and use tax laws and regulations and attempts to regulate activities on the Internet. In addition to being directly subject to certain requirements of the HIPAA privacy and security regulations, we are required through contracts with our customers known as “business associate agreements” to protect the privacy and security of certain personal and health related information. Our current and past privacy and security practices, including any breaches of PHI or other data, could also be subject to review or other investigation by various state and federal regulatory authorities or could become the subject of future pending or threatened litigation.

The rapidly evolving and uncertain regulatory and technology environment could require us to change how we do business or incur additional costs. Further, we cannot predict how changes to these laws and regulations might affect our business. Failure to comply with applicable laws and regulations, including those governing privacy and security, could subject us to civil and criminal penalties, subject us to contractual penalties (including termination of our customer agreements), adversely affect our ability to retain clients and attract new clients, damage our reputation and have a detrimental impact on our business.

We may not be able to maintain our certification to conduct CMS mandated surveys, and this could adversely affect our business.

Our survey product offerings include providing survey services to assist customers in their compliance with CMS regulations. We are currently designated by CMS as a certified vendor to offer CAHPS® Hospital Surveys and CAHPS® Home Health Care Surveys, including data collection and submission services. We are also a certified vendor for CG-CAHPS; ICH-CAHPS, ED-CAHPS; PCMH-CAHPS; Hospice CAHPS; and ACO-CAHPS. If we are unable to maintain these certifications, or secure certifications for future CMS mandated surveys, we would not be able to administer these survey instruments for our customers and our business may suffer.

Any reduction or change in the regulation of continuing education and training in the healthcare industry may adversely affect our business.

Our business model is dependent in part on required training and continuing education for healthcare professionals and other healthcare workers resulting from regulations of state and federal agencies, state licensing boards and professional organizations. Any change in these regulations that reduce the requirements for continuing education and training for the healthcare industry could harm our business. In addition, a portion of our business with pharmaceutical and medical device manufacturers and hospitals is predicated on our ability to maintain accreditation status with organizations such as the ACCME, ANCC, and ACPE. The failure to maintain status as an accredited provider could have a detrimental effect on our business.

We may be liable to third parties for content that is available from our online library.

We may be liable to third parties for the content in our online library if the text, graphics, software or other content in our library violates copyright, trademark, or other intellectual property rights, our content partners violate their contractual obligations to others by providing content to our library, or the content does not conform to accepted standards of care in the healthcare profession. We attempt to minimize these types of liabilities by requiring representations and warranties relating to our content partners’ ownership of the rights to distribute as well as the accuracy of their content. We also take necessary measures to review this content ourselves. Although our agreements with our content partners in most instances contain provisions providing for indemnification by the content providers in the event of inaccurate content, our content partners may not have the financial resources to meet this obligation. Alleged liability could harm our business by damaging our reputation, requiring us to incur legal costs in defense, exposing us to awards of damages and costs, and diverting management’s attention away from our business.

Protection of certain intellectual property may be difficult and costly, and our inability to protect our intellectual property could reduce the value of our products and services.

Despite our efforts to protect our intellectual proprietary rights, a third party could, without authorization, copy or otherwise misappropriate our content, information from our databases, or other intellectual property. Our agreements with employees, consultants and others who participate in development activities could be breached and result in our trade secrets becoming known, or our trade secrets and other intellectual property could be independently developed by competitors. We may not have adequate remedies for such breaches or protections against such competitor developments. In addition, the laws of some foreign countries do not protect our proprietary rights to the same extent as the laws of the United States, and effective intellectual property protection may not be available in those jurisdictions. We currently own several applications and registrations for trademarks and domain names in the United States and other countries as well as certain common law trademarks and service marks. The current system for registering, allocating and managing domain names has been the subject of litigation and proposed regulatory reform. Additionally, legislative proposals have been made by the federal government that would afford broad protection to owners of databases of information, such as stock quotes. This protection of databases already exists in the European Union.

Our business could be harmed if unauthorized parties infringe upon or misappropriate our intellectual property, proprietary systems, content, platform, services or other information. Our efforts to protect our intellectual property through copyright, trademarks and other controls may not be adequate. For instance, we may not be able to secure trademark or service mark registrations for marks in the United States or in foreign countries, or to secure patents for our proprietary products and services, and even if we are successful in obtaining patent and/or trademark registrations, these registrations may be opposed or invalidated by a third party.

 

17


Table of Contents

There has been substantial litigation in the computer and online industries regarding intellectual property assets, particularly patents. Third parties may claim infringement by us with respect to current and future products, trademarks or other proprietary rights, and we may counterclaim against such third parties in such actions. Any such claims or counterclaims could be time-consuming, result in costly litigation, divert management’s attention, cause product release delays, require us to redesign our products, restrict our use of the intellectual property subject to such claim, or require us to enter into royalty or licensing agreements, any of which could have a material adverse effect upon our business, financial condition and operating results. Such royalty and licensing agreements may not be available on terms acceptable to us, if at all.

We may be liable for infringing the intellectual property rights of others.

Our competitors may develop similar intellectual property, duplicate our products and/or services, or design around any patents or other intellectual property rights we hold. In the future, litigation may be necessary to enforce our intellectual property rights or to determine the validity and scope of the patents, intellectual property or other proprietary rights of third parties, which could be time consuming and costly and have an adverse effect on our business and financial condition. Intellectual property infringement claims could be made against us, especially as the number of our competitors grows. These claims, even if not meritorious, could be expensive and divert our attention from operating our company and result in a temporary inability to use the intellectual property subject to such claim. In addition, if we and/or our affiliates and customers become liable to third parties for infringing their intellectual property rights, we could be required to pay a substantial damage award and develop comparable non-infringing intellectual property, to obtain a license, or to cease providing the content or services that contain the infringing intellectual property. We may be unable to develop non-infringing intellectual property or obtain a license on commercially reasonable terms, if at all.

Item 1B. Unresolved Staff Comments

None.

Item 2. Properties

Our principal office is located in Nashville, Tennessee, which is primarily used to support our workforce development operations and corporate functions. Our lease for approximately 73,000 square feet at this location expires in April 2017. The lease provides for a two-year renewal option with rates increasing during the renewal period. We also lease other facilities in Laurel, Maryland; Nashville, Tennessee; Jericho, New York; Brentwood, Tennessee; San Diego, Colorado; Boulder, Colorado; and Pensacola, Florida. The facilities in Laurel, Maryland and Nashville, Tennessee are used to support our survey operations, while the other leased locations are satellite offices for acquired businesses.

Item 3. Legal Proceedings

None.

Item 4. Mine Safety Disclosures

Not applicable.

 

18


Table of Contents

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Our common stock is traded on the NASDAQ Global Select Market under the symbol “HSTM”. Our common stock began trading on the NASDAQ National Market on April 14, 2000.

The following table sets forth, for each quarter of the two most recent years, the high and low closing prices per share of our common stock as reported on the NASDAQ Global Select Market:

 

     Common Stock Price  
     2015      2014  
     High      Low      High      Low  

First Quarter

   $ 30.36       $ 24.63       $ 34.43       $ 26.49   

Second Quarter

     31.91         25.15         27.10         21.02   

Third Quarter

     32.14         21.60         27.14         21.80   

Fourth Quarter

     25.63         21.31         31.95         23.38   

As of February 17, 2016, the Company had a total of 8,086 shareholders, including 650 registered holders and 7,436 beneficial holders.

SHARE REPURCHASE PROGRAM

In February 2016, our Board of Directors authorized a share repurchase program for up to $25 million of our outstanding common stock. Repurchases will be made under the repurchase program in accordance with applicable securities laws and may be made at management’s discretion from time to time in the open market, through privately negotiated transactions, or otherwise. The share repurchase program will terminate on the earlier of December 31, 2016 or when the maximum dollar amount has been expended. The share repurchase program may be suspended or discontinued at any time.

DIVIDEND POLICY

We have never declared or paid any cash dividends on our common stock, and we do not anticipate paying cash dividends in the foreseeable future. We intend to retain earnings for use in the operation of our business.

See the table labeled “Securities Authorized for Issuance Under Equity Compensation Plans” to be contained in our 2016 Proxy Statement, incorporated by reference in Part III, Item 12 of this Annual Report on Form 10-K.

 

19


Table of Contents

STOCK PERFORMANCE GRAPH

The graph below compares HealthStream, Inc.’s cumulative total shareholder return on common stock with the cumulative total returns of companies on the NASDAQ Composite Index and the NASDAQ Computer & Data Processing Index for each of the last five fiscal years ended December 31, 2015, assuming an initial investment of $100. Data for the NASDAQ Composite Index and the NASDAQ Computer & Data Processing Index assume the reinvestment of dividends.

The comparisons in the graph below are based on historical data and are not necessarily indicative of future performance of our common stock.

COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN (1)

Among HealthStream, Inc., The NASDAQ Composite Index

And The NASDAQ Computer & Data Processing Index

 

LOGO

 

(1) $100 invested on 12/31/10 in stock or index, including reinvestment of dividends. Fiscal year ending December 31.

RECENT SALES OF UNREGISTERED SECURITIES

None.

ISSUER PURCHASES OF EQUITY SECURITIES

None.

 

20


Table of Contents

Item 6. Selected Financial Data

The selected statement of income and balance sheet data for the past five years are derived from our audited consolidated financial statements. You should read the following selected financial data in conjunction with our consolidated financial statements and the notes to those statements and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” located elsewhere in this report.

HealthStream acquired Decision Critical, Inc. on June 29, 2012, Sy.Med Development, Inc. on October 19, 2012, substantially all of the assets of BLG on September 9, 2013, HCCS on March 3, 2014 and HLS on March 16, 2015. The results of operations for these acquired companies are included within our consolidated statement of income data effective from the respective date of acquisition. Revenues may be subject to fluctuations as discussed further in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” located elsewhere in this report. As a result of these factors, the annual results presented below are not comparable. The operating results for any single year are not necessarily indicative of the results to be expected in the future.

 

     Year Ended December 31,  
     (in thousands, except per share data)  
     2015      2014      2013      2012      2011  

STATEMENT OF INCOME DATA:

              

Revenues, net

   $ 209,002       $ 170,690       $ 132,274       $ 103,732       $ 82,066   

Total operating costs and expenses

     195,445         154,315         117,608         90,273         70,728   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Operating income

     13,557         16,375         14,666         13,459         11,338   

Net income

   $ 8,621       $ 10,394       $ 8,418       $ 7,645       $ 6,944   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Net income per share – basic

   $ 0.29       $ 0.38       $ 0.31       $ 0.29       $ 0.31   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Net income per share – diluted

   $ 0.28       $ 0.37       $ 0.30       $ 0.28       $ 0.29   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Weighted average shares of common stock outstanding – basic

     30,057         27,570         26,853         26,128         22,445   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Weighted average shares of common stock outstanding – diluted

     30,436         28,023         27,663         27,507         23,748   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

BALANCE SHEET DATA:

              

Cash and cash equivalents

   $ 82,010       $ 81,995       $ 59,537       $ 41,365       $ 76,904   

Marketable securities – short and long term

     66,976         38,973         48,659         51,952         12,548   

Accounts receivable, net

     36,348         33,167         25,314         15,348         16,014   

Goodwill and intangible assets

     139,039         56,709         44,616         38,104         23,104   

Working capital

     120,459         97,352         90,912         83,259         78,631   

Total assets

     379,569         257,262         212,594         174,528         154,237   

Deferred revenue – current and noncurrent

     69,448         57,373         38,168         23,146         22,759   

Shareholders’ equity

     280,320         167,859         149,433         132,196         120,915   

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of the financial condition and results of operations of HealthStream should be read in conjunction with “Selected Financial Data” and HealthStream’s Consolidated Financial Statements and related notes thereto included elsewhere in this report. This discussion contains forward-looking statements that involve risks and uncertainties. HealthStream’s actual results may differ significantly from the results discussed and those anticipated in these forward-looking statements as a result of many factors, including but not limited to those described under “Risk Factors” and elsewhere in this report.

OVERVIEW

HealthStream provides workforce development, patient experience, and provider solutions for healthcare organizations—all designed to assess and develop the people that deliver patient care which, in turn, supports the improvement of business and clinical outcomes. Workforce development products are used by healthcare organizations to meet a broad range of their training, certification, competency assessment, performance appraisal, and development needs. Patient experience products provide our customers information about patients’ experiences and how to improve them, workforce engagement, physician relations, and community perceptions of their services. Provider products are used by healthcare organizations for provider credentialing, privileging, call center and enrollment needs. HealthStream’s customers include healthcare organizations, pharmaceutical and medical device companies, and other participants in the healthcare industry.

 

21


Table of Contents

Revenues for the year ended December 31, 2015 were approximately $209.0 million compared to $170.7 million for the year ended December 31, 2014, an increase of 22%. Operating income decreased by 17% to $13.6 million for 2015, compared to $16.4 million for 2014. Net income decreased by 17% to $8.6 million for 2015, compared to $10.4 million for 2014. Earnings per share (EPS) were $0.28 per share (diluted) for 2015 compared to $0.37 per share (diluted) for 2014. Revenues from HealthStream Workforce Solutions grew by 20%, or $27.0 million; revenues from HealthStream Patient Experience Solutions grew by 7%, or $2.3 million; and revenues from HealthStream Provider Solutions grew by 197%, or $9.0 million. As of December 31, 2015, the Company had approximately 4.62 million total subscribers, of which approximately 4.48 million were fully implemented subscribers on its SaaS-based platform. Annualized revenue per implemented subscriber increased to $36.96 per subscriber at the end of 2015, up from $34.43 per subscriber at the end of 2014, representing a 7% increase. As of December 31, 2015 cash and investment balances approximated $149.0 million, and the Company maintained full availability under its $50.0 million revolving credit facility.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Revenue Recognition

Revenues are recognized from subscription-based workforce development products and courseware subscriptions based on a per person subscription basis, and in some cases on a per license basis. Fees are based on the size of the facilities’ or organizations’ employee user population and the service offerings to which they subscribe. Subscription-based revenue is recognized ratably over the service period of the underlying contract. All other service revenues are recognized as the related services are performed or products are delivered.

Revenues from provider solutions products are predominantly related to software licensing and support/maintenance renewals. Revenues derived from the license of installed software products are recognized upon shipment or installation of the software when vendor specific objective evidence (VSOE) of fair value for the software license can be established. Software support and maintenance revenues are recognized ratably over the term of the related agreement.

Revenues from patient experience services are recognized when survey results are delivered to customers via either Internet-based reporting throughout the survey period or by providing final survey results once all services are complete. A significant portion of revenues for survey and reporting services that are provided through the use of Internet-based reporting methodologies are recognized using the proportional performance method, reflecting recognition throughout the service period which corresponds with the survey cycle and reporting access by the customer, which typically ranges from one to five months. If survey results are delivered to the customer after all services have been completed, then the corresponding revenues are recognized in full in the period such results are provided to the customer. Coaching and consulting revenues are generally recognized using the proportional performance method as these services are performed throughout the contract term. All other revenues are recognized as the related services are performed or products are delivered to the customer. Revenues for these services can be subject to seasonal factors based on customers’ requirements that can impact the timing, frequency, and volume of survey cycles.

Revenues from professional services primarily include consulting and courseware development services. Fees are based on the time and efforts involved, and revenue is recognized upon completion of performance milestones using the proportional performance method.

The Company offers training services for clients to facilitate integration of its software solutions. Fees for training are based on the time and efforts of the personnel involved. Basic online training is generally included in the initial contract; however, incremental training is fee based and revenues are generally recognized upon completion of training services.

Accounting for Income Taxes

The Company accounts for income taxes using the asset and liability method, whereby deferred tax assets and liabilities are determined based on the temporary differences between the financial statement and tax bases of assets and liabilities measured at tax rates that will be in effect for the year in which the differences are expected to affect taxable income. Management periodically assesses the realizability of its deferred tax assets, and to the extent that we believe a recovery is not likely, we establish a valuation allowance to reduce the deferred tax asset to the amount we estimate will be recoverable. The Company maintains a valuation allowance of approximately $346,000 for the portion of its deferred tax assets that are not more likely than not expected to be realized.

Software Development Costs

Capitalized software development includes costs to develop and maintain our products and applications, including our SaaS-based workforce development platform products and our survey reporting applications, which are accounted for as internal use software. For internal use software development, once planning is completed and the software development process begins, internal costs and payments to third parties associated with the software development efforts are capitalized when the life expectancy is greater than one year and the anticipated cash flows are expected to exceed the cost of the related asset. During 2015 and 2014, we capitalized approximately $7.3 million and $5.7 million, respectively, for software development. Such amounts are included in the accompanying consolidated balance sheets under the caption “capitalized software development.” The Company amortizes capitalized software development costs over their expected life, which is generally three to five years. Capitalized software development costs are subject to a periodic impairment review in accordance with our impairment review policy. In connection with capitalized software development, significant estimates involve the assessment of the development period for new products and feature enhancements, as well as the expected useful life of underlying software, feature enhancements, or product created. Once capitalized, software development costs are subject to the policies and estimates described below regarding goodwill, intangibles and other long-lived assets.

 

22


Table of Contents

Goodwill, Intangibles and Other Long-lived Assets

The Company evaluates goodwill for impairment at the reporting unit level by assessing whether it is more likely than not that the fair value of a reporting unit exceeds its carrying value. If this assessment concludes that is more likely than not that the fair value of a reporting unit exceeds its carrying value, then goodwill is not considered impaired and no further impairment testing is required. Conversely, if the assessment concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying value, a goodwill impairment test is performed to compare the fair value of the reporting unit to its carrying value. The Company determines fair value of the reporting units using both income and market based models. Our models contain significant assumptions and accounting estimates about discount rates, future cash flows and terminal values that could materially affect our operating results or financial position if they were to change significantly in the future and could result in an impairment. We perform our goodwill impairment assessment whenever events or changes in facts or circumstances indicate that impairment may exist and also during the fourth quarter each year. Intangible assets and other long-lived assets are also reviewed for events or changes in facts and circumstances, both internally and externally, which may indicate an impairment is present. We measure any impairment using observable market values or discounted future cash flows from the related long-lived assets. The cash flow estimates and discount rates incorporate management’s best estimates, using appropriate and customary assumptions and projections at the date of evaluation.

Allowance for Doubtful Accounts

The Company estimates the allowance for doubtful accounts using both a specific and non-specific identification method. Management’s evaluation includes reviewing past due accounts on a case-by-case basis, and determining whether an account should be reserved, based on the facts and circumstances surrounding each potentially uncollectible account. An allowance is also maintained for accounts not specifically identified that may become uncollectible in the future. Uncollectible accounts are written-off in the period management believes it has exhausted every opportunity to collect payment from the customer. Bad debt expense is recorded when events or circumstances indicate an additional allowance is necessary based on our specific and non-specific identification approach. Our allowance for doubtful accounts totaled approximately $303,000 as of December 31, 2015.

Stock Based Compensation

The Company recognizes compensation expense using a fair-value based method for costs related to share based payments including stock options and restricted share units. Measurement of such compensation expense requires significant estimation and assumptions; however, we believe that the Black Scholes option pricing model used for calculating the fair value of our stock based compensation plans provides a reasonable measurement methodology using a framework that is widely adopted.

As of December 31, 2015, the Company had two stock incentive plans which qualified as stock based compensation plans. During the years ended December 31, 2015, 2014, and 2013, approximately $3.3 million, $1.6 million, and $1.5 million of stock based compensation expense was recorded, respectively. The Company has historically granted equity based awards to both its management group and members of the Company’s board of directors on an annual basis, and expects to continue providing equity awards to these groups for the foreseeable future. The Company also provides grants of equity based awards when new members of the management group begin their employment, or when new board of director members join the Company. As of December 31, 2015, total future compensation cost related to non-vested awards not yet recognized was approximately $3.0 million net of estimated forfeitures, with a weighted average expense recognition period of 2.3 years. Future compensation expense recognition for new equity based award grants will vary depending on the timing and size of new awards granted, changes in the market price or volatility of our common stock, changes in risk-free interest rates, or if actual forfeitures vary significantly from initial estimates.

 

23


Table of Contents

RESULTS OF OPERATIONS

Revenues and Expense Components

The following descriptions of the components of revenues and expenses apply to the comparison of results of operations.

Revenues, net. Revenues for our HealthStream Workforce Solutions business segment primarily consist of the following products and services: provision of services through our SaaS-based platform, authoring tools, a variety of courseware subscriptions, competency and performance appraisal tools, implementation and consulting services, content development, online sales training courses (RepDirect™), HospitalDirect®, SimVentures, and a variety of other educational activities to serve professionals that work within healthcare organizations. Revenues for our HealthStream Patient Experience Solutions business segment consist of quality and satisfaction surveys, data analyses of survey results, coaching/consulting services, and other research-based measurement tools focused on patients, employees, physicians, and other members of the community. Revenues for our HealthStream Provider Solutions business segment consist of proprietary software applications to help facilitate provider credentialing, privileging, call center and enrollment administration for healthcare organizations.

Cost of Revenues (excluding depreciation and amortization). Cost of revenues (excluding depreciation and amortization) consists primarily of salaries and employee benefits, stock based compensation, employee travel and lodging, materials, outsourced phone survey support, contract labor, hosting costs, and other direct expenses associated with revenues, as well as royalties paid by us to content providers based on a percentage of revenues. Personnel costs within cost of revenues are associated with individuals that facilitate product delivery, provide services, conduct, process and manage phone and paper-based surveys, handle customer support calls or inquiries, manage the technology infrastructure for our hosted applications, manage content and survey services, coordinate content maintenance services, and provide training or implementation services.

Product Development. Product development consists primarily of salaries and employee benefits, contract labor, stock based compensation, costs associated with the development of new software feature enhancements, new products, and costs associated with maintaining and developing our platform products. Personnel costs within product development include our systems, application development, and quality assurance teams, product managers, and other personnel associated with software and product development.

Sales and Marketing. Sales and marketing consists primarily of salaries, commissions and employee benefits, stock based compensation, employee travel and lodging, advertising, trade shows, promotions, and related marketing costs. We host a national customer conference in Nashville, Tennessee known as “Summit,” a significant portion of the costs of which are included in sales and marketing expenses. Personnel costs within sales and marketing include our sales teams and marketing personnel.

Other General and Administrative Expenses. Other general and administrative expenses consist primarily of salaries and employee benefits, stock based compensation, employee travel and lodging, facility costs, office expenses, fees for professional services, business development and acquisition related costs, and other operational expenses. Personnel costs within general and administrative expenses include individuals associated with normal corporate functions (accounting, legal, business development, human resources, administrative, internal information systems, and executive management).

Depreciation and Amortization. Depreciation and amortization consist of fixed asset depreciation, amortization of intangibles considered to have definite lives, and amortization of capitalized software development.

Other Income (Expense), Net. The primary component of other income is interest income related to interest earned on cash, cash equivalents and investments in marketable securities. The primary component of other expense is interest expense related to our revolving credit facility. In addition, the income or loss attributed to equity method investments is included in this category.

2015 Compared to 2014

Revenues, net. Revenues increased approximately $38.3 million, or 22%, to $209.0 million for 2015 from $170.7 million for 2014. A comparison of revenues by business segment is as follows (in thousands):

 

     2015     2014     Percentage
Change
 

Revenues by Business Segment:

      

Workforce

   $ 161,289      $ 134,242        20

Patient Experience

     34,193        31,901        7

Provider

     13,520        4,547        197
  

 

 

   

 

 

   

 

 

 

Total revenues, net

   $ 209,002      $ 170,690        22
  

 

 

   

 

 

   

% of Revenues

      

Workforce

     77     79  

Patient Experience

     16     19  

Provider

     7     2  

 

24


Table of Contents

Revenues for HealthStream Workforce Solutions increased approximately $27.0 million, or 20%, over 2014. Revenues from our subscription-based workforce products increased by $26.0 million, or 20% over 2014 due to a higher number of subscribers and more courseware consumption by subscribers. Annualized revenue per implemented subscriber increased by 7%, to $36.96 per subscriber at the end of 2015 compared to $34.43 per subscriber at the end of 2014. Implemented subscribers increased by 9% during 2015 to 4.48 million subscribers at the end of 2015 compared to 4.15 million subscribers at the end of 2014. Additionally, total subscribers increased by 8%, with 4.62 million total subscribers at December 31, 2015 compared to 4.28 million total subscribers at December 31, 2014.

Revenues for HealthStream Patient Experience Solutions increased approximately $2.3 million, or 7%, over 2014. Revenues from Patient Insights™ surveys, our survey research product that generates recurring revenues, increased approximately $2.8 million, or 12%, over 2014, primarily due to growth in survey volumes over the prior year. Revenues from other products, including surveys conducted on annual or bi-annual cycles and consulting/coaching services, collectively decreased by $554,000 or 7%, compared to 2014 due to fewer engagements.

Revenues for HealthStream Provider Solutions increased approximately $9.0 million, or 197%, over 2014. Revenues from the HLS acquisition, which was consummated on March 16, 2015, were approximately $8.5 million during 2015. Such revenues take into account the deferred revenue reduction noted below. Revenues from other products increased by approximately $431,000, or 9% over 2014. Revenues for HealthStream Provider Solutions during 2015 were adversely impacted by a $6.7 million reduction resulting from the deferred revenue write-down associated with the HLS acquisition.

Cost of Revenues (excluding depreciation and amortization). Cost of revenues increased approximately $15.3 million, or 21%, to $89.4 million for 2015 from $74.1 million for 2014. Cost of revenues as a percentage of revenues was approximately 43% of revenues for both 2015 and 2014. Cost of revenues for HealthStream Workforce Solutions increased approximately $10.3 million to $63.5 million and approximated 39% and 40% of revenues for HealthStream Workforce Solutions for 2015 and 2014, respectively. The increase in both amount and as a percentage of revenues is primarily associated with increased royalties paid by us resulting from growth in courseware subscription revenues, as well as increases in personnel expenses, stock based compensation, and other support costs. Cost of revenues for HealthStream Patient Experience Solutions increased approximately $2.2 million to $22.4 million and approximated 65% and 63% of revenues for HealthStream Patient Experience Solutions for 2015 and 2014, respectively. The increase in both amount and as a percentage of revenues is primarily the result of increased personnel costs, including personnel to support the growth in patient survey volume over the prior year, and increased stock based compensation. Cost of revenues for HealthStream Provider Solutions increased approximately $2.8 million to $3.5 million, and approximated 26% and 16% of revenues for HealthStream Provider Solutions for 2015 and 2014, respectively. The increase in both amount and as a percentage of revenue is primarily the result of the HLS acquisition.

Product Development. Product development expenses increased approximately $7.8 million, or 47%, to $24.2 million for 2015 from $16.5 million for 2014. Product development expenses as a percentage of revenues were approximately 12% and 10% of revenues for 2015 and 2014, respectively.

Product development expenses for HealthStream Workforce Solutions increased approximately $4.8 million and approximated 12% and 11% of revenues for HealthStream Workforce for 2015 and 2014, respectively. The increase in both amount and as a percentage of revenues is due to additional personnel expenses associated with new product development initiatives for our subscription-based products, as well as increased stock based compensation. Product development expenses for HealthStream Patient Experience Solutions increased approximately $1.0 million and approximated 7% and 4% of revenues for HealthStream Patient Experience Solutions in 2015 and 2014, respectively. The increase in both amount and as a percentage of revenues is due to additional personnel and related expenses compared to the prior year period. Product development expenses for HealthStream Provider Solutions increased approximately $2.0 million and approximated 18% and 11% of revenues for HealthStream Provider Solutions for 2015 and 2014, respectively. The increase is in both amount and as a percentage of revenues is due primarily to the HLS acquisition.

Sales and Marketing. Sales and marketing expenses, including personnel costs, increased approximately $5.7 million, or 19%, to $35.6 million for 2015 from $29.9 million for 2014. Sales and marketing expenses as a percentage of revenues were approximately 17% and 18% of revenues for 2015 and 2014, respectively.

Sales and marketing expenses for HealthStream Workforce Solutions increased approximately $5.1 million and approximated 17% and 16% of revenues for HealthStream Workforce Solutions for 2015 and 2014, respectively. The increase in both amount and as a percentage of revenues is primarily due to additional personnel and related expenses, commissions, and expenses associated with our customer Summit, increased marketing spending, and increased stock based compensation. Sales and marketing expenses for HealthStream Patient Experience Solutions decreased approximately $1.7 million, and approximated 13% and 19% of revenues for HealthStream Patient Experience Solutions for 2015 and 2014, respectively. The decrease in amount and as a percentage of revenues is primarily due to fewer account management personnel compared to the prior year. Sales and marketing expenses for HealthStream Provider Solutions increased approximately $2.2 million and approximated 26% and 30% of revenues for HealthStream Provider Solutions for 2015 and 2014, respectively. The increase in amount is primarily due to the HLS acquisition.

 

25


Table of Contents

Other General and Administrative Expenses. Other general and administrative expenses increased approximately $6.4 million, or 28%, to $29.3 million for 2015 from $22.9 million for 2014. Other general and administrative expenses as a percentage of revenues were approximately 14% and 13% of revenues for 2015 and 2014, respectively.

Other general and administrative expenses for HealthStream Workforce Solutions increased approximately $253,000 over the prior year. The increase is primarily due to the HCCS acquisition, additional personnel, and increased other support costs. Other general and administrative expenses for HealthStream Patient Experience Solutions increased approximately $305,000 compared to the prior year period primarily due to increased facilities costs for a new patient interview center in Nashville, Tennessee. Other general and administrative expenses for HealthStream Provider Solutions increased approximately $2.1 million compared to the prior year period primarily due to the HLS acquisition. The unallocated corporate portion of other general and administrative expenses increased approximately $3.7 million over the prior year period, primarily associated with additional personnel, professional fees, stock based compensation, and other general expenses, as well as higher acquisition costs during 2015 than in 2014. Acquisition costs during 2015 approximated $1.1 million, of which $965,000 were associated with the HLS acquisition. Acquisition costs during 2014 approximated $762,000, of which $329,000 were associated with the HLS acquisition and $365,000 were associated with the HCCS acquisition.

Depreciation and Amortization. Depreciation and amortization increased approximately $6.1 million, or 55%, to $17.0 million for 2015 from $10.9 million for 2014. The increase primarily resulted from amortization of capitalized software development, amortization of intangible assets in relation to the acquisition of HLS, and depreciation expense associated with capital expenditures.

Other Income, Net. Other income, net was approximately $162,000 for 2015 compared to $146,000 for 2014. The increase is attributable to both interest income from investments in marketable securities and a gain on disposal of long lived assets, but was partially offset by higher interest expense from borrowings under a revolving credit facility during 2015 and losses from equity method investments.

Income Tax Provision. The Company recorded a provision for income taxes of approximately $5.1 million for 2015 compared to approximately $6.1 million for 2014. The Company’s effective tax rate was approximately 37% for both 2015 and 2014. The decrease in income tax expense during 2015 is attributable to lower taxable income compared to the prior year period.

Net Income. Net income decreased approximately $1.8 million, or 17%, to $8.6 million for 2015 from $10.4 million for 2014. Earnings per diluted share were $0.28 per share for 2015, compared to $0.37 per diluted share for 2014.

Adjusted EBITDA (a non-GAAP measure which we define as net income before interest, income taxes, stock-based compensation, and depreciation and amortization) increased by 17% to approximately $33.8 million for 2015 compared to $28.9 million for 2014. This improvement is consistent with the factors mentioned above. See Reconciliation of Non-GAAP Financial Measures in Management’s Discussion and Analysis of Financial Condition and Results of Operations for a reconciliation of this calculation to measures under US GAAP and disclosure regarding why we believe Adjusted EBITDA provides useful information to investors.

2014 Compared to 2013

Revenues, net. Revenues increased approximately $38.4 million, or 29%, to $170.7 million for 2014 from $132.3 million for 2013. A comparison of revenues by business segment is as follows (in thousands):

 

     2014     2013     Percentage
Change
 

Revenues by Business Segment:

      

Workforce

   $ 134,242      $ 99,963        34

Patient Experience

     31,901        28,454        12

Provider

     4,547        3,857        18
  

 

 

   

 

 

   

 

 

 

Total revenues, net

   $ 170,690      $ 132,274        29
  

 

 

   

 

 

   

% of Revenues

      

Workforce

     79     75  

Patient Experience

     19     22  

Provider

     2     3  

Revenues for HealthStream Workforce Solutions increased approximately $34.3 million, or 34%, over 2013. Revenues from our subscription-based workforce products increased by $34.3 million, or 36% over 2013 due to a higher number of subscribers and more courseware consumption by subscribers, as well as revenue associated with the HCCS acquisition. Annualized revenue per implemented subscriber increased by 6%, to $34.43 per subscriber at the end of 2014 compared to $32.41 per subscriber at the end of 2013. Implemented subscribers increased by 22% during 2014 to 4.15 million subscribers at the end of 2014 compared to 3.39 million subscribers at the end of 2013. Additionally, total subscribers increased by 15%, with 4.28 million total subscribers at December 31, 2014 compared to 3.71 million total subscribers at December 31, 2013. Revenues in 2014 were positively influenced by courseware subscriptions associated with, among other products, ICD-10 readiness training. Revenues from ICD-10 readiness training were approximately $28.4 million in 2014, compared to $13.9 million in 2013. Revenues from the HCCS acquisition, consummated on March 3, 2014, were approximately $4.8 million during 2014.

 

26


Table of Contents

Revenues for HealthStream Patient Experience Solutions increased approximately $3.4 million, or 12%, over 2013. Revenues from Patient Insights™ surveys, our survey research product that generates recurring revenues, increased by $1.8 million, or 8%, over 2013, primarily due to growth in survey volumes over the prior year. Revenues from other surveys, which are conducted on annual or bi-annual cycles, declined by $72,000, or 2%, compared to 2013. Revenues from the Baptist Leadership Group (BLG) acquisition, consummated on September 9, 2013, were $2.9 million in 2014 compared to $1.2 million in 2013.

Revenues for HealthStream Provider Solutions increased approximately $690,000, or 18%, over 2013. $565,000 of the increase was due to lower revenues in 2013 associated with the deferred revenue write-down of acquired balances from the Sy.Med acquisition, which was consummated in October 2012, and $125,000 of the increase was due to growth in sales during 2014.

Cost of Revenues (excluding depreciation and amortization). Cost of revenues increased approximately $18.5 million, or 33%, to $74.1 million for 2014 from $55.6 million for 2013. Cost of revenues as a percentage of revenues was 43% of revenues for 2014 compared to 42% of revenues for 2013. Cost of revenues for HealthStream Workforce Solutions increased approximately $14.4 million to $53.2 million and approximated 40% and 39% of revenues for HealthStream Workforce Solutions for 2014 and 2013, respectively. The increase in both amount and as a percentage of revenues is primarily associated with increased royalties paid by us resulting from growth in courseware subscription revenues and increased personnel expenses. Cost of revenues for HealthStream Patient Experience Solutions increased approximately $4.0 million to $20.2 million and approximated 63% and 57% of revenues for HealthStream Patient Experience Solutions for 2014 and 2013, respectively. The increase in both amount and as a percentage of revenues is primarily the result of increased personnel costs from the BLG acquisition as well as additional costs associated with the growth in patient survey volume over the prior year. Cost of revenues for HealthStream Provider Solutions increased approximately $111,000 to $738,000, and approximated 16% of revenues for HealthStream Provider Solutions for both 2014 and 2013.

Product Development. Product development expenses increased approximately $4.7 million, or 40%, to $16.5 million for 2014 from $11.8 million for 2013. Product development expenses as a percentage of revenues were approximately 10% and 9% of revenues for 2014 and 2013, respectively.

Product development expenses for HealthStream Workforce Solutions increased approximately $4.8 million and approximated 11% and 10% of revenues for HealthStream Workforce for 2014 and 2013, respectively. The increase in both amount and as a percentage of revenues is due to additional personnel expenses associated with new product development initiatives for our subscription-based products. Product development expenses for HealthStream Patient Experience Solutions decreased approximately $137,000 and approximated 4% and 5% of revenues for HealthStream Patient Experience Solutions in 2014 and 2013, respectively. The decrease in both amount and as a percentage of revenues is due to lower personnel expenses. Product development expenses for HealthStream Provider Solutions increased approximately $35,000 and approximated 11% and 12% of revenues for HealthStream Provider Solutions for 2014 and 2013, respectively.

Sales and Marketing. Sales and marketing expenses, including personnel costs, increased approximately $5.8 million, or 24%, to $29.9 million for 2014 from $24.1 million for 2013. Sales and marketing expenses as a percentage of revenues were approximately 18% of revenues for both 2014 and 2013.

Sales and marketing expenses for HealthStream Workforce Solutions increased approximately $4.6 million and approximated 16% and 17% of revenues for HealthStream Workforce Solutions for 2014 and 2013, respectively. The expense increase is primarily due to additional personnel and related expenses, increased commissions associated with higher sales performance compared to the prior year, and increased marketing spending. Sales and marketing expenses for HealthStream Patient Experience Solutions increased approximately $768,000, and approximated 19% of revenues for HealthStream Patient Experience Solutions for both 2014 and 2013. The increase in amount and as a percentage of revenues is primarily due to additional personnel associated with the BLG acquisition and increased commissions associated with higher sales performance compared to the prior year. Sales and marketing expenses for HealthStream Provider Solutions increased approximately $259,000 and approximated 30% and 28% of revenues for HealthStream Provider Solutions for 2014 and 2013, respectively. The increase is primarily due to additional personnel and related expenses and increased commissions.

Other General and Administrative Expenses. Other general and administrative expenses increased approximately $4.6 million, or 25%, to $22.9 million for 2014 from $18.3 million for 2013. Other general and administrative expenses as a percentage of revenues were approximately 13% and 14% of revenues for 2014 and 2013, respectively.

 

27


Table of Contents

Other general and administrative expenses for HealthStream Workforce Solutions increased approximately $1.3 million over the prior year period primarily due to the HCCS acquisition, additional personnel, and other support costs. Other general and administrative expenses for HealthStream Patient Experience Solutions increased approximately $543,000 compared to the prior year period primarily due to the BLG acquisition. Other general and administrative expenses for HealthStream Provider Solutions decreased approximately $265,000 compared to the prior year period primarily due to fewer personnel and related expenses. The unallocated corporate portion of other general and administrative expenses increased approximately $3.0 million over the prior year period, primarily associated with additional personnel, professional fees, rent, and other general expenses, as well as expenses associated with the acquisition of HCCS. During 2014, we incurred approximately $762,000 of costs associated with both the completed acquisition of HCCS and other costs for evaluating potential transactions as part of our business development initiatives.

Depreciation and Amortization. Depreciation and amortization increased approximately $3.1 million, or 39%, to $10.9 million for 2014 from $7.8 million for 2013. The increase primarily resulted from amortization of capitalized software development, amortization of intangible assets, and depreciation expense associated with capital expenditures, including leasehold improvements to our Nashville, Tennessee office space.

Other Income, Net. Other income, net was approximately $146,000 for 2014 compared to $176,000 for 2013. The decrease is attributable to losses from equity method investments.

Income Tax Provision. The Company recorded a provision for income taxes of approximately $6.1 million for 2014 compared to approximately $6.4 million for 2013. The Company’s effective tax rate was approximately 37% for 2014 compared to approximately 43% for 2013. The decrease in the effective tax rate resulted primarily from the recognition of approximately $1.2 million in tax benefits associated with research and development tax credits during 2014.

Net Income. Net income increased approximately $2.0 million, or 23%, to $10.4 million for 2014 from $8.4 million for 2013. Earnings per diluted share were $0.37 per share for 2014, compared to $0.30 per diluted share for 2013.

Adjusted EBITDA (a non-GAAP measure which we define as net income before interest, income taxes, stock-based compensation, and depreciation and amortization) increased by 21% to approximately $28.9 million for 2014 compared to $23.9 million for 2013. This improvement is consistent with the factors mentioned above. See Reconciliation of Non-GAAP Financial Measures in Management’s Discussion and Analysis of Financial Condition and Results of Operations for a reconciliation of this calculation to measures under US GAAP.

Reconciliation of Non-GAAP Financial Measures

This report contains certain non-GAAP financial measures, including non-GAAP net income, non-GAAP operating income, non-GAAP revenue and adjusted EBITDA, which are used by management in analyzing the Company’s financial results and ongoing operational performance. These non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance which are prepared in accordance with US GAAP and may be different from non-GAAP financial measures used by other companies.

In order to better assess the Company’s financial results, management believes that adjusted EBITDA is a useful measure for evaluating the operating performance of the Company because adjusted EBITDA reflects net income adjusted for certain non-cash and non-operating items. The Company believes that adjusted EBITDA is also used by many investors and securities analysts to assess the Company’s results from current operations. Adjusted EBITDA is a non-GAAP financial measure and should not be considered as a measure of financial performance under US GAAP. Because adjusted EBITDA is not a measurement determined in accordance with US GAAP, it is susceptible to varying calculations. Accordingly, adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies.

The Company understands that, although adjusted EBITDA is frequently used by investors and securities analysts in their evaluation of companies, this measure has limitations as an analytical tool, and should not be considered in isolation, or as a substitute for an analysis of the Company’s results as reported under US GAAP.

Management addresses these inherent limitations associated with using adjusted EBITDA through disclosure of such limitations, presentation of our financial statements in accordance with US GAAP, and reconciliation of adjusted EBITDA to net income, the most directly comparable US GAAP measure.

In recent years, the Company has acquired businesses whose net tangible assets include deferred revenue. In accordance with GAAP reporting requirements, following the completion of any such acquisition, the Company may record a write down of deferred revenue to fair value as defined in GAAP. If the Company is required to record a write-down of deferred revenue, it may result in lower recognized revenue, operating income, and net income in subsequent periods.

 

28


Table of Contents

As discussed elsewhere in this report, the Company completed the acquisitions of BLG in September 2013, HCCS in March 2014 and HLS in March 2015. In accordance with US GAAP reporting requirements for fair value, deferred revenue write-downs of $254,000 for BLG, $1.5 million for HCCS and $9.0 million for HLS have been recorded in periods following such acquisitions. These write-downs result in lower revenues than would have otherwise been recognized for such services.

In connection therewith, this report presents below non-GAAP revenues, non-GAAP operating income and non-GAAP net income, which in each such case reflects the corresponding GAAP figures adjusted to exclude the impact of the deferred revenue write-down associated with fair value accounting for acquired businesses as referenced above. Management believes that the presentation of these non-GAAP financial measures assists investors in understanding the Company’s performance between periods by excluding the impact of this deferred revenue write-down and provides a useful measure of the ongoing performance of the Company. Both on a quarterly and year-to-date basis, the revenue for the acquired business is deferred and typically recognized over a one-to-two year period following the completion of any particular acquisition, so our GAAP revenues for this one-to-two year period will not reflect the full amount of revenues that would have been reported if the acquired deferred revenue was not written down to fair value. A reconciliation of these non-GAAP financial measures to the corresponding GAAP measures is set forth below.

 

     2015      2014      2013  

GAAP net income

   $ 8,621       $ 10,394       $ 8,418   

Interest income

     (401      (265      (263

Interest expense

     188         56         51   

Income tax provision

     5,098         6,127         6,424   

Stock based compensation expense

     3,280         1,625         1,458   

Depreciation and amortization

     16,997         10,931         7,852   
  

 

 

    

 

 

    

 

 

 

Adjusted EBITDA

   $ 33,783       $ 28,868       $ 23,940   
  

 

 

    

 

 

    

 

 

 

GAAP revenues

   $ 209,002       $ 170,690       $ 132,274   

Adjustment for deferred revenue write-down

     6,822         1,465         839   
  

 

 

    

 

 

    

 

 

 

Non-GAAP revenues

   $ 215,824       $ 172,155       $ 133,113   
  

 

 

    

 

 

    

 

 

 

GAAP operating income

   $ 13,557       $ 16,375       $ 14,666   

Adjustment for deferred revenue write-down

     6,822         1,465         839   
  

 

 

    

 

 

    

 

 

 

Non-GAAP operating income

   $ 20,379       $ 17,840       $ 15,505   
  

 

 

    

 

 

    

 

 

 

GAAP net income

   $ 8,621       $ 10,394       $ 8,418   

Adjustment for deferred revenue write-down, net of tax

     4,287         921         476   
  

 

 

    

 

 

    

 

 

 

Non-GAAP net income

   $ 12,908       $ 11,315       $ 8,894   
  

 

 

    

 

 

    

 

 

 

FINANCIAL OUTLOOK FOR 2016

The Company provides projections and other forward-looking information in this “Financial Outlook for 2016” section within “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” This section contains many forward-looking statements, particularly relating to the Company’s future financial performance. These forward-looking statements are estimates based on information currently available to the Company, are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are subject to the precautionary statements set forth in the introduction in Part I of this Annual Report on Form 10-K and the risks and uncertainties described in Item 1A, Risk Factors and elsewhere in this document. Actual results are likely to differ, and in the past have differed, materially from those forecast by the Company, depending on the outcome of various factors, including, but not limited to, those set forth in Item 1A, Risk Factors.

For 2016, we anticipate that consolidated revenues will grow 8 to 12 percent as compared to 2015. We anticipate that revenue growth in our Workforce Solutions segment will be in the two to six percent range and approximately 8 to 12 percent in our Patient Experience Solutions segment. We anticipate our Provider Solutions segment’s revenue to grow 80 to 84 percent as compared to 2015.

Revenues from ICD-10 readiness training, which were approximately $26.8 million in 2015, are expected to decline by approximately $20 million in 2016 and are reflected in the above guidance range for Workforce Solutions.

We anticipate operating income for 2016 to increase between 10 and 14 percent as compared to 2015.

We anticipate that capital expenditures will be between $14 million and $16 million during 2016. We expect the annual effective income tax rate to range between 39 percent and 41 percent for 2016.

The aforementioned guidance does not include the impact from any acquisitions that we may complete during 2016.

 

29


Table of Contents

SELECTED QUARTERLY OPERATING RESULTS

The following tables set forth selected statements of income data for each of the four quarters in the periods ended December 31, 2015 and December 31, 2014, respectively. The information for each quarter has been prepared on the same basis as the audited statements included in other parts of this report and, in our opinion, includes all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of the results of operations for these periods. You should read this information in conjunction with HealthStream’s Consolidated Financial Statements and related notes thereto included elsewhere in this report. The operating results for any quarter are not necessarily indicative of the results to be expected in the future.

Revenues from our subscription-based products are recognized ratably over the subscription term. Survey and research revenues are impacted by seasonal factors resulting from the volume, timing, and frequency of survey cycles.

 

     Quarter Ended  
     March 31,
2015
     June 30,
2015
     September 30,
2015
     December 31,
2015
 
     (In thousands, except per share data)  

STATEMENT OF INCOME DATA:

           

Revenues, net

   $ 47,156       $ 52,145       $ 53,835       $ 55,866   

Total operating costs and expenses

     42,366         49,581         49,510         53,988   
  

 

 

    

 

 

    

 

 

    

 

 

 

Income from operations

     4,790         2,564         4,325         1,878   

Net income

   $ 2,722       $ 1,473       $ 2,614       $ 1,811   
  

 

 

    

 

 

    

 

 

    

 

 

 

Net income per share (1):

           

Basic

   $ 0.10       $ 0.05       $ 0.08       $ 0.06   
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted

   $ 0.10       $ 0.05       $ 0.08       $ 0.06   
  

 

 

    

 

 

    

 

 

    

 

 

 

Weighted average shares of common stock outstanding:

           

Basic

     27,703         29,234         31,643         31,646   
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted

     28,068         29,617         32,029         32,031   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

     Quarter Ended  
     March 31,
2014
     June 30,
2014
     September 30,
2014
     December 31,
2014
 
     (In thousands, except per share data)  

STATEMENT OF INCOME DATA:

           

Revenues, net

   $ 38,350       $ 42,476       $ 44,525       $ 45,339   

Total operating costs and expenses

     35,052         38,366         39,784         41,113   
  

 

 

    

 

 

    

 

 

    

 

 

 

Income from operations

     3,298         4,110         4,741         4,226   

Net income

   $ 1,947       $ 2,364       $ 3,436       $ 2,647   
  

 

 

    

 

 

    

 

 

    

 

 

 

Net income per share (1):

           

Basic

   $ 0.07       $ 0.09       $ 0.12       $ 0.10   
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted

   $ 0.07       $ 0.08       $ 0.12       $ 0.09   
  

 

 

    

 

 

    

 

 

    

 

 

 

Weighted average shares of common stock outstanding:

           

Basic

     27,453         27,567         27,605         27,655   
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted

     27,906         28,044         28,047         28,095   
  

 

 

    

 

 

    

 

 

    

 

 

 

(1) – Due to the nature of interim earnings per share calculations, the sum of quarterly earnings per share amounts may not equal the reported earnings per share for the full year.

Liquidity and Capital Resources

Net cash provided by operating activities increased by $660,000, or 2%, to $34.9 million during 2015 from $34.3 million during 2014. The primary sources of cash were generated from receipts from the sales of our products and services. The number of days sales outstanding (DSO) was 61 days for 2015 and 63 days for 2014. The Company calculates DSO by dividing the average accounts receivable balance (excluding unbilled and other receivables) by average daily revenues for the year. The primary uses of cash to fund our operations include personnel expenses, sales commissions, royalty payments, payments for contract labor and other direct expenses associated with delivery of our products and services, and general corporate expenses.

Net cash used in investing activities was approximately $134.9 million during 2015 and $15.5 million during 2014. During 2015, the Company purchased $84.2 million of marketable securities, utilized $88.1 million (net of cash acquired) for business combinations, spent $7.3 million for capitalized software development, purchased $8.1 million of property and equipment, and made $2.0 million in non-marketable equity investments. These uses of cash were partially offset by maturities of marketable securities of $54.8 million. During 2014, the Company purchased $44.3 million of marketable securities, utilized $12.3 million (net of cash acquired) for business combinations, spent $5.7 million for capitalized software development, purchased $4.5 million of property and equipment, and made $1.3 million in non-marketable equity investments. These uses of cash were partially offset by maturities of marketable securities of $52.6 million.

 

30


Table of Contents

Cash provided by financing activities was approximately $100.0 million during 2015 and $3.7 million during 2014. The primary sources of cash from financing activities for 2015 resulted from $98.0 million in proceeds from the issuance of 3.9 million shares of our common stock in our underwritten public offering that was completed on May 28, 2015, $3.0 million of excess tax benefits from equity awards, and $328,000 of proceeds from the exercise of employee stock options. The primary uses of cash during 2015 related to payments of payroll taxes from stock based compensation arrangements of $756,000 and earn-outs for prior business combinations of $633,000. During 2014 the primary source of cash from financing activities resulted from $1.1 million of proceeds from the exercise of employee stock options and $3.2 million of excess tax benefits from equity awards. The primary uses of cash during 2014 resulted from $424,000 for payments of earn-outs from prior business combinations and $161,000 for payments of payroll taxes from stock based compensation arrangements.

Revenues increased over the prior year, and our balance sheet reflects positive working capital of $120.4 million at December 31, 2015 compared to $97.4 million at December 31, 2014. The increase in working capital primarily resulted from increases in investment balances. At December 31, 2015, the Company’s primary source of liquidity was $149.0 million of cash and cash equivalents and marketable securities. The Company also has a $50.0 million revolving credit facility loan agreement, all of which was available at December 31, 2015.

We believe that our existing cash and cash equivalents, marketable securities, cash generated from operations, and available borrowings under our revolving credit facility will be sufficient to meet anticipated working capital needs, new product development and capital expenditures for at least the next 12 months. Over the past ten years, the Company utilized federal and state net operating loss carryforwards to offset taxable income, therefore reducing its income tax liabilities. The federal net operating loss carryforwards have been fully utilized as of December 31, 2015; therefore, actual income tax payments are expected to increase significantly in the future and will more closely approximate the provision for income taxes.

The Company’s growth strategy includes acquiring businesses that provide complementary product and services. It is anticipated that future acquisitions, if any, would be effected through cash consideration, stock consideration, or a combination of both. The issuance of our stock as consideration for an acquisition or to raise additional capital could have a dilutive effect on earnings per share and could adversely affect our stock price. The revolving credit facility contains financial covenants and availability calculations designed to set a maximum leverage ratio of outstanding debt to adjusted EBITDA and an interest coverage ratio of adjusted EBITDA to interest expense. Therefore, the maximum borrowings against the revolving credit facility would be dependent on the covenant values at the time of borrowing. As of December 31, 2015, the Company was in material compliance with all covenants. There can be no assurance that amounts available for borrowing under our revolving credit facility will be sufficient to consummate any possible acquisitions, and we cannot assure you that if we need additional financing that it will be available on terms favorable to us, or at all. Failure to generate sufficient cash flow from operations or raise additional capital when required in sufficient amounts and on terms acceptable to us could harm our business, financial condition and results of operations.

Off-Balance Sheet Arrangements and Contractual Obligations

The Company’s off-balance sheet arrangements primarily consist of operating leases, contractual obligations, and our revolving credit facility, which is described further in Note 14 to the Company’s consolidated financial statements contained elsewhere in this report.

The following table presents a summary of future anticipated payments due by the Company under contractual obligations with firm minimum commitments as of December 31, 2015, excluding amounts already recorded in the consolidated balance sheets (in thousands):

 

     Payments due by period  
     Less than
1 year
     1-3 years      3-5 years      More than
5 years
     Total  

Operating leases

   $ 3,876       $ 3,990       $ 1,618       $ 2,604       $ 12,088   

Purchase obligations

     597         1,001         —           —           1,598   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 4,473       $ 4,991       $ 1,618       $ 2,604       $ 13,686   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific revenue recognition guidance throughout the Industry Topics of the Accounting Standards Codification. The updated guidance states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also provides for additional disclosures with respect to revenues and cash flows arising from contracts with customers. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2017, and early adoption is permitted for the first interim period within annual reporting periods beginning after December 15, 2016. The Company is currently reviewing this standard to determine the method of adoption and to assess the impact on its future consolidated financial statements.

 

31


Table of Contents

Item 7A. Quantitative and Qualitative Disclosures about Market Risk

The Company is exposed to market risk from changes in interest rates. We do not have any foreign currency exchange rate risk or commodity price risk. As of December 31, 2015, the Company had no outstanding debt. We may become subject to interest rate market risk associated with any future borrowings under our revolving credit facility. The interest rate under the revolving credit facility varies depending on the interest rate option selected by the Company plus a margin determined in accordance with a pricing grid. We are exposed to market risk with respect to our cash and investment balances, which approximated $149.0 million at December 31, 2015. Assuming a hypothetical 10% decrease in interest rates, interest income from cash and investments would decrease on an annualized basis by approximately $90,000.

The Company’s investment policy and strategy is focused on investing in highly rated securities, with the objective of minimizing the potential risk of principal loss. The Company’s policy limits the amount of credit exposure to any single issuer and sets limits on the average portfolio maturity.

The above market risk discussion and the estimated amounts presented are forward-looking statements of market risk assuming the occurrence of certain adverse market conditions. Actual results in the future may differ materially from those projected as a result of actual developments in the market.

 

32


Table of Contents

Item 8. Financial Statements and Supplementary Data

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

     Page

Reports of Independent Registered Public Accounting Firm

   34

Consolidated Balance Sheets

   36

Consolidated Statements of Income

   37

Consolidated Statements of Comprehensive Income

   38

Consolidated Statements of Shareholders’ Equity

   39

Consolidated Statements of Cash Flows

   40

Notes to Consolidated Financial Statements

   41

 

33


Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Board of Directors and Shareholders of

HealthStream, Inc.

We have audited the accompanying consolidated balance sheets of HealthStream, Inc. as of December 31, 2015 and 2014, and the related consolidated statements of income, comprehensive income, shareholders’ equity, and cash flows for each of the three years in the period ended December 31, 2015. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of HealthStream, Inc. at December 31, 2015 and 2014, and the consolidated results of its operations and its cash flows for each of the three years in the period ended December 31, 2015, in conformity with U.S. generally accepted accounting principles.

As discussed in Note 1 to the consolidated financial statements, the Company changed the classification of all deferred tax assets and liabilities to noncurrent on the December 31, 2015 balance sheet as a result of the adoption of the amendments to the FASB Accounting Standards Codification resulting from Accounting Standards Update No. 2015-17, Balance Sheet Classification of Deferred Taxes, effective December 31, 2015.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), HealthStream, Inc.’s internal control over financial reporting as of December 31, 2015, based on criteria established in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 26, 2016 expressed an unqualified opinion thereon.

 

/s/ Ernst & Young LLP

Nashville, Tennessee

February 26, 2016

 

34


Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Board of Directors and Shareholders of

HealthStream, Inc.

We have audited HealthStream, Inc.’s internal control over financial reporting as of December 31, 2015, based on criteria established in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). HealthStream, Inc.’s management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, HealthStream, Inc. maintained, in all material respects, effective internal control over financial reporting as of December 31, 2015, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the 2015 consolidated financial statements of HealthStream, Inc. and our report dated February 26, 2016 expressed an unqualified opinion thereon.

 

/s/ Ernst & Young LLP

Nashville, Tennessee

February 26, 2016

 

35


Table of Contents

HEALTHSTREAM, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands)

 

     December 31,
2015
    December 31,
2014
 
ASSETS     

Current assets:

    

Cash and cash equivalents

   $ 82,010      $ 81,995   

Marketable securities

     66,976        38,973   

Accounts receivable, net of allowance for doubtful accounts of $303 and $331 at December 31, 2015 and 2014, respectively

     36,348        33,167   

Accounts receivable - unbilled

     1,998        1,678   

Prepaid royalties, net of amortization

     14,036        13,030   

Other prepaid expenses and other current assets

     8,169        5,768   
  

 

 

   

 

 

 

Total current assets

     209,537        174,611   

Property and equipment, net

     12,471        9,442   

Capitalized software development, net of accumulated amortization of $24,130 and $18,114 at December 31, 2015 and 2014, respectively

     13,955        12,706   

Goodwill

     83,073        41,914   

Intangible assets, net of accumulated amortization of $8,685 and $13,834 at December 31, 2015 and 2014, respectively

     55,966        14,795   

Non-marketable equity investments

     3,640        1,757   

Other assets

     927        2,037   
  

 

 

   

 

 

 

Total assets

   $ 379,569      $ 257,262   
  

 

 

   

 

 

 
LIABILITIES AND SHAREHOLDERS’ EQUITY     

Current liabilities:

    

Accounts payable

   $ 4,616      $ 4,753   

Accrued royalties

     9,053        9,255   

Accrued liabilities

     7,003        7,224   

Accrued compensation and related expenses

     3,308        2,311   

Deferred revenue

     65,098        53,716   
  

 

 

   

 

 

 

Total current liabilities

     89,078        77,259   

Deferred tax liabilities

     4,763        5,838   

Deferred revenue, noncurrent

     4,350        3,657   

Other long term liabilities

     1,058        2,649   

Commitments and contingencies

     —          —     

Shareholders’ equity:

    

Common stock, no par value, 75,000 shares authorized; 31,647 and 27,677 shares issued and outstanding at December 31, 2015 and 2014, respectively

     278,799        174,926   

Retained earnings (accumulated deficit)

     1,591        (7,030

Accumulated other comprehensive loss

     (70     (37
  

 

 

   

 

 

 

Total shareholders’ equity

     280,320        167,859   
  

 

 

   

 

 

 

Total liabilities and shareholders’ equity

   $ 379,569      $ 257,262   
  

 

 

   

 

 

 

See accompanying notes to the consolidated financial statements.

 

36


Table of Contents

HEALTHSTREAM, INC.

CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except per share data)

 

     For the Year Ended December 31,  
     2015      2014      2013  

Revenues, net

   $ 209,002       $ 170,690       $ 132,274   

Operating costs and expenses:

        

Cost of revenues (excluding depreciation and amortization)

     89,386         74,145         55,605   

Product development

     24,214         16,463         11,757   

Sales and marketing

     35,589         29,867         24,052   

Other general and administrative expenses

     29,259         22,909         18,342   

Depreciation and amortization

     16,997         10,931         7,852   
  

 

 

    

 

 

    

 

 

 

Total operating costs and expenses

     195,445         154,315         117,608   

Operating income

     13,557         16,375         14,666   

Other income, net

     162         146         176   
  

 

 

    

 

 

    

 

 

 

Income before income tax provision

     13,719         16,521         14,842   

Income tax provision

     5,098         6,127         6,424   
  

 

 

    

 

 

    

 

 

 

Net income

   $ 8,621       $ 10,394       $ 8,418   
  

 

 

    

 

 

    

 

 

 

Net income per share:

        

Basic

   $ 0.29       $ 0.38       $ 0.31   
  

 

 

    

 

 

    

 

 

 

Diluted

   $ 0.28       $ 0.37       $ 0.30   
  

 

 

    

 

 

    

 

 

 

Weighted average shares of common stock outstanding:

        

Basic

     30,057         27,570         26,853   
  

 

 

    

 

 

    

 

 

 

Diluted

     30,436         28,023         27,663   
  

 

 

    

 

 

    

 

 

 

See accompanying notes to the consolidated financial statements.

 

37


Table of Contents

HEALTHSTREAM, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands)

 

     For the Year Ended December 31,  
     2015     2014     2013  

Net income

   $ 8,621      $ 10,394      $ 8,418   

Other comprehensive income, net of taxes:

      

Unrealized loss on marketable securities

     (33     (6     (49
  

 

 

   

 

 

   

 

 

 

Total other comprehensive loss

     (33     (6     (49

Comprehensive income

   $ 8,588      $ 10,388      $ 8,369   
  

 

 

   

 

 

   

 

 

 

See accompanying notes to the consolidated financial statements.

 

38


Table of Contents

HEALTHSTREAM, INC.

CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(In thousands)

 

                 Retained     Accumulated        
                 Earnings     Other     Total  
     Common Stock     (Accumulated     Comprehensive     Shareholders’  
     Shares     Amount     Deficit)     Income (Loss)     Equity  

Balance at December 31, 2012

     26,233      $ 158,020      $ (25,842   $ 18      $ 132,196   

Net income

     —          —          8,418        —          8,418   

Comprehensive loss

     —          —          —          (49     (49

Issuance of common stock in acquisition

     15        534        —          —          534   

Stock based compensation

     —          1,458        —          —          1,458   

Tax benefits from equity awards

     —          3,722        —          —          3,722   

Common stock issued under stock plans, net of shares withheld for employee taxes

     1,079        3,154        —          —          3,154   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance at December 31, 2013

     27,327        166,888        (17,424     (31     149,433   

Net income

     —          —          10,394        —          10,394   

Comprehensive loss

     —          —          —          (6     (6

Issuance of common stock in acquisition

     82        2,246        —          —          2,246   

Stock based compensation

     —          1,625        —          —          1,625   

Tax benefits from equity awards

     —          3,234        —          —          3,234   

Common stock issued under stock plans, net of shares withheld for employee taxes

     268        933        —          —          933   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance at December 31, 2014

     27,677        174,926        (7,030     (37     167,859   

Net income

     —          —          8,621        —          8,621   

Comprehensive loss

     —          —          —          (33     (33

Issuance of common stock

     3,870        98,014        —          —          98,014   

Stock donated to Company

     (54     —          —          —          —     

Stock based compensation

     —          3,280        —          —          3,280   

Tax benefits from equity awards

     —          3,008        —          —          3,008   

Common stock issued under stock plans, net of shares withheld for employee taxes

     154        (429     —          —          (429
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance at December 31, 2015

     31,647      $ 278,799      $ 1,591      $ (70   $ 280,320   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

See accompanying notes to the consolidated financial statements.

 

39


Table of Contents

HEALTHSTREAM, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

 

     For the Year Ended December 31,  
     2015     2014     2013  

OPERATING ACTIVITIES:

      

Net income

   $ 8,621      $ 10,394      $ 8,418   

Adjustments to reconcile net income to net cash provided by operating activities:

      

Depreciation and amortization

     16,997        10,931        7,852   

Deferred income taxes

     392        1,324        2,506   

Stock based compensation expense

     3,280        1,625        1,458   

Excess tax benefits from equity awards

     (3,008     (3,234     (3,722

Provision for doubtful accounts

     284        237        115   

Loss on non-marketable equity investments

     117        65        37   

Gain on sale of long-lived assets

     (72     —          —     

Other

     1,401        1,394        1,660   

Changes in assets and liabilities, net of business combinations:

      

Accounts and unbilled receivables

     (736     (6,690     (10,056

Prepaid royalties

     (1,006     (4,174     (5,119

Other prepaid expenses and other current assets

     (1,372     (2,022     (1,207

Other assets

     1,110        (1,761     105   

Accounts payable

     (137     2,442        1,254   

Accrued royalties

     (202     820        3,399   

Accrued liabilities, accrued compensation and related expenses, and other long-term liabilities

     3,075        5,434        5,593   

Deferred revenue

     6,173        17,471        14,761   
  

 

 

   

 

 

   

 

 

 

Net cash provided by operating activities

     34,917        34,256        27,054   
  

 

 

   

 

 

   

 

 

 

INVESTING ACTIVITIES:

      

Business combinations, net of cash acquired

     (88,075     (12,298     (7,560

Proceeds from sales of marketable securities

     —          —          5,062   

Proceeds from maturities of marketable securities

     54,799        52,625        82,661   

Purchases of marketable securities

     (84,228     (44,341     (86,139

Payments to acquire equity method investments

     (1,000     (325     (300

Payments to acquire cost method investments

     (1,000     (1,000     —     

Payments associated with capitalized software development

     (7,265     (5,658     (4,267

Purchases of property and equipment

     (8,094     (4,544     (4,444
  

 

 

   

 

 

   

 

 

 

Net cash used in investing activities

     (134,863     (15,541     (14,987
  

 

 

   

 

 

   

 

 

 

FINANCING ACTIVITIES:

      

Proceeds from issuance of common stock

     98,014        —          —     

Proceeds from exercise of stock options

     328        1,094        3,318   

Proceeds from borrowings under revolving line of credit facility

     28,000        —          —     

Repayments under revolving line of credit facility

     (28,000     —          —     

Taxes paid related to net settlement of equity awards

     (756     (161     (164

Excess tax benefits from equity awards

     3,008        3,234        3,722   

Payment of earn-outs related to business combinations

     (633     (424     (771
  

 

 

   

 

 

   

 

 

 

Net cash provided by financing activities

     99,961        3,743        6,105   
  

 

 

   

 

 

   

 

 

 

Net increase in cash and cash equivalents

     15        22,458        18,172   

Cash and cash equivalents at beginning of year

     81,995        59,537        41,365   
  

 

 

   

 

 

   

 

 

 

Cash and cash equivalents at end of year

   $ 82,010      $ 81,995      $ 59,537   
  

 

 

   

 

 

   

 

 

 

SUPPLEMENTAL CASH FLOW INFORMATION:

      

Interest paid

   $ 190      $ 56      $ 51   
  

 

 

   

 

 

   

 

 

 

Income taxes paid

   $ 2,648      $ 1,641      $ 371   
  

 

 

   

 

 

   

 

 

 

NON-CASH INVESTING AND FINANCING ACTIVITIES:

      

Receivable from sale of long-lived assets

   $ 975        —          —     
  

 

 

   

 

 

   

 

 

 

Issuance of common stock in connection with business combinations

   $ —        $ 2,246      $ 534   
  

 

 

   

 

 

   

 

 

 

See accompanying notes to the consolidated financial statements.

 

40


Table of Contents

HEALTHSTREAM, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Reporting Entity and Segments

HealthStream, Inc. (the “Company”) was incorporated in 1990 as a Tennessee corporation and is headquartered in Nashville, Tennessee. The Company operates in three segments: HealthStream Workforce Solutions, HealthStream Patient Experience Solutions, and HealthStream Provider Solutions. Workforce Solutions products consist of SaaS-based services and subscription-based solutions to meet the ongoing training, certification, assessment and development needs of the healthcare community. These solutions provide, deliver and track computer based education for our customers in the United States through our software-as-a-service (SaaS) model. Patient Experience products offer healthcare organizations a wide range of quality and satisfaction surveys, consulting services, analyses of survey results, and other research-based services. Provider Solutions products offer healthcare organizations software applications for administering and tracking provider credentialing, privileging, call center and enrollment.

Change in Goodwill Impairment Testing Date

During the quarter ended December 31, 2015, the Company voluntarily changed its annual goodwill impairment testing date from December 31 to October 1 of each year. This change provides additional time for the completion of the annual goodwill impairment testing prior to the end of the annual reporting period and results in further alignment with the Company’s annual strategic planning process. Accordingly, management considers this accounting change preferable. The Company is unable to objectively determine, without the use of hindsight, the assumptions that would have been used in earlier periods. Therefore, the change will be applied prospectively as retrospective application to prior periods is deemed impracticable. This change does not result in the delay, acceleration or avoidance of any potential impairment charge.

Recently Adopted Accounting Standards

The Company has adopted the provisions of Accounting Standards Update (ASU) 2015-17 — Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes, which serves to simplify the balance sheet presentation of deferred taxes. In connection with the adoption of ASU 2015-17, the Company has elected prospective application; therefore, all deferred tax assets and liabilities as of December 31, 2015 are presented as noncurrent in the accompanying consolidated balance sheet.

Recognition of Revenue

Revenues are derived from providing services through our SaaS-based workforce development platform products, courseware subscriptions, provision of survey and research services, sales of software licensing arrangements, software maintenance and support, professional services, custom courseware development and other education and training services.

The Company recognizes revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when persuasive evidence of an arrangement exists, prices are fixed or determinable, services and products are provided to the customer and collectability is probable or reasonably assured.

Revenue recognized from software and other arrangements is allocated to each element of the arrangement based on the relative fair values of the elements. While elements include software products and post contract customer support, the fair value of each element is based on vendor specific objective evidence (VSOE). If fair value cannot be determined for each element of the arrangement, all revenue from the arrangement is deferred until fair value can be determined or until all elements of the arrangement are delivered and customer acceptance has occurred. Sales of the Company’s SaaS-based workforce development platform products include customer support, implementation services, and training; therefore all revenues are deferred until the SaaS-based product is implemented, at which time revenues are recognized ratably over the subscription service period. In the event that circumstances occur, which give rise to uncertainty regarding the collectibility of contracted amounts, revenue recognition is suspended until such uncertainty is resolved. Fees for these services are billed on either a monthly, quarterly, or annual basis.

Revenues derived from the delivery of services through the Company’s SaaS-based workforce development platform products and courseware subscriptions are recognized ratably over the term of the subscription service agreement or over the historical usage period, if usage typically differs from the subscription period. Other training revenues are generally recognized upon the completion of training.

Revenues derived from the license of installed software products are recognized upon shipment or installation of the software, when VSOE of the fair value of the software license can be established. Software support and maintenance revenues are recognized ratably over the term of the related agreement.

 

41


Table of Contents

HEALTHSTREAM, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

Revenues recognized from the Company’s survey and research services are determined using both the proportional performance method and the completed contract method. Revenues are generally earned over the estimated survey cycle, which typically ranges from less than one month to up to five months. The survey cycle is generally initiated based on the receipt of the first survey response and runs through provision of related survey reports to the customer. If survey results are not available to the customer during the survey fielding cycle, revenues are recognized at time of report delivery. Revenues for coaching and consulting engagements are recognized using the proportional performance method over the term of the underlying contract. Fees for survey services are billed upon initiation of the survey cycle, with progress billings made throughout the survey cycle. Fees for coaching and consulting engagements are billed upon initiation of the engagement with progress billings throughout the term of the contract.

Revenues from professional services and courseware development services are recognized upon the completion of performance milestones and deliverables using the proportional performance method. All other revenues are recognized as the related services are performed or products are delivered. Fees for these services are generally billed at project initiation and upon completion of various milestones.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its subsidiaries, all of which are wholly-owned. All inter-company accounts and transactions have been eliminated in consolidation.

Use of Estimates

The consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles. These accounting principles require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates and such differences could be material to the consolidated financial statements.

Cash Equivalents

The Company considers cash equivalents to be unrestricted, highly liquid investments with initial maturities of less than three months.

Marketable Securities

Marketable securities are classified as available for sale and are stated at fair market value, with the unrealized gains and losses, net of tax, reported in other comprehensive income (loss) on the accompanying consolidated balance sheets. Realized gains and losses and declines in market value judged to be other than temporary on investments in marketable securities are included in interest and other income on the accompanying consolidated statements of income. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available for sale are included in other income (expense) on the accompanying consolidated statements of income. Premiums and discounts are amortized over the life of the related available for sale security as an adjustment to yield using the effective interest method.

Accounts Receivable-Unbilled

Accounts receivable-unbilled represents the following: 1) revenue earned and recognized on contracts accounted for using the proportional performance method for which invoices have not been generated or contractual billing dates have not been reached; and 2) the difference between billings for contracts containing escalated pricing over the term of the agreement and the recognition of revenue ratably over the subscription period.

Deferred Revenue

Deferred revenue represents amounts that have been billed or collected in advance of revenue recognition. The Company typically invoices customers in quarterly, bi-annual, or annual installments, and occasionally customers will pay for multi-year contracts in advance. Deferred revenue is recognized as the revenue recognition criteria are met.

Prepaid Royalties

Prepaid royalties represents advance payments associated with the sale of third party products, such as courseware subscriptions. Royalties are typically paid in advance at the commencement of the revenue cycle, or periodically throughout the revenue cycle, such as quarterly, bi-annual, or annual installments. Royalty payments are amortized over the term of the underlying contracts, which generally range from 12 to 36 months, in order to match the direct royalty costs to the same period the subscription revenue is recognized. Amortization of royalties is included under the caption “cost of revenues (excluding depreciation and amortization)” in the accompanying consolidated statements of income.

 

42


Table of Contents

HEALTHSTREAM, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

Allowance for Doubtful Accounts

The Company estimates its allowance for doubtful accounts using a specific identification method in which management considers the facts and circumstances surrounding each potentially uncollectible receivable. An allowance is also maintained for accounts that are not specifically identified that may become uncollectible in the future. Uncollectible receivables are written-off in the period management believes it has exhausted every opportunity to collect payment from the customer. Bad debt expense is recorded when events or circumstances indicate an additional allowance is required based on the Company’s specific identification approach.

Changes in the allowance for doubtful accounts and the amounts charged to bad debt expense for the years ended December 31, were as follows (in thousands):

 

     Allowance Balance at
Beginning of Period
     Charged to Costs and
Expenses
     Write-offs      Allowance Balance at
End of Period
 

2015

   $ 331       $ 284       $ (312    $ 303   

2014

   $ 211       $ 237       $ (117    $ 331   

2013

   $ 142       $ 115       $ (46    $ 211   

Capitalized Software Development

Capitalized software development is stated on the basis of cost, and is presented net of accumulated amortization. The Company capitalizes costs incurred during the software development phase for projects when such costs are material. These assets are amortized using the straight-line method, generally ranging between three to five years. The Company capitalized approximately $7.3 million and $5.7 million during 2015 and 2014, respectively. Amortization of capitalized software development was approximately $6.2 million and $4.3 million during 2015 and 2014, respectively. Maintenance and operating costs are expensed as incurred. As of December 31, 2015 and 2014, there were no capitalized internal development costs for computer software developed for resale.

Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes the inputs to valuation techniques used in measuring fair value. There are three levels to the fair value hierarchy based on the reliability of inputs, as follows:

 

Level 1      Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
Level 2      Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly.
Level 3      Unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions.

The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period. This determination requires significant judgments to be made by the Company. At December 31, 2015 and 2014, our assets measured at fair value on a recurring basis consisted of marketable securities, which are classified as available for sale (see Note 4 – Marketable Securities). The Company did not have any financial liabilities that were subject to fair value measurements as of such dates.

Property and Equipment

Property and equipment are stated on the basis of cost. Depreciation and amortization are provided on the straight-line method over the following estimated useful lives, except for assets under capital leases and leasehold improvements, which are amortized over the shorter of the estimated useful life or their respective lease term.

 

     Years  
Furniture and fixtures      5-10   
Equipment      3-5   

 

43


Table of Contents

HEALTHSTREAM, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

Goodwill and Intangible Assets

Goodwill represents the excess of purchase price in a business combination over the fair value of the net identifiable assets acquired. The carrying amount of our goodwill is evaluated for impairment at least annually during the fourth quarter and whenever events or changes in facts or circumstances indicate that impairment may exist. In accordance with ASC 350, Intangibles – Goodwill and Other, companies may opt to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. A qualitative assessment includes factors such as financial performance, industry and market metrics, and other factors affecting the reporting unit. If this assessment concludes that is more likely than not that the fair value of a reporting unit exceeds its carrying value, then goodwill is not considered impaired and no further impairment testing is required. Conversely, if the qualitative assessment concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we must then compare the fair value of the reporting unit to its carrying value. The Company determines fair value of the reporting units using both income and market based models. These models require the use of various assumptions relating to cash flow projections, growth rates, discount rates and terminal value calculations. The Company did not recognize any impairment charges for the years ended December 31, 2015, 2014 or 2013.

As of December 31, 2015, intangible assets with remaining unamortized balances include contract rights and customer relationships, internally-developed technology and patents, non-competition agreements, and trade names. These intangible assets are considered to have definite useful lives and are being amortized on a straight line basis over periods typically ranging between three and fifteen years. The weighted average amortization period for definite lived intangible assets as of December 31, 2015 was 11.3 years. Intangible assets are reviewed for impairment whenever events or changes in facts or circumstances indicate that the carrying amount of the assets may not be recoverable. There were no impairments identified or recorded for the years ended December 31, 2015, 2014, or 2013.

Long-Lived Assets

Long-lived assets to be held for use are reviewed for events or changes in facts and circumstances, both internally and externally, which may indicate that an impairment of long-lived assets held for use is present. The Company measures any impairment using observable market values or discounted future cash flows from the related long-lived assets. The cash flow estimates and discount rates incorporate management’s best estimates, using appropriate and customary assumptions and projections at the date of evaluation. Management periodically evaluates whether the carrying value of long-lived assets, including intangible assets, property and equipment, capitalized software development, and other assets will be recoverable. There were no impairments identified or recorded for the years ended December 31, 2015, 2014, or 2013.

Non-Marketable Equity Investments

Non-marketable equity investments are accounted for using the equity method when the Company can exercise significant influence over the investee. Investments for which the Company is not able to exercise significant influence over the investee are accounted for under the cost method. The proportionate share of income or loss from equity method investments are recorded under the caption “other income, net” in the accompanying consolidated statements of income.

Financial Instruments

The Company has various financial instruments, including cash and cash equivalents, accounts receivable, accounts receivable-unbilled, accounts payable, accrued liabilities, and deferred revenue. The carrying amounts of these financial instruments approximate fair value because of the short term maturity or short term nature of such instruments. The Company also has marketable securities, which are recorded at approximate fair value based on quoted market prices or alternative pricing sources (see Note 4 – Marketable Securities).

Advertising

The Company expenses the costs of advertising as incurred. Advertising expense for the years ended December 31, 2015, 2014, and 2013 was approximately $1.1 million, $0.7 million, and $0.4 million, respectively.

Shipping and Handling Costs

Shipping and handling costs that are associated with our products and services are included in cost of revenues.

 

44


Table of Contents

HEALTHSTREAM, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

Income Taxes

Income taxes are accounted for using the asset and liability method, whereby deferred tax assets and liabilities are determined based on the temporary differences between the financial statement and tax bases of assets and liabilities measured at tax rates that will be in effect for the year in which the differences are expected to affect taxable income. Management evaluates all available evidence, both positive and negative, to determine whether, based on the weight of that evidence, a valuation allowance is needed. Future realization of the tax benefit of an existing deductible temporary difference or carryforward ultimately depends on the existence of sufficient taxable income of the appropriate character within the carryback or carryforward period available under the tax law. There are four possible sources of taxable income that may be available under the tax law to realize a tax benefit for deductible temporary differences and carryforwards: 1) future reversals of existing taxable temporary differences, 2) future taxable income exclusive of reversing temporary differences and carryforwards, 3) taxable income in prior carryback year(s) if carryback is permitted under the tax law, and 4) tax-planning strategies that would, if necessary, be implemented to realize deductible temporary differences or carryforwards prior to their expiration. Management reviews the realizability of its deferred tax assets each reporting period to identify whether any significant changes in circumstances or assumptions have occurred that could materially affect the realizability of deferred tax assets. As of December 31, 2015, the Company had established a valuation allowance of $346,000 for the portion of its net deferred tax assets that are not more likely than not expected to be realized.

The Company accounts for income tax uncertainties using a more-likely-than-not recognition threshold based on the technical merits of the tax position taken. Tax positions that meet the more-likely-than-not recognition threshold are measured in order to determine the tax benefit to be recognized in the financial statements. The Company expenses any penalties or interest associated with tax obligations as general and administrative expenses and interest expense, respectively.

Earnings Per Share

Basic earnings per share is computed by dividing the net income available to common shareholders for the period by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing the net income for the period by the weighted average number of common and common equivalent shares outstanding during the period. Common equivalent shares are composed of incremental common shares issuable upon the exercise of stock options and restricted share units subject to vesting. The dilutive effect of common equivalent shares is included in diluted earnings per share by application of the treasury stock method. Common equivalent shares that have an anti-dilutive effect on diluted net income per share have been excluded from the calculation of diluted weighted average shares outstanding for the years ended December 31, 2015, 2014, and 2013.

Concentrations of Credit Risk and Significant Customers

The Company’s credit risks relate primarily to cash and cash equivalents, marketable securities and accounts receivable. The Company places its temporary excess cash investments in high quality, short-term money market instruments. At times, such investments may be in excess of the FDIC insurance limits. Marketable securities consists primarily of investment grade corporate debt securities and certificates of deposit.

The Company sells its products and services to various companies in the healthcare industry that are located in the United States. We perform ongoing credit evaluations of our customers’ financial condition and generally require no collateral from customers. An allowance for doubtful accounts is maintained for potentially uncollectible accounts receivable. The Company did not have any single customer representing over 10% of net revenues during 2015, 2014, or 2013.

Stock Based Compensation

As of December 31, 2015, the Company maintains two stock based compensation plans, which are described in Note 11. The Company accounts for stock based compensation using the fair-value based method for costs related to share-based payments, including stock options and restricted share units. The Company uses the Black Scholes option pricing model for calculating the fair value of option awards issued under its stock based compensation plan. The Company measures compensation cost of restricted share units based on the closing fair market value of the Company’s stock on the date of grant. Stock based compensation cost is measured at the grant date, based on the fair value of the award that is ultimately expected to vest, and is recognized as an expense over the requisite service period. The Company recognizes tax benefits from stock based compensation if an excess tax benefit is realized. Excess tax benefits are recorded as an increase to common stock when realized.

 

45


Table of Contents

HEALTHSTREAM, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

Newly Issued Accounting Standards

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific revenue recognition guidance throughout the Industry Topics of the Accounting Standards Codification. The updated guidance states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also provides for additional disclosures with respect to revenues and cash flows arising from contracts with customers. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2017, and early adoption is permitted for the first interim period within annual reporting periods beginning after December 15, 2016. The Company is currently reviewing this standard to determine the method of adoption and to assess the impact on its future consolidated financial statements.

2. SHAREHOLDERS’ EQUITY

Common Stock

The Company is authorized to issue up to 75 million shares of common stock. The number of common shares issued and outstanding as of December 31, 2015 and 2014 was approximately 31.6 million and 27.7 million, respectively. The Company issued approximately 3.9 million shares of common stock in connection with an underwritten public offering, which was completed in May 2015, raising approximately $98.0 million of cash.

Preferred Stock

The Company is authorized to issue up to 10 million shares of preferred stock in one or more series, having the relative voting powers, designations, preferences, rights and qualifications, limitations or restrictions, and other terms as the Board of Directors may fix in providing for the issuance of such series, without any vote or action of the shareholders.

3. EARNINGS PER SHARE

The following table sets forth the computation of basic and diluted earnings per share for the three years ended December 31, 2015 (in thousands, except per share amounts):

 

     2015      2014      2013  

Numerator:

        

Net income

   $ 8,621       $ 10,394       $ 8,418   
  

 

 

    

 

 

    

 

 

 

Denominator:

        

Weighted-average shares outstanding

     30,057         27,570         26,853   

Effect of dilutive shares

     379         453         810   
  

 

 

    

 

 

    

 

 

 

Weighted-average diluted shares

     30,436         28,023         27,663   
  

 

 

    

 

 

    

 

 

 

Basic earnings per share

   $ 0.29       $ 0.38       $ 0.31   
  

 

 

    

 

 

    

 

 

 

Diluted earnings per share

   $ 0.28       $ 0.37       $ 0.30   
  

 

 

    

 

 

    

 

 

 

Potentially dilutive shares representing approximately 16,000, 70,000, and 70,000 shares of common stock for 2015, 2014, and 2013, respectively, were excluded from the calculation of diluted earnings per share because their effect would have been anti-dilutive.

 

46


Table of Contents

HEALTHSTREAM, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

 

4. MARKETABLE SECURITIES

At December 31, 2015 and 2014, the fair value of marketable securities, which were all classified as available for sale, included the following (in thousands):

 

     December 31, 2015  
     Adjusted Cost      Unrealized
Gains
     Unrealized
Losses
     Fair Value  

Level 2:

           

Certificates of deposit

   $ 1,000       $ —         $ —         $ 1,000   

Corporate debt securities

     66,046         —           (70      65,976   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 67,046       $ —         $ (70    $ 66,976   
  

 

 

    

 

 

    

 

 

    

 

 

 
     December 31, 2014  
     Adjusted Cost      Unrealized
Gains
     Unrealized
Losses
     Fair Value  

Level 2:

           

Certificates of deposit

   $ 6,278       $ —         $ —         $ 6,278   

Corporate debt securities

     32,732         —           (37      32,695   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 39,010       $ —         $ (37    $ 38,973   
  

 

 

    

 

 

    

 

 

    

 

 

 

The carrying amounts of the marketable securities reported in the consolidated balance sheets approximate fair value based on quoted market prices or alternative pricing sources and models utilizing market observable inputs. As of December 31, 2015, the Company does not consider any of its marketable securities to be other than temporarily impaired. During the years ended December 31, 2015 and 2014, the Company did not reclassify any items out of accumulated other comprehensive income to net income. All investments in marketable securities are classified as a current asset on the balance sheet because the underlying securities mature within one year from the balance sheet date.

5. BUSINESS COMBINATIONS

HealthLine Systems

On March 16, 2015, the Company acquired all of the membership interests of HealthLine Systems, LLC (HLS), a San Diego, California based company that specializes in credentialing, privileging, call center, and quality management solutions for the healthcare industry. The acquisition of HLS enables the Company to provide a comprehensive solution set for healthcare provider credentialing, privileging, enrollment, referral, onboarding, and analytics in support of HealthStream’s approach to talent management for healthcare organizations. The consideration paid for HLS consisted of approximately $88.1 million in cash (taking into account an estimated closing working capital adjustment). The Company incurred approximately $1.3 million in transaction costs associated with the acquisition, of which $965,000 were incurred during the year ended December 31, 2015 and $329,000 were incurred during the year ended December 31, 2014. The transaction costs were recorded under the caption “other general and administrative” in the consolidated statements of income. The results of operations for HLS have been included in the Company’s consolidated financial statements from the date of acquisition, and are also included in the HealthStream Provider Solutions segment.

A summary of the purchase price is as follows (in thousands):

 

Cash paid at closing

   $  81,379   

Cash held in escrow

     6,750   
  

 

 

 

Total consideration paid

   $ 88,129   
  

 

 

 

 

47


Table of Contents

HEALTHSTREAM, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

5. BUSINESS COMBINATIONS (continued)

 

The following table summarizes the preliminary fair value of the assets acquired and liabilities assumed as of the date of acquisition (in thousands):

 

Cash

   $ 54   

Accounts receivable, net

     3,052   

Prepaid assets

     546   

Property and equipment

     200   

Deferred tax assets

     2,523   

Goodwill

     41,618   

Intangible assets

     47,200   

Accounts payable and accrued liabilities

     (1,085

Deferred revenue

     (5,979
  

 

 

 

Preliminary net assets acquired

   $ 88,129   
  

 

 

 

The excess of preliminary purchase price over the preliminary fair values of net tangible and intangible assets is recorded as goodwill. The preliminary fair values of tangible and identifiable intangible assets, deferred tax assets, deferred revenue, and other liabilities are based on management’s estimates and assumptions. The preliminary fair values of assets acquired and liabilities assumed are considered preliminary and are based on the information that was available at the time of the acquisition. The preliminary fair values of assets acquired and liabilities assumed are subject to change during the measurement period (up to one year from the acquisition date) as we finalize the valuation of tax liabilities and determine final working capital adjustments. Included in the preliminary assets and liabilities is an estimated indemnification asset of $300,000 and a contingent liability of $700,000, both of which are associated with tax liabilities. The contingent liability is measured based on management’s estimate of a range of probable outcomes. During the fourth quarter of 2015, the Company reduced the preliminary fair value for accounts receivable by $115,000, prepaid assets by $200,000, and accrued liabilities by $800,000. The goodwill balance is primarily attributed to the assembled workforce, additional market opportunities from offering HLS’s products, and expected synergies from integrating HLS with other products or other combined functional areas within the Company. The goodwill balance is deductible for U.S. income tax purposes. The net tangible assets include deferred revenue, which was adjusted down from a book value at the acquisition date of $15.0 million to an estimated fair value of $6.0 million. The $9.0 million write-down of deferred revenue will result in lower revenues than would have otherwise been recognized for such services.

The following table sets forth the components of identifiable intangible assets and their estimated useful lives as of the acquisition date (in thousands):

 

     Preliminary
fair

Value
     Useful life  

Customer relationships

   $ 42,600         13 years   

Developed technology

     3,700         5 years   

Trade names

     900         6 years   
  

 

 

    

Total preliminary intangible assets subject to amortization

   $ 47,200      
  

 

 

    

The weighted average amortization period for the identifiable intangible assets acquired is 12.2 years.

The amounts of revenue and operating income (loss) of HLS included in the Company’s consolidated statements of income from the date of acquisition of March 16, 2015 to the period ending December 31, 2015 are as follows (in thousands):

 

Total revenues

   $ 8,543   
  

 

 

 

Operating loss

   $ (2,541
  

 

 

 

 

48


Table of Contents

HEALTHSTREAM, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

5. BUSINESS COMBINATIONS (continued)

 

The following unaudited pro forma financial information summarizes the combined results of operations of the Company and HLS, which was significant for purposes of the unaudited pro forma financial information disclosure, as though the companies were combined as of January 1, 2014 (in thousands, except per share data):

 

     Year Ended
December 31,
 
     2015      2014  

Total revenues

   $ 219,108       $ 182,548   
  

 

 

    

 

 

 

Net income

   $ 13,551       $ 8,658   
  

 

 

    

 

 

 

Basic earnings per share

   $ 0.45       $ 0.31   
  

 

 

    

 

 

 

Diluted earnings per share

   $ 0.44       $ 0.31   
  

 

 

    

 

 

 

These unaudited pro forma combined results of operations include certain adjustments arising from the acquisition such as adjustment for amortization of intangible assets, depreciation of property and equipment, fair value adjustments of acquired deferred revenue balances, and interest expense associated with borrowings under a revolving credit facility by the Company to partially fund the acquisition. The pro forma combined results for the year ended December 31, 2014 include nonrecurring adjustments of $4.2 million, which reduce net income due to the revaluation of HLS’s historic deferred revenue to fair value. The unaudited pro forma combined results of operations is for informational purposes only and is not indicative of what the Company’s results of operations would have been had such transactions occurred at the beginning of the period presented or to project the Company’s results of operations in any future period.

The unaudited pro forma financial information for the years ended December 31, 2015 and 2014 combines the historical results of the Company and HLS for the years ended December 31, 2015 and 2014 and the pro forma adjustments listed above.

Health Care Compliance Strategies

On March 3, 2014, the Company acquired all of the stock of Health Care Compliance Strategies, Inc. (HCCS), a Jericho, New York based company that specializes in healthcare compliance solutions and services. The Company acquired HCCS to further advance its suite of workforce development solutions, including its offering of compliance solutions. The consideration paid for HCCS consisted of approximately $12.8 million in cash (taking into account a post-closing working capital adjustment) and 81,614 shares of our common stock. The Company made an additional payment of $750,000 during the second quarter of 2015, upon the achievement of certain performance milestones within one year post-closing. The Company incurred approximately $515,000 in transaction costs associated with the acquisition, of which $365,000 were incurred during the year ended December 31, 2014 and $150,000 were incurred during the year ended December 31, 2013. The transaction costs were recorded under the caption “other general and administrative” in the consolidated statements of income. In allocating the purchase price, the Company recorded approximately $6.2 million of goodwill, $8.4 million of identifiable intangible assets, $2.6 million of tangible assets, $625,000 of deferred tax assets, and $2.7 million of liabilities. Included in the recorded liabilities was an accrual for contingent consideration of approximately $600,000. The goodwill balance is primarily attributed to assembled workforce, additional market opportunities of HCCS’s compliance solutions, and expected synergies from integrating HCCS’s products into our platform. The goodwill balance is deductible for U.S. income tax purposes. The net tangible assets include deferred revenue, which was adjusted down from a book value at the acquisition date of $3.2 million to an estimated fair value of $1.7 million. The $1.5 million write-down of deferred revenue resulted in lower revenues than would have otherwise been recognized for such services. The results of operations for HCCS have been included in the Company’s consolidated financial statements from the date of acquisition, and are also included in the HealthStream Workforce Development Solutions segment.

 

49


Table of Contents

HEALTHSTREAM, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

5. BUSINESS COMBINATIONS (continued)

 

Baptist Leadership Group

On September 9, 2013, the Company acquired substantially all of the assets of Baptist Leadership Group (BLG), a Pensacola, Florida based company that provides consulting services focused on patient-centered performance excellence in healthcare. The Company acquired BLG to strengthen its Patient Experience Solutions. The consideration paid for BLG consisted of approximately $7.4 million in cash (taking into account the working capital adjustment) and 15,230 shares of our common stock. The Company incurred approximately $145,000 in transaction costs associated with the acquisition, which are included on the accompanying consolidated statements of income under the caption “other general and administrative.” In allocating the purchase price, the Company recorded approximately $6.3 million of goodwill, $1.6 million of identifiable intangible assets, and $28,000 of net tangible assets. The goodwill balance is primarily attributed to the assembled workforce, additional market opportunities from BLG’s consulting services, and expected synergies from integrating BLG into the operations of the HealthStream Patient Experience Solutions segment. The goodwill balance is deductible for U.S. income tax purposes. The net tangible assets include deferred revenue, which was adjusted down from a book value of $508,000 to an estimated fair value of $254,000. The $254,000 write-down of deferred revenue resulted in lower revenues than would have otherwise been recognized for such services. The results of operations for BLG have been included in the Company’s consolidated financial statements from the date of acquisition, and are included in the HealthStream Patient Experience Solutions segment.

6. PROPERTY AND EQUIPMENT

Property and equipment consist of the following:

 

     December 31,  
     2015      2014  

Equipment

   $ 23,057       $ 25,133   

Leasehold improvements

     4,435         5,860   

Furniture and fixtures

     4,338         4,554   
  

 

 

    

 

 

 

Gross property and equipment

     31,830         35,547   

Accumulated depreciation and amortization

     (19,359      (26,105
  

 

 

    

 

 

 

Property and equipment, net

   $ 12,471       $ 9,442   
  

 

 

    

 

 

 

Depreciation of property and equipment totaled approximately $5.3 million and $4.1 million for the years ended December 31, 2015 and 2014, respectively.

7. GOODWILL

The changes in the carrying amount of goodwill for the years ended December 31, 2015 and 2014 are as follows (in thousands):

 

     Workforce      Patient
Experience
     Provider      Total  

Balance at January 1, 2015

   $ 12,336       $ 24,154       $ 5,424       $ 41,914   

Acquisition of HealthLine Systems, LLC

     —           —           41,618         41,618   

Disposal of long lived assets

     —           —           (459      (459
  

 

 

    

 

 

    

 

 

    

 

 

 

Balance at December 31, 2015

   $ 12,336       $ 24,154       $ 46,583       $ 83,073   
  

 

 

    

 

 

    

 

 

    

 

 

 
     Workforce      Patient
Experience
     Provider      Total  

Balance at January 1, 2014

   $ 6,168       $ 24,154       $ 5,424       $ 35,746   

Acquisition of Health Care Compliance Strategies, Inc.

     6,168         —           —           6,168   
  

 

 

    

 

 

    

 

 

    

 

 

 

Balance at December 31, 2014

   $ 12,336       $ 24,154       $ 5,424       $ 41,914   
  

 

 

    

 

 

    

 

 

    

 

 

 

During the quarter ended December 31, 2015, the Company disposed of certain long lived assets meeting the definition of a business. Accordingly, we have allocated approximately $459,000 of reporting unit goodwill to this disposition of assets pursuant to ASC 350, Intangibles – Goodwill and other.

 

50


Table of Contents

HEALTHSTREAM, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

 

8. INTANGIBLE ASSETS

Intangible assets other than goodwill are considered to have finite useful lives. Customer related intangibles are amortized over their estimated useful lives ranging from five to thirteen years. Other intangible assets include non-competition agreements, technology and patents, and trade names, and are being amortized over periods ranging from three to nine years. During the quarter ended December 31, 2015, the Company retired approximately $10.7 million of fully amortized identifiable intangible assets. Gross amounts and related accumulated amortization presented below as of December 31, 2015 are reflective of such retirements. Such amounts are also inclusive of identifiable intangible assets recorded in relation to our acquisition of HealthLine Systems, LLC (see Note 5 – Business Combinations). Amortization of intangible assets was approximately $5.6 million and $2.4 million for the years ended December 31, 2015 and 2014, respectively.

Identifiable intangible assets are comprised of the following (in thousands):

 

     As of December 31, 2015      As of December 31, 2014  
     Gross Amount      Accumulated
Amortization
    Net      Gross Amount      Accumulated
Amortization
    Net  

Customer related

   $ 55,571       $ (6,068   $ 49,503       $ 23,329       $ (11,880   $ 11,449   

Other

     9,080         (2,617     6,463         5,300         (1,954     3,346   
  

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

 

Total

   $ 64,651       $ (8,685   $ 55,966       $ 28,629       $ (13,834   $ 14,795   
  

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

 

The expected future annual amortization expense for the years ending December 31, is as follows (in thousands):

 

2016

   $ 6,400   

2017

     6,323   

2018

     6,211   

2019

     5,566   

2020

     4,913   

Thereafter

     26,553   
  

 

 

 

Total

   $ 55,966   
  

 

 

 

9. BUSINESS SEGMENTS

The Company provides services to healthcare organizations and other members within the healthcare industry. The Company’s services are focused on the delivery of workforce development products and services (HealthStream Workforce Solutions), survey and research services (HealthStream Patient Experience Solutions), and provider credentialing, privileging, call center and enrollment products and services (HealthStream Provider Solutions).

The Company measures segment performance based on operating income before income taxes and prior to the allocation of certain corporate overhead expenses, interest income, interest expense, gains and losses from equity investments, and depreciation. The Unallocated component below includes corporate functions, such as accounting, human resources, legal, investor relations, administrative and executive personnel, depreciation, a portion of amortization, and certain other expenses, which are not currently allocated in measuring segment performance. The following is the Company’s business segment information as of and for the years ended December 31, 2015, 2014 and 2013 (in thousands).

 

51


Table of Contents

HEALTHSTREAM, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

9. BUSINESS SEGMENTS (continued)

 

Revenues, net:    2015      2014      2013  

Workforce

   $ 161,289       $ 134,242       $ 99,963   

Patient Experience

     34,193         31,901         28,454   

Provider

     13,520         4,547         3,857   
  

 

 

    

 

 

    

 

 

 

Total revenues, net

   $ 209,002       $ 170,690       $ 132,274   
  

 

 

    

 

 

    

 

 

 

 

Operating income:    2015      2014      2013  

Workforce

   $ 39,986       $ 35,374       $ 28,203   

Patient Experience

     1,548         810         2,819   

Provider

     (2,559      826         277   

Unallocated

     (25,418      (20,635      (16,633
  

 

 

    

 

 

    

 

 

 

Total operating income

   $ 13,557       $ 16,375       $ 14,666   
  

 

 

    

 

 

    

 

 

 

 

     Assets *      Purchases of long-lived assets      Depreciation and amortization  
     2015      2014      2013      2015      2014      2013      2015      2014      2013  

Workforce

   $ 82,375       $ 81,116       $ 48,514       $ 11,403       $ 7,179       $ 6,243       $ 6,693       $ 4,813       $ 2,829   

Patient Experience

     34,902         34,536         34,727         2,007         1,277         726         1,061         1,272         1,068   

Provider

     100,948         10,976         11,499         332         200         67         3,986         683         683   

Unallocated

     161,344         130,634         117,854         1,617         1,546         1,675         5,257         4,163         3,272   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 379,569       $ 257,262       $ 212,594       $ 15,359       $ 10,202       $ 8,711       $ 16,997       $ 10,931       $ 7,852   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

* Segment assets include accounts and unbilled receivables, prepaid royalties, prepaid and other current assets, other assets, capitalized software development, certain property and equipment, and intangible assets. Cash and cash equivalents and marketable securities are not allocated to individual segments, and are included within Unallocated. A significant portion of property and equipment assets are included within Unallocated.

10. INCOME TAXES

The provision (benefit) for income taxes is comprised of the following (in thousands):

 

     Year Ended December 31,  
     2015      2014      2013  

Current federal

   $ 3,608       $ 3,198       $ 2,474   

Current state

     1,098         1,605         1,444   

Deferred federal

     501         1,092         2,315   

Deferred state

     (109      232         191   
  

 

 

    

 

 

    

 

 

 

Provision for income taxes

   $ 5,098       $ 6,127       $ 6,424   
  

 

 

    

 

 

    

 

 

 

A reconciliation of income taxes at the statutory federal income tax rate to the provision for income taxes included in the accompanying consolidated statements of income is as follows (in thousands):

 

     Year Ended December 31,  
     2015      2014      2013  

Federal tax provision at the statutory rate

   $ 4,802       $ 5,782       $ 5,194   

State income tax provision, net of federal benefit

     673         1,350         898   

Tax credits

     (425      (1,160      (54

Change in state valuation allowance

     (8      37         231   

Other

     56         118         155   
  

 

 

    

 

 

    

 

 

 

Provision for income taxes

   $ 5,098       $ 6,127       $ 6,424   
  

 

 

    

 

 

    

 

 

 

Management periodically evaluates the realizability of its deferred tax assets, and to the extent that a recovery is not likely, a valuation allowance is established to reduce the deferred tax asset to the amount estimated to be recoverable. At December 31, 2015, a valuation allowance of $346,000 exists. The Company adjusts deferred tax liabilities and assets in the period of enactment for the effect of an enacted change in tax laws or rates. Accordingly, the state income tax provision for the period ended December 31, 2015 is inclusive of a deferred tax benefit of $188,000 related to a change in state tax law that will be effective for the Company’s tax year beginning on or after January 1, 2017.

 

52


Table of Contents

HEALTHSTREAM, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

10. INCOME TAXES (continued)

 

As of December 31, 2015, the Company had state net operating loss carryforwards of $13.0 million. These loss carryforwards will expire in years 2016 through 2025. The Company is subject to income taxation at the federal and various state levels. The Company is subject to U.S. federal tax examinations for tax years 2012 through 2015. Loss carryforwards and credit carryforwards generated or utilized in years earlier than 2012 are also subject to examination and adjustment. The Company has examinations in process with the Internal Revenue Service for tax years 2013 and 2014. The Company has research and development tax credit carryforwards of $1.9 million that expire in varying amounts through 2035. As of December 31, 2015, the Company had alternative minimum tax credit carryforwards of $816,000 that are available to offset future regular tax liabilities and they do not expire.

A reconciliation of the beginning and ending liability for gross unrecognized tax benefits at December 31, 2015 and 2014, are as follows (in thousands):

 

     December 31,  
     2015      2014  

Balance at beginning of year

   $ 2,168       $ 167   

Additions for tax positions in the current year

     351         2,168   

Reductions for tax positions of prior years

     (1,861      (167
  

 

 

    

 

 

 

Balance at end of year

   $ 658       $ 2,168   
  

 

 

    

 

 

 

The Company recognized approximately $14,000 and $125,000 for interest and penalties related to unrecognized tax benefits within the provision for income taxes during the years ended December 31, 2015 and 2014, respectively. Unrecognized tax benefits included tax positions of approximately $278,000 at both December 31, 2015 and 2014 that if recognized would impact the Company’s effective tax rate. The reduction for tax positions of prior years reflected in the table above as of December 31, 2015 relates to a change in tax accounting method filed with the IRS for tangible property and deferred revenue. The Company estimates that it is reasonably possible the liability for unrecognized tax benefits could decrease up to $0.3 million within the next 12 months.

Deferred federal and state income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of deferred tax assets and deferred tax liabilities are as follows (in thousands):

 

     December 31,  
     2015      2014  

Deferred tax assets:

     

Allowance for doubtful accounts

   $ 122       $ 134   

Accrued liabilities

     2,062         1,565   

Tax credits

     816         791   

Stock based compensation

     1,107         1,015   

Deferred revenue

     1,563         616   

Depreciation

     348         715   

Basis difference on investments

     80         —     

Net operating loss carryforwards

     407         355   
  

 

 

    

 

 

 

Total deferred tax assets

     6,505         5,191   

Less: Valuation allowance

     (346      (355
  

 

 

    

 

 

 

Deferred tax assets, net of valuation allowance

     6,159         4,836   

Deferred tax liabilities:

     

Deductible goodwill

     2,646         2,369   

Nondeductible intangible assets

     1,806         2,171   

Prepaid assets

     1,911         1,602   

Capitalized software development

     4,559         3,836   

Basis difference on investments

     —           343   
  

 

 

    

 

 

 

Total deferred tax liabilities

     10,922         10,321   
  

 

 

    

 

 

 

Net deferred tax liabilities

   $ (4,763    $ (5,485
  

 

 

    

 

 

 

 

53


Table of Contents

HEALTHSTREAM, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

 

11. STOCK BASED COMPENSATION

Stock Incentive Plans

The Company’s 2010 Stock Incentive Plan (2010 Plan) and 2000 Stock Incentive Plan (2000 Plan; collectively, the 2010 Plan and the 2000 Plan referred to as the Plan) authorize the grant of options, restricted share units (RSU), or other forms of stock based compensation to employees, officers, directors and others, and such grants must be approved by the Compensation Committee of the Board of Directors. Options granted under the Plan have terms of no more than ten years, with certain restrictions. The Plan allows the Compensation Committee of the Board of Directors to determine the vesting period and parameters of each grant. The vesting period of the options and RSUs granted has historically ranged from immediate vesting to annual vesting up to four years, generally beginning one year after the grant date. As of December 31, 2015, approximately 487,000 shares of unissued common stock remained reserved for future stock incentive grants under the Plan. The Company issues new shares of common stock when options are exercised or when RSUs become vested.

Stock Option Activity

A summary of activity and various other information relative to stock options for the year ended December 31, 2015 is presented in the tables below (in thousands, except exercise price).

 

     Common
Shares
     Weighted-
Average
Exercise Price
     Aggregate
Intrinsic Value
 
          
          

Outstanding at beginning of period

     596       $ 6.18      

Granted

     —           —        

Exercised

     (76      4.29      

Expired

     —           —        

Forfeited

     —           —        
  

 

 

    

 

 

    

Outstanding at end of period

     520       $ 6.45       $ 8,081   
  

 

 

    

 

 

    

 

 

 

Exercisable at end of period.

     520       $ 6.45       $ 8,081   
  

 

 

    

 

 

    

 

 

 

The aggregate intrinsic value for stock options in the table above represents the total difference between the Company’s closing stock price on December 31, 2015 (the last trading day of the year) of $22.00 per share and the option exercise price, multiplied by the number of in-the-money options as of December 31, 2015. The weighted average remaining contractual term of options outstanding at December 31, 2015 was 2.5 years. Options exercisable at December 31, 2015 have a weighted average remaining contractual term of 2.5 years.

Other information relative to option activity during the three years ended December 31, 2015 is as follows (in thousands):

 

     2015      2014      2013  

Total grant date fair value of stock options vested

   $ 232       $ 630       $ 723   
  

 

 

    

 

 

    

 

 

 

Total intrinsic value of stock options exercised

   $ 1,662       $ 5,912       $ 25,846   
  

 

 

    

 

 

    

 

 

 

Cash proceeds from exercise of stock options

   $ 328       $ 1,094       $ 3,318   
  

 

 

    

 

 

    

 

 

 

Restricted Share Unit Activity

A summary of activity relative to RSUs for the year ended December 31, 2015 is follows (in thousands, except weighted average grant date fair value):

 

     Number of
RSU’s
     Weighted-
Average
Grant Date Fair Value
     Aggregate
Intrinsic Value
 
          
          

Outstanding at beginning of period

     164       $ 25.04      

Granted

     110         24.97      

Vested

     (54      24.17      

Forfeited

     (2      26.03      
  

 

 

    

 

 

    

Outstanding at end of period

     218       $ 25.21       $ 4,793   
  

 

 

    

 

 

    

 

 

 

 

54


Table of Contents

HEALTHSTREAM, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

11. STOCK BASED COMPENSATION (continued)

 

The aggregate fair value of RSU awards that vested in 2015 and 2014, as of the respective vesting dates, was approximately $1.4 million and $1.1 million, respectively. A portion of RSUs that vested in 2015 and 2014 were net-share settled such that the Company withheld shares with value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. The total shares withheld for RSUs during 2015 and 2014 were 8,922 and 5,327, respectively, and were based on the value of the RSUs on their respective settlement dates as determined by the Company’s closing stock price. Total payments related to RSUs for the employees’ tax obligations to taxing authorities were approximately $230,000 in 2015 and $161,000 in 2014, and are reflected as a financing activity within the consolidated statements of cash flows. These net-share settlements had the effect of share repurchases by the Company as they reduced and retired the number of shares that would have otherwise been issued as a result of the vesting and did not represent an expense to the Company.

Stock Based Compensation

Total stock based compensation expense, which is recorded in our consolidated statements of income, recorded for the years ended December 31, is as follows (in thousands):

 

     Years Ended December 31,  
     2015      2014      2013  

Cost of revenues (excluding depreciation and amortization)

   $ 824       $ 86       $ 81   

Product development

     569         201         144   

Sales and marketing

     547         224         175   

Other general and administrative

     1,340         1,114         1,058   
  

 

 

    

 

 

    

 

 

 

Total stock based compensation expense

   $ 3,280       $ 1,625       $ 1,458   
  

 

 

    

 

 

    

 

 

 

The Company amortizes the fair value of all stock based awards, net of estimated forfeitures, on a straight-line basis over the requisite service period, which generally is the vesting period. As of December 31, 2015, total unrecognized compensation expense related to non-vested stock options and RSUs was approximately $3.0 million, net of estimated forfeitures, with a weighted average expense recognition period remaining of 2.3 years. The Company realized approximately $3.0 million of excess tax benefits related to stock based awards during the year ended December 31, 2015, which was recorded as an increase to common stock.

Stock based compensation cost for RSUs is measured based on the closing fair market value of the Company’s stock on the date of grant. Stock based compensation cost for stock options is estimated at the grant date based on the fair value calculated using the Black-Scholes method. The Company did not grant any stock options during 2015, 2014, or 2013.

Stock Awards

During June 2015, the Company’s CEO, Robert A. Frist, Jr., entered into an agreement with the Company pursuant to which he contributed 54,241 of his personally owned shares of HealthStream, Inc. common stock to the Company, without any consideration paid to him. In connection with this contribution, the Company approved the grant of 49,310 shares of HealthStream, Inc. common stock to over 600 employees who were not otherwise eligible to receive equity awards and had at least one year of service with the Company. The Company recognized approximately $1.5 million of stock based compensation expense for these stock awards during the three months ended June 30, 2015 based on the closing fair market value of the Company’s stock on the date of the Company’s approval of these grants. In connection with these equity awards, effective in the second quarter of 2015, the Company withheld shares with value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. The total shares withheld were 17,279, and were based on the value of the stock awards on the date of the Company’s approval of these grants, as determined by the Company’s closing stock price on that date. Total payments related to the employees’ tax obligations to taxing authorities for these stock awards were approximately $526,000 and are reflected as a financing activity within the consolidated statements of cash flows for the year ended December 31, 2015. These share withholdings had the effect of share repurchases by the Company as they reduced and retired the number of shares otherwise issuable as a result of the stock awards and did not represent an expense to the Company.

 

55


Table of Contents

HEALTHSTREAM, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

 

12. EMPLOYEE BENEFIT PLAN

401(k) Plan

The Company has a defined-contribution employee benefit plan (401(k) Plan) incorporating provisions of Section 401(k) of the Internal Revenue Code. Employees must have attained the age of 21 and have completed thirty days of service to be eligible to participate in the 401(k) Plan. Under the provisions of the 401(k) Plan, a plan member may make contributions, on a tax-deferred basis, subject to IRS limitations. The Company elected to provide eligible employees with matching contributions totaling approximately $645,000 and $274,000 for the years ended December 31, 2015 and 2014, respectively.

13. DEBT

At December 31, 2015 and 2014, the Company had no debt outstanding.

Revolving Credit Facility

The Company maintains a Loan Agreement (the “Revolving Credit Facility”) with SunTrust Bank (“SunTrust”) in the aggregate principal amount of $50.0 million, which matures on November 24, 2017. Under the Revolving Credit Facility, the Company may borrow up to $50.0 million, which includes a $5.0 million swing line subfacility, as well as an accordion feature that allows the Company to increase the Revolving Credit Facility by a total of up to $25.0 million, subject to securing additional commitments from existing lenders or new lending institutions. The Revolving Credit Facility includes a $5.0 million letter of credit subfacility. The obligations under the Revolving Credit Facility are guaranteed by each of the Company’s subsidiaries. At the Company’s election, the borrowings under the Revolving Credit Facility bear interest at either (1) a rate per annum equal to the highest of SunTrust’s prime rate or 0.5% in excess of the Federal Funds Rate or 1.0% in excess of one-month LIBOR (the “Base Rate”), plus an applicable margin, or (2) the one, two, three, or six-month per annum LIBOR for deposits in the applicable currency (the “Eurocurrency Rate”), as selected by the Company, plus an applicable margin. The applicable margin for Eurocurrency Rate loans depends on the Company’s funded debt leverage ratio and varies from 1.50% to 2.00%. The applicable margin for Base Rate loans depends on the Company’s funded debt leverage ratio and varies from 0.50% to 1.50%. Commitment fees and letter of credit fees are also payable under the Revolving Credit Facility. Principal is payable in full at maturity on November 24, 2017, and there are no scheduled principal payments prior to maturity. The Company is required to pay a commitment fee ranging between 20 and 30 basis points per annum of the average daily unused portion of the Revolving Credit Facility, depending on the Company’s funded debt leverage ratio.

The purpose of the Revolving Credit Facility is for general working capital needs, permitted acquisitions (as defined in the Loan Agreement), and for stock repurchase and/or redemption transactions that the Company may authorize.

The Revolving Credit Facility contains certain covenants that, among other things, restrict additional indebtedness, liens and encumbrances, changes to the character of the Company’s business, acquisitions, asset dispositions, mergers and consolidations, sale or discount of receivables, creation or acquisitions of additional subsidiaries, and other matters customarily restricted in such agreements.

As of December 31, 2015, the Company was in material compliance with all covenants. There were no balances outstanding on the Revolving Credit Facility as of December 31, 2015. During the three months ended March 31, 2015, the Company borrowed approximately $28.0 million under the Revolving Credit Facility. During the three months ended June 30, 2015, the Company repaid approximately $28.0 million of balances previously outstanding under the Revolving Credit Facility from proceeds received in the Company’s public offering of 3,869,750 shares which closed on May 28, 2015. The weighted average interest rate was 1.68% for borrowings under Revolving Credit Facility during the year ended December 31, 2015.

 

56


Table of Contents

HEALTHSTREAM, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

 

 

14. LEASES

The Company has non-cancellable operating leases primarily for office space, hosting facilities, and office equipment. Some lease agreements contain provisions for escalating rent payments over the initial terms of the lease. The Company accounts for these leases by recognizing rent expense on a straight-line basis and adjusting the deferred rent expense liability for the difference between the straight-line rent expense and the amount of rent paid. The terms of the lease agreements generally provide the Company the option to renew. The Company also leases certain office equipment under operating leases. Total rent expense under all operating leases was approximately $4.3 million, $3.1 million, and $2.4 million, for the years ended December 31, 2015, 2014, and 2013, respectively.

Future rental payment commitments at December 31, 2015 under non-cancelable operating leases, with initial terms of one year or more, are as follows (in thousands):

 

2016

   $ 3,876   

2017

     2,625   

2018

     1,365   

2019

     808   

2020

     810   

Thereafter

     2,604   
  

 

 

 

Total minimum lease payments

   $ 12,088   
  

 

 

 

15. LITIGATION

In connection with its business, the Company is from time to time involved in various legal actions. The litigation process is inherently uncertain and it is possible that the resolution of such matters might have a material adverse effect upon the financial condition and/or results of operations of the Company. However, in the opinion of the Company’s management, matters currently pending or threatened against the Company are not expected to have a material adverse effect on the financial position or results of operations of the Company.

16. RELATED PARTY TRANSACTIONS

During the three months ended June 30, 2015, the Company’s CEO, Robert A. Frist, Jr., entered into an agreement with the Company pursuant to which he contributed 54,241 of his personally owned shares of HealthStream, Inc. common stock to the Company, without any consideration paid to him. In connection with this contribution, the Company approved the grant of 49,310 shares of common stock to over 600 employees, with a fair market value of approximately $1.5 million. Mr. Frist contributed 4,931 of the contributed shares noted above to take into account the estimated Company costs, such as administrative expenses and employer payroll taxes associated with the grants. (See Note 11).

17. SUBSEQUENT EVENTS

In February 2016, the Board of Directors authorized a share repurchase program for up to $25 million of the Company’s outstanding common stock. Repurchases will be made under the repurchase program in accordance with applicable securities laws and may be made at management’s discretion from time to time in the open market, through privately negotiated transactions, or otherwise. The share repurchase program will terminate on the earlier of December 31, 2016 or when the maximum dollar amount has been expended. The share repurchase program may be suspended or discontinued at any time.

 

57


Table of Contents

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None.

Item 9A. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

HealthStream’s chief executive officer and principal financial officer have reviewed and evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934 (the “Exchange Act”)) as of December 31, 2015. Based on that evaluation, the chief executive officer and principal financial officer have concluded that HealthStream’s disclosure controls and procedures were effective to ensure that the information required to be disclosed by the Company in the reports the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and the information required to be disclosed in the reports the Company files or submits under the Exchange Act was accumulated and communicated to the Company’s management, including its principal executive and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Management’s Annual Report On Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, and for assessing the effectiveness of internal control over financial reporting. The Company’s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. The Company’s internal control over financial reporting includes those policies and procedures that: (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2015. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (2013 Framework). Management’s assessment included an evaluation of the design of our internal control over financial reporting and testing of the operational effectiveness of our internal control over financial reporting. Management believes that, as of December 31, 2015, the Company’s internal control over financial reporting was effective based on those criteria. The Company’s independent registered public accounting firm, Ernst & Young LLP, has issued an audit report on the Company’s internal control over financial reporting, which appears in Item 8 of this Annual Report on Form 10-K.

Changes in Internal Control Over Financial Reporting

There were no changes in HealthStream’s internal control over financial reporting that occurred during the fourth quarter of 2015 that have materially affected, or that are reasonably likely to materially affect, HealthStream’s internal control over financial reporting.

Item 9B. Other Information

None.

 

58


Table of Contents

PART III

Item 10. Directors, Executive Officers and Corporate Governance

Information as to directors of the Company and corporate governance is incorporated by reference from the information contained in our 2016 proxy statement for the 2016 Annual Meeting of Shareholders (2016 Proxy Statement) that we will file with the Securities and Exchange Commission within 120 days of the end of the fiscal year to which this report relates. Pursuant to General Instruction G(3), certain information concerning executive officers of the Company is included in Part I of this Form 10-K, under the caption “Executive Officers of the Registrant.”

Item 11. Executive Compensation

Incorporated by reference from the information contained in the Company’s 2016 Proxy Statement.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Incorporated by reference from the information contained in the Company’s 2016 Proxy Statement.

Item 13. Certain Relationships and Related Transactions, and Director Independence

Incorporated by reference from the information contained in the Company’s 2016 Proxy Statement.

Item 14. Principal Accounting Fees and Services

Incorporated by reference from the information contained in the Company’s 2016 Proxy Statement.

 

59


Table of Contents

PART IV

Item 15. Exhibits, Financial Statement Schedules

(a)(1) Financial Statements

Reference is made to the financial statements included in Item 8 to this Report on Form 10-K.

(a)(2) Financial Statement Schedules

All schedules are omitted because they are not applicable or the required information is shown in the Consolidated Financial Statements or the notes thereto.

(a)(3) Exhibits

 

Number

 

Description

    2.1 (1)   Membership Interest Purchase Agreement, dated as of February 12, 2015, between HealthStream, Inc., Littrell Holdings, Inc., HealthLine Systems, Inc., the Shareholders of HealthLine Systems, Inc., and Dan Littrell in his individual capacity and as the Shareholders Representative.
    3.1*   Form of Fourth Amended and Restated Charter of HealthStream, Inc.
    3.2(7)*   Form of Second Amended and Restated Bylaws of HealthStream, Inc.
    4.1*   Form of certificate representing the common stock, no par value per share, of HealthStream, Inc.
    4.2*   Reference is made to Exhibits 3.1 and 3.2.
  10.1^*   2000 Stock Incentive Plan, effective as of April 10, 2000
  10.2^ (5)   2010 Stock Incentive Plan, effective as of May 27, 2010
  10.3^*   Form of Indemnification Agreement
  10.4^ (2)   Executive Employment Agreement, dated July 21, 2005, between HealthStream, Inc. and Robert A. Frist, Jr.
  10.5^ (3)   Form of HealthStream, Inc. Non-Qualified Stock Option Agreement (Employees)
  10.6^ (3)   Form of HealthStream, Inc. Incentive Stock Option Agreement (Employees)
  10.7^ (3)   Form of HealthStream, Inc. Non-Qualified Stock Option Agreement (Directors)
  10.8^ (4)   Form of HealthStream, Inc. Restricted Share Unit Agreement (Officers)
  10.9^ (4)   Form of HealthStream, Inc. Restricted Share Unit Agreement (Non-Employee Director)
  10.10 (6)   Revolving Credit Agreement, dated November 24, 2014, by and among HealthStream, Inc., the several banks and other financial institutions and lenders from time to time party thereto and SunTrust Bank, as administrative agent, issuing bank, and swingline lender
  10.11^   Summary of Director and Executive Officer Compensation
  10.12^(8)   HealthStream, Inc. 2015 Cash Incentive Bonus Plan
  10.13 (8)   Contribution Agreement, dated as of June 30, 2015, between HealthStream, Inc. and Robert A. Frist, Jr.
  10.14^(9)   Letter Agreement, dated as of September 24, 2015, between HealthStream, Inc. and Michael Sousa.
  10.15^ (9)   Form of HealthStream, Inc. Restricted Share Unit Agreement (Performance) between HealthStream, Inc. and Michael Sousa.
  10.16^ (9)   Form of HealthStream, Inc. Restricted Share Unit Agreement (Cumulative) between HealthStream, Inc. and Michael Sousa.
  10.17^ (9)   2015 Provider Solutions Cash Incentive Bonus Plan.
  21.1   Subsidiaries of HealthStream, Inc.
  23.1   Consent of Independent Registered Public Accounting Firm
  31.1   Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
  31.2   Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
  32.1   Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
  32.2   Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.1 INS   XBRL Instance Document
101.1 SCH   XBRL Taxonomy Extension Schema
101.1 CAL   XBRL Taxonomy Extension Calculation Linkbase
101.1 DEF   XBRL Taxonomy Extension Definition Linkbase
101.1 LAB   XBRL Taxonomy Extension Label Linkbase
101.1 PRE   XBRL Taxonomy Extension Presentation Linkbase

 

* Incorporated by reference to Registrant’s Registration Statement on Form S-1, as amended (Reg. No. 333-88939).
^ Management contract or compensatory plan or arrangement
(1) Incorporated by reference from exhibit filed on our Current Report on Form 8-K, dated February 13, 2015.
(2) Incorporated by reference from exhibit filed on our Current Report on Form 8-K, dated July 25, 2005.
(3) Incorporated by reference from exhibit filed on our Current Report on Form 8-K, dated June 1, 2010.
(4) Incorporated by reference from exhibit filed on our Quarterly Report on Form 10-Q, for the quarterly period ended March 31, 2012 filed with the SEC on April 30, 2012.
(5) Incorporated by reference to Appendix B of the Company’s Definitive Proxy Statement filed with the SEC on April 29, 2010.
(6) Incorporated by reference from exhibit filed on our Current Report on Form 8-K, dated November 25, 2014.
(7) Incorporated by reference from exhibit filed on our Current Report on Form 8-K, dated October 23, 2015.
(8) Incorporated by reference from exhibit filed on our Quarterly Report on Form 10-Q, for the quarterly period ended June 30, 2015, filed with the SEC on July 31, 2015.
(9) Incorporated by reference from exhibit filed on our Quarterly Report on Form 10-Q, for the quarterly period ended September 30, 2015, filed with the SEC on October 30, 2015.

 

60


Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 26th day of February, 2016.

 

HEALTHSTREAM, INC.
By:  

/s/ ROBERT A. FRIST, JR.

Robert A. Frist, Jr.
Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated:

 

Signature

  

Title(s)

 

Date

/s/ ROBERT A. FRIST, JR.

Robert A. Frist, Jr.

  

President, Chief Executive Officer and Chairman (Principal Executive Officer)

  February 26, 2016

/s/ GERARD M. HAYDEN, JR.

Gerard M. Hayden, Jr.

  

Chief Financial Officer and Senior Vice President (Principal Financial and Accounting Officer)

  February 26, 2016

/s/ THOMPSON DENT

Thompson Dent

  

Director

  February 26, 2016

/s/ FRANK GORDON

Frank Gordon

  

Director

  February 26, 2016

/s/ C. MARTIN HARRIS

C. Martin Harris

  

Director

  February 26, 2016

/s/ JEFFREY L. MCLAREN

Jeffrey L. McLaren

  

Director

  February 26, 2016

/s/ DALE POLLEY

Dale Polley

  

Director

  February 26, 2016

/s/ LINDA REBROVICK

Linda Rebrovick

  

Director

  February 26, 2016

/s/ MICHAEL SHMERLING

Michael Shmerling

  

Director

  February 26, 2016

/s/ WILLIAM STEAD

William Stead

  

Director

  February 26, 2016

/s/ DEBORAH TAYLOR TATE

Deborah Taylor Tate

  

Director

  February 26, 2016

 

61


Table of Contents

INDEX TO EXHIBITS

 

Exhibit
Number

 

Description

    2.1 (1)   Membership Interest Purchase Agreement, dated as of February 12, 2015, between HealthStream, Inc., Littrell Holdings, Inc., HealthLine Systems, Inc., the Shareholders of HealthLine Systems, Inc., and Dan Littrell in his individual capacity and as the Shareholders Representative.
    3.1*   Form of Fourth Amended and Restated Charter of HealthStream, Inc.
    3.2(7)*   Form of Second Amended and Restated Bylaws of HealthStream, Inc.
    4.1*   Form of certificate representing the common stock, no par value per share, of HealthStream, Inc.
    4.2*   Reference is made to Exhibits 3.1 and 3.2.
  10.1^*   2000 Stock Incentive Plan, effective as of April 10, 2000
  10.2^ (5)   2010 Stock Incentive Plan, effective as of May 27, 2010
  10.3^*   Form of Indemnification Agreement
  10.4^ (2)   Executive Employment Agreement, dated July 21, 2005, between HealthStream, Inc. and Robert A. Frist, Jr.
  10.5^ (3)   Form of HealthStream, Inc. Non-Qualified Stock Option Agreement (Employees)
  10.6^ (3)   Form of HealthStream, Inc. Incentive Stock Option Agreement (Employees)
  10.7^ (3)   Form of HealthStream, Inc. Non-Qualified Stock Option Agreement (Directors)
  10.8^ (4)   Form of HealthStream, Inc. Restricted Share Unit Agreement (Officers)
  10.9^ (4)   Form of HealthStream, Inc. Restricted Share Unit Agreement (Non-Employee Director)
  10.10 (6)   Revolving Credit Agreement, dated November 24, 2014, by and among HealthStream, Inc., the several banks and other financial institutions and lenders from time to time party thereto and SunTrust Bank, as administrative agent, issuing bank, and swingline lender
  10.11^   Summary of Director and Executive Officer Compensation
  10.12^(8)   HealthStream, Inc. 2015 Cash Incentive Bonus Plan
  10.13 (8)   Contribution Agreement, dated as of June 30, 2015, between HealthStream, Inc. and Robert A. Frist, Jr.
  10.14^(9)   Letter Agreement, dated as of September 24, 2015, between HealthStream, Inc. and Michael Sousa.
  10.15^ (9)   Form of HealthStream, Inc. Restricted Share Unit Agreement (Performance) between HealthStream, Inc. and Michael Sousa.
  10.16^ (9)   Form of HealthStream, Inc. Restricted Share Unit Agreement (Cumulative) between HealthStream, Inc. and Michael Sousa.
  10.17^ (9)   2015 Provider Solutions Cash Incentive Bonus Plan.
  21.1   Subsidiaries of HealthStream, Inc.
  23.1   Consent of Independent Registered Public Accounting Firm
  31.1   Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
  31.2   Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
  32.1   Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
  32.2   Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.1 INS   XBRL Instance Document
101.1 SCH   XBRL Taxonomy Extension Schema
101.1 CAL   XBRL Taxonomy Extension Calculation Linkbase
101.2 DEF   XBRL Taxonomy Extension Definition Linkbase
101.1 LAB   XBRL Taxonomy Extension Label Linkbase
101.1 PRE   XBRL Taxonomy Extension Presentation Linkbase

 

* Incorporated by reference to Registrant’s Registration Statement on Form S-1, as amended (Reg. No. 333-88939).
^ Management contract or compensatory plan or arrangement
(1) Incorporated by reference from exhibit filed on our Current Report on Form 8-K, dated February 13, 2015.
(2) Incorporated by reference from exhibit filed on our Current Report on Form 8-K, dated July 25, 2005.
(3) Incorporated by reference from exhibit filed on our Current Report on Form 8-K, dated June 1, 2010.
(4) Incorporated by reference from exhibit filed on our Quarterly Report on Form 10-Q, for the quarterly period ended March 31, 2012 filed with the SEC on April 30, 2012.
(5) Incorporated by reference to Appendix B of the Company’s Definitive Proxy Statement filed with the SEC on April 29, 2010.
(6) Incorporated by reference from exhibit filed on our Current Report on Form 8-K, dated November 25, 2014.
(7) Incorporated by reference from exhibit filed on our Current Report on Form 8-K, dated October 23, 2015.
(8) Incorporated by reference from exhibit filed on our Quarterly Report on Form 10-Q, for the quarterly period ended June 30, 2015, filed with the SEC on July 31, 2015.
(9) Incorporated by reference from exhibit filed on our Quarterly Report on Form 10-Q, for the quarterly period ended September 30, 2015, filed with the SEC on October 30, 2015.
EX-10.11 2 d111635dex1011.htm EX-10.11 EX-10.11

EXHIBIT 10.11

HealthStream, Inc. (the “Company”)

Summary of Director and Executive Officer Compensation

I. Director Compensation. Directors who are employees of the Company do not receive additional compensation for serving as directors of the Company. The following table sets forth current rates of cash compensation for the Company’s non-employee directors. For fiscal year 2016, each director will receive an annual retainer of $5,000, except for the Audit Committee Chair and Nominating and Corporate Governance Chair, who will receive an additional annual retainer of $7,500, and the Compensation Committee Chair, who will receive an additional annual retainer of $2,000. Non-employee directors will also receive a $15,000 flat-fee for board and committee meeting attendance and participation.

In addition to the cash compensation set forth above, each non-employee director is eligible to receive a nondiscretionary annual grant of restricted share units for conversion to shares of the Company’s common stock. The restricted share units are granted annually and vest ratably over a three year period.

II. Executive Officer Compensation. The following table sets forth the current base salaries and fiscal 2015 performance bonuses provided to our executive officers, including the individuals who the Company expects to be its Named Executive Officers for 2015.

 

Executive Officer

   Current Base Salary      Fiscal 2015 Bonus Amount  

Robert A. Frist, Jr.

   $ 296,801       $ 89,040   

J. Edward Pearson

   $ 280,446       $ 84,134   

Gerard M. Hayden, Jr.

   $ 258,695       $ 77,609   

Jeffrey S. Doster

   $ 256,208       $ 76,862   

Michael Sousa

   $ 270,400       $ 108,160   

Thomas Schultz

   $ 207,000         N/A   

Bonus targets for 2016 cash bonuses and 2016 equity grants for executive officers have not yet been determined by the Compensation Committee.

III. Additional Information. The foregoing information is summary in nature. Additional information regarding Director and Named Executive Officer compensation will be contained in the Company’s 2016 Proxy Statement.

EX-21.1 3 d111635dex211.htm EX-21.1 EX-21.1

EXHIBIT 21.1

SUBSIDIARIES OF HEALTHSTREAM, INC.

 

Names Under Which We Do Business

  

State or Other Jurisdiction of

Incorporation or

Organization

Data Management & Research, Inc.    Tennessee
The Jackson Organization, Research Consultants, Inc.    Maryland
Decision Critical, Inc.    Texas
Echo, Inc.    Tennessee
Health Care Compliance Strategies, Inc.    New York
HealthStream Acquisition I, Inc.    Tennessee
HealthStream Acquisition II, Inc.    Tennessee
EX-23.1 4 d111635dex231.htm EX-23.1 EX-23.1

EXHIBIT 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the following Registration Statements:

 

  (1) Registration Statement (Form S-8 No. 333-167241) pertaining to the 2010 Stock Incentive Plan of HealthStream, Inc.,

 

  (2) Registration Statement (Form S-8 No. 333-37440) pertaining to the 1994 Employee Stock Option Plan, 2000 Stock Incentive Plan and Employee Stock Purchase Plan of HealthStream, Inc., and

 

  (3) Registration Statement (Form S-3 No. 333-206897) of HealthStream, Inc.

of our reports dated February 26, 2016, with respect to the consolidated financial statements of HealthStream, Inc., and the effectiveness of internal control over financial reporting of HealthStream, Inc., included in this Annual Report (Form 10-K) of HealthStream, Inc. for the year ended December 31, 2015.

/s/ Ernst & Young LLP

Nashville, Tennessee

February 26, 2016

EX-31.1 5 d111635dex311.htm EX-31.1 EX-31.1

EXHIBIT 31.1

CERTIFICATION

I, Robert A. Frist, Jr., certify that:

 

1. I have reviewed this annual report on Form 10-K of HealthStream, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: February 26, 2016    

/s/ ROBERT A. FRIST, JR.

    Robert A. Frist, Jr.
    Chief Executive Officer
EX-31.2 6 d111635dex312.htm EX-31.2 EX-31.2

EXHIBIT 31.2

CERTIFICATION

I, Gerard M. Hayden, Jr., certify that:

 

1. I have reviewed this annual report on Form 10-K of HealthStream, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: February 26, 2016    

/s/ GERARD M. HAYDEN, JR.

    Gerard M. Hayden, Jr.
    Chief Financial Officer
EX-32.1 7 d111635dex321.htm EX-32.1 EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of HealthStream, Inc. (the “Company”) on Form 10-K for the year ending December 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Robert A. Frist, Jr., Chief Executive Officer of the Company certifies, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ ROBERT A. FRIST, JR.

Robert A. Frist, Jr.
Chief Executive Officer
February 26, 2016
EX-32.2 8 d111635dex322.htm EX-32.2 EX-32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of HealthStream, Inc. (the “Company”) on Form 10-K for the year ending December 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Gerard M. Hayden, Jr., Chief Financial Officer of the Company certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ GERARD M. HAYDEN, JR.

Gerard M. Hayden, Jr.
Chief Financial Officer
February 26, 2016
EX-101.INS 9 hstm-20151231.xml XBRL INSTANCE DOCUMENT 31651860 25000000 28000000 768800000 4931 132196000 142000 41365000 -25842000 26233000 158020000 18000 149433000 167000 211000 212594000 35746000 59537000 24154000 34727000 6168000 48514000 5424000 11499000 117854000 -17424000 27327000 166888000 -31000 596000 75000000 6.18 27677000 27677000 5485000 2311000 167859000 125000 2649000 13834000 2369000 2168000 1602000 278000 53716000 4753000 331000 7224000 -7030000 257262000 343000 3657000 174926000 10321000 0 26105000 3836000 77259000 355000 2171000 9255000 -37000 5838000 18114000 1565000 0 355000 715000 5191000 2037000 13030000 12706000 1015000 257262000 616000 33167000 9442000 38973000 1678000 4836000 174611000 5768000 134000 28629000 14795000 41914000 81995000 35547000 1757000 791000 1954000 5300000 3346000 11880000 23329000 11449000 25133000 4554000 5860000 0 38973000 37000 39010000 0 32695000 37000 32732000 0 6278000 6278000 24154000 34536000 12336000 81116000 5424000 10976000 130634000 164000 25.04 -7030000 27677000 174926000 -37000 520000 75000000 6.45 31647000 520000 487000 31647000 6.45 22.00 2625000 3876000 4763000 12088000 3308000 280320000 810000 14000 1058000 8685000 2646000 658000 1911000 278000 65098000 4616000 303000 7003000 1591000 379569000 4350000 278799000 10922000 808000 0 19359000 4559000 2604000 89078000 346000 1806000 9053000 -70000 1365000 4763000 24130000 2062000 8081000 0 407000 348000 6505000 927000 14036000 13955000 1107000 379569000 816000 6211000 6323000 1563000 36348000 300000 12471000 66976000 6400000 1998000 6159000 26553000 4913000 209537000 8169000 80000 122000 64651000 47200000 55966000 83073000 82010000 5566000 31830000 8081000 3640000 816000 3700000 2617000 9080000 6463000 6068000 55571000 42600000 49503000 900000 50000000 50000000 0 25000000 5000000 5000000 23057000 4338000 4435000 0 66976000 70000 67046000 0 65976000 70000 66046000 0 1000000 1000000 3900000 1900000 24154000 34902000 12336000 82375000 46583000 100948000 75000000 10000000 161344000 13000000 218000 25.21 3000000 4793000 1591000 31647000 278799000 -70000 254000 28000 1600000 145000 6300000 508000 1700000 600000 2700000 8400000 2600000 6200000 625000 3200000 5979000 1085000 700000 200000 2523000 300000 3052000 47200000 41618000 546000 54000 88129000 15000000 2 600 P1Y 49310 54241 0.30 27054000 70000 27663000 810000 26853000 0.31 4267000 4444000 54000 3722000 86139000 8418000 164000 132274000 51000 1458000 1207000 723000 7560000 14666000 -105000 176000 5119000 300000 -49000 534000 3722000 771000 8369000 -49000 10056000 14842000 3154000 371000 534000 -37000 6424000 5062000 2315000 191000 14761000 24052000 155000 18342000 2400000 18172000 231000 -14987000 117608000 6105000 11757000 46000 2506000 0 1660000 5593000 1444000 3318000 1458000 8711000 400000 2474000 3722000 5194000 25846000 82661000 1254000 3399000 7852000 55605000 0 115000 898000 175000 81000 1058000 144000 28454000 2819000 726000 1068000 99963000 28203000 6243000 2829000 3857000 277000 67000 683000 -16633000 1675000 3272000 8418000 15000 1079000 1458000 534000 3722000 3154000 -49000 150000 0.37 34256000 70000 28023000 453000 27570000 0.38 5658000 4544000 1160000 3234000 44341000 10394000 161000 170690000 56000 1625000 2022000 630000 12298000 16375000 1761000 146000 4174000 325000 -6000 2246000 3234000 424000 10388000 -6000 6690000 16521000 4300000 933000 1641000 2246000 2168000 -65000 6127000 274000 167000 1092000 232000 17471000 29867000 118000 22909000 3100000 22458000 37000 -15541000 154315000 3743000 16463000 117000 1324000 0 1394000 5434000 1605000 1094000 1625000 10202000 700000 3198000 3234000 5782000 5912000 2400000 52625000 2442000 820000 4100000 10931000 74145000 0 237000 1350000 1000000 224000 86000 1114000 201000 4200000 31901000 810000 1277000 1272000 134242000 35374000 7179000 4813000 6168000 4547000 826000 200000 683000 -20635000 1546000 4163000 5327 161000 1100000 10394000 82000 268000 1625000 2246000 3234000 933000 -6000 365000 6168000 0.31 0.31 8658000 182548000 329000 FY 0.28 34917000 0 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Significant components of deferred tax assets and deferred tax liabilities are as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="6" align="center"> <b>December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Deferred tax assets:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Allowance for doubtful accounts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">122</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">134</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Accrued liabilities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,062</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,565</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Tax credits</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">816</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">791</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Stock based compensation</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,107</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,015</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Deferred revenue</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,563</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">616</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Depreciation</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">348</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">715</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Basis difference on investments</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">80</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Net operating loss carryforwards</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">407</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">355</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total deferred tax assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,505</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,191</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Less: Valuation allowance</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(346</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(355</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Deferred tax assets, net of valuation allowance</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,159</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,836</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Deferred tax liabilities:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Deductible goodwill</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,646</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,369</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Nondeductible intangible assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,806</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,171</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Prepaid assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,911</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,602</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Capitalized software development</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,559</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,836</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Basis difference on investments</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">343</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total deferred tax liabilities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10,922</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10,321</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Net deferred tax liabilities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(4,763</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(5,485</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 3 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b>12. EMPLOYEE BENEFIT PLAN</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b>401(k) Plan</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The Company has a defined-contribution employee benefit plan (401(k)&#xA0;Plan) incorporating provisions of Section&#xA0;401(k) of the Internal Revenue Code. Employees must have attained the age of 21 and have completed thirty days of service to be eligible to participate in the 401(k) Plan. Under the provisions of the 401(k) Plan, a plan member may make contributions, on a tax-deferred basis, subject to IRS limitations. The Company elected to provide eligible employees with matching contributions totaling approximately $645,000 and $274,000 for the years ended December&#xA0;31, 2015 and 2014, respectively.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> The following table summarizes the preliminary fair value of the assets acquired and liabilities assumed as of the date of acquisition (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Cash</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">54</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Accounts receivable, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,052</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Prepaid assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">546</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Property and equipment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">200</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Deferred tax assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,523</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Goodwill</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">41,618</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Intangible assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">47,200</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Accounts payable and accrued liabilities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1,085</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Deferred revenue</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(5,979</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Preliminary net assets acquired</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">88,129</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The amounts of revenue and operating income (loss) of HLS included in the Company&#x2019;s consolidated statements of income from the date of acquisition of March&#xA0;16, 2015 to the period ending December&#xA0;31, 2015 are as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total revenues</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,543</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Operating loss</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,541</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The following unaudited pro forma financial information summarizes the combined results of operations of the Company and HLS, which was significant for purposes of the unaudited pro forma financial information disclosure, as though the companies were combined as of January&#xA0;1, 2014 (in thousands, except per share data):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Year Ended</b><br /> <b>December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total revenues</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">219,108</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">182,548</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Net income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,551</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,658</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Basic earnings per share</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.45</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.31</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Diluted earnings per share</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.44</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.31</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /> </div> 2015 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The provision (benefit) for income taxes is comprised of the following (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="10" align="center"><b>Year Ended December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Current federal</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,608</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,198</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,474</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Current state</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,098</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,605</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,444</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Deferred federal</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">501</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,092</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,315</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Deferred state</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(109</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">232</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">191</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Provision for income taxes</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,098</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,127</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,424</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> false <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b>4. MARKETABLE SECURITIES</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> At December&#xA0;31, 2015 and 2014, the fair value of marketable securities, which were all classified as available for sale, included the following (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>December&#xA0;31, 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Adjusted&#xA0;Cost</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Unrealized<br /> Gains</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Unrealized<br /> Losses</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Fair&#xA0;Value</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Level 2:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Certificates of deposit</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Corporate debt securities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">66,046</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(70</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">65,976</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">67,046</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(70</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">66,976</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="16"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>December&#xA0;31, 2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Adjusted&#xA0;Cost</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Unrealized<br /> Gains</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Unrealized<br /> Losses</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Fair&#xA0;Value</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Level 2:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Certificates of deposit</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,278</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,278</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Corporate debt securities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">32,732</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(37</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">32,695</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">39,010</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(37</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">38,973</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The carrying amounts of the marketable securities reported in the consolidated balance sheets approximate fair value based on quoted market prices or alternative pricing sources and models utilizing market observable inputs. As of December&#xA0;31, 2015, the Company does not consider any of its marketable securities to be other than temporarily impaired. During the years ended December&#xA0;31, 2015 and 2014, the Company did not reclassify any items out of accumulated other comprehensive income to net income. All investments in marketable securities are classified as a current asset on the balance sheet because the underlying securities mature within one year from the balance sheet date.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> A summary of activity relative to RSUs for the year ended December&#xA0;31, 2015 is follows (in thousands, except weighted average grant date fair value):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="59%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="3" colspan="2" align="center"><b>Number&#xA0;of</b><br /> <b>RSU&#x2019;s</b></td> <td valign="bottom" rowspan="3">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="3" colspan="2" align="center"><b>Weighted-</b><br /> <b>Average</b><br /> <b>Grant&#xA0;Date&#xA0;Fair&#xA0;Value</b></td> <td valign="bottom" rowspan="3">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="3" colspan="2" align="center"><b>Aggregate</b><br /> <b>Intrinsic&#xA0;Value</b></td> <td valign="bottom" rowspan="3">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Outstanding at beginning of period</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">164</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">25.04</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Granted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">110</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">24.97</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Vested</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(54</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">24.17</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Forfeited</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">26.03</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Outstanding at end of period</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">218</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">25.21</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,793</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The expected future annual amortization expense for the years ending December&#xA0;31, is as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2016</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,400</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2017</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,323</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,211</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2019</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,566</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2020</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,913</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Thereafter</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">26,553</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">55,966</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Recognition of Revenue</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Revenues are derived from providing services through our SaaS-based workforce development platform products, courseware subscriptions, provision of survey and research services, sales of software licensing arrangements, software maintenance and support, professional services, custom courseware development and other education and training services.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The Company recognizes revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when persuasive evidence of an arrangement exists, prices are fixed or determinable, services and products are provided to the customer and collectability is probable or reasonably assured.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Revenue recognized from software and other arrangements is allocated to each element of the arrangement based on the relative fair values of the elements. While elements include software products and post contract customer support, the fair value of each element is based on vendor specific objective evidence (VSOE). If fair value cannot be determined for each element of the arrangement, all revenue from the arrangement is deferred until fair value can be determined or until all elements of the arrangement are delivered and customer acceptance has occurred. Sales of the Company&#x2019;s SaaS-based workforce development platform products include customer support, implementation services, and training; therefore all revenues are deferred until the SaaS-based product is implemented, at which time revenues are recognized ratably over the subscription service period. In the event that circumstances occur, which give rise to uncertainty regarding the collectibility of contracted amounts, revenue recognition is suspended until such uncertainty is resolved. Fees for these services are billed on either a monthly, quarterly, or annual basis.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Revenues derived from the delivery of services through the Company&#x2019;s SaaS-based workforce development platform products and courseware subscriptions are recognized ratably over the term of the subscription service agreement or over the historical usage period, if usage typically differs from the subscription period. Other training revenues are generally recognized upon the completion of training.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Revenues derived from the license of installed software products are recognized upon shipment or installation of the software, when VSOE of the fair value of the software license can be established. Software support and maintenance revenues are recognized ratably over the term of the related agreement.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> Revenues recognized from the Company&#x2019;s survey and research services are determined using both the proportional performance method and the completed contract method. Revenues are generally earned over the estimated survey cycle, which typically ranges from less than one month to up to five months. The survey cycle is generally initiated based on the receipt of the first survey response and runs through provision of related survey reports to the customer. If survey results are not available to the customer during the survey fielding cycle, revenues are recognized at time of report delivery. Revenues for coaching and consulting engagements are recognized using the proportional performance method over the term of the underlying contract. Fees for survey services are billed upon initiation of the survey cycle, with progress billings made throughout the survey cycle. Fees for coaching and consulting engagements are billed upon initiation of the engagement with progress billings throughout the term of the contract.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Revenues from professional services and courseware development services are recognized upon the completion of performance milestones and deliverables using the proportional performance method. All other revenues are recognized as the related services are performed or products are delivered. Fees for these services are generally billed at project initiation and upon completion of various milestones.</p> </div> 0 P12Y2M12D <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>5. BUSINESS COMBINATIONS</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b><i>HealthLine Systems</i></b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> On March&#xA0;16, 2015, the Company acquired all of the membership interests of HealthLine Systems, LLC (HLS), a San Diego, California based company that specializes in credentialing, privileging, call center, and quality management solutions for the healthcare industry. The acquisition of HLS enables the Company to provide a comprehensive solution set for healthcare provider credentialing, privileging, enrollment, referral, onboarding, and analytics in support of HealthStream&#x2019;s approach to talent management for healthcare organizations. The consideration paid for HLS consisted of approximately $88.1 million in cash (taking into account an estimated closing working capital adjustment). The Company incurred approximately $1.3 million in transaction costs associated with the acquisition, of which $965,000 were incurred during the year ended December&#xA0;31, 2015 and $329,000 were incurred during the year ended December&#xA0;31, 2014. The transaction costs were recorded under the caption &#x201C;other general and administrative&#x201D; in the consolidated statements of income. The results of operations for HLS have been included in the Company&#x2019;s consolidated financial statements from the date of acquisition, and are also included in the HealthStream Provider Solutions segment.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> A summary of the purchase price is as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="87%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Cash paid at closing</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">&#xA0;81,379</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Cash held in escrow</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,750</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Total consideration paid</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">88,129</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The following table summarizes the preliminary fair value of the assets acquired and liabilities assumed as of the date of acquisition (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Cash</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">54</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Accounts receivable, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,052</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Prepaid assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">546</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Property and equipment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">200</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Deferred tax assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,523</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Goodwill</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">41,618</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Intangible assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">47,200</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Accounts payable and accrued liabilities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1,085</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Deferred revenue</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(5,979</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Preliminary net assets acquired</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">88,129</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The excess of preliminary purchase price over the preliminary fair values of net tangible and intangible assets is recorded as goodwill. The preliminary fair values of tangible and identifiable intangible assets, deferred tax assets, deferred revenue, and other liabilities are based on management&#x2019;s estimates and assumptions. The preliminary fair values of assets acquired and liabilities assumed are considered preliminary and are based on the information that was available at the time of the acquisition. The preliminary fair values of assets acquired and liabilities assumed are subject to change during the measurement period (up to one year from the acquisition date) as we finalize the valuation of tax liabilities and determine final working capital adjustments. Included in the preliminary assets and liabilities is an estimated indemnification asset of $300,000 and a contingent liability of $700,000, both of which are associated with tax liabilities. The contingent liability is measured based on management&#x2019;s estimate of a range of probable outcomes. During the fourth quarter of 2015, the Company reduced the preliminary fair value for accounts receivable by $115,000, prepaid assets by $200,000, and accrued liabilities by $800,000. The goodwill balance is primarily attributed to the assembled workforce, additional market opportunities from offering HLS&#x2019;s products, and expected synergies from integrating HLS with other products or other combined functional areas within the Company. The goodwill balance is deductible for U.S. income tax purposes. The net tangible assets include deferred revenue, which was adjusted down from a book value at the acquisition date of $15.0 million to an estimated fair value of $6.0 million. The $9.0 million write-down of deferred revenue will result in lower revenues than would have otherwise been recognized for such services.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The following table sets forth the components of identifiable intangible assets and their estimated useful lives as of the acquisition date (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Preliminary<br /> fair</b><br /> <b>Value</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Useful&#xA0;life</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Customer relationships</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">42,600</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13&#xA0;years</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Developed technology</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,700</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5&#xA0;years</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Trade names</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">900</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6&#xA0;years</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total preliminary intangible assets subject to amortization</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">47,200</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The weighted average amortization period for the identifiable intangible assets acquired is 12.2 years.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The amounts of revenue and operating income (loss) of HLS included in the Company&#x2019;s consolidated statements of income from the date of acquisition of March&#xA0;16, 2015 to the period ending December&#xA0;31, 2015 are as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total revenues</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,543</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Operating loss</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,541</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The following unaudited pro forma financial information summarizes the combined results of operations of the Company and HLS, which was significant for purposes of the unaudited pro forma financial information disclosure, as though the companies were combined as of January&#xA0;1, 2014 (in thousands, except per share data):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Year Ended</b><br /> <b>December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total revenues</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">219,108</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">182,548</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Net income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,551</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,658</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Basic earnings per share</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.45</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.31</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Diluted earnings per share</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.44</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.31</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> These unaudited pro forma combined results of operations include certain adjustments arising from the acquisition such as adjustment for amortization of intangible assets, depreciation of property and equipment, fair value adjustments of acquired deferred revenue balances, and interest expense associated with borrowings under a revolving credit facility by the Company to partially fund the acquisition. The pro forma combined results for the year ended December&#xA0;31, 2014 include nonrecurring adjustments of $4.2 million, which reduce net income due to the revaluation of HLS&#x2019;s historic deferred revenue to fair value. The unaudited pro forma combined results of operations is for informational purposes only and is not indicative of what the Company&#x2019;s results of operations would have been had such transactions occurred at the beginning of the period presented or to project the Company&#x2019;s results of operations in any future period.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The unaudited pro forma financial information for the years ended December&#xA0;31, 2015 and 2014 combines the historical results of the Company and HLS for the years ended December&#xA0;31, 2015 and 2014 and the pro forma adjustments listed above.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b><i>Health Care Compliance Strategies</i></b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> On March&#xA0;3, 2014, the Company acquired all of the stock of Health Care Compliance Strategies, Inc. (HCCS), a Jericho, New York based company that specializes in healthcare compliance solutions and services. The Company acquired HCCS to further advance its suite of workforce development solutions, including its offering of compliance solutions. The consideration paid for HCCS consisted of approximately $12.8 million in cash (taking into account a post-closing working capital adjustment) and 81,614 shares of our common stock. The Company made an additional payment of $750,000 during the second quarter of 2015, upon the achievement of certain performance milestones within one year post-closing. The Company incurred approximately $515,000 in transaction costs associated with the acquisition, of which $365,000 were incurred during the year ended December&#xA0;31, 2014 and $150,000 were incurred during the year ended December&#xA0;31, 2013. The transaction costs were recorded under the caption &#x201C;other general and administrative&#x201D; in the consolidated statements of income. In allocating the purchase price, the Company recorded approximately $6.2 million of goodwill, $8.4 million of identifiable intangible assets, $2.6 million of tangible assets, $625,000 of deferred tax assets, and $2.7 million of liabilities. Included in the recorded liabilities was an accrual for contingent consideration of approximately $600,000. The goodwill balance is primarily attributed to assembled workforce, additional market opportunities of HCCS&#x2019;s compliance solutions, and expected synergies from integrating HCCS&#x2019;s products into our platform. The goodwill balance is deductible for U.S. income tax purposes. The net tangible assets include deferred revenue, which was adjusted down from a book value at the acquisition date of $3.2 million to an estimated fair value of $1.7 million. The $1.5 million write-down of deferred revenue resulted in lower revenues than would have otherwise been recognized for such services. The results of operations for HCCS have been included in the Company&#x2019;s consolidated financial statements from the date of acquisition, and are also included in the HealthStream Workforce Development Solutions segment.</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b><i>Baptist Leadership Group</i></b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> On September&#xA0;9, 2013, the Company acquired substantially all of the assets of Baptist Leadership Group (BLG), a Pensacola, Florida based company that provides consulting services focused on patient-centered performance excellence in healthcare. The Company acquired BLG to strengthen its Patient Experience Solutions. The consideration paid for BLG consisted of approximately $7.4 million in cash (taking into account the working capital adjustment) and 15,230 shares of our common stock. The Company incurred approximately $145,000 in transaction costs associated with the acquisition, which are included on the accompanying consolidated statements of income under the caption &#x201C;other general and administrative.&#x201D; In allocating the purchase price, the Company recorded approximately $6.3 million of goodwill, $1.6 million of identifiable intangible assets, and $28,000 of net tangible assets. The goodwill balance is primarily attributed to the assembled workforce, additional market opportunities from BLG&#x2019;s consulting services, and expected synergies from integrating BLG into the operations of the HealthStream Patient Experience Solutions segment. The goodwill balance is deductible for U.S. income tax purposes. The net tangible assets include deferred revenue, which was adjusted down from a book value of $508,000 to an estimated fair value of $254,000. The $254,000 write-down of deferred revenue resulted in lower revenues than would have otherwise been recognized for such services. The results of operations for BLG have been included in the Company&#x2019;s consolidated financial statements from the date of acquisition, and are included in the HealthStream Patient Experience Solutions segment.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>13. DEBT</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> At December&#xA0;31, 2015 and 2014, the Company had no debt outstanding.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <u>Revolving Credit Facility</u></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The Company maintains a Loan Agreement (the &#x201C;Revolving Credit Facility&#x201D;) with SunTrust Bank (&#x201C;SunTrust&#x201D;) in the aggregate principal amount of $50.0 million, which matures on November&#xA0;24, 2017. Under the Revolving Credit Facility, the Company may borrow up to $50.0 million, which includes a $5.0 million swing line subfacility, as well as an accordion feature that allows the Company to increase the Revolving Credit Facility by a total of up to $25.0 million, subject to securing additional commitments from existing lenders or new lending institutions. The Revolving Credit Facility includes a $5.0 million letter of credit subfacility. The obligations under the Revolving Credit Facility are guaranteed by each of the Company&#x2019;s subsidiaries. At the Company&#x2019;s election, the borrowings under the Revolving Credit Facility bear interest at either (1)&#xA0;a rate per annum equal to the highest of SunTrust&#x2019;s prime rate or 0.5% in excess of the Federal Funds Rate or 1.0% in excess of one-month LIBOR (the &#x201C;Base Rate&#x201D;), plus an applicable margin, or (2)&#xA0;the one, two, three, or six-month per annum LIBOR for deposits in the applicable currency (the &#x201C;Eurocurrency Rate&#x201D;), as selected by the Company, plus an applicable margin. The applicable margin for Eurocurrency Rate loans depends on the Company&#x2019;s funded debt leverage ratio and varies from 1.50% to 2.00%. The applicable margin for Base Rate loans depends on the Company&#x2019;s funded debt leverage ratio and varies from 0.50% to 1.50%. Commitment fees and letter of credit fees are also payable under the Revolving Credit Facility. Principal is payable in full at maturity on November&#xA0;24, 2017, and there are no scheduled principal payments prior to maturity. The Company is required to pay a commitment fee ranging between 20 and 30 basis points per annum of the average daily unused portion of the Revolving Credit Facility, depending on the Company&#x2019;s funded debt leverage ratio.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The purpose of the Revolving Credit Facility is for general working capital needs, permitted acquisitions (as defined in the Loan Agreement), and for stock repurchase and/or redemption transactions that the Company may authorize.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The Revolving Credit Facility contains certain covenants that, among other things, restrict additional indebtedness, liens and encumbrances, changes to the character of the Company&#x2019;s business, acquisitions, asset dispositions, mergers and consolidations, sale or discount of receivables, creation or acquisitions of additional subsidiaries, and other matters customarily restricted in such agreements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> As of December&#xA0;31, 2015, the Company was in material compliance with all covenants. There were no balances outstanding on the Revolving Credit Facility as of December&#xA0;31, 2015. During the three months ended March&#xA0;31, 2015, the Company borrowed approximately $28.0 million under the Revolving Credit Facility. During the three months ended June&#xA0;30, 2015, the Company repaid approximately $28.0 million of balances previously outstanding under the Revolving Credit Facility from proceeds received in the Company&#x2019;s public offering of 3,869,750 shares which closed on May&#xA0;28, 2015. The weighted average interest rate was 1.68% for borrowings under Revolving Credit Facility during the year ended December&#xA0;31, 2015.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b>Reporting Entity and Segments</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> HealthStream, Inc. (the &#x201C;Company&#x201D;) was incorporated in 1990 as a Tennessee corporation and is headquartered in Nashville, Tennessee. The Company operates in three segments: HealthStream Workforce Solutions, HealthStream Patient Experience Solutions, and HealthStream Provider Solutions. Workforce Solutions products consist of SaaS-based services and subscription-based solutions to meet the ongoing training, certification, assessment and development needs of the healthcare community. These solutions provide, deliver and track computer based education for our customers in the United States through our software-as-a-service (SaaS) model. Patient Experience products offer healthcare organizations a wide range of quality and satisfaction surveys, consulting services, analyses of survey results, and other research-based services. Provider Solutions products offer healthcare organizations software applications for administering and tracking provider credentialing, privileging, call center and enrollment.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Property and Equipment</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Property and equipment are stated on the basis of cost. Depreciation and amortization are provided on the <font style="WHITE-SPACE: nowrap">straight-line</font> method over the following estimated useful lives, except for assets under capital leases and leasehold improvements, which are amortized over the shorter of the estimated useful life or their respective lease term.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="91%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Years</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top">Furniture and fixtures</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="top">&#xA0;</td> <td valign="top" align="right"><font style="WHITE-SPACE: nowrap">5-10</font></td> <td valign="top" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top">Equipment</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="top">&#xA0;</td> <td valign="top" align="right"><font style="WHITE-SPACE: nowrap">3-5</font></td> <td valign="top" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> A reconciliation of the beginning and ending liability for gross unrecognized tax benefits at December&#xA0;31, 2015 and 2014, are as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="6" align="center"> <b>December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Balance at beginning of year</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,168</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">167</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Additions for tax positions in the current year</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">351</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,168</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Reductions for tax positions of prior years</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1,861</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(167</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Balance at end of year</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">658</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,168</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 16000 10-K 0001095565 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The following is the Company&#x2019;s business segment information as of and for the years ended December&#xA0;31, 2015, 2014 and 2013 (in thousands).</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="top"><font style="FONT-SIZE: 10pt">Revenues, net:</font></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Workforce</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">161,289</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">134,242</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">99,963</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Patient Experience</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">34,193</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">31,901</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">28,454</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Provider</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13,520</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,547</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,857</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total revenues, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">209,002</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">170,690</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">132,274</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> A summary of the purchase price is as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="87%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Cash paid at closing</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">&#xA0;81,379</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Cash held in escrow</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,750</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Total consideration paid</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">88,129</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> P2Y6M <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b>14. LEASES</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The Company has non-cancellable operating leases primarily for office space, hosting facilities, and office equipment. Some lease agreements contain provisions for escalating rent payments over the initial terms of the lease. The Company accounts for these leases by recognizing rent expense on a <font style="WHITE-SPACE: nowrap">straight-line</font> basis and adjusting the deferred rent expense liability for the difference between the <font style="WHITE-SPACE: nowrap">straight-line</font> rent expense and the amount of rent paid. The terms of the lease agreements generally provide the Company the option to renew. The Company also leases certain office equipment under operating leases. Total rent expense under all operating leases was approximately $4.3 million, $3.1 million, and $2.4 million, for the years ended December&#xA0;31, 2015, 2014, and 2013, respectively.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Future rental payment commitments at December&#xA0;31, 2015 under <font style="WHITE-SPACE: nowrap">non-cancelable</font> operating leases, with initial terms of one year or more, are as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2016</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,876</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2017</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,625</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,365</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2019</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">808</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2020</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">810</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Thereafter</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,604</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total minimum lease payments</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,088</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> The changes in the carrying amount of goodwill for the years ended December&#xA0;31, 2015 and 2014 are as follows (in thousands):</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="64%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Workforce</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Patient<br /> Experience</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Provider</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Total</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Balance at January&#xA0;1, 2015</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,336</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,154</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,424</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">41,914</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Acquisition of HealthLine Systems, LLC</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td nowrap="nowrap" valign="bottom">&#xA0;</td> <td nowrap="nowrap" valign="bottom" align="right"> &#x2014;&#xA0;&#xA0;</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td nowrap="nowrap" valign="bottom">&#xA0;</td> <td nowrap="nowrap" valign="bottom" align="right"> &#x2014;&#xA0;&#xA0;</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">41,618</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">41,618</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Disposal of long lived assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td nowrap="nowrap" valign="bottom">&#xA0;</td> <td nowrap="nowrap" valign="bottom" align="right"> &#x2014;&#xA0;&#xA0;</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td nowrap="nowrap" valign="bottom">&#xA0;</td> <td nowrap="nowrap" valign="bottom" align="right"> &#x2014;&#xA0;&#xA0;</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(459</td> <td nowrap="nowrap" valign="bottom">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(459</td> <td nowrap="nowrap" valign="bottom">)&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Balance at December&#xA0;31, 2015</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,336</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,154</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">46,583</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">83,073</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-size:1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Workforce</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Patient<br /> Experience</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Provider</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Total</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Balance at January&#xA0;1, 2014</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,168</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,154</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,424</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">35,746</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Acquisition of Health Care Compliance Strategies, Inc.</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,168</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td nowrap="nowrap" valign="bottom">&#xA0;</td> <td nowrap="nowrap" valign="bottom" align="right"> &#x2014;&#xA0;&#xA0;</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td nowrap="nowrap" valign="bottom">&#xA0;</td> <td nowrap="nowrap" valign="bottom" align="right"> &#x2014;&#xA0;&#xA0;</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,168</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Balance at December&#xA0;31, 2014</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,336</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,154</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,424</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">41,914</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> P2Y6M 0 Large Accelerated Filer <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Deferred Revenue</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Deferred revenue represents amounts that have been billed or collected in advance of revenue recognition. The Company typically invoices customers in quarterly, bi-annual, or annual installments, and occasionally customers will pay for multi-year contracts in advance. Deferred revenue is recognized as the revenue recognition criteria are met.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Shipping and Handling Costs</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Shipping and handling costs that are associated with our products and services are included in cost of revenues.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Changes in the allowance for doubtful accounts and the amounts charged to bad debt expense for the years ended December&#xA0;31, were as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="43%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Allowance&#xA0;Balance&#xA0;at<br /> Beginning of Period</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"> <b>Charged&#xA0;to&#xA0;Costs&#xA0;and<br /> Expenses</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b><font style="WHITE-SPACE: nowrap">Write-offs</font></b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Allowance&#xA0;Balance&#xA0;at<br /> End of Period</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2015</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">331</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">284</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(312</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">303</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2014</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">211</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">237</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(117</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">331</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2013</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">142</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">115</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(46</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">211</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> </div> The Company did not have any single customer representing over 10% of net revenues during 2015, 2014, or 2013. <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="45%"></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Assets *</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Purchases of long-lived assets</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Depreciation and amortization</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Workforce</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">82,375</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">81,116</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">48,514</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,403</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,179</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,243</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,693</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,813</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,829</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Patient Experience</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">34,902</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">34,536</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">34,727</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,007</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,277</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">726</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,061</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,272</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,068</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Provider</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">100,948</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10,976</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">11,499</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">332</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">200</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">67</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,986</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">683</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">683</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Unallocated</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">161,344</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">130,634</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">117,854</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,617</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,546</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,675</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,257</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,163</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,272</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">379,569</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">257,262</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">212,594</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,359</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,202</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,711</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,997</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,931</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,852</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="2%" align="left">*</td> <td valign="top" align="left">Segment assets include accounts and unbilled receivables, prepaid royalties, prepaid and other current assets, other assets, capitalized software development, certain property and equipment, and intangible assets. Cash and cash equivalents and marketable securities are not allocated to individual segments, and are included within Unallocated. A significant portion of property and equipment assets are included within Unallocated.</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Identifiable intangible assets are comprised of the following (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="51%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>As of December&#xA0;31, 2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>As of December&#xA0;31, 2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Gross&#xA0;Amount</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Accumulated<br /> Amortization</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Net</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Gross&#xA0;Amount</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Accumulated<br /> Amortization</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Net</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Customer related</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">55,571</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(6,068</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">49,503</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,329</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(11,880</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,449</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Other</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9,080</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2,617</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,463</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,300</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1,954</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,346</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">64,651</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(8,685</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">55,966</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">28,629</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(13,834</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,795</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> Less than three months <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Financial Instruments</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The Company has various financial instruments, including cash and cash equivalents, accounts receivable, accounts receivable-unbilled, accounts payable, accrued liabilities, and deferred revenue. The carrying amounts of these financial instruments approximate fair value because of the short term maturity or short term nature of such instruments. The Company also has marketable securities, which are recorded at approximate fair value based on quoted market prices or alternative pricing sources (see Note 4 &#x2013; Marketable Securities).</p> </div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"><font style="FONT-SIZE: 10pt">Operating income:</font></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Workforce</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">39,986</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">35,374</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">28,203</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Patient Experience</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,548</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">810</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,819</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Provider</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2,559</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">826</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">277</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Unallocated</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(25,418</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(20,635</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(16,633</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total operating income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,557</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,375</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,666</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 0 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Concentrations of Credit Risk and Significant Customers</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The Company&#x2019;s credit risks relate primarily to cash and cash equivalents, marketable securities and accounts receivable. The Company places its temporary excess cash investments in high quality, <font style="WHITE-SPACE: nowrap">short-term</font> money market instruments. At times, such investments may be in excess of the FDIC insurance limits. Marketable securities consists primarily of investment grade corporate debt securities and certificates of deposit.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The Company sells its products and services to various companies in the healthcare industry that are located in the United States. We perform ongoing credit evaluations of our customers&#x2019; financial condition and generally require no collateral from customers. An allowance for doubtful accounts is maintained for potentially uncollectible accounts receivable. The Company did not have any single customer representing over 10% of net revenues during 2015, 2014, or 2013.</p> </div> 2016-12-31 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b>8. INTANGIBLE ASSETS</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Intangible assets other than goodwill are considered to have finite useful lives. Customer related intangibles are amortized over their estimated useful lives ranging from five to thirteen years. Other intangible assets include non-competition agreements, technology and patents, and trade names, and are being amortized over periods ranging from three to nine years. During the quarter ended December&#xA0;31, 2015, the Company retired approximately $10.7 million of fully amortized identifiable intangible assets. Gross amounts and related accumulated amortization presented below as of December&#xA0;31, 2015 are reflective of such retirements. Such amounts are also inclusive of identifiable intangible assets recorded in relation to our acquisition of HealthLine Systems, LLC (see Note 5 &#x2013; Business Combinations). Amortization of intangible assets was approximately $5.6 million and $2.4 million for the years ended December&#xA0;31, 2015 and 2014, respectively.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Identifiable intangible assets are comprised of the following (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="51%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>As of December&#xA0;31, 2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>As of December&#xA0;31, 2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Gross&#xA0;Amount</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Accumulated<br /> Amortization</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Net</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Gross&#xA0;Amount</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Accumulated<br /> Amortization</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Net</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Customer related</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">55,571</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(6,068</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">49,503</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,329</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(11,880</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,449</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Other</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9,080</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2,617</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,463</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,300</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1,954</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,346</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">64,651</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(8,685</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">55,966</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">28,629</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(13,834</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,795</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The expected future annual amortization expense for the years ending December&#xA0;31, is as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2016</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,400</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2017</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,323</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,211</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2019</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,566</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2020</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,913</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Thereafter</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">26,553</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">55,966</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>6. PROPERTY AND EQUIPMENT</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Property and equipment consist of the following:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="6" align="center"> <b>December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Equipment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,057</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,133</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Leasehold improvements</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,435</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,860</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Furniture and fixtures</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,338</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,554</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Gross property and equipment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">31,830</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">35,547</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Accumulated depreciation and amortization</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(19,359</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(26,105</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Property and equipment, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,471</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,442</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Depreciation of property and equipment totaled approximately $5.3 million and $4.1 million for the years ended December&#xA0;31, 2015 and 2014, respectively.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Prepaid Royalties</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Prepaid royalties represents advance payments associated with the sale of third party products, such as courseware subscriptions. Royalties are typically paid in advance at the commencement of the revenue cycle, or periodically throughout the revenue cycle, such as quarterly, bi-annual, or annual installments. Royalty payments are amortized over the term of the underlying contracts, which generally range from 12 to 36 months, in order to match the direct royalty costs to the same period the subscription revenue is recognized. Amortization of royalties is included under the caption &#x201C;cost of revenues (excluding depreciation and amortization)&#x201D; in the accompanying consolidated statements of income.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>7. GOODWILL</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The changes in the carrying amount of goodwill for the years ended December&#xA0;31, 2015 and 2014 are as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Workforce</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Patient<br /> Experience</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Provider</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Balance at January&#xA0;1, 2015</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,336</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,154</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,424</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">41,914</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Acquisition of HealthLine Systems, LLC</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">41,618</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">41,618</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Disposal of long lived assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(459</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(459</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Balance at December&#xA0;31, 2015</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,336</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,154</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">46,583</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">83,073</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Workforce</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Patient<br /> Experience</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Provider</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Balance at January&#xA0;1, 2014</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,168</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,154</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,424</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">35,746</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Acquisition of Health Care Compliance Strategies, Inc.</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,168</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,168</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Balance at December&#xA0;31, 2014</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,336</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,154</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,424</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">41,914</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> During the quarter ended December&#xA0;31, 2015, the Company disposed of certain long lived assets meeting the definition of a business. Accordingly, we have allocated approximately $459,000 of reporting unit goodwill to this disposition of assets pursuant to ASC 350, <i>Intangibles &#x2013; Goodwill and other.</i></p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Marketable Securities</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Marketable securities are classified as available for sale and are stated at fair market value, with the unrealized gains and losses, net of tax, reported in other comprehensive income (loss) on the accompanying consolidated balance sheets. Realized gains and losses and declines in market value judged to be other than temporary on investments in marketable securities are included in interest and other income on the accompanying consolidated statements of income. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available for sale are included in other income (expense) on the accompanying consolidated statements of income. Premiums and discounts are amortized over the life of the related available for sale security as an adjustment to yield using the effective interest method.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b>Allowance for Doubtful Accounts</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The Company estimates its allowance for doubtful accounts using a specific identification method in which management considers the facts and circumstances surrounding each potentially uncollectible receivable. An allowance is also maintained for accounts that are not specifically identified that may become uncollectible in the future. Uncollectible receivables are written-off in the period management believes it has exhausted every opportunity to collect payment from the customer. Bad debt expense is recorded when events or circumstances indicate an additional allowance is required based on the Company&#x2019;s specific identification approach.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Changes in the allowance for doubtful accounts and the amounts charged to bad debt expense for the years ended December&#xA0;31, were as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="43%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Allowance&#xA0;Balance&#xA0;at<br /> Beginning of Period</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"> <b>Charged&#xA0;to&#xA0;Costs&#xA0;and<br /> Expenses</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b><font style="WHITE-SPACE: nowrap">Write-offs</font></b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Allowance&#xA0;Balance&#xA0;at<br /> End of Period</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2015</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">331</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">284</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(312</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">303</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2014</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">211</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">237</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(117</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">331</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2013</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">142</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">115</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(46</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">211</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>9. BUSINESS SEGMENTS</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The Company provides services to healthcare organizations and other members within the healthcare industry. The Company&#x2019;s services are focused on the delivery of workforce development products and services (HealthStream Workforce Solutions), survey and research services (HealthStream Patient Experience Solutions), and provider credentialing, privileging, call center and enrollment products and services (HealthStream Provider Solutions).</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The Company measures segment performance based on operating income before income taxes and prior to the allocation of certain corporate overhead expenses, interest income, interest expense, gains and losses from equity investments, and depreciation. The Unallocated component below includes corporate functions, such as accounting, human resources, legal, investor relations, administrative and executive personnel, depreciation, a portion of amortization, and certain other expenses, which are not currently allocated in measuring segment performance. The following is the Company&#x2019;s business segment information as of and for the years ended December&#xA0;31, 2015, 2014 and 2013 (in thousands).</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="top"><font style="FONT-SIZE: 10pt">Revenues, net:</font></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Workforce</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">161,289</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">134,242</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">99,963</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Patient Experience</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">34,193</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">31,901</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">28,454</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Provider</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13,520</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,547</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,857</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total revenues, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">209,002</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">170,690</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">132,274</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"><font style="FONT-SIZE: 10pt">Operating income:</font></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Workforce</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">39,986</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">35,374</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">28,203</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Patient Experience</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,548</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">810</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,819</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Provider</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2,559</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">826</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">277</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Unallocated</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(25,418</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(20,635</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(16,633</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total operating income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,557</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,375</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,666</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="45%"></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Assets *</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Purchases of long-lived assets</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Depreciation and amortization</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Workforce</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">82,375</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">81,116</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">48,514</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,403</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,179</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,243</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,693</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,813</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,829</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Patient Experience</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">34,902</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">34,536</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">34,727</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,007</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,277</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">726</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,061</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,272</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,068</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Provider</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">100,948</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10,976</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">11,499</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">332</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">200</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">67</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,986</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">683</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">683</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Unallocated</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">161,344</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">130,634</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">117,854</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,617</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,546</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,675</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,257</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,163</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,272</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">379,569</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">257,262</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">212,594</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,359</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,202</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,711</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,997</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,931</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,852</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="2%" align="left">*</td> <td valign="top" align="left">Segment assets include accounts and unbilled receivables, prepaid royalties, prepaid and other current assets, other assets, capitalized software development, certain property and equipment, and intangible assets. Cash and cash equivalents and marketable securities are not allocated to individual segments, and are included within Unallocated. A significant portion of property and equipment assets are included within Unallocated.</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Principles of Consolidation</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The consolidated financial statements include the accounts of the Company and its subsidiaries, all of which are <font style="WHITE-SPACE: nowrap">wholly-owned.</font> All <font style="WHITE-SPACE: nowrap">inter-company</font> accounts and transactions have been eliminated in consolidation.</p> </div> <div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Property and equipment consist of the following:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="78%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="6" align="center"> <b>December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Equipment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,057</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,133</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Leasehold improvements</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,435</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,860</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Furniture and fixtures</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,338</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,554</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Gross property and equipment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">31,830</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">35,547</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Accumulated depreciation and amortization</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(19,359</td> <td nowrap="nowrap" valign="bottom">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(26,105</td> <td nowrap="nowrap" valign="bottom">)&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Property and equipment, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,471</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,442</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> The following table sets forth the computation of basic and diluted earnings per share for the three years ended December&#xA0;31, 2015 (in thousands, except per share amounts):</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Numerator:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Net income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,621</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,394</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,418</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Denominator:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Weighted-average shares outstanding</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">30,057</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">27,570</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">26,853</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Effect of dilutive shares</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">379</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">453</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">810</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Weighted-average diluted shares</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">30,436</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">28,023</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">27,663</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-size:1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Basic earnings per share</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.29</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.38</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.31</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Diluted earnings per share</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.28</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.37</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.30</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Total stock based compensation expense, which is recorded in our consolidated statements of income, recorded for the years ended December&#xA0;31, is as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="10" align="center"><b>Years Ended December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Cost of revenues (excluding depreciation and amortization)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">824</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">86</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">81</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Product development</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">569</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">201</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">144</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Sales and marketing</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">547</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">224</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">175</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Other general and administrative</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,340</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,114</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,058</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Total stock based compensation expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,280</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,625</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,458</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 0 --12-31 Yes HEALTHSTREAM INC <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b>Goodwill and Intangible Assets</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Goodwill represents the excess of purchase price in a business combination over the fair value of the net identifiable assets acquired. The carrying amount of our goodwill is evaluated for impairment at least annually during the fourth quarter and whenever events or changes in facts or circumstances indicate that impairment may exist. In accordance with ASC 350, <i>Intangibles &#x2013; Goodwill and Other</i>, companies may opt to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. A qualitative assessment includes factors such as financial performance, industry and market metrics, and other factors affecting the reporting unit. If this assessment concludes that is more likely than not that the fair value of a reporting unit exceeds its carrying value, then goodwill is not considered impaired and no further impairment testing is required. Conversely, if the qualitative assessment concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we must then compare the fair value of the reporting unit to its carrying value. The Company determines fair value of the reporting units using both income and market based models. These models require the use of various assumptions relating to cash flow projections, growth rates, discount rates and terminal value calculations. The Company did not recognize any impairment charges for the years ended December&#xA0;31, 2015, 2014 or 2013.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> As of December&#xA0;31, 2015, intangible assets with remaining unamortized balances include contract rights and customer relationships, internally-developed technology and patents, non-competition agreements, and trade names. These intangible assets are considered to have definite useful lives and are being amortized on a straight line basis over periods typically ranging between three and fifteen years. The weighted average amortization period for definite lived intangible assets as of December&#xA0;31, 2015 was 11.3 years. Intangible assets are reviewed for impairment whenever events or changes in facts or circumstances indicate that the carrying amount of the assets may not be recoverable. There were no impairments identified or recorded for the years ended December&#xA0;31, 2015, 2014, or 2013.</p> </div> 2035-12-31 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Advertising</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The Company expenses the costs of advertising as incurred. Advertising expense for the years ended December&#xA0;31, 2015, 2014, and 2013 was approximately $1.1 million, $0.7 million, and $0.4 million, respectively.</p> </div> No 30436000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>10. INCOME TAXES</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The provision (benefit) for income taxes is comprised of the following (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="10" align="center"><b>Year Ended December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Current federal</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,608</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,198</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,474</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Current state</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,098</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,605</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,444</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Deferred federal</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">501</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,092</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,315</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Deferred state</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(109</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">232</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">191</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Provision for income taxes</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,098</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,127</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,424</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> A reconciliation of income taxes at the statutory federal income tax rate to the provision for income taxes included in the accompanying consolidated statements of income is as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="10" align="center"><b>Year Ended December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Federal tax provision at the statutory rate</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,802</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,782</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,194</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> State income tax provision, net of federal benefit</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">673</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,350</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">898</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Tax credits</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(425</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1,160</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(54</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Change in state valuation allowance</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(8</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">37</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">231</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Other</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">56</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">118</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">155</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Provision for income taxes</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,098</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,127</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,424</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Management periodically evaluates the realizability of its deferred tax assets, and to the extent that a recovery is not likely, a valuation allowance is established to reduce the deferred tax asset to the amount estimated to be recoverable. At December&#xA0;31, 2015, a valuation allowance of $346,000 exists. The Company adjusts deferred tax liabilities and assets in the period of enactment for the effect of an enacted change in tax laws or rates. Accordingly, the state income tax provision for the period ended December&#xA0;31, 2015 is inclusive of a deferred tax benefit of $188,000 related to a change in state tax law that will be effective for the Company&#x2019;s tax year beginning on or after January&#xA0;1, 2017.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> As of December&#xA0;31, 2015, the Company had state net operating loss carryforwards of $13.0 million. These loss carryforwards will expire in years 2016 through 2025. The Company is subject to income taxation at the federal and various state levels. The Company is subject to U.S. federal tax examinations for tax years 2012 through 2015. Loss carryforwards and credit carryforwards generated or utilized in years earlier than 2012 are also subject to examination and adjustment. The Company has examinations in process with the Internal Revenue Service for tax years 2013 and 2014. The Company has research and development tax credit carryforwards of $1.9 million that expire in varying amounts through 2035. As of December&#xA0;31, 2015, the Company had alternative minimum tax credit carryforwards of $816,000 that are available to offset future regular tax liabilities and they do not expire.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> A reconciliation of the beginning and ending liability for gross unrecognized tax benefits at December&#xA0;31, 2015 and 2014, are as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="6" align="center"> <b>December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Balance at beginning of year</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,168</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">167</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Additions for tax positions in the current year</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">351</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,168</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Reductions for tax positions of prior years</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1,861</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(167</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Balance at end of year</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">658</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,168</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The Company recognized approximately $14,000 and $125,000 for interest and penalties related to unrecognized tax benefits within the provision for income taxes during the years ended December&#xA0;31, 2015 and 2014, respectively. Unrecognized tax benefits included tax positions of approximately $278,000 at both December&#xA0;31, 2015 and 2014 that if recognized would impact the Company&#x2019;s effective tax rate. The reduction for tax positions of prior years reflected in the table above as of December&#xA0;31, 2015 relates to a change in tax accounting method filed with the IRS for tangible property and deferred revenue. The Company estimates that it is reasonably possible the liability for unrecognized tax benefits could decrease up to $0.3 million within the next 12 months.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Deferred federal and state income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of deferred tax assets and deferred tax liabilities are as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="6" align="center"> <b>December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Deferred tax assets:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Allowance for doubtful accounts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">122</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">134</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Accrued liabilities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,062</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,565</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Tax credits</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">816</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">791</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Stock based compensation</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,107</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,015</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Deferred revenue</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,563</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">616</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Depreciation</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">348</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">715</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Basis difference on investments</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">80</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Net operating loss carryforwards</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">407</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">355</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total deferred tax assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,505</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,191</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Less: Valuation allowance</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(346</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(355</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Deferred tax assets, net of valuation allowance</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,159</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,836</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Deferred tax liabilities:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Deductible goodwill</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,646</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,369</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Nondeductible intangible assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,806</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,171</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Prepaid assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,911</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,602</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Capitalized software development</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,559</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,836</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Basis difference on investments</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">343</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total deferred tax liabilities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10,922</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10,321</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Net deferred tax liabilities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(4,763</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(5,485</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> </table> </div> 379000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> A reconciliation of income taxes at the statutory federal income tax rate to the provision for income taxes included in the accompanying consolidated statements of income is as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="10" align="center"><b>Year Ended December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Federal tax provision at the statutory rate</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,802</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,782</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,194</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> State income tax provision, net of federal benefit</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">673</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,350</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">898</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Tax credits</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(425</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1,160</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(54</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Change in state valuation allowance</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(8</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">37</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">231</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Other</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">56</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">118</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">155</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Provision for income taxes</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,098</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,127</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,424</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> A summary of activity and various other information relative to stock options for the year ended December&#xA0;31, 2015 is presented in the tables below (in thousands, except exercise price).</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="3" colspan="2" align="center"><b>Common</b><br /> <b>Shares</b></td> <td valign="bottom" rowspan="3">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="3" colspan="2" align="center"><b>Weighted-</b><br /> <b>Average</b><br /> <b>Exercise&#xA0;Price</b></td> <td valign="bottom" rowspan="3">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="3" colspan="2" align="center"><b>Aggregate</b><br /> <b>Intrinsic&#xA0;Value</b></td> <td valign="bottom" rowspan="3">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Outstanding at beginning of period</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">596</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6.18</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Granted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Exercised</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(76</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4.29</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Expired</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Forfeited</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Outstanding at end of period</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">520</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6.45</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,081</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Exercisable at end of period.</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">520</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6.45</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,081</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> No <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><font style="WHITE-SPACE: nowrap">Long-Lived</font> Assets</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Long-lived assets to be held for use are reviewed for events or changes in facts and circumstances, both internally and externally, which may indicate that an impairment of <font style="WHITE-SPACE: nowrap">long-lived</font> assets held for use is present. The Company measures any impairment using observable market values or discounted future cash flows from the related long-lived assets. The cash flow estimates and discount rates incorporate management&#x2019;s best estimates, using appropriate and customary assumptions and projections at the date of evaluation. Management periodically evaluates whether the carrying value of <font style="WHITE-SPACE: nowrap">long-lived</font> assets, including intangible assets, property and equipment, capitalized software development, and other assets will be recoverable. There were no impairments identified or recorded for the years ended December&#xA0;31, 2015, 2014, or 2013.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>15. LITIGATION</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> In connection with its business, the Company is from time to time involved in various legal actions. The litigation process is inherently uncertain and it is possible that the resolution of such matters might have a material adverse effect upon the financial condition and/or results of operations of the Company. However, in the opinion of the Company&#x2019;s management, matters currently pending or threatened against the Company are not expected to have a material adverse effect on the financial position or results of operations of the Company.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The following table sets forth the components of identifiable intangible assets and their estimated useful lives as of the acquisition date (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Preliminary<br /> fair</b><br /> <b>Value</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Useful&#xA0;life</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Customer relationships</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">42,600</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13&#xA0;years</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Developed technology</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,700</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5&#xA0;years</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Trade names</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">900</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6&#xA0;years</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total preliminary intangible assets subject to amortization</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">47,200</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div> 4.29 30057000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Non-Marketable Equity Investments</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Non-marketable equity investments are accounted for using the equity method when the Company can exercise significant influence over the investee. Investments for which the Company is not able to exercise significant influence over the investee are accounted for under the cost method. The proportionate share of income or loss from equity method investments are recorded under the caption &#x201C;other income, net&#x201D; in the accompanying consolidated statements of income.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Fair Value Measurements</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes the inputs to valuation techniques used in measuring fair value. There are three levels to the fair value hierarchy based on the reliability of inputs, as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="5%"></td> <td valign="bottom" width="1%"></td> <td></td> <td valign="bottom" width="1%"></td> <td width="93%"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top" nowrap="nowrap"><u>Level&#xA0;1</u></td> <td valign="bottom">&#xA0;</td> <td valign="top">&#x2013;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="top">Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"><u>Level&#xA0;2</u></td> <td valign="bottom">&#xA0;</td> <td valign="top">&#x2013;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="top">Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly.</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"><u>Level&#xA0;3</u></td> <td valign="bottom">&#xA0;</td> <td valign="top">&#x2013;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="top">Unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period. This determination requires significant judgments to be made by the Company. At December&#xA0;31, 2015 and 2014, our assets measured at fair value on a recurring basis consisted of marketable securities, which are classified as available for sale (see Note 4 &#x2013; Marketable Securities). The Company did not have any financial liabilities that were subject to fair value measurements as of such dates.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Capitalized Software Development</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Capitalized software development is stated on the basis of cost, and is presented net of accumulated amortization. The Company capitalizes costs incurred during the software development phase for projects when such costs are material. These assets are amortized using the straight-line method, generally ranging between three to five years. The Company capitalized approximately $7.3 million and $5.7 million during 2015 and 2014, respectively. Amortization of capitalized software development was approximately $6.2 million and $4.3 million during 2015 and 2014, respectively. Maintenance and operating costs are expensed as incurred. As of December&#xA0;31, 2015 and 2014, there were no capitalized internal development costs for computer software developed for resale.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Stock Based Compensation</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> As of December&#xA0;31, 2015, the Company maintains two stock based compensation plans, which are described in Note 11. The Company accounts for stock based compensation using the fair-value based method for costs related to share-based payments, including stock options and restricted share units. The Company uses the Black Scholes option pricing model for calculating the fair value of option awards issued under its stock based compensation plan. The Company measures compensation cost of restricted share units based on the closing fair market value of the Company&#x2019;s stock on the date of grant. Stock based compensation cost is measured at the grant date, based on the fair value of the award that is ultimately expected to vest, and is recognized as an expense over the requisite service period. The Company recognizes tax benefits from stock based compensation if an excess tax benefit is realized. Excess tax benefits are recorded as an increase to common stock when realized.</p> </div> 2015-12-31 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>2. SHAREHOLDERS&#x2019; EQUITY</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b>Common Stock</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The Company is authorized to issue up to 75&#xA0;million shares of common stock. The number of common shares issued and outstanding as of December&#xA0;31, 2015 and 2014 was approximately 31.6&#xA0;million and 27.7&#xA0;million, respectively. The Company issued approximately 3.9&#xA0;million shares of common stock in connection with an underwritten public offering, which was completed in May 2015, raising approximately $98.0 million of cash.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Preferred Stock</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The Company is authorized to issue up to 10&#xA0;million shares of preferred stock in one or more series, having the relative voting powers, designations, preferences, rights and qualifications, limitations or restrictions, and other terms as the Board of Directors may fix in providing for the issuance of such series, without any vote or action of the shareholders.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles. These accounting principles require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates and such differences could be material to the consolidated financial statements.</p> </div> 76000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Cash Equivalents</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The Company considers cash equivalents to be unrestricted, highly liquid investments with initial maturities of less than three months.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b>11. STOCK BASED COMPENSATION</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <u>Stock Incentive Plans</u></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The Company&#x2019;s 2010 Stock Incentive Plan (2010 Plan) and 2000 Stock Incentive Plan (2000 Plan; collectively, the 2010 Plan and the 2000 Plan referred to as the Plan) authorize the grant of options, restricted share units (RSU), or other forms of stock based compensation to employees, officers, directors and others, and such grants must be approved by the Compensation Committee of the Board of Directors. Options granted under the Plan have terms of no more than ten years, with certain restrictions. The Plan allows the Compensation Committee of the Board of Directors to determine the vesting period and parameters of each grant. The vesting period of the options and RSUs granted has historically ranged from immediate vesting to annual vesting up to four years, generally beginning one year after the grant date. As of December&#xA0;31, 2015, approximately 487,000 shares of unissued common stock remained reserved for future stock incentive grants under the Plan. The Company issues new shares of common stock when options are exercised or when RSUs become vested.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <u>Stock Option Activity</u></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> A summary of activity and various other information relative to stock options for the year ended December&#xA0;31, 2015 is presented in the tables below (in thousands, except exercise price).</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="3" colspan="2" align="center"><b>Common</b><br /> <b>Shares</b></td> <td valign="bottom" rowspan="3">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="3" colspan="2" align="center"><b>Weighted-</b><br /> <b>Average</b><br /> <b>Exercise&#xA0;Price</b></td> <td valign="bottom" rowspan="3">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="3" colspan="2" align="center"><b>Aggregate</b><br /> <b>Intrinsic&#xA0;Value</b></td> <td valign="bottom" rowspan="3">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Outstanding at beginning of period</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">596</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6.18</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Granted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Exercised</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(76</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4.29</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Expired</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Forfeited</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Outstanding at end of period</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">520</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6.45</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,081</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Exercisable at end of period.</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">520</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6.45</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,081</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The aggregate intrinsic value for stock options in the table above represents the total difference between the Company&#x2019;s closing stock price on December&#xA0;31, 2015 (the last trading day of the year) of $22.00 per share and the option exercise price, multiplied by the number of in-the-money options as of December&#xA0;31, 2015. The weighted average remaining contractual term of options outstanding at December&#xA0;31, 2015 was 2.5 years. Options exercisable at December&#xA0;31, 2015 have a weighted average remaining contractual term of 2.5 years.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Other information relative to option activity during the three years ended December&#xA0;31, 2015 is as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total grant date fair value of stock options vested</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">232</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">630</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">723</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total intrinsic value of stock options exercised</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,662</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,912</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,846</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Cash proceeds from exercise of stock options</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">328</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,094</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,318</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <u>Restricted Share Unit Activity</u></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> A summary of activity relative to RSUs for the year ended December&#xA0;31, 2015 is follows (in thousands, except weighted average grant date fair value):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="59%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="3" colspan="2" align="center"><b>Number&#xA0;of</b><br /> <b>RSU&#x2019;s</b></td> <td valign="bottom" rowspan="3">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="3" colspan="2" align="center"><b>Weighted-</b><br /> <b>Average</b><br /> <b>Grant&#xA0;Date&#xA0;Fair&#xA0;Value</b></td> <td valign="bottom" rowspan="3">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="3" colspan="2" align="center"><b>Aggregate</b><br /> <b>Intrinsic&#xA0;Value</b></td> <td valign="bottom" rowspan="3">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Outstanding at beginning of period</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">164</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">25.04</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Granted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">110</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">24.97</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Vested</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(54</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">24.17</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Forfeited</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">26.03</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Outstanding at end of period</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">218</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">25.21</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,793</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> The aggregate fair value of RSU awards that vested in 2015 and 2014, as of the respective vesting dates, was approximately $1.4 million and $1.1 million, respectively. A portion of RSUs that vested in 2015 and 2014 were net-share settled such that the Company withheld shares with value equivalent to the employees&#x2019; minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. The total shares withheld for RSUs during 2015 and 2014 were 8,922 and 5,327, respectively, and were based on the value of the RSUs on their respective settlement dates as determined by the Company&#x2019;s closing stock price. Total payments related to RSUs for the employees&#x2019; tax obligations to taxing authorities were approximately $230,000 in 2015 and $161,000 in 2014, and are reflected as a financing activity within the consolidated statements of cash flows. These net-share settlements had the effect of share repurchases by the Company as they reduced and retired the number of shares that would have otherwise been issued as a result of the vesting and did not represent an expense to the Company.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <u>Stock Based Compensation</u></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Total stock based compensation expense, which is recorded in our consolidated statements of income, recorded for the years ended December&#xA0;31, is as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="10" align="center"><b>Years Ended December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Cost of revenues (excluding depreciation and amortization)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">824</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">86</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">81</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Product development</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">569</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">201</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">144</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Sales and marketing</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">547</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">224</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">175</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Other general and administrative</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,340</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,114</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,058</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Total stock based compensation expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,280</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,625</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,458</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The Company amortizes the fair value of all stock based awards, net of estimated forfeitures, on a straight-line basis over the requisite service period, which generally is the vesting period. As of December&#xA0;31, 2015, total unrecognized compensation expense related to non-vested stock options and RSUs was approximately $3.0 million, net of estimated forfeitures, with a weighted average expense recognition period remaining of 2.3 years. The Company realized approximately $3.0 million of excess tax benefits related to stock based awards during the year ended December&#xA0;31, 2015, which was recorded as an increase to common stock.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Stock based compensation cost for RSUs is measured based on the closing fair market value of the Company&#x2019;s stock on the date of grant. Stock based compensation cost for stock options is estimated at the grant date based on the fair value calculated using the <font style="WHITE-SPACE: nowrap">Black-Scholes</font> method. The Company did not grant any stock options during 2015, 2014, or 2013.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <u>Stock Awards</u></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> During June 2015, the Company&#x2019;s CEO, Robert A. Frist, Jr., entered into an agreement with the Company pursuant to which he contributed 54,241 of his personally owned shares of HealthStream, Inc. common stock to the Company, without any consideration paid to him. In connection with this contribution, the Company approved the grant of 49,310 shares of HealthStream, Inc. common stock to over 600 employees who were not otherwise eligible to receive equity awards and had at least one year of service with the Company. The Company recognized approximately $1.5 million of stock based compensation expense for these stock awards during the three months ended June&#xA0;30, 2015 based on the closing fair market value of the Company&#x2019;s stock on the date of the Company&#x2019;s approval of these grants. In connection with these equity awards, effective in the second quarter of 2015, the Company withheld shares with value equivalent to the employees&#x2019; minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. The total shares withheld were 17,279, and were based on the value of the stock awards on the date of the Company&#x2019;s approval of these grants, as determined by the Company&#x2019;s closing stock price on that date. Total payments related to the employees&#x2019; tax obligations to taxing authorities for these stock awards were approximately $526,000 and are reflected as a financing activity within the consolidated statements of cash flows for the year ended December&#xA0;31, 2015. These share withholdings had the effect of share repurchases by the Company as they reduced and retired the number of shares otherwise issuable as a result of the stock awards and did not represent an expense to the Company.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Earnings Per Share</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Basic earnings per share is computed by dividing the net income available to common shareholders for the period by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing the net income for the period by the weighted average number of common and common equivalent shares outstanding during the period. Common equivalent shares are composed of incremental common shares issuable upon the exercise of stock options and restricted share units subject to vesting. The dilutive effect of common equivalent shares is included in diluted earnings per share by application of the treasury stock method. Common equivalent shares that have an anti-dilutive effect on diluted net income per share have been excluded from the calculation of diluted weighted average shares outstanding for the years ended December&#xA0;31, 2015, 2014, and 2013.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b>Newly Issued Accounting Standards</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> In May 2014, the Financial Accounting Standards Board (&#x201C;FASB&#x201D;) issued Accounting Standards Update (&#x201C;ASU&#x201D;) 2014-09, <i>Revenue from Contracts with Customers (Topic 606)</i>, which supersedes the revenue recognition requirements in Topic 605, <i>Revenue Recognition</i>, and most industry-specific revenue recognition guidance throughout the Industry Topics of the Accounting Standards Codification. The updated guidance states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also provides for additional disclosures with respect to revenues and cash flows arising from contracts with customers. The standard will be effective for the first interim period within annual reporting periods beginning after December&#xA0;15, 2017, and early adoption is permitted for the first interim period within annual reporting periods beginning after December&#xA0;15, 2016. The Company is currently reviewing this standard to determine the method of adoption and to assess the impact on its future consolidated financial statements.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Future rental payment commitments at December&#xA0;31, 2015 under <font style="WHITE-SPACE: nowrap">non-cancelable</font> operating leases, with initial terms of one year or more, are as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2016</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,876</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2017</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,625</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,365</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2019</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">808</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2020</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">810</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Thereafter</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,604</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total minimum lease payments</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,088</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <b>1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b>Reporting Entity and Segments</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> HealthStream, Inc. (the &#x201C;Company&#x201D;) was incorporated in 1990 as a Tennessee corporation and is headquartered in Nashville, Tennessee. The Company operates in three segments: HealthStream Workforce Solutions, HealthStream Patient Experience Solutions, and HealthStream Provider Solutions. Workforce Solutions products consist of SaaS-based services and subscription-based solutions to meet the ongoing training, certification, assessment and development needs of the healthcare community. These solutions provide, deliver and track computer based education for our customers in the United States through our software-as-a-service (SaaS) model. Patient Experience products offer healthcare organizations a wide range of quality and satisfaction surveys, consulting services, analyses of survey results, and other research-based services. Provider Solutions products offer healthcare organizations software applications for administering and tracking provider credentialing, privileging, call center and enrollment.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Change in Goodwill Impairment Testing Date</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> During the quarter ended December&#xA0;31, 2015, the Company voluntarily changed its annual goodwill impairment testing date from December&#xA0;31 to October&#xA0;1 of each year. This change provides additional time for the completion of the annual goodwill impairment testing prior to the end of the annual reporting period and results in further alignment with the Company&#x2019;s annual strategic planning process. Accordingly, management considers this accounting change preferable. The Company is unable to objectively determine, without the use of hindsight, the assumptions that would have been used in earlier periods. Therefore, the change will be applied prospectively as retrospective application to prior periods is deemed impracticable. This change does not result in the delay, acceleration or avoidance of any potential impairment charge.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Recently Adopted Accounting Standards</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The Company has adopted the provisions of Accounting Standards Update (ASU) 2015-17 <i>&#x2014; Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes</i>, which serves to simplify the balance sheet presentation of deferred taxes. In connection with the adoption of ASU 2015-17, the Company has elected prospective application; therefore, all deferred tax assets and liabilities as of December&#xA0;31, 2015 are presented as noncurrent in the accompanying consolidated balance sheet.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Recognition of Revenue</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Revenues are derived from providing services through our SaaS-based workforce development platform products, courseware subscriptions, provision of survey and research services, sales of software licensing arrangements, software maintenance and support, professional services, custom courseware development and other education and training services.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The Company recognizes revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when persuasive evidence of an arrangement exists, prices are fixed or determinable, services and products are provided to the customer and collectability is probable or reasonably assured.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Revenue recognized from software and other arrangements is allocated to each element of the arrangement based on the relative fair values of the elements. While elements include software products and post contract customer support, the fair value of each element is based on vendor specific objective evidence (VSOE). If fair value cannot be determined for each element of the arrangement, all revenue from the arrangement is deferred until fair value can be determined or until all elements of the arrangement are delivered and customer acceptance has occurred. Sales of the Company&#x2019;s SaaS-based workforce development platform products include customer support, implementation services, and training; therefore all revenues are deferred until the SaaS-based product is implemented, at which time revenues are recognized ratably over the subscription service period. In the event that circumstances occur, which give rise to uncertainty regarding the collectibility of contracted amounts, revenue recognition is suspended until such uncertainty is resolved. Fees for these services are billed on either a monthly, quarterly, or annual basis.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Revenues derived from the delivery of services through the Company&#x2019;s SaaS-based workforce development platform products and courseware subscriptions are recognized ratably over the term of the subscription service agreement or over the historical usage period, if usage typically differs from the subscription period. Other training revenues are generally recognized upon the completion of training.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Revenues derived from the license of installed software products are recognized upon shipment or installation of the software, when VSOE of the fair value of the software license can be established. Software support and maintenance revenues are recognized ratably over the term of the related agreement.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> Revenues recognized from the Company&#x2019;s survey and research services are determined using both the proportional performance method and the completed contract method. Revenues are generally earned over the estimated survey cycle, which typically ranges from less than one month to up to five months. The survey cycle is generally initiated based on the receipt of the first survey response and runs through provision of related survey reports to the customer. If survey results are not available to the customer during the survey fielding cycle, revenues are recognized at time of report delivery. Revenues for coaching and consulting engagements are recognized using the proportional performance method over the term of the underlying contract. Fees for survey services are billed upon initiation of the survey cycle, with progress billings made throughout the survey cycle. Fees for coaching and consulting engagements are billed upon initiation of the engagement with progress billings throughout the term of the contract.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Revenues from professional services and courseware development services are recognized upon the completion of performance milestones and deliverables using the proportional performance method. All other revenues are recognized as the related services are performed or products are delivered. Fees for these services are generally billed at project initiation and upon completion of various milestones.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Principles of Consolidation</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The consolidated financial statements include the accounts of the Company and its subsidiaries, all of which are <font style="WHITE-SPACE: nowrap">wholly-owned.</font> All <font style="WHITE-SPACE: nowrap">inter-company</font> accounts and transactions have been eliminated in consolidation.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles. These accounting principles require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates and such differences could be material to the consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Cash Equivalents</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The Company considers cash equivalents to be unrestricted, highly liquid investments with initial maturities of less than three months.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Marketable Securities</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Marketable securities are classified as available for sale and are stated at fair market value, with the unrealized gains and losses, net of tax, reported in other comprehensive income (loss) on the accompanying consolidated balance sheets. Realized gains and losses and declines in market value judged to be other than temporary on investments in marketable securities are included in interest and other income on the accompanying consolidated statements of income. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available for sale are included in other income (expense) on the accompanying consolidated statements of income. Premiums and discounts are amortized over the life of the related available for sale security as an adjustment to yield using the effective interest method.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Accounts <font style="WHITE-SPACE: nowrap">Receivable-Unbilled</font></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Accounts <font style="WHITE-SPACE: nowrap">receivable-unbilled</font> represents the following: 1) revenue earned and recognized on contracts accounted for using the proportional performance method for which invoices have not been generated or contractual billing dates have not been reached; and 2) the difference between billings for contracts containing escalated pricing over the term of the agreement and the recognition of revenue ratably over the subscription period.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Deferred Revenue</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Deferred revenue represents amounts that have been billed or collected in advance of revenue recognition. The Company typically invoices customers in quarterly, bi-annual, or annual installments, and occasionally customers will pay for multi-year contracts in advance. Deferred revenue is recognized as the revenue recognition criteria are met.</p> <p style="MARGIN-BOTTOM: 0pt; PAGE-BREAK-BEFORE: always; MARGIN-TOP: 0pt"> </p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Prepaid Royalties</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Prepaid royalties represents advance payments associated with the sale of third party products, such as courseware subscriptions. Royalties are typically paid in advance at the commencement of the revenue cycle, or periodically throughout the revenue cycle, such as quarterly, bi-annual, or annual installments. Royalty payments are amortized over the term of the underlying contracts, which generally range from 12 to 36 months, in order to match the direct royalty costs to the same period the subscription revenue is recognized. Amortization of royalties is included under the caption &#x201C;cost of revenues (excluding depreciation and amortization)&#x201D; in the accompanying consolidated statements of income.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b>Allowance for Doubtful Accounts</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The Company estimates its allowance for doubtful accounts using a specific identification method in which management considers the facts and circumstances surrounding each potentially uncollectible receivable. An allowance is also maintained for accounts that are not specifically identified that may become uncollectible in the future. Uncollectible receivables are written-off in the period management believes it has exhausted every opportunity to collect payment from the customer. Bad debt expense is recorded when events or circumstances indicate an additional allowance is required based on the Company&#x2019;s specific identification approach.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Changes in the allowance for doubtful accounts and the amounts charged to bad debt expense for the years ended December&#xA0;31, were as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="43%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Allowance&#xA0;Balance&#xA0;at<br /> Beginning of Period</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"> <b>Charged&#xA0;to&#xA0;Costs&#xA0;and<br /> Expenses</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b><font style="WHITE-SPACE: nowrap">Write-offs</font></b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Allowance&#xA0;Balance&#xA0;at<br /> End of Period</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2015</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">331</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">284</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(312</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">303</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2014</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">211</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">237</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(117</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">331</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2013</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">142</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">115</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(46</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">211</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Capitalized Software Development</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Capitalized software development is stated on the basis of cost, and is presented net of accumulated amortization. The Company capitalizes costs incurred during the software development phase for projects when such costs are material. These assets are amortized using the straight-line method, generally ranging between three to five years. The Company capitalized approximately $7.3 million and $5.7 million during 2015 and 2014, respectively. Amortization of capitalized software development was approximately $6.2 million and $4.3 million during 2015 and 2014, respectively. Maintenance and operating costs are expensed as incurred. As of December&#xA0;31, 2015 and 2014, there were no capitalized internal development costs for computer software developed for resale.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Fair Value Measurements</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes the inputs to valuation techniques used in measuring fair value. There are three levels to the fair value hierarchy based on the reliability of inputs, as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="5%"></td> <td valign="bottom" width="1%"></td> <td></td> <td valign="bottom" width="1%"></td> <td width="93%"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top" nowrap="nowrap"><u>Level&#xA0;1</u></td> <td valign="bottom">&#xA0;</td> <td valign="top">&#x2013;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="top">Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"><u>Level&#xA0;2</u></td> <td valign="bottom">&#xA0;</td> <td valign="top">&#x2013;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="top">Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly.</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"><u>Level&#xA0;3</u></td> <td valign="bottom">&#xA0;</td> <td valign="top">&#x2013;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="top">Unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period. This determination requires significant judgments to be made by the Company. At December&#xA0;31, 2015 and 2014, our assets measured at fair value on a recurring basis consisted of marketable securities, which are classified as available for sale (see Note 4 &#x2013; Marketable Securities). The Company did not have any financial liabilities that were subject to fair value measurements as of such dates.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Property and Equipment</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Property and equipment are stated on the basis of cost. Depreciation and amortization are provided on the <font style="WHITE-SPACE: nowrap">straight-line</font> method over the following estimated useful lives, except for assets under capital leases and leasehold improvements, which are amortized over the shorter of the estimated useful life or their respective lease term.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="91%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Years</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top">Furniture and fixtures</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="top">&#xA0;</td> <td valign="top" align="right"><font style="WHITE-SPACE: nowrap">5-10</font></td> <td valign="top" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top">Equipment</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="top">&#xA0;</td> <td valign="top" align="right"><font style="WHITE-SPACE: nowrap">3-5</font></td> <td valign="top" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b>Goodwill and Intangible Assets</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Goodwill represents the excess of purchase price in a business combination over the fair value of the net identifiable assets acquired. The carrying amount of our goodwill is evaluated for impairment at least annually during the fourth quarter and whenever events or changes in facts or circumstances indicate that impairment may exist. In accordance with ASC 350, <i>Intangibles &#x2013; Goodwill and Other</i>, companies may opt to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. A qualitative assessment includes factors such as financial performance, industry and market metrics, and other factors affecting the reporting unit. If this assessment concludes that is more likely than not that the fair value of a reporting unit exceeds its carrying value, then goodwill is not considered impaired and no further impairment testing is required. Conversely, if the qualitative assessment concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we must then compare the fair value of the reporting unit to its carrying value. The Company determines fair value of the reporting units using both income and market based models. These models require the use of various assumptions relating to cash flow projections, growth rates, discount rates and terminal value calculations. The Company did not recognize any impairment charges for the years ended December&#xA0;31, 2015, 2014 or 2013.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> As of December&#xA0;31, 2015, intangible assets with remaining unamortized balances include contract rights and customer relationships, internally-developed technology and patents, non-competition agreements, and trade names. These intangible assets are considered to have definite useful lives and are being amortized on a straight line basis over periods typically ranging between three and fifteen years. The weighted average amortization period for definite lived intangible assets as of December&#xA0;31, 2015 was 11.3 years. Intangible assets are reviewed for impairment whenever events or changes in facts or circumstances indicate that the carrying amount of the assets may not be recoverable. There were no impairments identified or recorded for the years ended December&#xA0;31, 2015, 2014, or 2013.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><font style="WHITE-SPACE: nowrap">Long-Lived</font> Assets</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Long-lived assets to be held for use are reviewed for events or changes in facts and circumstances, both internally and externally, which may indicate that an impairment of <font style="WHITE-SPACE: nowrap">long-lived</font> assets held for use is present. The Company measures any impairment using observable market values or discounted future cash flows from the related long-lived assets. The cash flow estimates and discount rates incorporate management&#x2019;s best estimates, using appropriate and customary assumptions and projections at the date of evaluation. Management periodically evaluates whether the carrying value of <font style="WHITE-SPACE: nowrap">long-lived</font> assets, including intangible assets, property and equipment, capitalized software development, and other assets will be recoverable. There were no impairments identified or recorded for the years ended December&#xA0;31, 2015, 2014, or 2013.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Non-Marketable Equity Investments</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Non-marketable equity investments are accounted for using the equity method when the Company can exercise significant influence over the investee. Investments for which the Company is not able to exercise significant influence over the investee are accounted for under the cost method. The proportionate share of income or loss from equity method investments are recorded under the caption &#x201C;other income, net&#x201D; in the accompanying consolidated statements of income.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Financial Instruments</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The Company has various financial instruments, including cash and cash equivalents, accounts receivable, accounts receivable-unbilled, accounts payable, accrued liabilities, and deferred revenue. The carrying amounts of these financial instruments approximate fair value because of the short term maturity or short term nature of such instruments. The Company also has marketable securities, which are recorded at approximate fair value based on quoted market prices or alternative pricing sources (see Note 4 &#x2013; Marketable Securities).</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Advertising</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The Company expenses the costs of advertising as incurred. Advertising expense for the years ended December&#xA0;31, 2015, 2014, and 2013 was approximately $1.1 million, $0.7 million, and $0.4 million, respectively.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Shipping and Handling Costs</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Shipping and handling costs that are associated with our products and services are included in cost of revenues.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b>Income Taxes</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Income taxes are accounted for using the asset and liability method, whereby deferred tax assets and liabilities are determined based on the temporary differences between the financial statement and tax bases of assets and liabilities measured at tax rates that will be in effect for the year in which the differences are expected to affect taxable income. Management evaluates all available evidence, both positive and negative, to determine whether, based on the weight of that evidence, a valuation allowance is needed. Future realization of the tax benefit of an existing deductible temporary difference or carryforward ultimately depends on the existence of sufficient taxable income of the appropriate character within the carryback or carryforward period available under the tax law. There are four possible sources of taxable income that may be available under the tax law to realize a tax benefit for deductible temporary differences and carryforwards: 1) future reversals of existing taxable temporary differences, 2) future taxable income exclusive of reversing temporary differences and carryforwards, 3) taxable income in prior carryback year(s) if carryback is permitted under the tax law, and 4) tax-planning strategies that would, if necessary, be implemented to realize deductible temporary differences or carryforwards prior to their expiration. Management reviews the realizability of its deferred tax assets each reporting period to identify whether any significant changes in circumstances or assumptions have occurred that could materially affect the realizability of deferred tax assets. As of December&#xA0;31, 2015, the Company had established a valuation allowance of $346,000 for the portion of its net deferred tax assets that are not more likely than not expected to be realized.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The Company accounts for income tax uncertainties using a more-likely-than-not recognition threshold based on the technical merits of the tax position taken. Tax positions that meet the more-likely-than-not recognition threshold are measured in order to determine the tax benefit to be recognized in the financial statements. The Company expenses any penalties or interest associated with tax obligations as general and administrative expenses and interest expense, respectively.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Earnings Per Share</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Basic earnings per share is computed by dividing the net income available to common shareholders for the period by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing the net income for the period by the weighted average number of common and common equivalent shares outstanding during the period. Common equivalent shares are composed of incremental common shares issuable upon the exercise of stock options and restricted share units subject to vesting. The dilutive effect of common equivalent shares is included in diluted earnings per share by application of the treasury stock method. Common equivalent shares that have an anti-dilutive effect on diluted net income per share have been excluded from the calculation of diluted weighted average shares outstanding for the years ended December&#xA0;31, 2015, 2014, and 2013.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Concentrations of Credit Risk and Significant Customers</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The Company&#x2019;s credit risks relate primarily to cash and cash equivalents, marketable securities and accounts receivable. The Company places its temporary excess cash investments in high quality, <font style="WHITE-SPACE: nowrap">short-term</font> money market instruments. At times, such investments may be in excess of the FDIC insurance limits. Marketable securities consists primarily of investment grade corporate debt securities and certificates of deposit.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The Company sells its products and services to various companies in the healthcare industry that are located in the United States. We perform ongoing credit evaluations of our customers&#x2019; financial condition and generally require no collateral from customers. An allowance for doubtful accounts is maintained for potentially uncollectible accounts receivable. The Company did not have any single customer representing over 10% of net revenues during 2015, 2014, or 2013.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Stock Based Compensation</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> As of December&#xA0;31, 2015, the Company maintains two stock based compensation plans, which are described in Note 11. The Company accounts for stock based compensation using the fair-value based method for costs related to share-based payments, including stock options and restricted share units. The Company uses the Black Scholes option pricing model for calculating the fair value of option awards issued under its stock based compensation plan. The Company measures compensation cost of restricted share units based on the closing fair market value of the Company&#x2019;s stock on the date of grant. Stock based compensation cost is measured at the grant date, based on the fair value of the award that is ultimately expected to vest, and is recognized as an expense over the requisite service period. The Company recognizes tax benefits from stock based compensation if an excess tax benefit is realized. Excess tax benefits are recorded as an increase to common stock when realized.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b>Newly Issued Accounting Standards</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> In May 2014, the Financial Accounting Standards Board (&#x201C;FASB&#x201D;) issued Accounting Standards Update (&#x201C;ASU&#x201D;) 2014-09, <i>Revenue from Contracts with Customers (Topic 606)</i>, which supersedes the revenue recognition requirements in Topic 605, <i>Revenue Recognition</i>, and most industry-specific revenue recognition guidance throughout the Industry Topics of the Accounting Standards Codification. The updated guidance states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also provides for additional disclosures with respect to revenues and cash flows arising from contracts with customers. The standard will be effective for the first interim period within annual reporting periods beginning after December&#xA0;15, 2017, and early adoption is permitted for the first interim period within annual reporting periods beginning after December&#xA0;15, 2016. The Company is currently reviewing this standard to determine the method of adoption and to assess the impact on its future consolidated financial statements.</p> </div> HSTM 0.29 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> At December&#xA0;31, 2015 and 2014, the fair value of marketable securities, which were all classified as available for sale, included the following (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>December&#xA0;31, 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Adjusted&#xA0;Cost</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Unrealized<br /> Gains</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Unrealized<br /> Losses</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Fair&#xA0;Value</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Level 2:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Certificates of deposit</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Corporate debt securities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">66,046</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(70</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">65,976</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">67,046</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(70</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">66,976</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="16"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>December&#xA0;31, 2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Adjusted&#xA0;Cost</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Unrealized<br /> Gains</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Unrealized<br /> Losses</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Fair&#xA0;Value</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Level 2:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Certificates of deposit</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,278</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,278</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Corporate debt securities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">32,732</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(37</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">32,695</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">39,010</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(37</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">38,973</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>3. EARNINGS PER SHARE</b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> The following table sets forth the computation of basic and diluted earnings per share for the three years ended December&#xA0;31, 2015 (in thousands, except per share amounts):</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Numerator:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Net income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,621</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,394</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,418</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Denominator:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Weighted-average shares outstanding</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">30,057</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">27,570</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">26,853</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Effect of dilutive shares</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">379</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">453</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">810</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Weighted-average diluted shares</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">30,436</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">28,023</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">27,663</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-size:1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Basic earnings per share</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.29</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.38</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.31</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Diluted earnings per share</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.28</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.37</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.30</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Potentially dilutive shares representing approximately 16,000, 70,000, and 70,000 shares of common stock for 2015, 2014, and 2013, respectively, were excluded from the calculation of diluted earnings per share because their effect would have been anti-dilutive.</p> </div> P2Y3M18D <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b>Income Taxes</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Income taxes are accounted for using the asset and liability method, whereby deferred tax assets and liabilities are determined based on the temporary differences between the financial statement and tax bases of assets and liabilities measured at tax rates that will be in effect for the year in which the differences are expected to affect taxable income. Management evaluates all available evidence, both positive and negative, to determine whether, based on the weight of that evidence, a valuation allowance is needed. Future realization of the tax benefit of an existing deductible temporary difference or carryforward ultimately depends on the existence of sufficient taxable income of the appropriate character within the carryback or carryforward period available under the tax law. There are four possible sources of taxable income that may be available under the tax law to realize a tax benefit for deductible temporary differences and carryforwards: 1) future reversals of existing taxable temporary differences, 2) future taxable income exclusive of reversing temporary differences and carryforwards, 3) taxable income in prior carryback year(s) if carryback is permitted under the tax law, and 4) tax-planning strategies that would, if necessary, be implemented to realize deductible temporary differences or carryforwards prior to their expiration. Management reviews the realizability of its deferred tax assets each reporting period to identify whether any significant changes in circumstances or assumptions have occurred that could materially affect the realizability of deferred tax assets. As of December&#xA0;31, 2015, the Company had established a valuation allowance of $346,000 for the portion of its net deferred tax assets that are not more likely than not expected to be realized.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The Company accounts for income tax uncertainties using a more-likely-than-not recognition threshold based on the technical merits of the tax position taken. Tax positions that meet the more-likely-than-not recognition threshold are measured in order to determine the tax benefit to be recognized in the financial statements. The Company expenses any penalties or interest associated with tax obligations as general and administrative expenses and interest expense, respectively.</p> </div> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>16. RELATED PARTY TRANSACTIONS</b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> During the three months ended June&#xA0;30, 2015, the Company&#x2019;s CEO, Robert A. Frist, Jr., entered into an agreement with the Company pursuant to which he contributed 54,241 of his personally owned shares of HealthStream, Inc. common stock to the Company, without any consideration paid to him. In connection with this contribution, the Company approved the grant of 49,310 shares of common stock to over 600 employees, with a fair market value of approximately $1.5 million. Mr.&#xA0;Frist contributed 4,931 of the contributed shares noted above to take into account the estimated Company costs, such as administrative expenses and employer payroll taxes associated with the grants. (See Note 11).</p> </div> 0 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>17. SUBSEQUENT EVENTS</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> In February 2016, the Board of Directors authorized a share repurchase program for up to $25 million of the Company&#x2019;s outstanding common stock. Repurchases will be made under the repurchase program in accordance with applicable securities laws and may be made at management&#x2019;s discretion from time to time in the open market, through privately negotiated transactions, or otherwise. The share repurchase program will terminate on the earlier of December&#xA0;31, 2016 or when the maximum dollar amount has been expended. The share repurchase program may be suspended or discontinued at any time.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Accounts <font style="WHITE-SPACE: nowrap">Receivable-Unbilled</font></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Accounts <font style="WHITE-SPACE: nowrap">receivable-unbilled</font> represents the following: 1) revenue earned and recognized on contracts accounted for using the proportional performance method for which invoices have not been generated or contractual billing dates have not been reached; and 2) the difference between billings for contracts containing escalated pricing over the term of the agreement and the recognition of revenue ratably over the subscription period.</p> </div> 7265000 8094000 425000 3008000 84228000 8621000 756000 3000000 209002000 190000 3280000 98014000 1372000 232000 88075000 13557000 -1110000 72000 162000 1006000 1000000 -33000 3008000 633000 8588000 -33000 736000 13719000 6200000 -429000 2648000 459000 351000 28000000 -117000 5098000 645000 1861000 501000 -109000 6173000 35589000 56000 29259000 4300000 15000 -8000 -134863000 195445000 99961000 24214000 312000 392000 0 1401000 98014000 3075000 1098000 328000 3280000 28000000 15359000 1100000 3608000 3008000 4802000 1662000 5600000 975000 54799000 0 -137000 -202000 5300000 16997000 89386000 0 284000 673000 1000000 P21Y 4 P30D <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Recently Adopted Accounting Standards</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The Company has adopted the provisions of Accounting Standards Update (ASU) 2015-17 <i>&#x2014; Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes</i>, which serves to simplify the balance sheet presentation of deferred taxes. In connection with the adoption of ASU 2015-17, the Company has elected prospective application; therefore, all deferred tax assets and liabilities as of December&#xA0;31, 2015 are presented as noncurrent in the accompanying consolidated balance sheet.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Other information relative to option activity during the three years ended December&#xA0;31, 2015 is as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total grant date fair value of stock options vested</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">232</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">630</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">723</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total intrinsic value of stock options exercised</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,662</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,912</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,846</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Cash proceeds from exercise of stock options</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">328</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,094</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,318</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="91%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Years</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top">Furniture and fixtures</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="top">&#xA0;</td> <td valign="top" align="right"><font style="WHITE-SPACE: nowrap">5-10</font></td> <td valign="top" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top">Equipment</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="top">&#xA0;</td> <td valign="top" align="right"><font style="WHITE-SPACE: nowrap">3-5</font></td> <td valign="top" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Change in Goodwill Impairment Testing Date</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> During the quarter ended December&#xA0;31, 2015, the Company voluntarily changed its annual goodwill impairment testing date from December&#xA0;31 to October&#xA0;1 of each year. This change provides additional time for the completion of the annual goodwill impairment testing prior to the end of the annual reporting period and results in further alignment with the Company&#x2019;s annual strategic planning process. Accordingly, management considers this accounting change preferable. The Company is unable to objectively determine, without the use of hindsight, the assumptions that would have been used in earlier periods. Therefore, the change will be applied prospectively as retrospective application to prior periods is deemed impracticable. This change does not result in the delay, acceleration or avoidance of any potential impairment charge.</p> </div> 2012 2014 2016-12-31 2025-12-31 2015 2013 P5Y P9Y P3Y P13Y P13Y P5Y P6Y The borrowings under the Revolving Credit Facility bear interest at either (1) a rate per annum equal to the highest of SunTrust’s prime rate or 0.5% in excess of the Federal Funds Rate or 1.0% in excess of one-month LIBOR (the “Base Rate”), plus an applicable margin, or (2) the one, two, three, or six-month per annum LIBOR for deposits in the applicable currency (the “Eurocurrency Rate”), as selected by the Company, plus an applicable margin. The applicable margin for Eurocurrency Rate loans depends on the Company’s funded debt leverage ratio and varies from 1.50% to 2.00%. The applicable margin for Base Rate loans depends on the Company’s funded debt leverage ratio and varies from 0.50% to 1.50% 2017-11-24 0.0168 0 0.0150 0.0200 0.0050 0.0150 0.010 0.005 0.003 0.002 547000 824000 1340000 569000 P5Y P3Y P10Y P5Y 6750000 81379000 98000000 34193000 1548000 2007000 1061000 161289000 39986000 11403000 6693000 459000 13520000 -2559000 332000 3986000 41618000 P11Y3M18D P15Y P5M P36M P5Y P10Y P4Y P3Y P1M P12M P3Y -25418000 1617000 5257000 -188000 110000 2000 54000 8922 24.17 26.03 24.97 230000 1400000 526000 8621000 0 3870000 154000 54000 3280000 98014000 3008000 -429000 0 -33000 0 2013-09-09 15230 7400000 254000 2014-03-03 81614 12800000 P1Y 1500000 0.44 0.45 2015-03-16 13551000 88129000 8543000 -2541000 219108000 965000 41618000 P1Y 9000000 1300000 515000 3869750 28000000 17279 1500000 49310 54241 1500000 600 750000 459000 10700000 -800000 -115000 -200000 0001095565 hstm:HealthlineSystemsMember 2015-10-01 2015-12-31 0001095565 2015-10-01 2015-12-31 0001095565 hstm:HealthCareComplianceStrategiesIncMember 2015-04-01 2015-06-30 0001095565 us-gaap:ChiefExecutiveOfficerMember 2015-04-01 2015-06-30 0001095565 hstm:StockAwardsMember 2015-04-01 2015-06-30 0001095565 us-gaap:RevolvingCreditFacilityMember hstm:SunTrustBankMember 2015-04-01 2015-06-30 0001095565 hstm:HealthCareComplianceStrategiesIncMember 2013-01-01 2014-12-31 0001095565 hstm:HealthlineSystemsMember 2014-01-01 2015-03-31 0001095565 hstm:HealthlineSystemsMember 2015-01-01 2015-12-31 0001095565 hstm:HealthCareComplianceStrategiesIncMember 2015-01-01 2015-12-31 0001095565 hstm:BaptistLeadershipGroupMember 2015-01-01 2015-12-31 0001095565 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-01-01 2015-12-31 0001095565 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2015-01-01 2015-12-31 0001095565 us-gaap:RetainedEarningsMember 2015-01-01 2015-12-31 0001095565 hstm:StockAwardsMember 2015-01-01 2015-12-31 0001095565 us-gaap:RestrictedStockUnitsRSUMember 2015-01-01 2015-12-31 0001095565 us-gaap:StateAndLocalJurisdictionMember 2015-01-01 2015-12-31 0001095565 us-gaap:MaterialReconcilingItemsMember 2015-01-01 2015-12-31 0001095565 us-gaap:MinimumMember 2015-01-01 2015-12-31 0001095565 us-gaap:RestrictedStockUnitsRSUMember us-gaap:MaximumMember 2015-01-01 2015-12-31 0001095565 us-gaap:EmployeeStockOptionMember us-gaap:MaximumMember 2015-01-01 2015-12-31 0001095565 us-gaap:MaximumMember 2015-01-01 2015-12-31 0001095565 us-gaap:WeightedAverageMember 2015-01-01 2015-12-31 0001095565 hstm:HealthlineSystemsMember hstm:HealthstreamProviderSolutionsMember 2015-01-01 2015-12-31 0001095565 us-gaap:OperatingSegmentsMember hstm:HealthstreamProviderSolutionsMember 2015-01-01 2015-12-31 0001095565 hstm:HealthstreamProviderSolutionsMember 2015-01-01 2015-12-31 0001095565 us-gaap:OperatingSegmentsMember hstm:HealthstreamWorkforceSolutionsMember 2015-01-01 2015-12-31 0001095565 us-gaap:OperatingSegmentsMember hstm:PatientExperienceSolutionsMember 2015-01-01 2015-12-31 0001095565 hstm:UnderwrittenPublicOfferingMember 2015-01-01 2015-12-31 0001095565 hstm:HealthlineSystemsMember hstm:NonEscrowMember 2015-01-01 2015-12-31 0001095565 hstm:HealthlineSystemsMember hstm:EscrowMember 2015-01-01 2015-12-31 0001095565 us-gaap:FurnitureAndFixturesMember us-gaap:MinimumMember 2015-01-01 2015-12-31 0001095565 us-gaap:FurnitureAndFixturesMember us-gaap:MaximumMember 2015-01-01 2015-12-31 0001095565 us-gaap:EquipmentMember us-gaap:MinimumMember 2015-01-01 2015-12-31 0001095565 us-gaap:EquipmentMember us-gaap:MaximumMember 2015-01-01 2015-12-31 0001095565 hstm:ProductDevelopmentMember 2015-01-01 2015-12-31 0001095565 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-12-31 0001095565 us-gaap:CostOfSalesMember 2015-01-01 2015-12-31 0001095565 us-gaap:SellingAndMarketingExpenseMember 2015-01-01 2015-12-31 0001095565 hstm:SunTrustBankMember us-gaap:MinimumMember 2015-01-01 2015-12-31 0001095565 hstm:SunTrustBankMember us-gaap:MaximumMember 2015-01-01 2015-12-31 0001095565 us-gaap:RevolvingCreditFacilityMember hstm:SunTrustBankMember us-gaap:FederalFundsEffectiveSwapRateMember 2015-01-01 2015-12-31 0001095565 us-gaap:RevolvingCreditFacilityMember hstm:SunTrustBankMember us-gaap:BaseRateMember 2015-01-01 2015-12-31 0001095565 us-gaap:RevolvingCreditFacilityMember hstm:SunTrustBankMember us-gaap:MinimumMember us-gaap:EurodollarMember 2015-01-01 2015-12-31 0001095565 us-gaap:RevolvingCreditFacilityMember hstm:SunTrustBankMember us-gaap:MinimumMember us-gaap:BaseRateMember 2015-01-01 2015-12-31 0001095565 us-gaap:RevolvingCreditFacilityMember hstm:SunTrustBankMember us-gaap:MaximumMember us-gaap:EurodollarMember 2015-01-01 2015-12-31 0001095565 us-gaap:RevolvingCreditFacilityMember hstm:SunTrustBankMember us-gaap:MaximumMember us-gaap:BaseRateMember 2015-01-01 2015-12-31 0001095565 us-gaap:RevolvingCreditFacilityMember hstm:SunTrustBankMember 2015-01-01 2015-12-31 0001095565 us-gaap:TradeNamesMember 2015-01-01 2015-12-31 0001095565 us-gaap:CustomerRelationshipsMember us-gaap:MinimumMember 2015-01-01 2015-12-31 0001095565 us-gaap:CustomerRelationshipsMember us-gaap:MaximumMember 2015-01-01 2015-12-31 0001095565 us-gaap:CustomerRelationshipsMember 2015-01-01 2015-12-31 0001095565 us-gaap:OtherIntangibleAssetsMember us-gaap:MinimumMember 2015-01-01 2015-12-31 0001095565 us-gaap:OtherIntangibleAssetsMember us-gaap:MaximumMember 2015-01-01 2015-12-31 0001095565 us-gaap:DevelopedTechnologyRightsMember 2015-01-01 2015-12-31 0001095565 us-gaap:InternalRevenueServiceIRSMember us-gaap:TaxYear2013Member 2015-01-01 2015-12-31 0001095565 us-gaap:InternalRevenueServiceIRSMember us-gaap:LatestTaxYearMember 2015-01-01 2015-12-31 0001095565 us-gaap:LatestTaxYearMember 2015-01-01 2015-12-31 0001095565 us-gaap:EarliestTaxYearMember 2015-01-01 2015-12-31 0001095565 us-gaap:InternalRevenueServiceIRSMember us-gaap:TaxYear2014Member 2015-01-01 2015-12-31 0001095565 us-gaap:InternalRevenueServiceIRSMember us-gaap:TaxYear2012Member 2015-01-01 2015-12-31 0001095565 2015-01-01 2015-12-31 0001095565 hstm:HealthlineSystemsMember 2014-01-01 2014-12-31 0001095565 hstm:HealthCareComplianceStrategiesIncMember 2014-01-01 2014-12-31 0001095565 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-01-01 2014-12-31 0001095565 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2014-01-01 2014-12-31 0001095565 us-gaap:RetainedEarningsMember 2014-01-01 2014-12-31 0001095565 us-gaap:RestrictedStockUnitsRSUMember 2014-01-01 2014-12-31 0001095565 us-gaap:MaterialReconcilingItemsMember 2014-01-01 2014-12-31 0001095565 us-gaap:OperatingSegmentsMember hstm:HealthstreamProviderSolutionsMember 2014-01-01 2014-12-31 0001095565 hstm:HealthCareComplianceStrategiesIncMember hstm:HealthstreamWorkforceSolutionsMember 2014-01-01 2014-12-31 0001095565 us-gaap:OperatingSegmentsMember hstm:HealthstreamWorkforceSolutionsMember 2014-01-01 2014-12-31 0001095565 us-gaap:OperatingSegmentsMember hstm:PatientExperienceSolutionsMember 2014-01-01 2014-12-31 0001095565 hstm:HealthlineSystemsMember hstm:FairValueAdjustmentToDeferredRevenueMember 2014-01-01 2014-12-31 0001095565 hstm:ProductDevelopmentMember 2014-01-01 2014-12-31 0001095565 us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-12-31 0001095565 us-gaap:CostOfSalesMember 2014-01-01 2014-12-31 0001095565 us-gaap:SellingAndMarketingExpenseMember 2014-01-01 2014-12-31 0001095565 2014-01-01 2014-12-31 0001095565 hstm:HealthCareComplianceStrategiesIncMember 2013-01-01 2013-12-31 0001095565 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-01-01 2013-12-31 0001095565 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2013-01-01 2013-12-31 0001095565 us-gaap:RetainedEarningsMember 2013-01-01 2013-12-31 0001095565 us-gaap:MaterialReconcilingItemsMember 2013-01-01 2013-12-31 0001095565 us-gaap:OperatingSegmentsMember hstm:HealthstreamProviderSolutionsMember 2013-01-01 2013-12-31 0001095565 us-gaap:OperatingSegmentsMember hstm:HealthstreamWorkforceSolutionsMember 2013-01-01 2013-12-31 0001095565 us-gaap:OperatingSegmentsMember hstm:PatientExperienceSolutionsMember 2013-01-01 2013-12-31 0001095565 hstm:ProductDevelopmentMember 2013-01-01 2013-12-31 0001095565 us-gaap:GeneralAndAdministrativeExpenseMember 2013-01-01 2013-12-31 0001095565 us-gaap:CostOfSalesMember 2013-01-01 2013-12-31 0001095565 us-gaap:SellingAndMarketingExpenseMember 2013-01-01 2013-12-31 0001095565 2013-01-01 2013-12-31 0001095565 hstm:StockAwardsMember us-gaap:ChiefExecutiveOfficerMember 2015-06-01 2015-06-30 0001095565 hstm:StockAwardsMember 2015-06-01 2015-06-30 0001095565 2015-12-31 2015-12-31 0001095565 hstm:HealthlineSystemsMember 2015-12-31 0001095565 hstm:HealthCareComplianceStrategiesIncMember 2015-12-31 0001095565 hstm:BaptistLeadershipGroupMember 2015-12-31 0001095565 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0001095565 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2015-12-31 0001095565 us-gaap:RetainedEarningsMember 2015-12-31 0001095565 us-gaap:RestrictedStockUnitsRSUMember 2015-12-31 0001095565 us-gaap:StateAndLocalJurisdictionMember 2015-12-31 0001095565 us-gaap:MaterialReconcilingItemsMember 2015-12-31 0001095565 us-gaap:MaximumMember 2015-12-31 0001095565 us-gaap:OperatingSegmentsMember hstm:HealthstreamProviderSolutionsMember 2015-12-31 0001095565 hstm:HealthstreamProviderSolutionsMember 2015-12-31 0001095565 us-gaap:OperatingSegmentsMember hstm:HealthstreamWorkforceSolutionsMember 2015-12-31 0001095565 hstm:HealthstreamWorkforceSolutionsMember 2015-12-31 0001095565 us-gaap:OperatingSegmentsMember hstm:PatientExperienceSolutionsMember 2015-12-31 0001095565 hstm:PatientExperienceSolutionsMember 2015-12-31 0001095565 hstm:ResearchAndDevelopmentMember 2015-12-31 0001095565 hstm:UnderwrittenPublicOfferingMember 2015-12-31 0001095565 us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2015-12-31 0001095565 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0001095565 us-gaap:FairValueInputsLevel2Member 2015-12-31 0001095565 us-gaap:LeaseholdImprovementsMember 2015-12-31 0001095565 us-gaap:FurnitureAndFixturesMember 2015-12-31 0001095565 us-gaap:EquipmentMember 2015-12-31 0001095565 us-gaap:RevolvingCreditFacilityMember hstm:SunTrustBankMember hstm:SwinglineSubFacilityMember 2015-12-31 0001095565 us-gaap:RevolvingCreditFacilityMember hstm:SunTrustBankMember hstm:LetterOfCreditSubfacilityMember 2015-12-31 0001095565 us-gaap:RevolvingCreditFacilityMember hstm:SunTrustBankMember 2015-12-31 0001095565 us-gaap:TradeNamesMember 2015-12-31 0001095565 us-gaap:CustomerRelationshipsMember 2015-12-31 0001095565 us-gaap:OtherIntangibleAssetsMember 2015-12-31 0001095565 us-gaap:DevelopedTechnologyRightsMember 2015-12-31 0001095565 2015-12-31 0001095565 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0001095565 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2014-12-31 0001095565 us-gaap:RetainedEarningsMember 2014-12-31 0001095565 us-gaap:RestrictedStockUnitsRSUMember 2014-12-31 0001095565 us-gaap:MaterialReconcilingItemsMember 2014-12-31 0001095565 us-gaap:OperatingSegmentsMember hstm:HealthstreamProviderSolutionsMember 2014-12-31 0001095565 hstm:HealthstreamProviderSolutionsMember 2014-12-31 0001095565 us-gaap:OperatingSegmentsMember hstm:HealthstreamWorkforceSolutionsMember 2014-12-31 0001095565 hstm:HealthstreamWorkforceSolutionsMember 2014-12-31 0001095565 us-gaap:OperatingSegmentsMember hstm:PatientExperienceSolutionsMember 2014-12-31 0001095565 hstm:PatientExperienceSolutionsMember 2014-12-31 0001095565 us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2014-12-31 0001095565 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2014-12-31 0001095565 us-gaap:FairValueInputsLevel2Member 2014-12-31 0001095565 us-gaap:LeaseholdImprovementsMember 2014-12-31 0001095565 us-gaap:FurnitureAndFixturesMember 2014-12-31 0001095565 us-gaap:EquipmentMember 2014-12-31 0001095565 us-gaap:CustomerRelationshipsMember 2014-12-31 0001095565 us-gaap:OtherIntangibleAssetsMember 2014-12-31 0001095565 2014-12-31 0001095565 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-12-31 0001095565 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2013-12-31 0001095565 us-gaap:RetainedEarningsMember 2013-12-31 0001095565 us-gaap:MaterialReconcilingItemsMember 2013-12-31 0001095565 us-gaap:OperatingSegmentsMember hstm:HealthstreamProviderSolutionsMember 2013-12-31 0001095565 hstm:HealthstreamProviderSolutionsMember 2013-12-31 0001095565 us-gaap:OperatingSegmentsMember hstm:HealthstreamWorkforceSolutionsMember 2013-12-31 0001095565 hstm:HealthstreamWorkforceSolutionsMember 2013-12-31 0001095565 us-gaap:OperatingSegmentsMember hstm:PatientExperienceSolutionsMember 2013-12-31 0001095565 hstm:PatientExperienceSolutionsMember 2013-12-31 0001095565 2013-12-31 0001095565 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-12-31 0001095565 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2012-12-31 0001095565 us-gaap:RetainedEarningsMember 2012-12-31 0001095565 2012-12-31 0001095565 us-gaap:ChiefExecutiveOfficerMember 2015-06-30 0001095565 2015-06-30 0001095565 us-gaap:RevolvingCreditFacilityMember hstm:SunTrustBankMember 2015-03-31 0001095565 us-gaap:MaximumMember us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember us-gaap:SubsequentEventMember 2016-02-29 0001095565 2016-02-23 shares iso4217:USD iso4217:USD shares hstm:Plans hstm:Employees hstm:Segment hstm:SourcesofTaxableIncome pure EX-101.SCH 10 hstm-20151231.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Consolidated Statements of Income link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Consolidated Statements of Comprehensive Income link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Consolidated Statements of Shareholders' Equity link:calculationLink link:presentationLink link:definitionLink 108 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Shareholders' Equity link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Earnings Per Share link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Marketable Securities link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Business Combinations link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Property and Equipment link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Goodwill link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Intangible Assets link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Business Segments link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Stock Based Compensation link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Employee Benefit Plan link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Debt link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Leases link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Litigation link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Summary of Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Earnings Per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Marketable Securities (Tables) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Business Combinations (Tables) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Property and Equipment (Tables) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Goodwill (Tables) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Intangible Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Business Segments (Tables) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Income Taxes (Tables) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Stock Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Leases (Tables) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Summary of Significant Accounting Policies - Changes in the Allowance for Doubtful Accounts and the Amounts Charged to Bad Debt Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Shareholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - Earnings Per Share - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 144 - Disclosure - Marketable Securities - Fair Value of Available for Sale Marketable Securities (Detail) link:calculationLink link:presentationLink link:definitionLink 145 - Disclosure - Business Combinations - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 146 - Disclosure - Business Combinations - Summary of Purchase Price (Detail) link:calculationLink link:presentationLink link:definitionLink 147 - Disclosure - Business Combinations - Summary of Preliminary Fair Value of Assets Acquired and Liabilities Assumed (Detail) link:calculationLink link:presentationLink link:definitionLink 148 - Disclosure - Business Combinations - Components of Identifiable Intangible Assets and Estimated Useful Lives (Detail) link:calculationLink link:presentationLink link:definitionLink 149 - Disclosure - Business Combinations - Summary of Unaudited Proforma Financial Information (Detail) link:calculationLink link:presentationLink link:definitionLink 150 - Disclosure - Property and Equipment - Summary of Property and Equipment (Detail) link:calculationLink link:presentationLink link:definitionLink 151 - Disclosure - Property and Equipment - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 152 - Disclosure - Goodwill - Changes in Carrying Amount of Goodwill (Detail) link:calculationLink link:presentationLink link:definitionLink 153 - Disclosure - Goodwill - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 154 - Disclosure - Intangible Assets - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 155 - Disclosure - Intangible Assets - Identifiable Intangible Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 156 - Disclosure - Intangible Assets - Expected Annual Amortization Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 157 - Disclosure - Business Segments - Business Segment Information Based on Net Revenues and Operating Income (Detail) link:calculationLink link:presentationLink link:definitionLink 158 - Disclosure - Business Segments - Business Segment Information Based on Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 159 - Disclosure - Income Taxes - Summary of Provision (Benefit) for Income Taxes (Detail) link:calculationLink link:presentationLink link:definitionLink 160 - Disclosure - Income Taxes - Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to the Provision for Income Taxes (Detail) link:calculationLink link:presentationLink link:definitionLink 161 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 162 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Liability for Gross Unrecognized Tax Benefits (Detail) link:calculationLink link:presentationLink link:definitionLink 163 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Deferred Tax Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 164 - Disclosure - Stock Based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 165 - Disclosure - Stock Based Compensation - Summary of Activity and Various Other Information Relative to Stock Options (Detail) link:calculationLink link:presentationLink link:definitionLink 166 - Disclosure - Stock Based Compensation - Other Information Relative to Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 167 - Disclosure - Stock Based Compensation - Summary of Activity Relative to RSU's (Detail) link:calculationLink link:presentationLink link:definitionLink 168 - Disclosure - Stock Based Compensation - Stock Based Compensation Expense Recorded in Consolidated Statements of Income (Detail) link:calculationLink link:presentationLink link:definitionLink 169 - Disclosure - Employee Benefit Plan - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 170 - Disclosure - Debt - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 171 - Disclosure - Leases - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 172 - Disclosure - Leases - Future Rental Payment Commitments under Non-Cancelable Operating Leases (Detail) link:calculationLink link:presentationLink link:definitionLink 173 - Disclosure - Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 174 - Disclosure - Subsequent Events - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 11 hstm-20151231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 12 hstm-20151231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 13 hstm-20151231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 14 hstm-20151231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 15 g111635tx_pg021.jpg GRAPHIC begin 644 g111635tx_pg021.jpg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帶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

WAO96U$Z//X^S/_ %5P3)BU;A_:;V+^V&/N[Z?PY0*H MK-( [3')7X'U]1Z'U/\ I/XRI)+BP_Y@& ?B!T]#ZCT'^@?A,9/!80D:@,22 M&Q5*R%JTR\MF3QYH):@+T1X52-:!N+1A2!5I%( F%&:!URS-:$'>MZZ:D()&L5*#S!#&89L0QC%O>][WO>47Y4%:]* MQZ >@_L])4]6+G\Q]3\3Z?\ (/\ 0)H=(_=9#_[DK^M5^(DFK-A"D5"&H,2 M"G/V)65WO9J8.BA;$H+T:4<5LPG7XVNL 8>G7=#O7H(_89-CN!%\7Y!$X\BS;5?D#V.9ZV/>?&FZRDV%FL;MLN;>S(@6 M"[R1I(-QW]%OFQA==M.H7]H8X*@WA77:% 5:^^'PG=,UZAY;R0+=*E57([\D MB.4;?<'$DR(,3_NU"6U7PM-K>,*;@?K!C)00P!U<1-?E8.6JW-.<^)Y>2C(& M(M6%O+WFUW_3NE^R*QMH=MO)C *HJ^*#H*E7*BH;PK^G^F!Y;)MK7DG)9&^G M7N>VG2+'QS)4OCB20[6GREJ_.202WTG'N=X]-'A:^'^:33?5DV5-;JFLKJ=Z MNI1:LA>>$D9HD:W"9CY%J9!E"/3BT(26 M[1@$IP473K1]12+$U.1\J-W9%X;BRC3_ )96=+^B7@4Y"SZQ=Z];0 ,$MVAJA@X*?2FQQ\I=I+?PXGF9.L^0C0 M.]SO454<0J:71W!05_-0%))K%)G8G-?,B1=!O\;W1_G6. M?NO@F(DHXB2WCU\]>+';\S56:. ML=?NN2&^G;R -9QQJ1!:A"UBR7-T6)N[;4=/(/X).R@_*NPFQN=T5KU7OC3Q M8F8K1FP TXX !MHE1F9NDVQPU^X!_Q&=G0 5P O\O.]N"YG M#?)DZ'TIW&?]9*^R[%;6OC^XRUD_\/=O;-S MS&W]%HFL4D?/D;1V_IE' MR-M=ZL UJBBP'Q-;9L&7N5:J*6DMEMJ%FKGD8E7EHD]YP-!)K6K^?P"'@C]' M'P9,RN+ORR:W=J=2H&5)DJ^#NR)8H4B*6)1:-UB:QY^:KW=<7/H-]&U:@#NV M(VW8'[5;X0@)5C=%P#!&U@I1++&,N-G\D.OLBH>25[4M).*DL^C#*+G7YN!: MWG2U+$ UW@YN6GA8:J9<\N'Q*%A,0-G"V!/%.6VFLAJ1R*Z'A+%K%9Y34XF< M^]X_8^@UG"'8O1;LWPDJ&](5Z(;D<(9R(*<0,_0HK0>3 =;*%*&M@6-7(;-X M/;:P"WNV*Y/#\J4T,MBJ1KS7[+DU>,+"T;C#]17XBP(VK6X+K6.WVU(06,Q# M?46(*@2=O'6_+$RI%1'WWNO[*H__ *NDN(DJXB<6N5,^G44Y;WPS4Q:ENN]J MRCX=-])J\K).Z2AV@T;OAE-A+Y5Z2OHDF:0P=)9SXRD.;@0:HVJ=E_0,OOG@ MQ8" :OE>VGY6JKN-2MGC[&903:M:MN#=6@^H[=!J;A6.1L>MCRWN(7<]*D<)Q ?E1:Z)1.Q(EC30$ZM]%QH=I/ M3XU,[PDO*(-0J+"3\9[/4VI')M-X\[I>0;>8?(C(HM:24*L+4"?(UQ*@O:KO MI&]EY46L^QV0%HKM\BVGV""[Z_#QJT#4/S+9>-EMSZ7ZGFIH&V0&"4E;'@Q6 M*-9KU+[YIT/K!9T5;^[N&P[ ;!5&J6A-D4%2KMI,<*UJV= [HY P(K@/#6VQ MVGD0Z6VEB-)UKY(RQTMNK;$3WY8E,-4DCZFZ+3K9-&&ML01MN=QO03ZT[#?JQI6&7MR,Y--\QM6-QFY3(A#$]75E%E#(F?$=?KE M-QSP;C*GA!M!L[:",[ J#KP\(C-I997_ ,0>1VZ*13XZM&X5L!\UVYR6L!>6 M M&LMMCA!QKOLTRO0$37UUWIX+1T[[!;O66<6<$Y2O59++3R*ABUFPU-",YY M64?5!NH!'7_-?-A(JEWWFU#_ .+._P#30,1)5Q$YG_$&FB& S?A/)C[5LB$B M;^4D,V]Q.'O;; I2MFR5XN?7@*#:[JN 5#%^2KB<]5LBN26S;DU ;2L.9P5WLAUY=QJ>VZ MQ1;DH3(>(-9QBY(XAXSNAI319*"M9#![7K90V[1#BZ"-NH$QBMP$YG:*=U1- MGQ85_$Z]FSQ6Q4U;]AFSQLW*_(5A]&Q2_("U!<@:MTK&O0N49=BEWR=RQ%\E M<=<-945LJI7IE=>SQ;N^Y5A<'LWE<*ZV6-L6X#*]9K6RZ6\Y,FX"W]#VEGLN M+V(BAG)LVBY11\>NAP?+(KZ#OC6RME\0,RTEDRE,4"KMGMY"0A/EH_;W?$6X5RM](R520M3) MUB4P)R9602I3G!Z>J:0>6$TDP/6UK?5&6/6]=.M;[N4=&KCBSZ>PU"MO57>T(@*_/\V%*DYE'>3;WR6<>0[Q)>+4X<+.FTR<6ZQ*R, MB=C6=K5:T2#BR^)5<%EM)'0D=.+(O*;1*(?F]^6NP'96^O:!, GOB4H L9EV MM;3W:G[AV:TWNXZ LQ5]7.I2BGY4OJO[34A Q?B[D\;-@+F(VG?MZCN4%+MI M+6C'BH=/( ;=S$=;*K-8VUW&S 11Q7YEI)FOA;:9$4D\K+B+A=TRK2;5+QN8 M8>EM+=Q/AT@YEGPN[)7<\8+DMA('E9!UZN)Q:/;DIRP2)@;'P82=]Z7J#23= MSO6)_O\ 5XI4MU_KMAO&*"%6S3JU:K,"UOF[1<$4M:2S.;U7DP*C4:BOC1M\ MHQJVSJHOD& +"O8LV%K0FL=.[\UG-*L**10S<5(:4R?7CE"AHSXJX^1;IRKI M*?.L!K6Q(L\QRU._M9-SN]-OR@JFN.RRLY3-GE@K\M&IT;;6L7J>RMC;%J4EC36A6@&U:KA M-@S67>3=VK5*+_#@D*5*TXVMVNL*?E'>-0IK:W@+F93<0A>@SZ):UE+1-J_A MTK8G4#VTOL=:ER-V %2 *\(TA835'56%$*PB&> 76T8 (^MK?3KIS9>45$\C M>*P!2;6*XQC@QY(1CI@J01CIB:GQ;.WC:#;GO"I0V*H#8S86OYR)QG%*BDM0\&ZF77S8H.0DEG8K 3WFVV=<;G7-$TTQ MV.;6$*&2@&^_%ZZZ6:O:9K?#;UJ@T5[6WL_3UC M#-J\V6U2[@GB-.ET95Y%7N(UZ>5+7,D^T?9G(J \Y+^GW*B#W?!H-*Z/@)R5 M(7)T]H49!SA\AYW7E6,=6"W?V%OK>FMNH2BLBE,Y6O])MBTH]_7(\NX&_K74 _0 MU4^1'R] :-<:=BW6+T9K7_7L"D-8.\->GN+2Q&@/UB7?">8?(*R.7%=\DXY0 M:[B?S8Y5UL,-6G;K4!E!8*UI4[#U@E:GN:I250&7NS&F7(J MI3[N6C_W68?ZTD.(D>\D?RCCS_,O7'U7+,1,FHOOHY7_ +1JW_<16F(ECL1& M(C$2+KM^Z"R_\E2'ZM/Q$E'$1B(Q$8B,1&(C$1B)0SEIQ7FO(^V*'6M,[>J\ MKJ-03DG!K7>X@IC!4X71ZY(Q!X\1'H^7+8?,&U.0\$LJO2E>06G7MXBRAIS= M"$+*)51;]53NCGH;'CWH>K^&WGLZEAK&_1Y.G91_7M]K6W:PZ@Y5G%E]>%=64J6)'0 U8-X%V-"DDC4Q^-$S^)AY3E MOA]+J+KF3.FG7$2,4F17E4U(W/#NI.9HJAKZQP(Y2*/[\';'(]M&8H4#4'] MX-L;U]M>QO$6V76^1MV!T^;8V=S9NUK\D#(IHL%*U]%I%I>I2]"JQFLP6MXJMA"6N5]JK>)W*&'R6K#+&4$V M<>QT_%K7M),E'@ M*!Q(.3N;.GVLS7MK6W6NT46M$V7=:[,LM"/557VSP91A K]IJ1R2W%W%ENMK M&*JDV;'U1+K95Q9TP&M(V#<&4.K -T4%+,UFFQ]W1QMN0.\J>R8S+WY;/X[''1N3-VU%,)XH>F RQY_0;=T!IIC M?M>K;B2-@U]U.=,Z^OR5*[=[MB MDF99F=;+.)N-&FMA7/#E1M>.=NR&^= U&OLBY79U:Q@:VQ??*77AQ3Y3436- M&QM$\'G1N7P3C)$N0:YZDW(.Y86YW/ *]Y,FVM.+/)A35+K$5,LF>GB&IV]T M+([PK>$#:%26G+1D;RFR:7L.BX==5NX:RN04!T.PY1@&X[!M(NJ9@W*RLV_/ M:2MC078UZFWW(?91B&7(/-6\AKW4JRG&:%UUOIM"X*UVBH#MD-7W(X9MIC-Q M/X[,IT3L2#G,M0P9F.C%MN6WBSFXYI8D;<:.=NPR$9[G)W$Q-M4K4')TB@XT M_8CDZ\D?RCCS_,O7'U7+,1, MFHOOHY7_ +1JW_<16F(ECL1&(C$359S&A3*&RB)@7:;!R-B+KE\\: MR]FLJ]Z^(CQ=+KE\\:R]FLJ]Z^(CQ= M+KE\\:R]FLJ]Z^(CQ=+KE\\:R]FLJ]Z^(CQ=+KE\\:R]FLJ]Z^(CQ=+KE\\:R]FLJ]Z^(CQ=+KE\\:R]FLJ]Z^(CQ=+KE\\:R]FLJ]Z^( MCQ=+KE\\:R]FLJ]Z^(CQ=AG;UW-?@UB)L7BZY?/&LO9 MK*O>OB(\77+YXUE[-95[U\1'BZY?/&LO9K*O>OB(\77+YXUE[-95[U\1'BZY M?/&LO9K*O>OB(\77+YXUE[-95[U\1-?:(7;3.ZRIW(G-+KE\\:R]FLJ]Z^(CQ=< MOGC67LUE7O7Q$>+KE\\:R]FLJ]Z^(CQ=+KE\\:R]FLJ]Z M^(CQ=^KU0ZZ.[TXB;%XNN7SQK+V:RKWKXB/%UR^>-9>S65>]?$1 MXNN7SQK+V:RKWKXB/%UR^>-9>S65>]?$1XNN7SQK+V:RKWKXB/%UR^>-9>S6 M5>]?$377*$VTZ/T:D)TYKHM5%Q/ D9!=:2;O"C;R@TWJ/"=BM;8]:**UU@=7 MH_&_#W,1-B\77+YXUE[-95[U\1'BZY?/&LO9K*O>OB(\77+YXUE[-95[U\1' MBZY?/&LO9K*O>OB(\77+YXUE[-95[U\1'BZY?/&LO9K*O>OB)KTIA5M2QF&R M+9S729.-P8W'9J:M)-L[OK"^-S\F+Z#;6V#O9ZEM ?_ !Z@M]&];Z-XB;#X MNN7SQK+V:RKWKXB/%UR^>-9>S65>]?$1XNN7SQK+V:RKWKXB/%UR^>-9>S65 M>]?$1XNN7SQK+V:RKWKXB/%UR^>-9>S65>]?$3S'N,V\^LSNR*)M6Y*=X;%[ M4><36DGV<42X)34AIA6AVML&S .WL/3K>NG7=Q$_1JCMP-+6VM1$UK8TAL0 M(V\DPVM)1HTPI$G+3%C,T&U]!T,8"];WT=SIQ$S_ !=+K ME\\:R]FLJ]Z^(CQ=+KE\\:R]FLJ]Z^(CQ=+KE\\:R]FLJ]Z^(GNP*+GPV*-<=5N)+LK1C<5"MP3H1MB92K=75<[J=I MF\UN/JN68B9-1??1RO_:- M6_[B*TQ$L=B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C M$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B)6CDC^4<>?YEZX^JY9B)DU%]]' M*_\ :-6_[B*TQ$L=B(Q$8B,1.>]L?%8^'K1MARBI[6Y0P6'6'"EX6N4QA8WR M]:L97$:8A9I$K/:8TX(?" IU(!"" T6P=;H%T;UO6N5WO>_M7QNV^CO;M=>W M6<,I#D@^N#A2/]<]^]J_TM_?[WM[?UO=/M;VSN[?@-ROG3%J7J&I&AN+(&H6OTC MD\GB@B4*,'0 D@I.E5J%!YFM=4!81F!YGSOW8]L^,U5M\:_UVRS8X)R0 ?%F M9EZ#X $D_@,F>X?:G_Y?/WP]]>=MT?>NN?:_A*:>9V=@5;#6.3A:J::;\LQ MZLS.]:JH]2Q53,54?'C^&A8=XK7MZ]NN*=A, K8BVW)8N0 M1R1U!1@R]<9-K*,^)!PIY02EW@''CD##+0GS5%G:7CB[4DDR!=MD9Q)B5KAK MQXQM))R9,I7$ ,[V,0PZ-UOHZ.[FRJ]Z^W_(4WCP^S5?NTZ]EH3##(1<]<@= M,X!P?C/,/>?].GWE^VWCZ/-_<'P.YXSP-VW7K]]VI=199DJOZ5MA!*JQ&0 < M8S*W0?XJL+6QJOIO/X^ZQZ*K>(S7?=CJ/5Y:$3/1V$_SVFJ]CL*KUPLUBA\: MF,>>I':0DI;D0N.1$F!(-/5DIA[.WVMM8%NRM(9DKLT:Z@>*,[[AV@>2N5*! M>PI#-Q 4N6/RX'A^L++]*N]L"XMNM8!EE6K45'+*RA@S%6;**68D *I)ZRBF M^)U0[R"J438U35O=[HD#_!XL!XU7F_$4Q;)!(X>V!?&MOL98^2.*ODICHR$C M]&$S^Q&E'DG"6%D#$:#6^0LNIT[WU"OU2^.NV:^0.,U:^Q>R.OYD95UK/442*2K2V@ MYX4:0E"*[\K. $L(#]EL5A-RI:PW9?RNSI\#CDPI\?\ 5"Q7R%4!WK+\^(6K MJ"6+BK7K98/'->Y4W?RVO:Y8/%2^_9J\"HRS$K4X3ADM8<$!0K63T;SPDCO: M]+I&Z#*:\I2S$SM&TTDLV&/JYTE%]QVT9G5,LXV%3>'2A7550VS3D];M*TK [3C/'B:MJ;"6W5_K ZB7ZR)\C["-JW;+,AM"+RJ[:I;0>-B MJ7MR4696Q^E7@?*]6V]%[M\R4%-BB@?$WA#[ M75>SBRJ7MBL%$FXTS'E?.2Q'U]+8S5E/09;XN=I"_P G9IL$YY-B ,AL>O+ M!%"7;%ZZU:9OLWMO7101DC3M2NZULD!406*7R2BGT9*W9K2)4;$3I$J0[&>4I M3E*4QQ +NOK/L[>OI5D=_98JH/P?O&A588)Q8XS7:H:DH0YL4!N./9LU5Z6Q MY!L_3:U8L8X/5#2UY(^')45@U3%;0ZE0AZ$_LG^)]41SCLHZGN1*&-@$N6G3 MM9$H#J)D1-GO8[CA()P;M/9JF0Z86&TPE$&IM-^WE0W'A<$B%2C ><5B>,<> M42AJOTSLKHL@?H?_ ,2!.B#CD ;V5D !/;89N[:,C-F;=3:C7J/U>P=T'AUY M'QY'U87/$GM*0X) %@/&HO8"@LGR8OI1Q^::QD.VE*ZLLIM$N)RW9OA E[;% M$MK=VS3JAKMGE]+7K;5S\1E ML:VI?LX4$@$L:@N,^A..LAV[;%5*./??8U:EY'"YV-O7ULL?4!1<6S^('PD) MQ/XB%>S9)'DL=IJ_54^F"^& A]4'L=:H9Q)(Y/*D=+N89LE5++3)@C7'?(!C M6&*"G)[0NJ9>1X$-'I4VL^G<79:Y*N(]0 M_24_PI,G4]Y/3^$$$G^#JB^\J2.^EA,[RH*Z1=Z/*ZW5&'IWU1:WK+;KP M6I=D4ALT;$K>M<(\Y%/1RU(F=$P5C>:?MO:EA /"DHPF!#L?6Z@M;WK73K.Q M\/\ ;[WEY_07R?A_'W7Z#DA77@ 2IPV.3 ]#T])S'D_>7MCPVVVAY/--,B>8@:Q,OBQ>K M%(#ESA#7,I43IV?LC[H\KM64^?2WQFLM7);&1; M [<@. "VJ0<$MG]F/C.4\[]UO >/UTL\,U>_>SX9%=J^*X)Y9-9SU &/VQQZ M^,!QTLJ-OKI=SK'./+^W/^VUHC3M(GF7FOK+XL0*PR E1 M!$+K)]BZ>@6M8]S?9'W1XK:KI\ EOD]9JN36*BUA&Y$<"&M8DX ;/[616,=21C]DN%5O./B==B5RTAJ2&KW :?;@U(R![2HB1FB#U^MU [WK6^C.(\Q]OO>?@-!O) M^8\?=1H(0&=BA +'"YXL3U) ]/6=7XSWG[7\QN+H>,W*KMQ@2%'($A1DXRH' M0=91ZC?B?2"5/[;&[PAT!K!<@DG)>3RY2@?G58C'QIJYLL1]K"ZV#P_O0RB' MDNNG1GD1*C9A;>]LZP)8M%&)MB\_KW@/$IY+85@U7A/K-A1_!<1XZVM$R>M5 MVMOBRMC@]Q+*LEJ;">N.N[^4?QM&#W/+G5UV/065J=RJPMC.+:;]54L4=.W; M7:!BU /#CGQ-+,F/';=I-,8K +W"[L,AO(*609%,^0$"H*J915P[LK&QY/"J MJ>13YZ1*(I)HVR2E4C4[31AV-:#6TLH?6NU4W"B5$;%6Q86XTCJMP;+5,Q=:ZK>^H^BY6/G7LUZP/U7UM@@"UD(#, MZ,MB&A '8J6'RHV9P-YDVXWS)^F)R.F)!QV9.4%*<:C_ "?')2YP-+>$'I1Q MCMNLL[.D"Z&RB-I)G]?9OGN]ZPY%TOQKCKK'3),QU++Y!R-(K! M?64Q=V]"K.JN(V3$,=BG4;7_3MVMW9U?F^ M<(VK2VS9:,<.:G6')4RA[W*@OA>\T2IILV&MQ911HU[0"D*S+;:^NM39+A&^ MHK*E\,!2RW<,\JA(4HY9*J'/-B%YL3A.Y7%F)BG5IS>C(AXOKRMJRF\[<8-! MIO+F*=6 IEJ8I>Y-#AX2A8C92M(3-"M8,LLCO8=Y&JJ[UZT4_)^O3KEG8YG'"33DP2>SE$@ MTP1^T>]$FI_%_CE4VGA<$:%2D+/-)L>-;^9]@5_IOL#1*J_0_P#XD#]$&QR M-[*R8R>V1RM[:,CM>V4.L+F7]5:?K,E.O(Z&#M<<\2>TA#@G L_)7SL!0;&J M^(]33:ZO38\0*Z6NL\0[)?::5;);@JJX7NYQ5O5;>?] M7.DYC=5'PVR(?9D@>K0BKA&YPD@;,7#)95B1F7.["ZNH+#.9IRZN35)6YS1( MH6KDRPQF5:7&ED)BSC2K.S;PT=G;UF1EH\?9M!L,014^S4ZA,"QC7=JVUVD* M*T/;)L"WTL^370XOJJVE9#9MTT8R,_K+38C\LFL*]=Z,G)N;$6(J-95:B0? M_BC1S<+D$TMJL9#&8I'JUXDR=IL%H=H*EC]F3'E7$VIZCL6CT;D<\3/,%"4Y M.6P /D*HA"G2$'&K%J?O8._9VQ6M*D@-W3Y*[41/ERW9UJMI[.60H"UNS,#@ M\0O#G8S5IBZXLO1+%PR'QR[;L 1Q#;5^JJ<>I)9Z0JD9R[-R"H%=^A%'7'%K M_JN(6]"TC^WQR9)%RA"@E#:!J?D!S6[.#$YHG!*G5." T:5U:SRP*4:E6@6% M!">E4'IC"CAQMJ-7#/H]5=@Z$'C8BV*"K ,K!6 96 96RI&1(56K;SX^J6V5 MGJ".5;LC$,I*LI*DJRDAEP1ZR5\MR[&(E-YU\07AK6DOD,!G-]Q&/R^*.)K1 M(6-2ED2A2U.1 0".1*#4+(J2[/)T/6A:"8+J[[F^[K>LT6Q[F\#J7OK;&U4E MZ'#*U_,['M_SWN#5U_,:EIKNK*7L4=?S*2E3+D>APQP M<@]09$\T^+!P=BK*6Z--QMLX5C>H^V"9(NV/PW(I$[O2)N/MZM.5>PMK<@,+DG!(!/H.BC+']@G&^?_K M^PWA= ;FKYE-ZTWTU]JBJ[F%LM5'M_4K1>%*,UKC/)E0J@+E0=M_^3W@7K\/ M).%_HZ6_9S+O_%WMO_WRK_7_ ,DW7_Q5?T_?_J;3_P#NMK_U$])UYWT=,J8Y M#3[CK8T,M*74C3DXLP3$8&0)&X*J/QA[=V,#YHUO;G#Q*OB?;O[L_;/[G^1LT?9 MWEJO(-KA&O6I;%=*V;'("U$SG! QD9QG&95*/?$[DKA5ED/-926W->C7%IXG+_4_55VX!_5TVU+ULX#B>T[#Y2IG:Z%[M559Y)2H M&GL;%W:!;-=::MFN]0P2$VTV:S7RR5:Q$.7#+-RB/Q!95-?]HDK*:X'%*:O* M.HVJ;V^>U3*?UV'D&FL]LJ.2\>V>;PI?MCJUX\J=+P1]\DVE35)%8"FXC92G MI&/(JKIV/)"J@O\ 1WZM-^JK*5MN2^B[8QR(""W71:>Y05%EO%(1#;D7*1JS7\1:QZ[@T9MGD M(S5,77-I5'R+LN"GPGRAB;O"WN@G+>BH-.3)A)7]JDI,\:URWJV=.5B)K#LQ*Y'I;IEJ=S?[(I6"/?%J5PN!35!!6Z-21A?)L&=2*R&-T04;"J$J/&>=HI.=D65FVX_19767QZ;.; 89:SPQ)61;#'^=)I!+FU,2P)Q M+6@?@"\2M09UD@DQ]F@_S TVZ64U;/$5^0/<&65+?HU6GY2 6%FZ@-OY2E;. M*\NJB_=6=);Z]K#[-/D?HAPR%9^.Q8;#D$J.UK/FOJRVL*B_RL\VN5<^('58 M9"ELZ(SM0FK]5)X3.K-@K$T.-6GW- J2 EM)OE-,-ZAP3&%DC2)%A F M]P.1+]A3BGY)T\33M7;IXG43;+J.K%]$U_4U*!D%T2VNU3D5V5MFNQF5U6QX MYAY1]==7\NR=4HQZ )N.:M>UL]51K@:6&.XCX+HM;H[>O6GQ"JCLF0P"([@M MQ0>4V:*"KH@P3F-1=&O71*S::M"[X).E/B":R-,WQY^C%.2!%L@XP#PB>$>D MZM"0 PLX4]P'1.PE_P#G:IVEN4=2CZB:]EB'X%FKV:FKXDJWSJ65T91;JOKN M36MKSV-Q:&I8] Z[%EM2M^("O4P?D >)1E#*P,C1%\4&N2D]D2V4U;8$4J>+ M1#C#)H+/7)ZK0L^QG'E,UIE\&B/D^JG"(R%/11ZT)9REW4)VDDLA0:I6)BRR M]G4Z#66XY[UF_9K(G3YNWJT[;6!B0 %JL9F#8/%5X=QV:M,BM>_Q>C)H_EXV MF.""H.UL:H3CU+%K*0JD9RS$,%0*[S;Q]YQ5KR6D[G'JZ@]JID$Z/#^8K@3IL9K.DTJC?X:O9L M#?S#MJ]JXXFHA*4V*[4RW;9-JS%"LW=LUGKNLK0.K,W;5I\M;K5%?HTN:I3D MGN9-CZ[UG Y]RFFXWLH-5=];4)8SI8J;2DYNVG#WMKFUK,M8'T1,.0W)SC\U M B9;U';$@CC0P;E>(_)I&\2V6*X3,&>71VD7,*\001L#.J5)S-C4)M'C*PJ; M@-;7;9&;]GQUFTA7 4&NP*:2'8=6K/);>8'-.V4_45DF>5NW=1K_ ):-ZG7( M(8EN\E>+ 44XXVV*IKXDE&+!RR<'VBM_B/PRVIM"VN$U3.E-=OM<\E)K,+(7 MR>I"$->.O&F90F(R=API*K\ZX(P7^28U]2K+Q/$\C=K-6IZJ>0=2P(S(.G;WF56>W3J1N*D -W%UW4YZX K MO#," P*LI QF8E>?$<:MQ0([>J^>H))'ZH<[BF%*?!]"6[O(&V /IZK>]QT$-9XEAM;Z* M:]4'Y?G5R0[6+4M8 [QK8\9;I8/<:396R=S<(L&0OT^D UNPPRV*PK #@UAM M*LU/4%8L<305B[NTYE3P39Y MT&=XF8S7''52/R==WQS7%KA (1C/2JRB(JU)J^J-B+HK6S66D,$J*W64<''' MGR+U6,.*LO:1K2P3!,[>[34SO6_=RH1!@M:&J:T%""4P A1N3*5NQ40&,AJ- M_%IXPR\A&LCK79#@V/$L@D9CK^8CK]LB3TDLSRDY2K;TQ348I<$A)M=9+-EZ*N)2Z^S@%;U4]I+1U&0Y*.?TZ39:&KM M!K';)C9/TIV0_7Z56+X^/"XTN!G'$*XR;+.%10AQ80>F\/\ S[@XWTYGBS8Z M(]Q#DX3QYL$,J;F@UU$K2Q6RI$[<899J*810U2"OA'-:R3-K:G=6X\E8B) M5(U1"K,3ZNA/'IY>WE]":=ZP@#]0#2U=C8<8_*KYH(-3$6@?*ZUET,NV4V+N M'QJK<0P%M*=H+5[[L#<[/;:][<4.D6D6 MU"A* Z[M6#4:RJT$[5-M]=E:@M8C:Z:]C@*.MC%-FDHE/<=B7'$&JWA330;W M%J604O33:CL0J,E]UE"'+8X#N56X^1+H MTQR8ABDJ9*CD3,2^MB5T*:WY&A6N2-(\H"U6BE)12@\LLX(@A,'K76WF[FL^ MEMVZ=C(UE5C(2IRI*D@\3@9&1T..HZS$U-E=S5KVT5E2U P### ,,C(ZX.#U M'J/0]9L^8TR(Q$8B,1&(C$2M')'\HX\_S+UQ]5RS$3)J+[Z.5_[1JW_<16F( MECL1&(C$1B)Y*A@8E9QBE6RM*I0;O6S3U#:C..,WH.@ZV8:82(8]Z"'6N[O\ M&LMFJICEE4G]PF77O[U2"NJZY:QZ .P _< <2OW(?ASQBY70A/7?(&FHC8D3 M1.Z9^;T2HI>Q.#6\)2CB"U[3(8JN8I&TGC3*#"C?!E903R1B+,T(&]AS5>6] MO^%\YK#4\KKUVT!N0!RI!'Q#*58?@<$9'0SOOM]]X/N9]J_--[A]@^8V_'^5 M>DU.RE;4>MB"5LJO6VEP" R\ZV*L RX(S)-@=-U35\-C5>U]7D0B<*A[2D8X MU'&AC0$-[2UH@=0A,G (D9@]_A$,P8AFFF"$,8A#$(6\W5\?HZ6NFIJU5UZU M:A54*, #_N_>?4SFO.^\/=7N;S&S[@\_Y#;VO,[=K6W6V6L7=VZDGJ /P " MJ %4 ";F5'V(@)X4S.V)?"4YJ0\21$G2&&ICP]4TD1J/#Q&([#G"NB#8_$:J24K%DI\%GA>D"UN)/3JRS [%O*M>RVU]@NZ[+O0Y=24QZGM7%C*1ELJI61LM:M:F=RBNK M#J<_)=7>BD^I1;J:W5"2@*_EP6!_9HX6<:V$YD&SUZH0)HZS40QM323-[!\0 MDIN,KNW/=%K5#".5#:'!^K]:U)P$.2@DUP5)2])E9RA/TE9DSCJ,U"X["HQ]65;BUB9 M)XL[\ Q5]"7%I>HL!KC/K&LH4!.G)UA/]KIY>\UT.7"@L MBD338\F6/#>K7MZDUO6[)&FV5I*ET38UJJ]05K0/EJJ%=8/S"M>T:/DY9X,: M6-3.,.R$@DRY<3>+ Y.+K&>S'R]QFL[Q#\<2 Z+U*Q!=KMK6Y:MZM>LDD\RNH+1K9LSSYTBZSA9R[@RI+$HA6=;M5N#> MK.-E;K[0?@'VFK;8/'\F+6J1G7CQ)#?+\[\O$>^#''&4;BIDK8+ E:V'DC1- MSO)KUO1]?G)GW*(Q-B8Y+7YRL=0\3B+(9;"FEP3M;P>N0$*4!8@%!ZQFAWZ+ MK=;;&]20-D65.3@$-92S/38ZD<7>IG-S]%Z MYSV.1QG///ZG.9+6NYMAW"W[3OX^K_=WL#./R?]'QGIAXR5HZ0DB#S[=I3VE8TE-S"VL]@.#6V-BFXN1@EK5MLY'IQYXKX!4"P4LNP^RIQ8VQ M5< /RJU#U/0%'H!6U%1_QLI:SFSN6\!QX7\RY:$MYK^5DL&M1RJ(-?*I'"!U#2S337KZZZM(XT)152HR?E MKH:UZ@I/4,C7W8<'GBQU+%"5D\0R#QZ MJYHC)3J2@<7]^DRDMWDDDE!P762 M.1[LZ:2+)0[/*QO:]+%(O!D"/W M5()<]R 2MV\ 1MGA7A4HL<$,C3+GJ.S1Y1A./2KC%)1.A& (T46<:$=FI$IL6VM1S77U:.H!!JTK*; MM5"#D,*;**B"P)(#*Q9;+%>Y8S6J5Q&^9+"R5UMS1LJRLE5 M:LC JW!202)(.ZE'K)2ZI0M;K\KU@,SKP=<,I1G=D((*%W*D0 &;#T]BV:CKAMQR P&%7!"H8$Z^<,^,K\4E+/J=D:1M\,C, M":U,37O\*7,\?A$H:)K!C&==$79D5-2!EN[4?HS:525H\_1EZ MZZZ_9LW+&;ZFVY+68'![E8V K+C 4\=K81@H =+61PR840JJJIUZ]554T55O M6H8EOF)(>M74AAF>3'>%-#QZ+VQ!A()S)H5=+^TS.VD56!OF6Q I0!U;*D M"O%>,<>"J""1F9"[A9QZ=W!A=WZ.3"2.S&E0MZISDUNV[(5TU:6F5^7#&Q6F MI=YRL,MJ/QV6;$M;6^2^-4;>888%.466:: =RBQ];8&SK'MV UMA>B\ZB[56 ME/RFZMK'9+2.XK-E6!"XBZ"RAM>PLU;=P$DDMQN1*[JPV>0JM2M$>H$5LJ@% M2,Y]/?#OC?MG,8!5HE$TFL;_ !PU(*13#?7991:P+N?D0C]R'PCH<+1+T[", MZ_?0#UWD @IO['+.M6FFU3:PXM0-'A\>/\M).EZYSV"3C.>?_2:UWY\C_ M )AVRW[?K@!M?N[H SC'#_H^,B2$?#MX_L2&Q 3IO>K2=K&FMX2Q4Z2*3S9& MGBJ>\+J-N]Y05TQI):8T5J\-\F1,XMO<>+:G56J8D:P9H3RP[#'6J&KX_6T: M6=6UZZ5%@9A9RU['MK=&!Y5<;'-G"M@G/YB"0,08\MN_:8*4N=R4*@IQLI&N MRNI'&S]'E5S<%A6[(" S9DY/PQX\$;B/?(E(7 ,-F2NQD9+S9MHOB>0V*K6& MN +!L%,[S):GLR;MB\WOS>ZR +DM;!@+\$,)T45H$[42Y#78H-?8LI Q@*ER MW)=P QVVM38O6VQ.+V=ZPNQ+9E0[X.68EK*W8DDEC2U+U!B>K)6VO3P1LHHJ M10H48. #@YQE(;M-+? G5G;RH74,$1)V.QK-9O%+701RDI9;?)DHBI"%.'O)BTPK\3)N6L)+%N1V3L9!((N:H4.RD8*BRE5JM1<);6. M%BL,@TJ/9K6JO 1=][$/>\,>1ST M'[AC_N_?ZGU/6050@P,GJ3U)/K^__4/0#H ,3W1*(3D@9_=,9]+3L8O954SGU)523_:1* MR\A>%W'WE%J+@N"*+WA/#]N@F-&SR%YC",DYXTC"N4J4S"K0%KE(BT!8 #.T M,18.MH'1H8NG5>2\'XWRW ;J%E3. "5'7U],9_MGE7W*^Q?VX^[/T@]ZZ=MU M>EW.TM5UM"@V<>3,M+(';Y% +9*C(&,G,UP:L(77D.C,$CK07M@B+(WQYET[ M#$\N);6U)P)$!"IU\S]?5HUJ$UZE_310HSU.! MT&2>I_MG=^W_ &GX+VSX/4]O>,I'\NTJ$IJ[GZKBNL!4#6/EW(4 98DX'4ST M)3 (;-(C+())(^A712GX$3?Z]-.H_( ^9B &8 MDNS7]/5J@8HIUZZ$ )&*:KQLI62.K*MZK9\Q))4 DJ,3_1\,^.HG4+D3"G5$ MB'/O6BNAS;8-D-M9O4]!*4,Y22*058AEI%=/JEMFS:2\)"U38:0E= [4EEA- M$(6Z4NVN:FJ)Y4X ')8F/)N;!2_P"GU(!(-0M%;#(Z.JW6H''S]MS66-8" MCRV/A11+#6,$J1&BG6HK4\CZ0!S< MRY0VO2)_9G"Q+,61ET<9)6QM//\ -%$743$Q@]9SS5Z@QC4RH*<,B-0FC"); ML0QB% UUE+:N*BNY75@ %2UU>Q*P.E26.@=UJX!FY,1EW+35G4U-R8O5V\$ MDDGM$FHV$Y-IK)^4VRR MPFBW?CDRR8EN5O.T"T]EJ9Y.; )C0[2G!WWTP&U/0?K'\QKMYG6VJ;W(NVUV M^3X!(?=K2O8?CT&7%=?3H!P^7CDYEXMJO%7Z]E" U:XUE5IPM MOS9ZDYPQ8=)%]<_#RXYP.KH?72IHEDCO547+VTTTUJV ./8?NHU:^E)%W*W M]/C\[OZAB#N@>#O&4AO\5-\!DJV MKQVE#_&V1<*03=@B$:F;_(I-*ID]2MI@B9\21DM_]/BMS5HR)(NT:I-$) M2LVH%M08;O0=AMM54^O9J.JG6NL9W4@%69ZJJ7)!]0U=-:D>AXYQEF))FNU; MU+=]$"*V3D*MEMJ@'/\ #9=8P^(Y<1\JJ!#U7\&.,5-V)'+8KR .C-84/A2B MKXG)5=BV9(%4;J4X\Q813K*GDX'F*5\>3MBP'?AA)-* ,0=V:D%%24TEE[80(P M8\T%=R;**EF>:*M]55H56 Y5UD@]M,2+9M:T@6 M!/%F_O-D5P4XQ ;=-2B"/KHE/;KH9WT;[:%KOZZ9M/(INO<)Z MWSD]B0J3R75,KL*Q9M(WJTH A?(!''F2R)@9.\)G(@AL.9WV7N"M.N1A3N!2@X(PGZ$23LNSVE%=E25BEZ; P;:Z[*QD CA=@6HRG*LM@ M4!E8$%A(,?H>&/'YN5L3LCCLO)DK&^/S^;-M6W;8I_*E4I\E R5OL2>"G M&Y=9<:?2(&QD*FE_6.+88F9T1&R.\IB0 NJ55E(2O@M;)QXJ4*M8UQY5D<'/ M>=[ S*6#NY!'-@;5B=ZMJ[6=N1!Y%FYKQK-(X69YIBHE!P9>F/B 1C*.$O'A M5 %]4J(_.#:R<3=E'U\*Z;H\C2HX-,I1&UXACFK TU-M4'H58R!Q1.47'1$: M 7M'U"20EVT0(:&ZLVNU;(6/,YI*FGD6R7%11&K#EN+*&'7)-RP]RRVP_*UW M!=H(- ILU6[&W=N"UTNV#>UC)TL M%EXUPU]3>E=RC5J5"5>L+S_2YD.M_5>K5UUU16K4HE%84]5--#VNM%@.>51: M^QFP5L)XCN< R->BN(BH@%?0:"JY5)ITJAL1CL64S::+0.4OERA@:$C6=)90 MXE$D%KI ^&)=J5AP0 T8H-$+HUTYG[=Z[6U9L*BUJ[DA1Z#)]/A_L'[AZ3"U M:3KZZTEBQ4>O_(,G 'HH)) P,G&9N>8\OQB(Q$8B,1&(E:.2/Y1QY_F7KCZK MEF(F347WT1 +WOH%ML'K)W)H5 4%A,UK7?4JLK\52WN"87X MAR90 I009K8# !%K>M(FVXB,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$ M8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$ M1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B)X4ED\0?\ N"G'E=ZJ._=]WWC_ &V?[DO]PG>^] Z?6;ZD/_(^ M,>G_ /J/[7J]3H[G1B)(8/4_U ]'^]3HZH>C_P#WG_!T:_\ N_&_^O=Q$_K] M4'\:G]KKUN5]Y+>K[QCX J](Z_^]#_ '3>5_5\+%WWU8>N+_\ Q?RB_#X)U/Q^^]3O?_=Q$ZX8B?_9 end XML 16 R1.htm IDEA: XBRL DOCUMENT v3.3.1.900
Document and Entity Information - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2015
Feb. 23, 2016
Jun. 30, 2015
Document And Entity Information [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2015    
Document Fiscal Year Focus 2015    
Document Fiscal Period Focus FY    
Trading Symbol HSTM    
Entity Registrant Name HEALTHSTREAM INC    
Entity Central Index Key 0001095565    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer No    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Filer Category Large Accelerated Filer    
Entity Common Stock, Shares Outstanding   31,651,860  
Entity Public Float     $ 768.8

XML 17 R2.htm IDEA: XBRL DOCUMENT v3.3.1.900
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2015
Dec. 31, 2014
Current assets:    
Cash and cash equivalents $ 82,010 $ 81,995
Marketable securities 66,976 38,973
Accounts receivable, net of allowance for doubtful accounts of $303 and $331 at December 31, 2015 and 2014, respectively 36,348 33,167
Accounts receivable - unbilled 1,998 1,678
Prepaid royalties, net of amortization 14,036 13,030
Other prepaid expenses and other current assets 8,169 5,768
Total current assets 209,537 174,611
Property and equipment, net 12,471 9,442
Capitalized software development, net of accumulated amortization of $24,130 and $18,114 at December 31, 2015 and 2014, respectively 13,955 12,706
Goodwill 83,073 41,914
Intangible assets, net of accumulated amortization of $8,685 and $13,834 at December 31, 2015 and 2014, respectively 55,966 14,795
Non-marketable equity investments 3,640 1,757
Other assets 927 2,037
Total assets 379,569 257,262
Current liabilities:    
Accounts payable 4,616 4,753
Accrued royalties 9,053 9,255
Accrued liabilities 7,003 7,224
Accrued compensation and related expenses 3,308 2,311
Deferred revenue 65,098 53,716
Total current liabilities 89,078 77,259
Deferred tax liabilities 4,763 5,838
Deferred revenue, noncurrent 4,350 3,657
Other long term liabilities $ 1,058 $ 2,649
Commitments and contingencies
Shareholders' equity:    
Common stock, no par value, 75,000 shares authorized; 31,647 and 27,677 shares issued and outstanding at December 31, 2015 and 2014, respectively $ 278,799 $ 174,926
Retained earnings (accumulated deficit) 1,591 (7,030)
Accumulated other comprehensive loss (70) (37)
Total shareholders' equity 280,320 167,859
Total liabilities and shareholders' equity $ 379,569 $ 257,262
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.3.1.900
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2015
Dec. 31, 2014
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts, net $ 303 $ 331
Accumulated amortization on capitalized software development 24,130 18,114
Accumulated amortization on intangible assets $ 8,685 $ 13,834
Common stock, no par value
Common stock, shares authorized 75,000,000 75,000,000
Common stock, shares issued 31,647,000 27,677,000
Common stock, shares outstanding 31,647,000 27,677,000
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.3.1.900
Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Income Statement [Abstract]      
Revenues, net $ 209,002 $ 170,690 $ 132,274
Operating costs and expenses:      
Cost of revenues (excluding depreciation and amortization) 89,386 74,145 55,605
Product development 24,214 16,463 11,757
Sales and marketing 35,589 29,867 24,052
Other general and administrative expenses 29,259 22,909 18,342
Depreciation and amortization 16,997 10,931 7,852
Total operating costs and expenses 195,445 154,315 117,608
Operating income 13,557 16,375 14,666
Other income, net 162 146 176
Income before income tax provision 13,719 16,521 14,842
Income tax provision 5,098 6,127 6,424
Net income $ 8,621 $ 10,394 $ 8,418
Net income per share:      
Basic $ 0.29 $ 0.38 $ 0.31
Diluted $ 0.28 $ 0.37 $ 0.30
Weighted average shares of common stock outstanding:      
Basic 30,057 27,570 26,853
Diluted 30,436 28,023 27,663
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.3.1.900
Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Statement of Comprehensive Income [Abstract]      
Net income $ 8,621 $ 10,394 $ 8,418
Other comprehensive income, net of taxes:      
Unrealized loss on marketable securities (33) (6) (49)
Total other comprehensive loss (33) (6) (49)
Comprehensive income $ 8,588 $ 10,388 $ 8,369
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.3.1.900
Consolidated Statements of Shareholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock [Member]
Retained Earnings (Accumulated Deficit) [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Beginning balance at Dec. 31, 2012 $ 132,196 $ 158,020 $ (25,842) $ 18
Beginning balance, shares at Dec. 31, 2012   26,233    
Net income 8,418   8,418  
Comprehensive loss (49)     (49)
Issuance of common stock in acquisition 534 $ 534    
Issuance of common stock in acquisition, shares   15    
Stock based compensation 1,458 $ 1,458    
Tax benefits from equity awards 3,722 3,722    
Common stock issued under stock plans, net of shares withheld for employee taxes 3,154 $ 3,154    
Common stock issued under stock plans, net of shares withheld for employee taxes, shares   1,079    
Ending balance at Dec. 31, 2013 149,433 $ 166,888 (17,424) (31)
Ending balance, shares at Dec. 31, 2013   27,327    
Net income 10,394   10,394  
Comprehensive loss (6)     (6)
Issuance of common stock in acquisition 2,246 $ 2,246    
Issuance of common stock in acquisition, shares   82    
Stock based compensation 1,625 $ 1,625    
Tax benefits from equity awards 3,234 3,234    
Common stock issued under stock plans, net of shares withheld for employee taxes 933 $ 933    
Common stock issued under stock plans, net of shares withheld for employee taxes, shares   268    
Ending balance at Dec. 31, 2014 $ 167,859 $ 174,926 (7,030) (37)
Ending balance, shares at Dec. 31, 2014 27,677 27,677    
Net income $ 8,621   8,621  
Comprehensive loss (33)     (33)
Issuance of common stock 98,014 $ 98,014    
Issuance of common stock, shares   3,870    
Stock donated to Company 0 $ 0 0 0
Stock donated to Company, shares   (54)    
Stock based compensation 3,280 $ 3,280    
Tax benefits from equity awards 3,008 3,008    
Common stock issued under stock plans, net of shares withheld for employee taxes (429) $ (429)    
Common stock issued under stock plans, net of shares withheld for employee taxes, shares   154    
Ending balance at Dec. 31, 2015 $ 280,320 $ 278,799 $ 1,591 $ (70)
Ending balance, shares at Dec. 31, 2015 31,647 31,647    
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.3.1.900
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
OPERATING ACTIVITIES:      
Net income $ 8,621 $ 10,394 $ 8,418
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 16,997 10,931 7,852
Deferred income taxes 392 1,324 2,506
Stock based compensation expense 3,280 1,625 1,458
Excess tax benefits from equity awards (3,008) (3,234) (3,722)
Provision for doubtful accounts 284 237 115
Loss on non-marketable equity investments 117 65 37
Gain on sale of long-lived assets (72)    
Other 1,401 1,394 1,660
Changes in assets and liabilities, net of business combinations:      
Accounts and unbilled receivables (736) (6,690) (10,056)
Prepaid royalties (1,006) (4,174) (5,119)
Other prepaid expenses and other current assets (1,372) (2,022) (1,207)
Other assets 1,110 (1,761) 105
Accounts payable (137) 2,442 1,254
Accrued royalties (202) 820 3,399
Accrued liabilities, accrued compensation and related expenses, and other long-term liabilities 3,075 5,434 5,593
Deferred revenue 6,173 17,471 14,761
Net cash provided by operating activities 34,917 34,256 27,054
INVESTING ACTIVITIES:      
Business combinations, net of cash acquired (88,075) (12,298) (7,560)
Proceeds from sales of marketable securities     5,062
Proceeds from maturities of marketable securities 54,799 52,625 82,661
Purchases of marketable securities (84,228) (44,341) (86,139)
Payments to acquire equity method investments (1,000) (325) (300)
Payments to acquire cost method investments (1,000) (1,000)  
Payments associated with capitalized software development (7,265) (5,658) (4,267)
Purchases of property and equipment (8,094) (4,544) (4,444)
Net cash used in investing activities (134,863) (15,541) (14,987)
FINANCING ACTIVITIES:      
Proceeds from issuance of common stock 98,014    
Proceeds from exercise of stock options 328 1,094 3,318
Proceeds from borrowings under revolving line of credit facility 28,000    
Repayments under revolving line of credit facility (28,000)    
Taxes paid related to net settlement of equity awards (756) (161) (164)
Excess tax benefits from equity awards 3,008 3,234 3,722
Payment of earn-outs related to business combinations (633) (424) (771)
Net cash provided by financing activities 99,961 3,743 6,105
Net increase in cash and cash equivalents 15 22,458 18,172
Cash and cash equivalents at beginning of year 81,995 59,537 41,365
Cash and cash equivalents at end of year 82,010 81,995 59,537
SUPPLEMENTAL CASH FLOW INFORMATION:      
Interest paid 190 56 51
Income taxes paid 2,648 1,641 371
NON-CASH INVESTING AND FINANCING ACTIVITIES:      
Receivable from sale of long-lived assets $ 975    
Issuance of common stock in connection with business combinations   $ 2,246 $ 534
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.3.1.900
Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2015
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Reporting Entity and Segments

HealthStream, Inc. (the “Company”) was incorporated in 1990 as a Tennessee corporation and is headquartered in Nashville, Tennessee. The Company operates in three segments: HealthStream Workforce Solutions, HealthStream Patient Experience Solutions, and HealthStream Provider Solutions. Workforce Solutions products consist of SaaS-based services and subscription-based solutions to meet the ongoing training, certification, assessment and development needs of the healthcare community. These solutions provide, deliver and track computer based education for our customers in the United States through our software-as-a-service (SaaS) model. Patient Experience products offer healthcare organizations a wide range of quality and satisfaction surveys, consulting services, analyses of survey results, and other research-based services. Provider Solutions products offer healthcare organizations software applications for administering and tracking provider credentialing, privileging, call center and enrollment.

Change in Goodwill Impairment Testing Date

During the quarter ended December 31, 2015, the Company voluntarily changed its annual goodwill impairment testing date from December 31 to October 1 of each year. This change provides additional time for the completion of the annual goodwill impairment testing prior to the end of the annual reporting period and results in further alignment with the Company’s annual strategic planning process. Accordingly, management considers this accounting change preferable. The Company is unable to objectively determine, without the use of hindsight, the assumptions that would have been used in earlier periods. Therefore, the change will be applied prospectively as retrospective application to prior periods is deemed impracticable. This change does not result in the delay, acceleration or avoidance of any potential impairment charge.

Recently Adopted Accounting Standards

The Company has adopted the provisions of Accounting Standards Update (ASU) 2015-17 — Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes, which serves to simplify the balance sheet presentation of deferred taxes. In connection with the adoption of ASU 2015-17, the Company has elected prospective application; therefore, all deferred tax assets and liabilities as of December 31, 2015 are presented as noncurrent in the accompanying consolidated balance sheet.

Recognition of Revenue

Revenues are derived from providing services through our SaaS-based workforce development platform products, courseware subscriptions, provision of survey and research services, sales of software licensing arrangements, software maintenance and support, professional services, custom courseware development and other education and training services.

The Company recognizes revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when persuasive evidence of an arrangement exists, prices are fixed or determinable, services and products are provided to the customer and collectability is probable or reasonably assured.

Revenue recognized from software and other arrangements is allocated to each element of the arrangement based on the relative fair values of the elements. While elements include software products and post contract customer support, the fair value of each element is based on vendor specific objective evidence (VSOE). If fair value cannot be determined for each element of the arrangement, all revenue from the arrangement is deferred until fair value can be determined or until all elements of the arrangement are delivered and customer acceptance has occurred. Sales of the Company’s SaaS-based workforce development platform products include customer support, implementation services, and training; therefore all revenues are deferred until the SaaS-based product is implemented, at which time revenues are recognized ratably over the subscription service period. In the event that circumstances occur, which give rise to uncertainty regarding the collectibility of contracted amounts, revenue recognition is suspended until such uncertainty is resolved. Fees for these services are billed on either a monthly, quarterly, or annual basis.

Revenues derived from the delivery of services through the Company’s SaaS-based workforce development platform products and courseware subscriptions are recognized ratably over the term of the subscription service agreement or over the historical usage period, if usage typically differs from the subscription period. Other training revenues are generally recognized upon the completion of training.

Revenues derived from the license of installed software products are recognized upon shipment or installation of the software, when VSOE of the fair value of the software license can be established. Software support and maintenance revenues are recognized ratably over the term of the related agreement.

 

Revenues recognized from the Company’s survey and research services are determined using both the proportional performance method and the completed contract method. Revenues are generally earned over the estimated survey cycle, which typically ranges from less than one month to up to five months. The survey cycle is generally initiated based on the receipt of the first survey response and runs through provision of related survey reports to the customer. If survey results are not available to the customer during the survey fielding cycle, revenues are recognized at time of report delivery. Revenues for coaching and consulting engagements are recognized using the proportional performance method over the term of the underlying contract. Fees for survey services are billed upon initiation of the survey cycle, with progress billings made throughout the survey cycle. Fees for coaching and consulting engagements are billed upon initiation of the engagement with progress billings throughout the term of the contract.

Revenues from professional services and courseware development services are recognized upon the completion of performance milestones and deliverables using the proportional performance method. All other revenues are recognized as the related services are performed or products are delivered. Fees for these services are generally billed at project initiation and upon completion of various milestones.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its subsidiaries, all of which are wholly-owned. All inter-company accounts and transactions have been eliminated in consolidation.

Use of Estimates

The consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles. These accounting principles require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates and such differences could be material to the consolidated financial statements.

Cash Equivalents

The Company considers cash equivalents to be unrestricted, highly liquid investments with initial maturities of less than three months.

Marketable Securities

Marketable securities are classified as available for sale and are stated at fair market value, with the unrealized gains and losses, net of tax, reported in other comprehensive income (loss) on the accompanying consolidated balance sheets. Realized gains and losses and declines in market value judged to be other than temporary on investments in marketable securities are included in interest and other income on the accompanying consolidated statements of income. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available for sale are included in other income (expense) on the accompanying consolidated statements of income. Premiums and discounts are amortized over the life of the related available for sale security as an adjustment to yield using the effective interest method.

Accounts Receivable-Unbilled

Accounts receivable-unbilled represents the following: 1) revenue earned and recognized on contracts accounted for using the proportional performance method for which invoices have not been generated or contractual billing dates have not been reached; and 2) the difference between billings for contracts containing escalated pricing over the term of the agreement and the recognition of revenue ratably over the subscription period.

Deferred Revenue

Deferred revenue represents amounts that have been billed or collected in advance of revenue recognition. The Company typically invoices customers in quarterly, bi-annual, or annual installments, and occasionally customers will pay for multi-year contracts in advance. Deferred revenue is recognized as the revenue recognition criteria are met.

Prepaid Royalties

Prepaid royalties represents advance payments associated with the sale of third party products, such as courseware subscriptions. Royalties are typically paid in advance at the commencement of the revenue cycle, or periodically throughout the revenue cycle, such as quarterly, bi-annual, or annual installments. Royalty payments are amortized over the term of the underlying contracts, which generally range from 12 to 36 months, in order to match the direct royalty costs to the same period the subscription revenue is recognized. Amortization of royalties is included under the caption “cost of revenues (excluding depreciation and amortization)” in the accompanying consolidated statements of income.

 

Allowance for Doubtful Accounts

The Company estimates its allowance for doubtful accounts using a specific identification method in which management considers the facts and circumstances surrounding each potentially uncollectible receivable. An allowance is also maintained for accounts that are not specifically identified that may become uncollectible in the future. Uncollectible receivables are written-off in the period management believes it has exhausted every opportunity to collect payment from the customer. Bad debt expense is recorded when events or circumstances indicate an additional allowance is required based on the Company’s specific identification approach.

Changes in the allowance for doubtful accounts and the amounts charged to bad debt expense for the years ended December 31, were as follows (in thousands):

 

     Allowance Balance at
Beginning of Period
     Charged to Costs and
Expenses
     Write-offs      Allowance Balance at
End of Period
 

2015

   $ 331       $ 284       $ (312    $ 303   

2014

   $ 211       $ 237       $ (117    $ 331   

2013

   $ 142       $ 115       $ (46    $ 211   

Capitalized Software Development

Capitalized software development is stated on the basis of cost, and is presented net of accumulated amortization. The Company capitalizes costs incurred during the software development phase for projects when such costs are material. These assets are amortized using the straight-line method, generally ranging between three to five years. The Company capitalized approximately $7.3 million and $5.7 million during 2015 and 2014, respectively. Amortization of capitalized software development was approximately $6.2 million and $4.3 million during 2015 and 2014, respectively. Maintenance and operating costs are expensed as incurred. As of December 31, 2015 and 2014, there were no capitalized internal development costs for computer software developed for resale.

Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes the inputs to valuation techniques used in measuring fair value. There are three levels to the fair value hierarchy based on the reliability of inputs, as follows:

 

Level 1      Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
Level 2      Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly.
Level 3      Unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions.

The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period. This determination requires significant judgments to be made by the Company. At December 31, 2015 and 2014, our assets measured at fair value on a recurring basis consisted of marketable securities, which are classified as available for sale (see Note 4 – Marketable Securities). The Company did not have any financial liabilities that were subject to fair value measurements as of such dates.

Property and Equipment

Property and equipment are stated on the basis of cost. Depreciation and amortization are provided on the straight-line method over the following estimated useful lives, except for assets under capital leases and leasehold improvements, which are amortized over the shorter of the estimated useful life or their respective lease term.

 

     Years  
Furniture and fixtures      5-10   
Equipment      3-5   

 

Goodwill and Intangible Assets

Goodwill represents the excess of purchase price in a business combination over the fair value of the net identifiable assets acquired. The carrying amount of our goodwill is evaluated for impairment at least annually during the fourth quarter and whenever events or changes in facts or circumstances indicate that impairment may exist. In accordance with ASC 350, Intangibles – Goodwill and Other, companies may opt to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. A qualitative assessment includes factors such as financial performance, industry and market metrics, and other factors affecting the reporting unit. If this assessment concludes that is more likely than not that the fair value of a reporting unit exceeds its carrying value, then goodwill is not considered impaired and no further impairment testing is required. Conversely, if the qualitative assessment concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we must then compare the fair value of the reporting unit to its carrying value. The Company determines fair value of the reporting units using both income and market based models. These models require the use of various assumptions relating to cash flow projections, growth rates, discount rates and terminal value calculations. The Company did not recognize any impairment charges for the years ended December 31, 2015, 2014 or 2013.

As of December 31, 2015, intangible assets with remaining unamortized balances include contract rights and customer relationships, internally-developed technology and patents, non-competition agreements, and trade names. These intangible assets are considered to have definite useful lives and are being amortized on a straight line basis over periods typically ranging between three and fifteen years. The weighted average amortization period for definite lived intangible assets as of December 31, 2015 was 11.3 years. Intangible assets are reviewed for impairment whenever events or changes in facts or circumstances indicate that the carrying amount of the assets may not be recoverable. There were no impairments identified or recorded for the years ended December 31, 2015, 2014, or 2013.

Long-Lived Assets

Long-lived assets to be held for use are reviewed for events or changes in facts and circumstances, both internally and externally, which may indicate that an impairment of long-lived assets held for use is present. The Company measures any impairment using observable market values or discounted future cash flows from the related long-lived assets. The cash flow estimates and discount rates incorporate management’s best estimates, using appropriate and customary assumptions and projections at the date of evaluation. Management periodically evaluates whether the carrying value of long-lived assets, including intangible assets, property and equipment, capitalized software development, and other assets will be recoverable. There were no impairments identified or recorded for the years ended December 31, 2015, 2014, or 2013.

Non-Marketable Equity Investments

Non-marketable equity investments are accounted for using the equity method when the Company can exercise significant influence over the investee. Investments for which the Company is not able to exercise significant influence over the investee are accounted for under the cost method. The proportionate share of income or loss from equity method investments are recorded under the caption “other income, net” in the accompanying consolidated statements of income.

Financial Instruments

The Company has various financial instruments, including cash and cash equivalents, accounts receivable, accounts receivable-unbilled, accounts payable, accrued liabilities, and deferred revenue. The carrying amounts of these financial instruments approximate fair value because of the short term maturity or short term nature of such instruments. The Company also has marketable securities, which are recorded at approximate fair value based on quoted market prices or alternative pricing sources (see Note 4 – Marketable Securities).

Advertising

The Company expenses the costs of advertising as incurred. Advertising expense for the years ended December 31, 2015, 2014, and 2013 was approximately $1.1 million, $0.7 million, and $0.4 million, respectively.

Shipping and Handling Costs

Shipping and handling costs that are associated with our products and services are included in cost of revenues.

 

Income Taxes

Income taxes are accounted for using the asset and liability method, whereby deferred tax assets and liabilities are determined based on the temporary differences between the financial statement and tax bases of assets and liabilities measured at tax rates that will be in effect for the year in which the differences are expected to affect taxable income. Management evaluates all available evidence, both positive and negative, to determine whether, based on the weight of that evidence, a valuation allowance is needed. Future realization of the tax benefit of an existing deductible temporary difference or carryforward ultimately depends on the existence of sufficient taxable income of the appropriate character within the carryback or carryforward period available under the tax law. There are four possible sources of taxable income that may be available under the tax law to realize a tax benefit for deductible temporary differences and carryforwards: 1) future reversals of existing taxable temporary differences, 2) future taxable income exclusive of reversing temporary differences and carryforwards, 3) taxable income in prior carryback year(s) if carryback is permitted under the tax law, and 4) tax-planning strategies that would, if necessary, be implemented to realize deductible temporary differences or carryforwards prior to their expiration. Management reviews the realizability of its deferred tax assets each reporting period to identify whether any significant changes in circumstances or assumptions have occurred that could materially affect the realizability of deferred tax assets. As of December 31, 2015, the Company had established a valuation allowance of $346,000 for the portion of its net deferred tax assets that are not more likely than not expected to be realized.

The Company accounts for income tax uncertainties using a more-likely-than-not recognition threshold based on the technical merits of the tax position taken. Tax positions that meet the more-likely-than-not recognition threshold are measured in order to determine the tax benefit to be recognized in the financial statements. The Company expenses any penalties or interest associated with tax obligations as general and administrative expenses and interest expense, respectively.

Earnings Per Share

Basic earnings per share is computed by dividing the net income available to common shareholders for the period by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing the net income for the period by the weighted average number of common and common equivalent shares outstanding during the period. Common equivalent shares are composed of incremental common shares issuable upon the exercise of stock options and restricted share units subject to vesting. The dilutive effect of common equivalent shares is included in diluted earnings per share by application of the treasury stock method. Common equivalent shares that have an anti-dilutive effect on diluted net income per share have been excluded from the calculation of diluted weighted average shares outstanding for the years ended December 31, 2015, 2014, and 2013.

Concentrations of Credit Risk and Significant Customers

The Company’s credit risks relate primarily to cash and cash equivalents, marketable securities and accounts receivable. The Company places its temporary excess cash investments in high quality, short-term money market instruments. At times, such investments may be in excess of the FDIC insurance limits. Marketable securities consists primarily of investment grade corporate debt securities and certificates of deposit.

The Company sells its products and services to various companies in the healthcare industry that are located in the United States. We perform ongoing credit evaluations of our customers’ financial condition and generally require no collateral from customers. An allowance for doubtful accounts is maintained for potentially uncollectible accounts receivable. The Company did not have any single customer representing over 10% of net revenues during 2015, 2014, or 2013.

Stock Based Compensation

As of December 31, 2015, the Company maintains two stock based compensation plans, which are described in Note 11. The Company accounts for stock based compensation using the fair-value based method for costs related to share-based payments, including stock options and restricted share units. The Company uses the Black Scholes option pricing model for calculating the fair value of option awards issued under its stock based compensation plan. The Company measures compensation cost of restricted share units based on the closing fair market value of the Company’s stock on the date of grant. Stock based compensation cost is measured at the grant date, based on the fair value of the award that is ultimately expected to vest, and is recognized as an expense over the requisite service period. The Company recognizes tax benefits from stock based compensation if an excess tax benefit is realized. Excess tax benefits are recorded as an increase to common stock when realized.

 

Newly Issued Accounting Standards

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific revenue recognition guidance throughout the Industry Topics of the Accounting Standards Codification. The updated guidance states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also provides for additional disclosures with respect to revenues and cash flows arising from contracts with customers. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2017, and early adoption is permitted for the first interim period within annual reporting periods beginning after December 15, 2016. The Company is currently reviewing this standard to determine the method of adoption and to assess the impact on its future consolidated financial statements.

XML 24 R9.htm IDEA: XBRL DOCUMENT v3.3.1.900
Shareholders' Equity
12 Months Ended
Dec. 31, 2015
Equity [Abstract]  
Shareholders' Equity

2. SHAREHOLDERS’ EQUITY

Common Stock

The Company is authorized to issue up to 75 million shares of common stock. The number of common shares issued and outstanding as of December 31, 2015 and 2014 was approximately 31.6 million and 27.7 million, respectively. The Company issued approximately 3.9 million shares of common stock in connection with an underwritten public offering, which was completed in May 2015, raising approximately $98.0 million of cash.

Preferred Stock

The Company is authorized to issue up to 10 million shares of preferred stock in one or more series, having the relative voting powers, designations, preferences, rights and qualifications, limitations or restrictions, and other terms as the Board of Directors may fix in providing for the issuance of such series, without any vote or action of the shareholders.

XML 25 R10.htm IDEA: XBRL DOCUMENT v3.3.1.900
Earnings Per Share
12 Months Ended
Dec. 31, 2015
Earnings Per Share [Abstract]  
Earnings Per Share

3. EARNINGS PER SHARE

The following table sets forth the computation of basic and diluted earnings per share for the three years ended December 31, 2015 (in thousands, except per share amounts):

 

     2015      2014      2013  

Numerator:

        

Net income

   $ 8,621       $ 10,394       $ 8,418   
  

 

 

    

 

 

    

 

 

 

Denominator:

        

Weighted-average shares outstanding

     30,057         27,570         26,853   

Effect of dilutive shares

     379         453         810   
  

 

 

    

 

 

    

 

 

 

Weighted-average diluted shares

     30,436         28,023         27,663   
  

 

 

    

 

 

    

 

 

 

Basic earnings per share

   $ 0.29       $ 0.38       $ 0.31   
  

 

 

    

 

 

    

 

 

 

Diluted earnings per share

   $ 0.28       $ 0.37       $ 0.30   
  

 

 

    

 

 

    

 

 

 

Potentially dilutive shares representing approximately 16,000, 70,000, and 70,000 shares of common stock for 2015, 2014, and 2013, respectively, were excluded from the calculation of diluted earnings per share because their effect would have been anti-dilutive.

XML 26 R11.htm IDEA: XBRL DOCUMENT v3.3.1.900
Marketable Securities
12 Months Ended
Dec. 31, 2015
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities

4. MARKETABLE SECURITIES

At December 31, 2015 and 2014, the fair value of marketable securities, which were all classified as available for sale, included the following (in thousands):

 

     December 31, 2015  
     Adjusted Cost      Unrealized
Gains
     Unrealized
Losses
     Fair Value  

Level 2:

           

Certificates of deposit

   $ 1,000       $ —         $ —         $ 1,000   

Corporate debt securities

     66,046         —           (70      65,976   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 67,046       $ —         $ (70    $ 66,976   
  

 

 

    

 

 

    

 

 

    

 

 

 
     December 31, 2014  
     Adjusted Cost      Unrealized
Gains
     Unrealized
Losses
     Fair Value  

Level 2:

           

Certificates of deposit

   $ 6,278       $ —         $ —         $ 6,278   

Corporate debt securities

     32,732         —           (37      32,695   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 39,010       $ —         $ (37    $ 38,973   
  

 

 

    

 

 

    

 

 

    

 

 

 

The carrying amounts of the marketable securities reported in the consolidated balance sheets approximate fair value based on quoted market prices or alternative pricing sources and models utilizing market observable inputs. As of December 31, 2015, the Company does not consider any of its marketable securities to be other than temporarily impaired. During the years ended December 31, 2015 and 2014, the Company did not reclassify any items out of accumulated other comprehensive income to net income. All investments in marketable securities are classified as a current asset on the balance sheet because the underlying securities mature within one year from the balance sheet date.

XML 27 R12.htm IDEA: XBRL DOCUMENT v3.3.1.900
Business Combinations
12 Months Ended
Dec. 31, 2015
Business Combinations [Abstract]  
Business Combinations

5. BUSINESS COMBINATIONS

HealthLine Systems

On March 16, 2015, the Company acquired all of the membership interests of HealthLine Systems, LLC (HLS), a San Diego, California based company that specializes in credentialing, privileging, call center, and quality management solutions for the healthcare industry. The acquisition of HLS enables the Company to provide a comprehensive solution set for healthcare provider credentialing, privileging, enrollment, referral, onboarding, and analytics in support of HealthStream’s approach to talent management for healthcare organizations. The consideration paid for HLS consisted of approximately $88.1 million in cash (taking into account an estimated closing working capital adjustment). The Company incurred approximately $1.3 million in transaction costs associated with the acquisition, of which $965,000 were incurred during the year ended December 31, 2015 and $329,000 were incurred during the year ended December 31, 2014. The transaction costs were recorded under the caption “other general and administrative” in the consolidated statements of income. The results of operations for HLS have been included in the Company’s consolidated financial statements from the date of acquisition, and are also included in the HealthStream Provider Solutions segment.

A summary of the purchase price is as follows (in thousands):

 

Cash paid at closing

   $  81,379   

Cash held in escrow

     6,750   
  

 

 

 

Total consideration paid

   $ 88,129   
  

 

 

 

 

The following table summarizes the preliminary fair value of the assets acquired and liabilities assumed as of the date of acquisition (in thousands):

 

Cash

   $ 54   

Accounts receivable, net

     3,052   

Prepaid assets

     546   

Property and equipment

     200   

Deferred tax assets

     2,523   

Goodwill

     41,618   

Intangible assets

     47,200   

Accounts payable and accrued liabilities

     (1,085

Deferred revenue

     (5,979
  

 

 

 

Preliminary net assets acquired

   $ 88,129   
  

 

 

 

The excess of preliminary purchase price over the preliminary fair values of net tangible and intangible assets is recorded as goodwill. The preliminary fair values of tangible and identifiable intangible assets, deferred tax assets, deferred revenue, and other liabilities are based on management’s estimates and assumptions. The preliminary fair values of assets acquired and liabilities assumed are considered preliminary and are based on the information that was available at the time of the acquisition. The preliminary fair values of assets acquired and liabilities assumed are subject to change during the measurement period (up to one year from the acquisition date) as we finalize the valuation of tax liabilities and determine final working capital adjustments. Included in the preliminary assets and liabilities is an estimated indemnification asset of $300,000 and a contingent liability of $700,000, both of which are associated with tax liabilities. The contingent liability is measured based on management’s estimate of a range of probable outcomes. During the fourth quarter of 2015, the Company reduced the preliminary fair value for accounts receivable by $115,000, prepaid assets by $200,000, and accrued liabilities by $800,000. The goodwill balance is primarily attributed to the assembled workforce, additional market opportunities from offering HLS’s products, and expected synergies from integrating HLS with other products or other combined functional areas within the Company. The goodwill balance is deductible for U.S. income tax purposes. The net tangible assets include deferred revenue, which was adjusted down from a book value at the acquisition date of $15.0 million to an estimated fair value of $6.0 million. The $9.0 million write-down of deferred revenue will result in lower revenues than would have otherwise been recognized for such services.

The following table sets forth the components of identifiable intangible assets and their estimated useful lives as of the acquisition date (in thousands):

 

     Preliminary
fair

Value
     Useful life  

Customer relationships

   $ 42,600         13 years   

Developed technology

     3,700         5 years   

Trade names

     900         6 years   
  

 

 

    

Total preliminary intangible assets subject to amortization

   $ 47,200      
  

 

 

    

The weighted average amortization period for the identifiable intangible assets acquired is 12.2 years.

The amounts of revenue and operating income (loss) of HLS included in the Company’s consolidated statements of income from the date of acquisition of March 16, 2015 to the period ending December 31, 2015 are as follows (in thousands):

 

Total revenues

   $ 8,543   
  

 

 

 

Operating loss

   $ (2,541
  

 

 

 

 

The following unaudited pro forma financial information summarizes the combined results of operations of the Company and HLS, which was significant for purposes of the unaudited pro forma financial information disclosure, as though the companies were combined as of January 1, 2014 (in thousands, except per share data):

 

     Year Ended
December 31,
 
     2015      2014  

Total revenues

   $ 219,108       $ 182,548   
  

 

 

    

 

 

 

Net income

   $ 13,551       $ 8,658   
  

 

 

    

 

 

 

Basic earnings per share

   $ 0.45       $ 0.31   
  

 

 

    

 

 

 

Diluted earnings per share

   $ 0.44       $ 0.31   
  

 

 

    

 

 

 

These unaudited pro forma combined results of operations include certain adjustments arising from the acquisition such as adjustment for amortization of intangible assets, depreciation of property and equipment, fair value adjustments of acquired deferred revenue balances, and interest expense associated with borrowings under a revolving credit facility by the Company to partially fund the acquisition. The pro forma combined results for the year ended December 31, 2014 include nonrecurring adjustments of $4.2 million, which reduce net income due to the revaluation of HLS’s historic deferred revenue to fair value. The unaudited pro forma combined results of operations is for informational purposes only and is not indicative of what the Company’s results of operations would have been had such transactions occurred at the beginning of the period presented or to project the Company’s results of operations in any future period.

The unaudited pro forma financial information for the years ended December 31, 2015 and 2014 combines the historical results of the Company and HLS for the years ended December 31, 2015 and 2014 and the pro forma adjustments listed above.

Health Care Compliance Strategies

On March 3, 2014, the Company acquired all of the stock of Health Care Compliance Strategies, Inc. (HCCS), a Jericho, New York based company that specializes in healthcare compliance solutions and services. The Company acquired HCCS to further advance its suite of workforce development solutions, including its offering of compliance solutions. The consideration paid for HCCS consisted of approximately $12.8 million in cash (taking into account a post-closing working capital adjustment) and 81,614 shares of our common stock. The Company made an additional payment of $750,000 during the second quarter of 2015, upon the achievement of certain performance milestones within one year post-closing. The Company incurred approximately $515,000 in transaction costs associated with the acquisition, of which $365,000 were incurred during the year ended December 31, 2014 and $150,000 were incurred during the year ended December 31, 2013. The transaction costs were recorded under the caption “other general and administrative” in the consolidated statements of income. In allocating the purchase price, the Company recorded approximately $6.2 million of goodwill, $8.4 million of identifiable intangible assets, $2.6 million of tangible assets, $625,000 of deferred tax assets, and $2.7 million of liabilities. Included in the recorded liabilities was an accrual for contingent consideration of approximately $600,000. The goodwill balance is primarily attributed to assembled workforce, additional market opportunities of HCCS’s compliance solutions, and expected synergies from integrating HCCS’s products into our platform. The goodwill balance is deductible for U.S. income tax purposes. The net tangible assets include deferred revenue, which was adjusted down from a book value at the acquisition date of $3.2 million to an estimated fair value of $1.7 million. The $1.5 million write-down of deferred revenue resulted in lower revenues than would have otherwise been recognized for such services. The results of operations for HCCS have been included in the Company’s consolidated financial statements from the date of acquisition, and are also included in the HealthStream Workforce Development Solutions segment.

 

Baptist Leadership Group

On September 9, 2013, the Company acquired substantially all of the assets of Baptist Leadership Group (BLG), a Pensacola, Florida based company that provides consulting services focused on patient-centered performance excellence in healthcare. The Company acquired BLG to strengthen its Patient Experience Solutions. The consideration paid for BLG consisted of approximately $7.4 million in cash (taking into account the working capital adjustment) and 15,230 shares of our common stock. The Company incurred approximately $145,000 in transaction costs associated with the acquisition, which are included on the accompanying consolidated statements of income under the caption “other general and administrative.” In allocating the purchase price, the Company recorded approximately $6.3 million of goodwill, $1.6 million of identifiable intangible assets, and $28,000 of net tangible assets. The goodwill balance is primarily attributed to the assembled workforce, additional market opportunities from BLG’s consulting services, and expected synergies from integrating BLG into the operations of the HealthStream Patient Experience Solutions segment. The goodwill balance is deductible for U.S. income tax purposes. The net tangible assets include deferred revenue, which was adjusted down from a book value of $508,000 to an estimated fair value of $254,000. The $254,000 write-down of deferred revenue resulted in lower revenues than would have otherwise been recognized for such services. The results of operations for BLG have been included in the Company’s consolidated financial statements from the date of acquisition, and are included in the HealthStream Patient Experience Solutions segment.

 

XML 28 R13.htm IDEA: XBRL DOCUMENT v3.3.1.900
Property and Equipment
12 Months Ended
Dec. 31, 2015
Property, Plant and Equipment [Abstract]  
Property and Equipment

6. PROPERTY AND EQUIPMENT

Property and equipment consist of the following:

 

     December 31,  
     2015      2014  

Equipment

   $ 23,057       $ 25,133   

Leasehold improvements

     4,435         5,860   

Furniture and fixtures

     4,338         4,554   
  

 

 

    

 

 

 

Gross property and equipment

     31,830         35,547   

Accumulated depreciation and amortization

     (19,359      (26,105
  

 

 

    

 

 

 

Property and equipment, net

   $ 12,471       $ 9,442   
  

 

 

    

 

 

 

Depreciation of property and equipment totaled approximately $5.3 million and $4.1 million for the years ended December 31, 2015 and 2014, respectively.

XML 29 R14.htm IDEA: XBRL DOCUMENT v3.3.1.900
Goodwill
12 Months Ended
Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill

7. GOODWILL

The changes in the carrying amount of goodwill for the years ended December 31, 2015 and 2014 are as follows (in thousands):

 

     Workforce      Patient
Experience
     Provider      Total  

Balance at January 1, 2015

   $ 12,336       $ 24,154       $ 5,424       $ 41,914   

Acquisition of HealthLine Systems, LLC

     —           —           41,618         41,618   

Disposal of long lived assets

     —           —           (459      (459
  

 

 

    

 

 

    

 

 

    

 

 

 

Balance at December 31, 2015

   $ 12,336       $ 24,154       $ 46,583       $ 83,073   
  

 

 

    

 

 

    

 

 

    

 

 

 
     Workforce      Patient
Experience
     Provider      Total  

Balance at January 1, 2014

   $ 6,168       $ 24,154       $ 5,424       $ 35,746   

Acquisition of Health Care Compliance Strategies, Inc.

     6,168         —           —           6,168   
  

 

 

    

 

 

    

 

 

    

 

 

 

Balance at December 31, 2014

   $ 12,336       $ 24,154       $ 5,424       $ 41,914   
  

 

 

    

 

 

    

 

 

    

 

 

 

During the quarter ended December 31, 2015, the Company disposed of certain long lived assets meeting the definition of a business. Accordingly, we have allocated approximately $459,000 of reporting unit goodwill to this disposition of assets pursuant to ASC 350, Intangibles – Goodwill and other.

XML 30 R15.htm IDEA: XBRL DOCUMENT v3.3.1.900
Intangible Assets
12 Months Ended
Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets

8. INTANGIBLE ASSETS

Intangible assets other than goodwill are considered to have finite useful lives. Customer related intangibles are amortized over their estimated useful lives ranging from five to thirteen years. Other intangible assets include non-competition agreements, technology and patents, and trade names, and are being amortized over periods ranging from three to nine years. During the quarter ended December 31, 2015, the Company retired approximately $10.7 million of fully amortized identifiable intangible assets. Gross amounts and related accumulated amortization presented below as of December 31, 2015 are reflective of such retirements. Such amounts are also inclusive of identifiable intangible assets recorded in relation to our acquisition of HealthLine Systems, LLC (see Note 5 – Business Combinations). Amortization of intangible assets was approximately $5.6 million and $2.4 million for the years ended December 31, 2015 and 2014, respectively.

Identifiable intangible assets are comprised of the following (in thousands):

 

     As of December 31, 2015      As of December 31, 2014  
     Gross Amount      Accumulated
Amortization
    Net      Gross Amount      Accumulated
Amortization
    Net  

Customer related

   $ 55,571       $ (6,068   $ 49,503       $ 23,329       $ (11,880   $ 11,449   

Other

     9,080         (2,617     6,463         5,300         (1,954     3,346   
  

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

 

Total

   $ 64,651       $ (8,685   $ 55,966       $ 28,629       $ (13,834   $ 14,795   
  

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

 

The expected future annual amortization expense for the years ending December 31, is as follows (in thousands):

 

2016

   $ 6,400   

2017

     6,323   

2018

     6,211   

2019

     5,566   

2020

     4,913   

Thereafter

     26,553   
  

 

 

 

Total

   $ 55,966   
  

 

 

 
XML 31 R16.htm IDEA: XBRL DOCUMENT v3.3.1.900
Business Segments
12 Months Ended
Dec. 31, 2015
Segment Reporting [Abstract]  
Business Segments

9. BUSINESS SEGMENTS

The Company provides services to healthcare organizations and other members within the healthcare industry. The Company’s services are focused on the delivery of workforce development products and services (HealthStream Workforce Solutions), survey and research services (HealthStream Patient Experience Solutions), and provider credentialing, privileging, call center and enrollment products and services (HealthStream Provider Solutions).

The Company measures segment performance based on operating income before income taxes and prior to the allocation of certain corporate overhead expenses, interest income, interest expense, gains and losses from equity investments, and depreciation. The Unallocated component below includes corporate functions, such as accounting, human resources, legal, investor relations, administrative and executive personnel, depreciation, a portion of amortization, and certain other expenses, which are not currently allocated in measuring segment performance. The following is the Company’s business segment information as of and for the years ended December 31, 2015, 2014 and 2013 (in thousands).

 

Revenues, net:    2015      2014      2013  

Workforce

   $ 161,289       $ 134,242       $ 99,963   

Patient Experience

     34,193         31,901         28,454   

Provider

     13,520         4,547         3,857   
  

 

 

    

 

 

    

 

 

 

Total revenues, net

   $ 209,002       $ 170,690       $ 132,274   
  

 

 

    

 

 

    

 

 

 

 

Operating income:    2015      2014      2013  

Workforce

   $ 39,986       $ 35,374       $ 28,203   

Patient Experience

     1,548         810         2,819   

Provider

     (2,559      826         277   

Unallocated

     (25,418      (20,635      (16,633
  

 

 

    

 

 

    

 

 

 

Total operating income

   $ 13,557       $ 16,375       $ 14,666   
  

 

 

    

 

 

    

 

 

 

 

     Assets *      Purchases of long-lived assets      Depreciation and amortization  
     2015      2014      2013      2015      2014      2013      2015      2014      2013  

Workforce

   $ 82,375       $ 81,116       $ 48,514       $ 11,403       $ 7,179       $ 6,243       $ 6,693       $ 4,813       $ 2,829   

Patient Experience

     34,902         34,536         34,727         2,007         1,277         726         1,061         1,272         1,068   

Provider

     100,948         10,976         11,499         332         200         67         3,986         683         683   

Unallocated

     161,344         130,634         117,854         1,617         1,546         1,675         5,257         4,163         3,272   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 379,569       $ 257,262       $ 212,594       $ 15,359       $ 10,202       $ 8,711       $ 16,997       $ 10,931       $ 7,852   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

* Segment assets include accounts and unbilled receivables, prepaid royalties, prepaid and other current assets, other assets, capitalized software development, certain property and equipment, and intangible assets. Cash and cash equivalents and marketable securities are not allocated to individual segments, and are included within Unallocated. A significant portion of property and equipment assets are included within Unallocated.
XML 32 R17.htm IDEA: XBRL DOCUMENT v3.3.1.900
Income Taxes
12 Months Ended
Dec. 31, 2015
Income Tax Disclosure [Abstract]  
Income Taxes

10. INCOME TAXES

The provision (benefit) for income taxes is comprised of the following (in thousands):

 

     Year Ended December 31,  
     2015      2014      2013  

Current federal

   $ 3,608       $ 3,198       $ 2,474   

Current state

     1,098         1,605         1,444   

Deferred federal

     501         1,092         2,315   

Deferred state

     (109      232         191   
  

 

 

    

 

 

    

 

 

 

Provision for income taxes

   $ 5,098       $ 6,127       $ 6,424   
  

 

 

    

 

 

    

 

 

 

A reconciliation of income taxes at the statutory federal income tax rate to the provision for income taxes included in the accompanying consolidated statements of income is as follows (in thousands):

 

     Year Ended December 31,  
     2015      2014      2013  

Federal tax provision at the statutory rate

   $ 4,802       $ 5,782       $ 5,194   

State income tax provision, net of federal benefit

     673         1,350         898   

Tax credits

     (425      (1,160      (54

Change in state valuation allowance

     (8      37         231   

Other

     56         118         155   
  

 

 

    

 

 

    

 

 

 

Provision for income taxes

   $ 5,098       $ 6,127       $ 6,424   
  

 

 

    

 

 

    

 

 

 

Management periodically evaluates the realizability of its deferred tax assets, and to the extent that a recovery is not likely, a valuation allowance is established to reduce the deferred tax asset to the amount estimated to be recoverable. At December 31, 2015, a valuation allowance of $346,000 exists. The Company adjusts deferred tax liabilities and assets in the period of enactment for the effect of an enacted change in tax laws or rates. Accordingly, the state income tax provision for the period ended December 31, 2015 is inclusive of a deferred tax benefit of $188,000 related to a change in state tax law that will be effective for the Company’s tax year beginning on or after January 1, 2017.

 

As of December 31, 2015, the Company had state net operating loss carryforwards of $13.0 million. These loss carryforwards will expire in years 2016 through 2025. The Company is subject to income taxation at the federal and various state levels. The Company is subject to U.S. federal tax examinations for tax years 2012 through 2015. Loss carryforwards and credit carryforwards generated or utilized in years earlier than 2012 are also subject to examination and adjustment. The Company has examinations in process with the Internal Revenue Service for tax years 2013 and 2014. The Company has research and development tax credit carryforwards of $1.9 million that expire in varying amounts through 2035. As of December 31, 2015, the Company had alternative minimum tax credit carryforwards of $816,000 that are available to offset future regular tax liabilities and they do not expire.

A reconciliation of the beginning and ending liability for gross unrecognized tax benefits at December 31, 2015 and 2014, are as follows (in thousands):

 

     December 31,  
     2015      2014  

Balance at beginning of year

   $ 2,168       $ 167   

Additions for tax positions in the current year

     351         2,168   

Reductions for tax positions of prior years

     (1,861      (167
  

 

 

    

 

 

 

Balance at end of year

   $ 658       $ 2,168   
  

 

 

    

 

 

 

The Company recognized approximately $14,000 and $125,000 for interest and penalties related to unrecognized tax benefits within the provision for income taxes during the years ended December 31, 2015 and 2014, respectively. Unrecognized tax benefits included tax positions of approximately $278,000 at both December 31, 2015 and 2014 that if recognized would impact the Company’s effective tax rate. The reduction for tax positions of prior years reflected in the table above as of December 31, 2015 relates to a change in tax accounting method filed with the IRS for tangible property and deferred revenue. The Company estimates that it is reasonably possible the liability for unrecognized tax benefits could decrease up to $0.3 million within the next 12 months.

Deferred federal and state income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of deferred tax assets and deferred tax liabilities are as follows (in thousands):

 

     December 31,  
     2015      2014  

Deferred tax assets:

     

Allowance for doubtful accounts

   $ 122       $ 134   

Accrued liabilities

     2,062         1,565   

Tax credits

     816         791   

Stock based compensation

     1,107         1,015   

Deferred revenue

     1,563         616   

Depreciation

     348         715   

Basis difference on investments

     80         —     

Net operating loss carryforwards

     407         355   
  

 

 

    

 

 

 

Total deferred tax assets

     6,505         5,191   

Less: Valuation allowance

     (346      (355
  

 

 

    

 

 

 

Deferred tax assets, net of valuation allowance

     6,159         4,836   

Deferred tax liabilities:

     

Deductible goodwill

     2,646         2,369   

Nondeductible intangible assets

     1,806         2,171   

Prepaid assets

     1,911         1,602   

Capitalized software development

     4,559         3,836   

Basis difference on investments

     —           343   
  

 

 

    

 

 

 

Total deferred tax liabilities

     10,922         10,321   
  

 

 

    

 

 

 

Net deferred tax liabilities

   $ (4,763    $ (5,485
XML 33 R18.htm IDEA: XBRL DOCUMENT v3.3.1.900
Stock Based Compensation
12 Months Ended
Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock Based Compensation

11. STOCK BASED COMPENSATION

Stock Incentive Plans

The Company’s 2010 Stock Incentive Plan (2010 Plan) and 2000 Stock Incentive Plan (2000 Plan; collectively, the 2010 Plan and the 2000 Plan referred to as the Plan) authorize the grant of options, restricted share units (RSU), or other forms of stock based compensation to employees, officers, directors and others, and such grants must be approved by the Compensation Committee of the Board of Directors. Options granted under the Plan have terms of no more than ten years, with certain restrictions. The Plan allows the Compensation Committee of the Board of Directors to determine the vesting period and parameters of each grant. The vesting period of the options and RSUs granted has historically ranged from immediate vesting to annual vesting up to four years, generally beginning one year after the grant date. As of December 31, 2015, approximately 487,000 shares of unissued common stock remained reserved for future stock incentive grants under the Plan. The Company issues new shares of common stock when options are exercised or when RSUs become vested.

Stock Option Activity

A summary of activity and various other information relative to stock options for the year ended December 31, 2015 is presented in the tables below (in thousands, except exercise price).

 

     Common
Shares
     Weighted-
Average
Exercise Price
     Aggregate
Intrinsic Value
 
          
          

Outstanding at beginning of period

     596       $ 6.18      

Granted

     —           —        

Exercised

     (76      4.29      

Expired

     —           —        

Forfeited

     —           —        
  

 

 

    

 

 

    

Outstanding at end of period

     520       $ 6.45       $ 8,081   
  

 

 

    

 

 

    

 

 

 

Exercisable at end of period.

     520       $ 6.45       $ 8,081   
  

 

 

    

 

 

    

 

 

 

The aggregate intrinsic value for stock options in the table above represents the total difference between the Company’s closing stock price on December 31, 2015 (the last trading day of the year) of $22.00 per share and the option exercise price, multiplied by the number of in-the-money options as of December 31, 2015. The weighted average remaining contractual term of options outstanding at December 31, 2015 was 2.5 years. Options exercisable at December 31, 2015 have a weighted average remaining contractual term of 2.5 years.

Other information relative to option activity during the three years ended December 31, 2015 is as follows (in thousands):

 

     2015      2014      2013  

Total grant date fair value of stock options vested

   $ 232       $ 630       $ 723   
  

 

 

    

 

 

    

 

 

 

Total intrinsic value of stock options exercised

   $ 1,662       $ 5,912       $ 25,846   
  

 

 

    

 

 

    

 

 

 

Cash proceeds from exercise of stock options

   $ 328       $ 1,094       $ 3,318   
  

 

 

    

 

 

    

 

 

 

Restricted Share Unit Activity

A summary of activity relative to RSUs for the year ended December 31, 2015 is follows (in thousands, except weighted average grant date fair value):

 

     Number of
RSU’s
     Weighted-
Average
Grant Date Fair Value
     Aggregate
Intrinsic Value
 
          
          

Outstanding at beginning of period

     164       $ 25.04      

Granted

     110         24.97      

Vested

     (54      24.17      

Forfeited

     (2      26.03      
  

 

 

    

 

 

    

Outstanding at end of period

     218       $ 25.21       $ 4,793   
  

 

 

    

 

 

    

 

 

 

 

The aggregate fair value of RSU awards that vested in 2015 and 2014, as of the respective vesting dates, was approximately $1.4 million and $1.1 million, respectively. A portion of RSUs that vested in 2015 and 2014 were net-share settled such that the Company withheld shares with value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. The total shares withheld for RSUs during 2015 and 2014 were 8,922 and 5,327, respectively, and were based on the value of the RSUs on their respective settlement dates as determined by the Company’s closing stock price. Total payments related to RSUs for the employees’ tax obligations to taxing authorities were approximately $230,000 in 2015 and $161,000 in 2014, and are reflected as a financing activity within the consolidated statements of cash flows. These net-share settlements had the effect of share repurchases by the Company as they reduced and retired the number of shares that would have otherwise been issued as a result of the vesting and did not represent an expense to the Company.

Stock Based Compensation

Total stock based compensation expense, which is recorded in our consolidated statements of income, recorded for the years ended December 31, is as follows (in thousands):

 

     Years Ended December 31,  
     2015      2014      2013  

Cost of revenues (excluding depreciation and amortization)

   $ 824       $ 86       $ 81   

Product development

     569         201         144   

Sales and marketing

     547         224         175   

Other general and administrative

     1,340         1,114         1,058   
  

 

 

    

 

 

    

 

 

 

Total stock based compensation expense

   $ 3,280       $ 1,625       $ 1,458   
  

 

 

    

 

 

    

 

 

 

The Company amortizes the fair value of all stock based awards, net of estimated forfeitures, on a straight-line basis over the requisite service period, which generally is the vesting period. As of December 31, 2015, total unrecognized compensation expense related to non-vested stock options and RSUs was approximately $3.0 million, net of estimated forfeitures, with a weighted average expense recognition period remaining of 2.3 years. The Company realized approximately $3.0 million of excess tax benefits related to stock based awards during the year ended December 31, 2015, which was recorded as an increase to common stock.

Stock based compensation cost for RSUs is measured based on the closing fair market value of the Company’s stock on the date of grant. Stock based compensation cost for stock options is estimated at the grant date based on the fair value calculated using the Black-Scholes method. The Company did not grant any stock options during 2015, 2014, or 2013.

Stock Awards

During June 2015, the Company’s CEO, Robert A. Frist, Jr., entered into an agreement with the Company pursuant to which he contributed 54,241 of his personally owned shares of HealthStream, Inc. common stock to the Company, without any consideration paid to him. In connection with this contribution, the Company approved the grant of 49,310 shares of HealthStream, Inc. common stock to over 600 employees who were not otherwise eligible to receive equity awards and had at least one year of service with the Company. The Company recognized approximately $1.5 million of stock based compensation expense for these stock awards during the three months ended June 30, 2015 based on the closing fair market value of the Company’s stock on the date of the Company’s approval of these grants. In connection with these equity awards, effective in the second quarter of 2015, the Company withheld shares with value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. The total shares withheld were 17,279, and were based on the value of the stock awards on the date of the Company’s approval of these grants, as determined by the Company’s closing stock price on that date. Total payments related to the employees’ tax obligations to taxing authorities for these stock awards were approximately $526,000 and are reflected as a financing activity within the consolidated statements of cash flows for the year ended December 31, 2015. These share withholdings had the effect of share repurchases by the Company as they reduced and retired the number of shares otherwise issuable as a result of the stock awards and did not represent an expense to the Company.

XML 34 R19.htm IDEA: XBRL DOCUMENT v3.3.1.900
Employee Benefit Plan
12 Months Ended
Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]  
Employee Benefit Plan

12. EMPLOYEE BENEFIT PLAN

401(k) Plan

The Company has a defined-contribution employee benefit plan (401(k) Plan) incorporating provisions of Section 401(k) of the Internal Revenue Code. Employees must have attained the age of 21 and have completed thirty days of service to be eligible to participate in the 401(k) Plan. Under the provisions of the 401(k) Plan, a plan member may make contributions, on a tax-deferred basis, subject to IRS limitations. The Company elected to provide eligible employees with matching contributions totaling approximately $645,000 and $274,000 for the years ended December 31, 2015 and 2014, respectively.

XML 35 R20.htm IDEA: XBRL DOCUMENT v3.3.1.900
Debt
12 Months Ended
Dec. 31, 2015
Debt Disclosure [Abstract]  
Debt

13. DEBT

At December 31, 2015 and 2014, the Company had no debt outstanding.

Revolving Credit Facility

The Company maintains a Loan Agreement (the “Revolving Credit Facility”) with SunTrust Bank (“SunTrust”) in the aggregate principal amount of $50.0 million, which matures on November 24, 2017. Under the Revolving Credit Facility, the Company may borrow up to $50.0 million, which includes a $5.0 million swing line subfacility, as well as an accordion feature that allows the Company to increase the Revolving Credit Facility by a total of up to $25.0 million, subject to securing additional commitments from existing lenders or new lending institutions. The Revolving Credit Facility includes a $5.0 million letter of credit subfacility. The obligations under the Revolving Credit Facility are guaranteed by each of the Company’s subsidiaries. At the Company’s election, the borrowings under the Revolving Credit Facility bear interest at either (1) a rate per annum equal to the highest of SunTrust’s prime rate or 0.5% in excess of the Federal Funds Rate or 1.0% in excess of one-month LIBOR (the “Base Rate”), plus an applicable margin, or (2) the one, two, three, or six-month per annum LIBOR for deposits in the applicable currency (the “Eurocurrency Rate”), as selected by the Company, plus an applicable margin. The applicable margin for Eurocurrency Rate loans depends on the Company’s funded debt leverage ratio and varies from 1.50% to 2.00%. The applicable margin for Base Rate loans depends on the Company’s funded debt leverage ratio and varies from 0.50% to 1.50%. Commitment fees and letter of credit fees are also payable under the Revolving Credit Facility. Principal is payable in full at maturity on November 24, 2017, and there are no scheduled principal payments prior to maturity. The Company is required to pay a commitment fee ranging between 20 and 30 basis points per annum of the average daily unused portion of the Revolving Credit Facility, depending on the Company’s funded debt leverage ratio.

The purpose of the Revolving Credit Facility is for general working capital needs, permitted acquisitions (as defined in the Loan Agreement), and for stock repurchase and/or redemption transactions that the Company may authorize.

The Revolving Credit Facility contains certain covenants that, among other things, restrict additional indebtedness, liens and encumbrances, changes to the character of the Company’s business, acquisitions, asset dispositions, mergers and consolidations, sale or discount of receivables, creation or acquisitions of additional subsidiaries, and other matters customarily restricted in such agreements.

As of December 31, 2015, the Company was in material compliance with all covenants. There were no balances outstanding on the Revolving Credit Facility as of December 31, 2015. During the three months ended March 31, 2015, the Company borrowed approximately $28.0 million under the Revolving Credit Facility. During the three months ended June 30, 2015, the Company repaid approximately $28.0 million of balances previously outstanding under the Revolving Credit Facility from proceeds received in the Company’s public offering of 3,869,750 shares which closed on May 28, 2015. The weighted average interest rate was 1.68% for borrowings under Revolving Credit Facility during the year ended December 31, 2015.

XML 36 R21.htm IDEA: XBRL DOCUMENT v3.3.1.900
Leases
12 Months Ended
Dec. 31, 2015
Leases [Abstract]  
Leases

14. LEASES

The Company has non-cancellable operating leases primarily for office space, hosting facilities, and office equipment. Some lease agreements contain provisions for escalating rent payments over the initial terms of the lease. The Company accounts for these leases by recognizing rent expense on a straight-line basis and adjusting the deferred rent expense liability for the difference between the straight-line rent expense and the amount of rent paid. The terms of the lease agreements generally provide the Company the option to renew. The Company also leases certain office equipment under operating leases. Total rent expense under all operating leases was approximately $4.3 million, $3.1 million, and $2.4 million, for the years ended December 31, 2015, 2014, and 2013, respectively.

Future rental payment commitments at December 31, 2015 under non-cancelable operating leases, with initial terms of one year or more, are as follows (in thousands):

 

2016

   $ 3,876   

2017

     2,625   

2018

     1,365   

2019

     808   

2020

     810   

Thereafter

     2,604   
  

 

 

 

Total minimum lease payments

   $ 12,088   
  

 

 

 
XML 37 R22.htm IDEA: XBRL DOCUMENT v3.3.1.900
Litigation
12 Months Ended
Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]  
Litigation

15. LITIGATION

In connection with its business, the Company is from time to time involved in various legal actions. The litigation process is inherently uncertain and it is possible that the resolution of such matters might have a material adverse effect upon the financial condition and/or results of operations of the Company. However, in the opinion of the Company’s management, matters currently pending or threatened against the Company are not expected to have a material adverse effect on the financial position or results of operations of the Company.

XML 38 R23.htm IDEA: XBRL DOCUMENT v3.3.1.900
Related Party Transactions
12 Months Ended
Dec. 31, 2015
Related Party Transactions [Abstract]  
Related Party Transactions

16. RELATED PARTY TRANSACTIONS

During the three months ended June 30, 2015, the Company’s CEO, Robert A. Frist, Jr., entered into an agreement with the Company pursuant to which he contributed 54,241 of his personally owned shares of HealthStream, Inc. common stock to the Company, without any consideration paid to him. In connection with this contribution, the Company approved the grant of 49,310 shares of common stock to over 600 employees, with a fair market value of approximately $1.5 million. Mr. Frist contributed 4,931 of the contributed shares noted above to take into account the estimated Company costs, such as administrative expenses and employer payroll taxes associated with the grants. (See Note 11).

XML 39 R24.htm IDEA: XBRL DOCUMENT v3.3.1.900
Subsequent Events
12 Months Ended
Dec. 31, 2015
Subsequent Events [Abstract]  
Subsequent Events

17. SUBSEQUENT EVENTS

In February 2016, the Board of Directors authorized a share repurchase program for up to $25 million of the Company’s outstanding common stock. Repurchases will be made under the repurchase program in accordance with applicable securities laws and may be made at management’s discretion from time to time in the open market, through privately negotiated transactions, or otherwise. The share repurchase program will terminate on the earlier of December 31, 2016 or when the maximum dollar amount has been expended. The share repurchase program may be suspended or discontinued at any time.

XML 40 R25.htm IDEA: XBRL DOCUMENT v3.3.1.900
Summary of Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2015
Accounting Policies [Abstract]  
Reporting Entity and Segments

Reporting Entity and Segments

HealthStream, Inc. (the “Company”) was incorporated in 1990 as a Tennessee corporation and is headquartered in Nashville, Tennessee. The Company operates in three segments: HealthStream Workforce Solutions, HealthStream Patient Experience Solutions, and HealthStream Provider Solutions. Workforce Solutions products consist of SaaS-based services and subscription-based solutions to meet the ongoing training, certification, assessment and development needs of the healthcare community. These solutions provide, deliver and track computer based education for our customers in the United States through our software-as-a-service (SaaS) model. Patient Experience products offer healthcare organizations a wide range of quality and satisfaction surveys, consulting services, analyses of survey results, and other research-based services. Provider Solutions products offer healthcare organizations software applications for administering and tracking provider credentialing, privileging, call center and enrollment.

Change in Goodwill Impairment Testing Date

Change in Goodwill Impairment Testing Date

During the quarter ended December 31, 2015, the Company voluntarily changed its annual goodwill impairment testing date from December 31 to October 1 of each year. This change provides additional time for the completion of the annual goodwill impairment testing prior to the end of the annual reporting period and results in further alignment with the Company’s annual strategic planning process. Accordingly, management considers this accounting change preferable. The Company is unable to objectively determine, without the use of hindsight, the assumptions that would have been used in earlier periods. Therefore, the change will be applied prospectively as retrospective application to prior periods is deemed impracticable. This change does not result in the delay, acceleration or avoidance of any potential impairment charge.

Recently Adopted Accounting Standards

Recently Adopted Accounting Standards

The Company has adopted the provisions of Accounting Standards Update (ASU) 2015-17 — Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes, which serves to simplify the balance sheet presentation of deferred taxes. In connection with the adoption of ASU 2015-17, the Company has elected prospective application; therefore, all deferred tax assets and liabilities as of December 31, 2015 are presented as noncurrent in the accompanying consolidated balance sheet.

Recognition of Revenue

Recognition of Revenue

Revenues are derived from providing services through our SaaS-based workforce development platform products, courseware subscriptions, provision of survey and research services, sales of software licensing arrangements, software maintenance and support, professional services, custom courseware development and other education and training services.

The Company recognizes revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when persuasive evidence of an arrangement exists, prices are fixed or determinable, services and products are provided to the customer and collectability is probable or reasonably assured.

Revenue recognized from software and other arrangements is allocated to each element of the arrangement based on the relative fair values of the elements. While elements include software products and post contract customer support, the fair value of each element is based on vendor specific objective evidence (VSOE). If fair value cannot be determined for each element of the arrangement, all revenue from the arrangement is deferred until fair value can be determined or until all elements of the arrangement are delivered and customer acceptance has occurred. Sales of the Company’s SaaS-based workforce development platform products include customer support, implementation services, and training; therefore all revenues are deferred until the SaaS-based product is implemented, at which time revenues are recognized ratably over the subscription service period. In the event that circumstances occur, which give rise to uncertainty regarding the collectibility of contracted amounts, revenue recognition is suspended until such uncertainty is resolved. Fees for these services are billed on either a monthly, quarterly, or annual basis.

Revenues derived from the delivery of services through the Company’s SaaS-based workforce development platform products and courseware subscriptions are recognized ratably over the term of the subscription service agreement or over the historical usage period, if usage typically differs from the subscription period. Other training revenues are generally recognized upon the completion of training.

Revenues derived from the license of installed software products are recognized upon shipment or installation of the software, when VSOE of the fair value of the software license can be established. Software support and maintenance revenues are recognized ratably over the term of the related agreement.

 

Revenues recognized from the Company’s survey and research services are determined using both the proportional performance method and the completed contract method. Revenues are generally earned over the estimated survey cycle, which typically ranges from less than one month to up to five months. The survey cycle is generally initiated based on the receipt of the first survey response and runs through provision of related survey reports to the customer. If survey results are not available to the customer during the survey fielding cycle, revenues are recognized at time of report delivery. Revenues for coaching and consulting engagements are recognized using the proportional performance method over the term of the underlying contract. Fees for survey services are billed upon initiation of the survey cycle, with progress billings made throughout the survey cycle. Fees for coaching and consulting engagements are billed upon initiation of the engagement with progress billings throughout the term of the contract.

Revenues from professional services and courseware development services are recognized upon the completion of performance milestones and deliverables using the proportional performance method. All other revenues are recognized as the related services are performed or products are delivered. Fees for these services are generally billed at project initiation and upon completion of various milestones.

Principles of Consolidation

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its subsidiaries, all of which are wholly-owned. All inter-company accounts and transactions have been eliminated in consolidation.

Use of Estimates

Use of Estimates

The consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles. These accounting principles require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates and such differences could be material to the consolidated financial statements.

Cash Equivalents

Cash Equivalents

The Company considers cash equivalents to be unrestricted, highly liquid investments with initial maturities of less than three months.

Marketable Securities

Marketable Securities

Marketable securities are classified as available for sale and are stated at fair market value, with the unrealized gains and losses, net of tax, reported in other comprehensive income (loss) on the accompanying consolidated balance sheets. Realized gains and losses and declines in market value judged to be other than temporary on investments in marketable securities are included in interest and other income on the accompanying consolidated statements of income. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available for sale are included in other income (expense) on the accompanying consolidated statements of income. Premiums and discounts are amortized over the life of the related available for sale security as an adjustment to yield using the effective interest method.

Accounts Receivable-Unbilled

Accounts Receivable-Unbilled

Accounts receivable-unbilled represents the following: 1) revenue earned and recognized on contracts accounted for using the proportional performance method for which invoices have not been generated or contractual billing dates have not been reached; and 2) the difference between billings for contracts containing escalated pricing over the term of the agreement and the recognition of revenue ratably over the subscription period.

Deferred Revenue

Deferred Revenue

Deferred revenue represents amounts that have been billed or collected in advance of revenue recognition. The Company typically invoices customers in quarterly, bi-annual, or annual installments, and occasionally customers will pay for multi-year contracts in advance. Deferred revenue is recognized as the revenue recognition criteria are met.

Prepaid Royalties

Prepaid Royalties

Prepaid royalties represents advance payments associated with the sale of third party products, such as courseware subscriptions. Royalties are typically paid in advance at the commencement of the revenue cycle, or periodically throughout the revenue cycle, such as quarterly, bi-annual, or annual installments. Royalty payments are amortized over the term of the underlying contracts, which generally range from 12 to 36 months, in order to match the direct royalty costs to the same period the subscription revenue is recognized. Amortization of royalties is included under the caption “cost of revenues (excluding depreciation and amortization)” in the accompanying consolidated statements of income.

Allowance for Doubtful Accounts

Allowance for Doubtful Accounts

The Company estimates its allowance for doubtful accounts using a specific identification method in which management considers the facts and circumstances surrounding each potentially uncollectible receivable. An allowance is also maintained for accounts that are not specifically identified that may become uncollectible in the future. Uncollectible receivables are written-off in the period management believes it has exhausted every opportunity to collect payment from the customer. Bad debt expense is recorded when events or circumstances indicate an additional allowance is required based on the Company’s specific identification approach.

Changes in the allowance for doubtful accounts and the amounts charged to bad debt expense for the years ended December 31, were as follows (in thousands):

 

     Allowance Balance at
Beginning of Period
     Charged to Costs and
Expenses
     Write-offs      Allowance Balance at
End of Period
 

2015

   $ 331       $ 284       $ (312    $ 303   

2014

   $ 211       $ 237       $ (117    $ 331   

2013

   $ 142       $ 115       $ (46    $ 211   
Capitalized Software Development

Capitalized Software Development

Capitalized software development is stated on the basis of cost, and is presented net of accumulated amortization. The Company capitalizes costs incurred during the software development phase for projects when such costs are material. These assets are amortized using the straight-line method, generally ranging between three to five years. The Company capitalized approximately $7.3 million and $5.7 million during 2015 and 2014, respectively. Amortization of capitalized software development was approximately $6.2 million and $4.3 million during 2015 and 2014, respectively. Maintenance and operating costs are expensed as incurred. As of December 31, 2015 and 2014, there were no capitalized internal development costs for computer software developed for resale.

Fair Value Measurements

Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes the inputs to valuation techniques used in measuring fair value. There are three levels to the fair value hierarchy based on the reliability of inputs, as follows:

 

Level 1      Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
Level 2      Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly.
Level 3      Unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions.

The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period. This determination requires significant judgments to be made by the Company. At December 31, 2015 and 2014, our assets measured at fair value on a recurring basis consisted of marketable securities, which are classified as available for sale (see Note 4 – Marketable Securities). The Company did not have any financial liabilities that were subject to fair value measurements as of such dates.

Property and Equipment

Property and Equipment

Property and equipment are stated on the basis of cost. Depreciation and amortization are provided on the straight-line method over the following estimated useful lives, except for assets under capital leases and leasehold improvements, which are amortized over the shorter of the estimated useful life or their respective lease term.

 

     Years  
Furniture and fixtures      5-10   
Equipment      3-5   
Goodwill and Intangible Assets

Goodwill and Intangible Assets

Goodwill represents the excess of purchase price in a business combination over the fair value of the net identifiable assets acquired. The carrying amount of our goodwill is evaluated for impairment at least annually during the fourth quarter and whenever events or changes in facts or circumstances indicate that impairment may exist. In accordance with ASC 350, Intangibles – Goodwill and Other, companies may opt to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. A qualitative assessment includes factors such as financial performance, industry and market metrics, and other factors affecting the reporting unit. If this assessment concludes that is more likely than not that the fair value of a reporting unit exceeds its carrying value, then goodwill is not considered impaired and no further impairment testing is required. Conversely, if the qualitative assessment concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we must then compare the fair value of the reporting unit to its carrying value. The Company determines fair value of the reporting units using both income and market based models. These models require the use of various assumptions relating to cash flow projections, growth rates, discount rates and terminal value calculations. The Company did not recognize any impairment charges for the years ended December 31, 2015, 2014 or 2013.

As of December 31, 2015, intangible assets with remaining unamortized balances include contract rights and customer relationships, internally-developed technology and patents, non-competition agreements, and trade names. These intangible assets are considered to have definite useful lives and are being amortized on a straight line basis over periods typically ranging between three and fifteen years. The weighted average amortization period for definite lived intangible assets as of December 31, 2015 was 11.3 years. Intangible assets are reviewed for impairment whenever events or changes in facts or circumstances indicate that the carrying amount of the assets may not be recoverable. There were no impairments identified or recorded for the years ended December 31, 2015, 2014, or 2013.

Long-Lived Assets

Long-Lived Assets

Long-lived assets to be held for use are reviewed for events or changes in facts and circumstances, both internally and externally, which may indicate that an impairment of long-lived assets held for use is present. The Company measures any impairment using observable market values or discounted future cash flows from the related long-lived assets. The cash flow estimates and discount rates incorporate management’s best estimates, using appropriate and customary assumptions and projections at the date of evaluation. Management periodically evaluates whether the carrying value of long-lived assets, including intangible assets, property and equipment, capitalized software development, and other assets will be recoverable. There were no impairments identified or recorded for the years ended December 31, 2015, 2014, or 2013.

Non-Marketable Equity Investments

Non-Marketable Equity Investments

Non-marketable equity investments are accounted for using the equity method when the Company can exercise significant influence over the investee. Investments for which the Company is not able to exercise significant influence over the investee are accounted for under the cost method. The proportionate share of income or loss from equity method investments are recorded under the caption “other income, net” in the accompanying consolidated statements of income.

Financial Instruments

Financial Instruments

The Company has various financial instruments, including cash and cash equivalents, accounts receivable, accounts receivable-unbilled, accounts payable, accrued liabilities, and deferred revenue. The carrying amounts of these financial instruments approximate fair value because of the short term maturity or short term nature of such instruments. The Company also has marketable securities, which are recorded at approximate fair value based on quoted market prices or alternative pricing sources (see Note 4 – Marketable Securities).

Advertising

Advertising

The Company expenses the costs of advertising as incurred. Advertising expense for the years ended December 31, 2015, 2014, and 2013 was approximately $1.1 million, $0.7 million, and $0.4 million, respectively.

Shipping and Handling Costs

Shipping and Handling Costs

Shipping and handling costs that are associated with our products and services are included in cost of revenues.

Income Taxes

Income Taxes

Income taxes are accounted for using the asset and liability method, whereby deferred tax assets and liabilities are determined based on the temporary differences between the financial statement and tax bases of assets and liabilities measured at tax rates that will be in effect for the year in which the differences are expected to affect taxable income. Management evaluates all available evidence, both positive and negative, to determine whether, based on the weight of that evidence, a valuation allowance is needed. Future realization of the tax benefit of an existing deductible temporary difference or carryforward ultimately depends on the existence of sufficient taxable income of the appropriate character within the carryback or carryforward period available under the tax law. There are four possible sources of taxable income that may be available under the tax law to realize a tax benefit for deductible temporary differences and carryforwards: 1) future reversals of existing taxable temporary differences, 2) future taxable income exclusive of reversing temporary differences and carryforwards, 3) taxable income in prior carryback year(s) if carryback is permitted under the tax law, and 4) tax-planning strategies that would, if necessary, be implemented to realize deductible temporary differences or carryforwards prior to their expiration. Management reviews the realizability of its deferred tax assets each reporting period to identify whether any significant changes in circumstances or assumptions have occurred that could materially affect the realizability of deferred tax assets. As of December 31, 2015, the Company had established a valuation allowance of $346,000 for the portion of its net deferred tax assets that are not more likely than not expected to be realized.

The Company accounts for income tax uncertainties using a more-likely-than-not recognition threshold based on the technical merits of the tax position taken. Tax positions that meet the more-likely-than-not recognition threshold are measured in order to determine the tax benefit to be recognized in the financial statements. The Company expenses any penalties or interest associated with tax obligations as general and administrative expenses and interest expense, respectively.

Earnings Per Share

Earnings Per Share

Basic earnings per share is computed by dividing the net income available to common shareholders for the period by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing the net income for the period by the weighted average number of common and common equivalent shares outstanding during the period. Common equivalent shares are composed of incremental common shares issuable upon the exercise of stock options and restricted share units subject to vesting. The dilutive effect of common equivalent shares is included in diluted earnings per share by application of the treasury stock method. Common equivalent shares that have an anti-dilutive effect on diluted net income per share have been excluded from the calculation of diluted weighted average shares outstanding for the years ended December 31, 2015, 2014, and 2013.

Concentrations of Credit Risk and Significant Customers

Concentrations of Credit Risk and Significant Customers

The Company’s credit risks relate primarily to cash and cash equivalents, marketable securities and accounts receivable. The Company places its temporary excess cash investments in high quality, short-term money market instruments. At times, such investments may be in excess of the FDIC insurance limits. Marketable securities consists primarily of investment grade corporate debt securities and certificates of deposit.

The Company sells its products and services to various companies in the healthcare industry that are located in the United States. We perform ongoing credit evaluations of our customers’ financial condition and generally require no collateral from customers. An allowance for doubtful accounts is maintained for potentially uncollectible accounts receivable. The Company did not have any single customer representing over 10% of net revenues during 2015, 2014, or 2013.

Stock Based Compensation

Stock Based Compensation

As of December 31, 2015, the Company maintains two stock based compensation plans, which are described in Note 11. The Company accounts for stock based compensation using the fair-value based method for costs related to share-based payments, including stock options and restricted share units. The Company uses the Black Scholes option pricing model for calculating the fair value of option awards issued under its stock based compensation plan. The Company measures compensation cost of restricted share units based on the closing fair market value of the Company’s stock on the date of grant. Stock based compensation cost is measured at the grant date, based on the fair value of the award that is ultimately expected to vest, and is recognized as an expense over the requisite service period. The Company recognizes tax benefits from stock based compensation if an excess tax benefit is realized. Excess tax benefits are recorded as an increase to common stock when realized.

Newly Issued Accounting Standards

Newly Issued Accounting Standards

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific revenue recognition guidance throughout the Industry Topics of the Accounting Standards Codification. The updated guidance states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also provides for additional disclosures with respect to revenues and cash flows arising from contracts with customers. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2017, and early adoption is permitted for the first interim period within annual reporting periods beginning after December 15, 2016. The Company is currently reviewing this standard to determine the method of adoption and to assess the impact on its future consolidated financial statements.

XML 41 R26.htm IDEA: XBRL DOCUMENT v3.3.1.900
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2015
Accounting Policies [Abstract]  
Changes in the Allowance for Doubtful Accounts and the Amounts Charged to Bad Debt Expense

Changes in the allowance for doubtful accounts and the amounts charged to bad debt expense for the years ended December 31, were as follows (in thousands):

 

     Allowance Balance at
Beginning of Period
     Charged to Costs and
Expenses
     Write-offs      Allowance Balance at
End of Period
 

2015

   $ 331       $ 284       $ (312    $ 303   

2014

   $ 211       $ 237       $ (117    $ 331   

2013

   $ 142       $ 115       $ (46    $ 211   
Estimated Useful Lives of Property and Equipment
     Years  
Furniture and fixtures      5-10   
Equipment      3-5   
XML 42 R27.htm IDEA: XBRL DOCUMENT v3.3.1.900
Earnings Per Share (Tables)
12 Months Ended
Dec. 31, 2015
Earnings Per Share [Abstract]  
Computation of Basic and Diluted Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share for the three years ended December 31, 2015 (in thousands, except per share amounts):

 

     2015      2014      2013  

Numerator:

        

Net income

   $ 8,621       $ 10,394       $ 8,418   
  

 

 

    

 

 

    

 

 

 

Denominator:

        

Weighted-average shares outstanding

     30,057         27,570         26,853   

Effect of dilutive shares

     379         453         810   
  

 

 

    

 

 

    

 

 

 

Weighted-average diluted shares

     30,436         28,023         27,663   
  

 

 

    

 

 

    

 

 

 

Basic earnings per share

   $ 0.29       $ 0.38       $ 0.31   
  

 

 

    

 

 

    

 

 

 

Diluted earnings per share

   $ 0.28       $ 0.37       $ 0.30   
  

 

 

    

 

 

    

 

 

 
XML 43 R28.htm IDEA: XBRL DOCUMENT v3.3.1.900
Marketable Securities (Tables)
12 Months Ended
Dec. 31, 2015
Investments, Debt and Equity Securities [Abstract]  
Fair Value of Available for Sale Marketable Securities

At December 31, 2015 and 2014, the fair value of marketable securities, which were all classified as available for sale, included the following (in thousands):

 

     December 31, 2015  
     Adjusted Cost      Unrealized
Gains
     Unrealized
Losses
     Fair Value  

Level 2:

           

Certificates of deposit

   $ 1,000       $ —         $ —         $ 1,000   

Corporate debt securities

     66,046         —           (70      65,976   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 67,046       $ —         $ (70    $ 66,976   
  

 

 

    

 

 

    

 

 

    

 

 

 
     December 31, 2014  
     Adjusted Cost      Unrealized
Gains
     Unrealized
Losses
     Fair Value  

Level 2:

           

Certificates of deposit

   $ 6,278       $ —         $ —         $ 6,278   

Corporate debt securities

     32,732         —           (37      32,695   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 39,010       $ —         $ (37    $ 38,973   
  

 

 

    

 

 

    

 

 

    

 

 

 
XML 44 R29.htm IDEA: XBRL DOCUMENT v3.3.1.900
Business Combinations (Tables)
12 Months Ended
Dec. 31, 2015
Business Combinations [Abstract]  
Summary of Purchase Price

A summary of the purchase price is as follows (in thousands):

 

Cash paid at closing

   $  81,379   

Cash held in escrow

     6,750   
  

 

 

 

Total consideration paid

   $ 88,129   
  

 

 

 
Summary of Preliminary Fair Value of Assets Acquired and Liabilities Assumed

The following table summarizes the preliminary fair value of the assets acquired and liabilities assumed as of the date of acquisition (in thousands):

 

Cash

   $ 54   

Accounts receivable, net

     3,052   

Prepaid assets

     546   

Property and equipment

     200   

Deferred tax assets

     2,523   

Goodwill

     41,618   

Intangible assets

     47,200   

Accounts payable and accrued liabilities

     (1,085

Deferred revenue

     (5,979
  

 

 

 

Preliminary net assets acquired

   $ 88,129   
  

 

 

 
Components of Identifiable Intangible Assets and Estimated Useful Lives

The following table sets forth the components of identifiable intangible assets and their estimated useful lives as of the acquisition date (in thousands):

 

     Preliminary
fair

Value
     Useful life  

Customer relationships

   $ 42,600         13 years   

Developed technology

     3,700         5 years   

Trade names

     900         6 years   
  

 

 

    

Total preliminary intangible assets subject to amortization

   $ 47,200      
  

 

 

    
Summary of Unaudited Proforma Financial Information

The amounts of revenue and operating income (loss) of HLS included in the Company’s consolidated statements of income from the date of acquisition of March 16, 2015 to the period ending December 31, 2015 are as follows (in thousands):

 

Total revenues

   $ 8,543   
  

 

 

 

Operating loss

   $ (2,541
  

 

 

 

 

The following unaudited pro forma financial information summarizes the combined results of operations of the Company and HLS, which was significant for purposes of the unaudited pro forma financial information disclosure, as though the companies were combined as of January 1, 2014 (in thousands, except per share data):

 

     Year Ended
December 31,
 
     2015      2014  

Total revenues

   $ 219,108       $ 182,548   
  

 

 

    

 

 

 

Net income

   $ 13,551       $ 8,658   
  

 

 

    

 

 

 

Basic earnings per share

   $ 0.45       $ 0.31   
  

 

 

    

 

 

 

Diluted earnings per share

   $ 0.44       $ 0.31   
  

 

 

    

 

 

 

XML 45 R30.htm IDEA: XBRL DOCUMENT v3.3.1.900
Property and Equipment (Tables)
12 Months Ended
Dec. 31, 2015
Property, Plant and Equipment [Abstract]  
Summary of Property and Equipment

Property and equipment consist of the following:

 

     December 31,  
     2015      2014  

Equipment

   $ 23,057       $ 25,133   

Leasehold improvements

     4,435         5,860   

Furniture and fixtures

     4,338         4,554   
  

 

 

    

 

 

 

Gross property and equipment

     31,830         35,547   

Accumulated depreciation and amortization

     (19,359      (26,105
  

 

 

    

 

 

 

Property and equipment, net

   $ 12,471       $ 9,442   
  

 

 

    

 

 

 
XML 46 R31.htm IDEA: XBRL DOCUMENT v3.3.1.900
Goodwill (Tables)
12 Months Ended
Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]  
Changes in Carrying Amount of Goodwill

The changes in the carrying amount of goodwill for the years ended December 31, 2015 and 2014 are as follows (in thousands):

 

     Workforce      Patient
Experience
     Provider      Total  

Balance at January 1, 2015

   $ 12,336       $ 24,154       $ 5,424       $ 41,914   

Acquisition of HealthLine Systems, LLC

     —           —           41,618         41,618   

Disposal of long lived assets

     —           —           (459      (459
  

 

 

    

 

 

    

 

 

    

 

 

 

Balance at December 31, 2015

   $ 12,336       $ 24,154       $ 46,583       $ 83,073   
  

 

 

    

 

 

    

 

 

    

 

 

 
     Workforce      Patient
Experience
     Provider      Total  

Balance at January 1, 2014

   $ 6,168       $ 24,154       $ 5,424       $ 35,746   

Acquisition of Health Care Compliance Strategies, Inc.

     6,168         —           —           6,168   
  

 

 

    

 

 

    

 

 

    

 

 

 

Balance at December 31, 2014

   $ 12,336       $ 24,154       $ 5,424       $ 41,914   
  

 

 

    

 

 

    

 

 

    

 

 

 
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.3.1.900
Intangible Assets (Tables)
12 Months Ended
Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]  
Identifiable Intangible Assets

Identifiable intangible assets are comprised of the following (in thousands):

 

     As of December 31, 2015      As of December 31, 2014  
     Gross Amount      Accumulated
Amortization
    Net      Gross Amount      Accumulated
Amortization
    Net  

Customer related

   $ 55,571       $ (6,068   $ 49,503       $ 23,329       $ (11,880   $ 11,449   

Other

     9,080         (2,617     6,463         5,300         (1,954     3,346   
  

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

 

Total

   $ 64,651       $ (8,685   $ 55,966       $ 28,629       $ (13,834   $ 14,795   
  

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

 
Expected Annual Amortization Expense

The expected future annual amortization expense for the years ending December 31, is as follows (in thousands):

 

2016

   $ 6,400   

2017

     6,323   

2018

     6,211   

2019

     5,566   

2020

     4,913   

Thereafter

     26,553   
  

 

 

 

Total

   $ 55,966   
  

 

 

 
XML 48 R33.htm IDEA: XBRL DOCUMENT v3.3.1.900
Business Segments (Tables)
12 Months Ended
Dec. 31, 2015
Segment Reporting [Abstract]  
Business Segment Information Based on Net Revenues

The following is the Company’s business segment information as of and for the years ended December 31, 2015, 2014 and 2013 (in thousands).

 

Revenues, net:    2015      2014      2013  

Workforce

   $ 161,289       $ 134,242       $ 99,963   

Patient Experience

     34,193         31,901         28,454   

Provider

     13,520         4,547         3,857   
  

 

 

    

 

 

    

 

 

 

Total revenues, net

   $ 209,002       $ 170,690       $ 132,274   
  

 

 

    

 

 

    

 

 

 
Business Segment Information Based on Operating Income
Operating income:    2015      2014      2013  

Workforce

   $ 39,986       $ 35,374       $ 28,203   

Patient Experience

     1,548         810         2,819   

Provider

     (2,559      826         277   

Unallocated

     (25,418      (20,635      (16,633
  

 

 

    

 

 

    

 

 

 

Total operating income

   $ 13,557       $ 16,375       $ 14,666   
  

 

 

    

 

 

    

 

 

 
Business Segment Information Based on Assets
     Assets *      Purchases of long-lived assets      Depreciation and amortization  
     2015      2014      2013      2015      2014      2013      2015      2014      2013  

Workforce

   $ 82,375       $ 81,116       $ 48,514       $ 11,403       $ 7,179       $ 6,243       $ 6,693       $ 4,813       $ 2,829   

Patient Experience

     34,902         34,536         34,727         2,007         1,277         726         1,061         1,272         1,068   

Provider

     100,948         10,976         11,499         332         200         67         3,986         683         683   

Unallocated

     161,344         130,634         117,854         1,617         1,546         1,675         5,257         4,163         3,272   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 379,569       $ 257,262       $ 212,594       $ 15,359       $ 10,202       $ 8,711       $ 16,997       $ 10,931       $ 7,852   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

* Segment assets include accounts and unbilled receivables, prepaid royalties, prepaid and other current assets, other assets, capitalized software development, certain property and equipment, and intangible assets. Cash and cash equivalents and marketable securities are not allocated to individual segments, and are included within Unallocated. A significant portion of property and equipment assets are included within Unallocated.
XML 49 R34.htm IDEA: XBRL DOCUMENT v3.3.1.900
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2015
Income Tax Disclosure [Abstract]  
Summary of Provision (Benefit) for Income Taxes

The provision (benefit) for income taxes is comprised of the following (in thousands):

 

     Year Ended December 31,  
     2015      2014      2013  

Current federal

   $ 3,608       $ 3,198       $ 2,474   

Current state

     1,098         1,605         1,444   

Deferred federal

     501         1,092         2,315   

Deferred state

     (109      232         191   
  

 

 

    

 

 

    

 

 

 

Provision for income taxes

   $ 5,098       $ 6,127       $ 6,424   
  

 

 

    

 

 

    

 

 

 
Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to the Provision for Income Taxes

A reconciliation of income taxes at the statutory federal income tax rate to the provision for income taxes included in the accompanying consolidated statements of income is as follows (in thousands):

 

     Year Ended December 31,  
     2015      2014      2013  

Federal tax provision at the statutory rate

   $ 4,802       $ 5,782       $ 5,194   

State income tax provision, net of federal benefit

     673         1,350         898   

Tax credits

     (425      (1,160      (54

Change in state valuation allowance

     (8      37         231   

Other

     56         118         155   
  

 

 

    

 

 

    

 

 

 

Provision for income taxes

   $ 5,098       $ 6,127       $ 6,424   
  

 

 

    

 

 

    

 

 

 
Reconciliation of the Beginning and Ending liability for Gross Unrecognized Tax Benefits

A reconciliation of the beginning and ending liability for gross unrecognized tax benefits at December 31, 2015 and 2014, are as follows (in thousands):

 

     December 31,  
     2015      2014  

Balance at beginning of year

   $ 2,168       $ 167   

Additions for tax positions in the current year

     351         2,168   

Reductions for tax positions of prior years

     (1,861      (167
  

 

 

    

 

 

 

Balance at end of year

   $ 658       $ 2,168   
  

 

 

    

 

 

 
Significant Components of Deferred Tax Assets and Deferred Tax Liabilities

Significant components of deferred tax assets and deferred tax liabilities are as follows (in thousands):

 

     December 31,  
     2015      2014  

Deferred tax assets:

     

Allowance for doubtful accounts

   $ 122       $ 134   

Accrued liabilities

     2,062         1,565   

Tax credits

     816         791   

Stock based compensation

     1,107         1,015   

Deferred revenue

     1,563         616   

Depreciation

     348         715   

Basis difference on investments

     80         —     

Net operating loss carryforwards

     407         355   
  

 

 

    

 

 

 

Total deferred tax assets

     6,505         5,191   

Less: Valuation allowance

     (346      (355
  

 

 

    

 

 

 

Deferred tax assets, net of valuation allowance

     6,159         4,836   

Deferred tax liabilities:

     

Deductible goodwill

     2,646         2,369   

Nondeductible intangible assets

     1,806         2,171   

Prepaid assets

     1,911         1,602   

Capitalized software development

     4,559         3,836   

Basis difference on investments

     —           343   
  

 

 

    

 

 

 

Total deferred tax liabilities

     10,922         10,321   
  

 

 

    

 

 

 

Net deferred tax liabilities

   $ (4,763    $ (5,485
  

 

 

    

 

 

 
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.3.1.900
Stock Based Compensation (Tables)
12 Months Ended
Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Summary of Activity and Various Other Information Relative to Stock Options

A summary of activity and various other information relative to stock options for the year ended December 31, 2015 is presented in the tables below (in thousands, except exercise price).

 

     Common
Shares
     Weighted-
Average
Exercise Price
     Aggregate
Intrinsic Value
 
          
          

Outstanding at beginning of period

     596       $ 6.18      

Granted

     —           —        

Exercised

     (76      4.29      

Expired

     —           —        

Forfeited

     —           —        
  

 

 

    

 

 

    

Outstanding at end of period

     520       $ 6.45       $ 8,081   
  

 

 

    

 

 

    

 

 

 

Exercisable at end of period.

     520       $ 6.45       $ 8,081   
  

 

 

    

 

 

    

 

 

 
Other Information Relative to Option Activity

Other information relative to option activity during the three years ended December 31, 2015 is as follows (in thousands):

 

     2015      2014      2013  

Total grant date fair value of stock options vested

   $ 232       $ 630       $ 723   
  

 

 

    

 

 

    

 

 

 

Total intrinsic value of stock options exercised

   $ 1,662       $ 5,912       $ 25,846   
  

 

 

    

 

 

    

 

 

 

Cash proceeds from exercise of stock options

   $ 328       $ 1,094       $ 3,318   
  

 

 

    

 

 

    

 

 

 
Summary of Activity Relative to RSU's

A summary of activity relative to RSUs for the year ended December 31, 2015 is follows (in thousands, except weighted average grant date fair value):

 

     Number of
RSU’s
     Weighted-
Average
Grant Date Fair Value
     Aggregate
Intrinsic Value
 
          
          

Outstanding at beginning of period

     164       $ 25.04      

Granted

     110         24.97      

Vested

     (54      24.17      

Forfeited

     (2      26.03      
  

 

 

    

 

 

    

Outstanding at end of period

     218       $ 25.21       $ 4,793   
  

 

 

    

 

 

    

 

 

 
Stock Based Compensation Expense Recorded in Consolidated Statements of Income

Total stock based compensation expense, which is recorded in our consolidated statements of income, recorded for the years ended December 31, is as follows (in thousands):

 

     Years Ended December 31,  
     2015      2014      2013  

Cost of revenues (excluding depreciation and amortization)

   $ 824       $ 86       $ 81   

Product development

     569         201         144   

Sales and marketing

     547         224         175   

Other general and administrative

     1,340         1,114         1,058   
  

 

 

    

 

 

    

 

 

 

Total stock based compensation expense

   $ 3,280       $ 1,625       $ 1,458   
  

 

 

    

 

 

    

 

 

 
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.3.1.900
Leases (Tables)
12 Months Ended
Dec. 31, 2015
Leases [Abstract]  
Future Rental Payment Commitments under Non-Cancelable Operating Leases

Future rental payment commitments at December 31, 2015 under non-cancelable operating leases, with initial terms of one year or more, are as follows (in thousands):

 

2016

   $ 3,876   

2017

     2,625   

2018

     1,365   

2019

     808   

2020

     810   

Thereafter

     2,604   
  

 

 

 

Total minimum lease payments

   $ 12,088   
  

 

 

 
XML 52 R37.htm IDEA: XBRL DOCUMENT v3.3.1.900
Summary of Significant Accounting Policies - Additional Information (Detail)
12 Months Ended
Dec. 31, 2015
USD ($)
Plans
Dec. 31, 2015
USD ($)
Segment
SourcesofTaxableIncome
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Business And Basis Of Presentation [Line Items]        
Number of operating segments | Segment   3    
Maturity of unrestricted cash equivalent   Less than three months    
Capitalized software development amount   $ 7,265,000 $ 5,658,000 $ 4,267,000
Amortization of capitalized software development   6,200,000 4,300,000  
Capitalized internal development costs for computer software developed for resale $ 0 0 0  
Impairments identified or recorded   0 0 0
Impairments identified or recorded for long-lived assets   0 0 0
Advertising expense   $ 1,100,000 700,000 $ 400,000
Number of sources of taxable income | SourcesofTaxableIncome   4    
Valuation allowance $ 346,000 $ 346,000 $ 355,000  
Concentration risk, customer   The Company did not have any single customer representing over 10% of net revenues during 2015, 2014, or 2013.    
Number of stock based compensation plans | Plans 2      
Minimum [Member]        
Business And Basis Of Presentation [Line Items]        
Revenues earned over the estimated survey cycle, period   1 month    
Royalty payments amortization period   12 months    
Assets amortized cost   3 years    
Finite lived intangible assets amortization period   3 years    
Maximum [Member]        
Business And Basis Of Presentation [Line Items]        
Revenues earned over the estimated survey cycle, period   5 months    
Royalty payments amortization period   36 months    
Assets amortized cost   5 years    
Finite lived intangible assets amortization period   15 years    
Weighted Average [Member]        
Business And Basis Of Presentation [Line Items]        
Finite lived intangible assets amortization period   11 years 3 months 18 days    
XML 53 R38.htm IDEA: XBRL DOCUMENT v3.3.1.900
Summary of Significant Accounting Policies - Changes in the Allowance for Doubtful Accounts and the Amounts Charged to Bad Debt Expense (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Accounting Policies [Abstract]      
Allowance Balance at Beginning of Period $ 331 $ 211 $ 142
Charged to Costs and Expenses 284 237 115
Write-offs (312) (117) (46)
Allowance Balance at End of Period $ 303 $ 331 $ 211
XML 54 R39.htm IDEA: XBRL DOCUMENT v3.3.1.900
Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Detail)
12 Months Ended
Dec. 31, 2015
Minimum [Member] | Furniture and Fixtures [Member]  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment useful life 5 years
Minimum [Member] | Equipment [Member]  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment useful life 3 years
Maximum [Member] | Furniture and Fixtures [Member]  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment useful life 10 years
Maximum [Member] | Equipment [Member]  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment useful life 5 years
XML 55 R40.htm IDEA: XBRL DOCUMENT v3.3.1.900
Shareholders' Equity - Additional Information (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Class of Stock [Line Items]    
Common stock, shares authorized 75,000,000 75,000,000
Common stock, shares issued 31,647,000 27,677,000
Common stock, shares outstanding 31,647,000 27,677,000
Proceeds from issuance of common stock $ 98,014  
Underwritten Public Offering [Member]    
Class of Stock [Line Items]    
Common stock, shares issued 3,900,000  
Proceeds from issuance of common stock $ 98,000  
Maximum [Member]    
Class of Stock [Line Items]    
Common stock, shares authorized 75,000,000  
Preferred stock, shares authorized 10,000,000  
XML 56 R41.htm IDEA: XBRL DOCUMENT v3.3.1.900
Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Numerator:      
Net income $ 8,621 $ 10,394 $ 8,418
Denominator:      
Weighted-average shares outstanding 30,057 27,570 26,853
Effect of dilutive shares 379 453 810
Weighted-average diluted shares 30,436 28,023 27,663
Basic earnings per share $ 0.29 $ 0.38 $ 0.31
Diluted earnings per share $ 0.28 $ 0.37 $ 0.30
XML 57 R42.htm IDEA: XBRL DOCUMENT v3.3.1.900
Earnings Per Share - Additional Information (Detail) - shares
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Earnings Per Share [Abstract]      
Total number of common equivalent shares excluded from the calculations of diluted earnings per share 16,000 70,000 70,000
XML 58 R43.htm IDEA: XBRL DOCUMENT v3.3.1.900
Marketable Securities - Fair Value of Available for Sale Marketable Securities (Detail) - Level 2 [Member] - USD ($)
$ in Thousands
Dec. 31, 2015
Dec. 31, 2014
Schedule of Available-for-sale Securities [Line Items]    
Available for sale securities, Adjusted Cost $ 67,046 $ 39,010
Available for sale securities, Unrealized Gains 0 0
Available for sale securities, Unrealized Losses (70) (37)
Available for sale securities, Fair Value 66,976 38,973
Certificates of Deposit [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Available for sale securities, Adjusted Cost 1,000 6,278
Available for sale securities, Unrealized Gains 0 0
Available for sale securities, Fair Value 1,000 6,278
Corporate Debt Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Available for sale securities, Adjusted Cost 66,046 32,732
Available for sale securities, Unrealized Gains 0 0
Available for sale securities, Unrealized Losses (70) (37)
Available for sale securities, Fair Value $ 65,976 $ 32,695
XML 59 R44.htm IDEA: XBRL DOCUMENT v3.3.1.900
Business Combinations - Additional Information (Detail) - USD ($)
3 Months Ended 12 Months Ended 15 Months Ended 24 Months Ended
Dec. 31, 2015
Jun. 30, 2015
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Mar. 31, 2015
Dec. 31, 2014
Business Acquisition [Line Items]              
Weighted average amortization period for identifiable intangible assets     12 years 2 months 12 days        
Purchase price allocation for goodwill $ 83,073,000   $ 83,073,000 $ 41,914,000 $ 35,746,000   $ 41,914,000
Purchase price allocation for identifiable intangible assets 47,200,000   $ 47,200,000        
HealthLine Systems LLC [Member]              
Business Acquisition [Line Items]              
Acquisition date of assets     Mar. 16, 2015        
Consideration paid for acquisition in cash     $ 88,129,000        
Transaction costs associated with the acquisition     $ 965,000 329,000   $ 1,300,000  
Preliminary purchase price allocation measurement period     1 year        
Net tangible assets include deferred revenue book value at acquisition date 15,000,000   $ 15,000,000        
Net tangible assets include deferred revenue estimated fair value 5,979,000   5,979,000        
Decrease in preliminary fair value for accounts receivable 115,000            
Decrease in preliminary fair value for prepaid assets 200,000            
Decrease in preliminary fair value for accrued liabilities 800,000            
Write-down of deferred revenue     9,000,000        
Estimated indemnification asset 300,000   300,000        
Contingent liability 700,000   700,000        
Net income     13,551,000 8,658,000      
Purchase price allocation for goodwill 41,618,000   41,618,000        
Purchase price allocation for identifiable intangible assets 47,200,000   47,200,000        
Purchase price allocation for net tangible assets 200,000   $ 200,000        
HealthLine Systems LLC [Member] | Fair Value Adjustment to Deferred Revenue[Member]              
Business Acquisition [Line Items]              
Net income       4,200,000      
Health Care Compliance Strategies, Inc. [Member]              
Business Acquisition [Line Items]              
Acquisition date of assets     Mar. 03, 2014        
Consideration paid for acquisition in cash     $ 12,800,000        
Transaction costs associated with the acquisition       $ 365,000 $ 150,000   $ 515,000
Net tangible assets include deferred revenue book value at acquisition date 3,200,000   3,200,000        
Net tangible assets include deferred revenue estimated fair value 1,700,000   1,700,000        
Write-down of deferred revenue     $ 1,500,000        
Consideration paid for acquisition in shares     81,614        
Payments related to achievement of certain performance milestones   $ 750,000          
Contingent upon achievement of certain financial targets and business outcome, term     1 year        
Purchase price allocation for goodwill 6,200,000   $ 6,200,000        
Purchase price allocation for identifiable intangible assets 8,400,000   8,400,000        
Purchase price allocation for net tangible assets 2,600,000   2,600,000        
Purchase price allocation for liabilities 2,700,000   2,700,000        
Purchase price allocation for deferred tax assets 625,000   625,000        
Accrual for contingent consideration 600,000   $ 600,000        
Baptist Leadership Group [Member]              
Business Acquisition [Line Items]              
Acquisition date of assets     Sep. 09, 2013        
Consideration paid for acquisition in cash     $ 7,400,000        
Net tangible assets include deferred revenue book value at acquisition date 508,000   508,000        
Net tangible assets include deferred revenue estimated fair value 254,000   254,000        
Write-down of deferred revenue     $ 254,000        
Consideration paid for acquisition in shares     15,230        
Purchase price allocation for goodwill 6,300,000   $ 6,300,000        
Purchase price allocation for identifiable intangible assets 1,600,000   1,600,000        
Transaction related costs 145,000   145,000        
Purchase price allocation for net tangible assets $ 28,000   $ 28,000        
XML 60 R45.htm IDEA: XBRL DOCUMENT v3.3.1.900
Business Combinations - Summary of Purchase Price (Detail) - HealthLine Systems LLC [Member]
$ in Thousands
12 Months Ended
Dec. 31, 2015
USD ($)
Business Acquisition [Line Items]  
Total consideration paid $ 88,129
Cash Paid at Closing [Member]  
Business Acquisition [Line Items]  
Total consideration paid 81,379
Cash Held in Escrow [Member]  
Business Acquisition [Line Items]  
Total consideration paid $ 6,750
XML 61 R46.htm IDEA: XBRL DOCUMENT v3.3.1.900
Business Combinations - Summary of Preliminary Fair Value of Assets Acquired and Liabilities Assumed (Detail) - USD ($)
$ in Thousands
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Business Acquisition [Line Items]      
Goodwill $ 83,073 $ 41,914 $ 35,746
Intangible assets 47,200    
HealthLine Systems LLC [Member]      
Business Acquisition [Line Items]      
Cash 54    
Accounts receivable, net 3,052    
Prepaid assets 546    
Property and equipment 200    
Deferred tax assets 2,523    
Goodwill 41,618    
Intangible assets 47,200    
Accounts payable and accrued liabilities (1,085)    
Deferred revenue (5,979)    
Preliminary net assets acquired $ 88,129    
XML 62 R47.htm IDEA: XBRL DOCUMENT v3.3.1.900
Business Combinations - Components of Identifiable Intangible Assets and Estimated Useful Lives (Detail)
$ in Thousands
12 Months Ended
Dec. 31, 2015
USD ($)
Finite-Lived Intangible Assets [Line Items]  
Preliminary intangible assets subject to amortization $ 47,200
Estimated useful lives 12 years 2 months 12 days
Customer Relationships [Member]  
Finite-Lived Intangible Assets [Line Items]  
Preliminary intangible assets subject to amortization $ 42,600
Estimated useful lives 13 years
Developed Technology [Member]  
Finite-Lived Intangible Assets [Line Items]  
Preliminary intangible assets subject to amortization $ 3,700
Estimated useful lives 5 years
Trade Names [Member]  
Finite-Lived Intangible Assets [Line Items]  
Preliminary intangible assets subject to amortization $ 900
Estimated useful lives 6 years
XML 63 R48.htm IDEA: XBRL DOCUMENT v3.3.1.900
Business Combinations - Summary of Unaudited Proforma Financial Information (Detail) - HealthLine Systems LLC [Member] - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Business Acquisition [Line Items]    
Total revenues $ 8,543  
Operating loss (2,541)  
Total revenues 219,108 $ 182,548
Net income $ 13,551 $ 8,658
Basic earnings per share $ 0.45 $ 0.31
Diluted earnings per share $ 0.44 $ 0.31
XML 64 R49.htm IDEA: XBRL DOCUMENT v3.3.1.900
Property and Equipment - Summary of Property and Equipment (Detail) - USD ($)
$ in Thousands
Dec. 31, 2015
Dec. 31, 2014
Property, Plant and Equipment [Line Items]    
Gross property and equipment $ 31,830 $ 35,547
Accumulated depreciation and amortization (19,359) (26,105)
Property and equipment, net 12,471 9,442
Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Gross property and equipment 23,057 25,133
Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Gross property and equipment 4,435 5,860
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Gross property and equipment $ 4,338 $ 4,554
XML 65 R50.htm IDEA: XBRL DOCUMENT v3.3.1.900
Property and Equipment - Additional Information (Detail) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Property, Plant and Equipment [Abstract]    
Depreciation of property and equipment $ 5.3 $ 4.1
XML 66 R51.htm IDEA: XBRL DOCUMENT v3.3.1.900
Goodwill - Changes in Carrying Amount of Goodwill (Detail) - USD ($)
3 Months Ended 12 Months Ended
Dec. 31, 2015
Dec. 31, 2015
Dec. 31, 2014
Goodwill [Line Items]      
Goodwill, beginning balance   $ 41,914,000 $ 35,746,000
Disposal of long lived assets $ (459,000) (459,000)  
Goodwill, ending balance 83,073,000 83,073,000 41,914,000
HealthLine Systems LLC [Member]      
Goodwill [Line Items]      
Goodwill acquired   41,618,000  
Goodwill, ending balance 41,618,000 41,618,000  
Health Care Compliance Strategies, Inc. [Member]      
Goodwill [Line Items]      
Goodwill acquired     6,168,000
Goodwill, ending balance 6,200,000 6,200,000  
Workforce [Member]      
Goodwill [Line Items]      
Goodwill, beginning balance   12,336,000 6,168,000
Goodwill, ending balance 12,336,000 12,336,000 12,336,000
Workforce [Member] | Health Care Compliance Strategies, Inc. [Member]      
Goodwill [Line Items]      
Goodwill acquired     6,168,000
Patient Experience [Member]      
Goodwill [Line Items]      
Goodwill, beginning balance   24,154,000 24,154,000
Goodwill, ending balance 24,154,000 24,154,000 24,154,000
Provider [Member]      
Goodwill [Line Items]      
Goodwill, beginning balance   5,424,000 5,424,000
Disposal of long lived assets   (459,000)  
Goodwill, ending balance $ 46,583,000 46,583,000 $ 5,424,000
Provider [Member] | HealthLine Systems LLC [Member]      
Goodwill [Line Items]      
Goodwill acquired   $ 41,618,000  
XML 67 R52.htm IDEA: XBRL DOCUMENT v3.3.1.900
Goodwill - Additional Information (Detail) - USD ($)
3 Months Ended 12 Months Ended
Dec. 31, 2015
Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]    
Disposal of long lived assets $ 459,000 $ 459,000
XML 68 R53.htm IDEA: XBRL DOCUMENT v3.3.1.900
Intangible Assets - Additional Information (Detail) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2015
Dec. 31, 2015
Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]      
Amortization of intangible assets $ 10.7 $ 5.6 $ 2.4
Minimum [Member]      
Finite-Lived Intangible Assets [Line Items]      
Estimated useful life of intangible assets   3 years  
Minimum [Member] | Customer Relationships [Member]      
Finite-Lived Intangible Assets [Line Items]      
Estimated useful life of intangible assets   5 years  
Minimum [Member] | Other [Member]      
Finite-Lived Intangible Assets [Line Items]      
Estimated useful life of intangible assets   3 years  
Maximum [Member]      
Finite-Lived Intangible Assets [Line Items]      
Estimated useful life of intangible assets   15 years  
Maximum [Member] | Customer Relationships [Member]      
Finite-Lived Intangible Assets [Line Items]      
Estimated useful life of intangible assets   13 years  
Maximum [Member] | Other [Member]      
Finite-Lived Intangible Assets [Line Items]      
Estimated useful life of intangible assets   9 years  
XML 69 R54.htm IDEA: XBRL DOCUMENT v3.3.1.900
Intangible Assets - Identifiable Intangible Assets (Detail) - USD ($)
$ in Thousands
Dec. 31, 2015
Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]    
Gross Amount $ 64,651 $ 28,629
Accumulated Amortization (8,685) (13,834)
Total 55,966 14,795
Customer Relationships [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Amount 55,571 23,329
Accumulated Amortization (6,068) (11,880)
Total 49,503 11,449
Other [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Amount 9,080 5,300
Accumulated Amortization (2,617) (1,954)
Total $ 6,463 $ 3,346
XML 70 R55.htm IDEA: XBRL DOCUMENT v3.3.1.900
Intangible Assets - Expected Annual Amortization Expense (Detail) - USD ($)
$ in Thousands
Dec. 31, 2015
Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]    
2016 $ 6,400  
2017 6,323  
2018 6,211  
2019 5,566  
2020 4,913  
Thereafter 26,553  
Total $ 55,966 $ 14,795
XML 71 R56.htm IDEA: XBRL DOCUMENT v3.3.1.900
Business Segments - Business Segment Information Based on Net Revenues and Operating Income (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Revenues, net      
Revenues, net $ 209,002 $ 170,690 $ 132,274
Operating income      
Operating income 13,557 16,375 14,666
Operating Segments [Member] | Workforce [Member]      
Revenues, net      
Revenues, net 161,289 134,242 99,963
Operating income      
Operating income 39,986 35,374 28,203
Operating Segments [Member] | Patient Experience [Member]      
Revenues, net      
Revenues, net 34,193 31,901 28,454
Operating income      
Operating income 1,548 810 2,819
Operating Segments [Member] | Provider [Member]      
Revenues, net      
Revenues, net 13,520 4,547 3,857
Operating income      
Operating income (2,559) 826 277
Unallocated [Member]      
Operating income      
Operating income $ (25,418) $ (20,635) $ (16,633)
XML 72 R57.htm IDEA: XBRL DOCUMENT v3.3.1.900
Business Segments - Business Segment Information Based on Assets (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Segment Reporting Information [Line Items]      
Total assets $ 379,569 $ 257,262 $ 212,594
Purchases of long-lived assets 15,359 10,202 8,711
Depreciation and amortization 16,997 10,931 7,852
Operating Segments [Member] | Workforce [Member]      
Segment Reporting Information [Line Items]      
Total assets 82,375 81,116 48,514
Purchases of long-lived assets 11,403 7,179 6,243
Depreciation and amortization 6,693 4,813 2,829
Operating Segments [Member] | Patient Experience [Member]      
Segment Reporting Information [Line Items]      
Total assets 34,902 34,536 34,727
Purchases of long-lived assets 2,007 1,277 726
Depreciation and amortization 1,061 1,272 1,068
Operating Segments [Member] | Provider [Member]      
Segment Reporting Information [Line Items]      
Total assets 100,948 10,976 11,499
Purchases of long-lived assets 332 200 67
Depreciation and amortization 3,986 683 683
Unallocated [Member]      
Segment Reporting Information [Line Items]      
Total assets 161,344 130,634 117,854
Purchases of long-lived assets 1,617 1,546 1,675
Depreciation and amortization $ 5,257 $ 4,163 $ 3,272
XML 73 R58.htm IDEA: XBRL DOCUMENT v3.3.1.900
Income Taxes - Summary of Provision (Benefit) for Income Taxes (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Income Tax Disclosure [Abstract]      
Current federal $ 3,608 $ 3,198 $ 2,474
Current state 1,098 1,605 1,444
Deferred federal 501 1,092 2,315
Deferred state (109) 232 191
Provision for income taxes $ 5,098 $ 6,127 $ 6,424
XML 74 R59.htm IDEA: XBRL DOCUMENT v3.3.1.900
Income Taxes - Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to the Provision for Income Taxes (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Income Tax Disclosure [Abstract]      
Federal tax provision at the statutory rate $ 4,802 $ 5,782 $ 5,194
State income tax provision, net of federal benefit 673 1,350 898
Tax credits (425) (1,160) (54)
Change in state valuation allowance (8) 37 231
Other 56 118 155
Provision for income taxes $ 5,098 $ 6,127 $ 6,424
XML 75 R60.htm IDEA: XBRL DOCUMENT v3.3.1.900
Income Taxes - Additional Information (Detail) - USD ($)
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Income Taxes Disclosure [Line Items]    
Valuation allowance $ 346,000 $ 355,000
Research and development tax credit carryforward expiration year Dec. 31, 2035  
Alternative minimum tax credit carryforward $ 816,000  
Accrued interest and penalties 14,000 125,000
Unrecognized tax benefits 278,000 $ 278,000
Decrease in unrecognized tax benefits $ 300,000  
Earliest Tax Year [Member]    
Income Taxes Disclosure [Line Items]    
Loss carryforwards will expire in years Dec. 31, 2016  
Latest Tax Year [Member]    
Income Taxes Disclosure [Line Items]    
Loss carryforwards will expire in years Dec. 31, 2025  
Federal [Member] | Latest Tax Year [Member]    
Income Taxes Disclosure [Line Items]    
U.S. federal tax examinations for tax period 2015  
Federal [Member] | Tax Year 2012 [Member]    
Income Taxes Disclosure [Line Items]    
U.S. federal tax examinations for tax period 2012  
Federal [Member] | Tax Year 2013 [Member]    
Income Taxes Disclosure [Line Items]    
U.S. federal tax examinations for tax period 2013  
Federal [Member] | Tax Year 2014 [Member]    
Income Taxes Disclosure [Line Items]    
U.S. federal tax examinations for tax period 2014  
State [Member]    
Income Taxes Disclosure [Line Items]    
Deferred tax benefit $ 188,000  
Net operating loss carryforwards 13,000,000  
Research and Development [Member]    
Income Taxes Disclosure [Line Items]    
Research and development tax credit carryforward $ 1,900,000  
XML 76 R61.htm IDEA: XBRL DOCUMENT v3.3.1.900
Income Taxes - Reconciliation of the Beginning and Ending Liability for Gross Unrecognized Tax Benefits (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Income Tax Disclosure [Abstract]    
Balance at beginning of year $ 2,168 $ 167
Additions for tax positions in the current year 351 2,168
Reductions for tax positions of prior years (1,861) (167)
Balance at end of year $ 658 $ 2,168
XML 77 R62.htm IDEA: XBRL DOCUMENT v3.3.1.900
Income Taxes - Significant Components of Deferred Tax Assets and Deferred Tax Liabilities (Detail) - USD ($)
$ in Thousands
Dec. 31, 2015
Dec. 31, 2014
Deferred tax assets:    
Allowance for doubtful accounts $ 122 $ 134
Accrued liabilities 2,062 1,565
Tax credits 816 791
Stock based compensation 1,107 1,015
Deferred revenue 1,563 616
Depreciation 348 715
Basis difference on investments 80  
Net operating loss carryforwards 407 355
Total deferred tax assets 6,505 5,191
Less: Valuation allowance (346) (355)
Deferred tax assets, net of valuation allowance 6,159 4,836
Deferred tax liabilities:    
Deductible goodwill 2,646 2,369
Nondeductible intangible assets 1,806 2,171
Prepaid assets 1,911 1,602
Capitalized software development 4,559 3,836
Basis difference on investments   343
Total deferred tax liabilities 10,922 10,321
Net deferred tax liabilities $ (4,763) $ (5,485)
XML 78 R63.htm IDEA: XBRL DOCUMENT v3.3.1.900
Stock Based Compensation - Additional Information (Detail)
1 Months Ended 3 Months Ended 12 Months Ended
Jun. 30, 2015
Employees
shares
Jun. 30, 2015
USD ($)
Employees
shares
Dec. 31, 2015
USD ($)
$ / shares
shares
Dec. 31, 2014
USD ($)
shares
Dec. 31, 2013
USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Unissued common stock reserved for future stock option grants | shares     487,000    
Closing stock price | $ / shares     $ 22.00    
Weighted average remaining contractual term of options, outstanding     2 years 6 months    
Weighted average remaining contractual term of options, exercisable     2 years 6 months    
Payments related to RSUs and stock options for the employees' tax obligations to taxing authorities     $ 756,000 $ 161,000 $ 164,000
Weighted average expense recognition period     2 years 3 months 18 days    
Excess tax benefits related to stock based awards     $ 3,000,000    
Stock based compensation expense     3,280,000 1,625,000 $ 1,458,000
RSUs [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Aggregate fair value of RSU awards that vested     $ 1,400,000 $ 1,100,000  
Shares withheld for RSUs | shares     8,922 5,327  
Payments related to RSUs and stock options for the employees' tax obligations to taxing authorities     $ 230,000 $ 161,000  
Total unrecognized compensation expense related to non-vested stock options     $ 3,000,000    
Number of common shares granted to employees | shares     110,000    
Stock Awards [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of employees eligible to receive common stock | Employees 600        
Minimum eligible period of service required for the employees to receive common stock 1 year        
Stock based compensation expense   $ 1,500,000      
Common stock issued under stock plans, number of shares withheld | shares   17,279      
Total payments to taxing authorities for stock awards     $ 526,000    
Chief Executive Officer [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of common stock contributed | shares   54,241      
Number of common shares granted to employees | shares   49,310      
Number of employees eligible to receive common stock | Employees   600      
Stock based compensation expense   $ 1,500,000      
Chief Executive Officer [Member] | Stock Awards [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of common stock contributed | shares 54,241        
Number of common shares granted to employees | shares 49,310        
Maximum [Member] | RSUs [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting period of the options and RSU's granted     4 years    
Maximum [Member] | Stock Options [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Term of options granted     10 years    
XML 79 R64.htm IDEA: XBRL DOCUMENT v3.3.1.900
Stock Based Compensation - Summary of Activity and Various Other Information Relative to Stock Options (Detail)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2015
USD ($)
$ / shares
shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Outstanding at beginning of period, Common Shares | shares 596
Granted, Common Shares | shares 0
Exercised, Common Shares | shares (76)
Expired, Common Shares | shares 0
Forfeited, Common Shares | shares 0
Outstanding at end of period, Common Shares | shares 520
Exercisable at end of period, Common Shares | shares 520
Outstanding at beginning of period, Weighted-Average Exercise Price | $ / shares $ 6.18
Granted, Weighted-Average Exercise Price | $ / shares 0
Exercised, Weighted-Average Exercise Price | $ / shares 4.29
Expired, Weighted-Average Exercise Price | $ / shares 0
Forfeited, Weighted-Average Exercise Price | $ / shares 0
Outstanding at end of period, Weighted-Average Exercise Price | $ / shares 6.45
Exercisable at end of period, Weighted-Average Exercise Price | $ / shares $ 6.45
Outstanding at end of period, Aggregate Intrinsic Value | $ $ 8,081
Exercisable at end of period, Aggregate Intrinsic Value | $ $ 8,081
XML 80 R65.htm IDEA: XBRL DOCUMENT v3.3.1.900
Stock Based Compensation - Other Information Relative to Option Activity (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]      
Total grant date fair value of stock options vested $ 232 $ 630 $ 723
Total intrinsic value of stock options exercised 1,662 5,912 25,846
Cash proceeds from exercise of stock options $ 328 $ 1,094 $ 3,318
XML 81 R66.htm IDEA: XBRL DOCUMENT v3.3.1.900
Stock Based Compensation - Summary of Activity Relative to RSU's (Detail) - RSUs [Member]
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2015
USD ($)
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Outstanding at beginning of period, shares | shares 164
Granted | shares 110
Vested | shares (54)
Forfeited | shares (2)
Outstanding at end of period, shares | shares 218
Outstanding at beginning of period, Weighted-Average Grant Date Fair Value | $ / shares $ 25.04
Granted, Weighted-Average Grant Date Fair Value | $ / shares 24.97
Vested, Weighted-Average Grant Date Fair Value | $ / shares 24.17
Forfeited, Weighted-Average Grant Date Fair Value | $ / shares 26.03
Outstanding at end of period, Weighted-Average Grant Date Fair Value | $ / shares $ 25.21
Aggregate intrinsic Value | $ $ 4,793
XML 82 R67.htm IDEA: XBRL DOCUMENT v3.3.1.900
Stock Based Compensation - Stock Based Compensation Expense Recorded in Consolidated Statements of Income (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Total stock based compensation expense $ 3,280 $ 1,625 $ 1,458
Cost of Revenues (Excluding Depreciation and Amortization) [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Total stock based compensation expense 824 86 81
Product Development [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Total stock based compensation expense 569 201 144
Sales and Marketing [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Total stock based compensation expense 547 224 175
Other General and Administrative [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Total stock based compensation expense $ 1,340 $ 1,114 $ 1,058
XML 83 R68.htm IDEA: XBRL DOCUMENT v3.3.1.900
Employee Benefit Plan - Additional Information (Detail) - USD ($)
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Schedule Of Sale Of Subsidiary [Abstract]    
Employees minimum age eligibility to participate in plan 21 years  
Minimum number of days required to be eligible for participation in plan 30 days  
Defined contribution plan, employer matching contribution amount $ 645,000 $ 274,000
XML 84 R69.htm IDEA: XBRL DOCUMENT v3.3.1.900
Debt - Additional Information (Detail) - USD ($)
3 Months Ended 12 Months Ended
Jun. 30, 2015
Dec. 31, 2015
Mar. 31, 2015
Dec. 31, 2014
Line of Credit Facility [Line Items]        
Debt outstanding   $ 0   $ 0
Repayment of balances outstanding on the revolving credit facility   $ 28,000,000    
SunTrust Bank [Member] | Maximum [Member]        
Line of Credit Facility [Line Items]        
Commitment fee paid per annum   0.30%    
SunTrust Bank [Member] | Minimum [Member]        
Line of Credit Facility [Line Items]        
Commitment fee paid per annum   0.20%    
Revolving Credit Facility [Member] | SunTrust Bank [Member]        
Line of Credit Facility [Line Items]        
Aggregate principal amount of loan agreement   $ 50,000,000    
Maturity date of Loan agreement   Nov. 24, 2017    
Maximum borrowing capacity under credit facility   $ 50,000,000    
Increase in revolving credit facility   $ 25,000,000    
Line of Credit Facility, Interest Rate During Period   1.68%    
Interest rate under credit facility   The borrowings under the Revolving Credit Facility bear interest at either (1) a rate per annum equal to the highest of SunTrust’s prime rate or 0.5% in excess of the Federal Funds Rate or 1.0% in excess of one-month LIBOR (the “Base Rate”), plus an applicable margin, or (2) the one, two, three, or six-month per annum LIBOR for deposits in the applicable currency (the “Eurocurrency Rate”), as selected by the Company, plus an applicable margin. The applicable margin for Eurocurrency Rate loans depends on the Company’s funded debt leverage ratio and varies from 1.50% to 2.00%. The applicable margin for Base Rate loans depends on the Company’s funded debt leverage ratio and varies from 0.50% to 1.50%    
Principal payments prior to maturity   $ 0    
Balances outstanding on the revolving credit facility   0 $ 28,000,000  
Repayment of balances outstanding on the revolving credit facility $ 28,000,000      
Shares issued during period, public offering 3,869,750      
Revolving Credit Facility [Member] | SunTrust Bank [Member] | Swingline Sub Facility [Member]        
Line of Credit Facility [Line Items]        
Maximum borrowing capacity under credit facility   5,000,000    
Revolving Credit Facility [Member] | SunTrust Bank [Member] | Letter of Credit Subfacility [Member]        
Line of Credit Facility [Line Items]        
Maximum borrowing capacity under credit facility   $ 5,000,000    
Revolving Credit Facility [Member] | SunTrust Bank [Member] | Federal Funds Effective Swap Rate [Member]        
Line of Credit Facility [Line Items]        
Line of Credit Facility, Interest Rate During Period   0.50%    
Revolving Credit Facility [Member] | SunTrust Bank [Member] | Base Rate [Member]        
Line of Credit Facility [Line Items]        
Line of Credit Facility, Interest Rate During Period   1.00%    
Revolving Credit Facility [Member] | SunTrust Bank [Member] | Maximum [Member] | Base Rate [Member]        
Line of Credit Facility [Line Items]        
Applicable margin for loans   1.50%    
Revolving Credit Facility [Member] | SunTrust Bank [Member] | Maximum [Member] | Eurodollar [Member]        
Line of Credit Facility [Line Items]        
Applicable margin for loans   2.00%    
Revolving Credit Facility [Member] | SunTrust Bank [Member] | Minimum [Member] | Base Rate [Member]        
Line of Credit Facility [Line Items]        
Applicable margin for loans   0.50%    
Revolving Credit Facility [Member] | SunTrust Bank [Member] | Minimum [Member] | Eurodollar [Member]        
Line of Credit Facility [Line Items]        
Applicable margin for loans   1.50%    
XML 85 R70.htm IDEA: XBRL DOCUMENT v3.3.1.900
Leases - Additional Information (Detail) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Leases [Abstract]      
Total rent expense under all operating leases $ 4.3 $ 3.1 $ 2.4
XML 86 R71.htm IDEA: XBRL DOCUMENT v3.3.1.900
Leases - Future Rental Payment Commitments under Non-Cancelable Operating Leases (Detail)
$ in Thousands
Dec. 31, 2015
USD ($)
Leases [Abstract]  
2016 $ 3,876
2017 2,625
2018 1,365
2019 808
2020 810
Thereafter 2,604
Total minimum lease payments $ 12,088
XML 87 R72.htm IDEA: XBRL DOCUMENT v3.3.1.900
Related Party Transactions - Additional Information (Detail)
$ in Thousands
3 Months Ended 12 Months Ended
Jun. 30, 2015
USD ($)
Employees
shares
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Related Party Transaction [Line Items]        
Stock based compensation expense | $   $ 3,280 $ 1,625 $ 1,458
Chief Executive Officer [Member]        
Related Party Transaction [Line Items]        
Number of common stock contributed 54,241      
Number of common shares granted to employees 49,310      
Number of employees eligible to receive common stock | Employees 600      
Stock based compensation expense | $ $ 1,500      
Common stock unissued shares treated as expense 4,931      
XML 88 R73.htm IDEA: XBRL DOCUMENT v3.3.1.900
Subsequent Events - Additional Information (Detail) - USD ($)
12 Months Ended
Dec. 31, 2015
Feb. 29, 2016
Subsequent Event [Line Items]    
Share repurchase program, termination date Dec. 31, 2016  
Maximum [Member] | Common Stock [Member] | Subsequent Event [Member]    
Subsequent Event [Line Items]    
Share repurchase program, authorized amount   $ 25,000,000
EXCEL 89 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 90 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 91 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 93 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.1.900 html 167 362 1 false 52 0 false 8 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.healthstream.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Consolidated Balance Sheets Sheet http://www.healthstream.com/taxonomy/role/StatementOfFinancialPositionClassified Consolidated Balance Sheets Statements 2 false false R3.htm 104 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.healthstream.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 105 - Statement - Consolidated Statements of Income Sheet http://www.healthstream.com/taxonomy/role/StatementOfIncomeAlternative Consolidated Statements of Income Statements 4 false false R5.htm 106 - Statement - Consolidated Statements of Comprehensive Income Sheet http://www.healthstream.com/taxonomy/role/StatementOfOtherComprehensiveIncome Consolidated Statements of Comprehensive Income Statements 5 false false R6.htm 107 - Statement - Consolidated Statements of Shareholders' Equity Sheet http://www.healthstream.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome Consolidated Statements of Shareholders' Equity Statements 6 false false R7.htm 108 - Statement - Consolidated Statements of Cash Flows Sheet http://www.healthstream.com/taxonomy/role/StatementOfCashFlowsIndirect Consolidated Statements of Cash Flows Statements 7 false false R8.htm 109 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Summary of Significant Accounting Policies Notes 8 false false R9.htm 110 - Disclosure - Shareholders' Equity Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Shareholders' Equity Notes 9 false false R10.htm 111 - Disclosure - Earnings Per Share Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Earnings Per Share Notes 10 false false R11.htm 112 - Disclosure - Marketable Securities Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock Marketable Securities Notes 11 false false R12.htm 113 - Disclosure - Business Combinations Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock Business Combinations Notes 12 false false R13.htm 114 - Disclosure - Property and Equipment Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock Property and Equipment Notes 13 false false R14.htm 115 - Disclosure - Goodwill Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsGoodwillDisclosureTextBlock Goodwill Notes 14 false false R15.htm 116 - Disclosure - Intangible Assets Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock Intangible Assets Notes 15 false false R16.htm 117 - Disclosure - Business Segments Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock Business Segments Notes 16 false false R17.htm 118 - Disclosure - Income Taxes Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Income Taxes Notes 17 false false R18.htm 119 - Disclosure - Stock Based Compensation Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock Based Compensation Notes 18 false false R19.htm 120 - Disclosure - Employee Benefit Plan Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock Employee Benefit Plan Notes 19 false false R20.htm 121 - Disclosure - Debt Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock Debt Notes 20 false false R21.htm 122 - Disclosure - Leases Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsLeasesOfLesseeDisclosureTextBlock Leases Notes 21 false false R22.htm 123 - Disclosure - Litigation Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Litigation Notes 22 false false R23.htm 124 - Disclosure - Related Party Transactions Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock Related Party Transactions Notes 23 false false R24.htm 125 - Disclosure - Subsequent Events Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock Subsequent Events Notes 24 false false R25.htm 126 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock 25 false false R26.htm 127 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables Summary of Significant Accounting Policies (Tables) Tables http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock 26 false false R27.htm 128 - Disclosure - Earnings Per Share (Tables) Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables Earnings Per Share (Tables) Tables http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock 27 false false R28.htm 129 - Disclosure - Marketable Securities (Tables) Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables Marketable Securities (Tables) Tables http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock 28 false false R29.htm 130 - Disclosure - Business Combinations (Tables) Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables Business Combinations (Tables) Tables http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock 29 false false R30.htm 131 - Disclosure - Property and Equipment (Tables) Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables Property and Equipment (Tables) Tables http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock 30 false false R31.htm 132 - Disclosure - Goodwill (Tables) Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsGoodwillDisclosureTextBlockTables Goodwill (Tables) Tables http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsGoodwillDisclosureTextBlock 31 false false R32.htm 133 - Disclosure - Intangible Assets (Tables) Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables Intangible Assets (Tables) Tables http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock 32 false false R33.htm 134 - Disclosure - Business Segments (Tables) Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables Business Segments (Tables) Tables http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock 33 false false R34.htm 135 - Disclosure - Income Taxes (Tables) Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables Income Taxes (Tables) Tables http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock 34 false false R35.htm 136 - Disclosure - Stock Based Compensation (Tables) Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Stock Based Compensation (Tables) Tables http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock 35 false false R36.htm 137 - Disclosure - Leases (Tables) Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsLeasesOfLesseeDisclosureTextBlockTables Leases (Tables) Tables http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsLeasesOfLesseeDisclosureTextBlock 36 false false R37.htm 138 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation Summary of Significant Accounting Policies - Additional Information (Detail) Details 37 false false R38.htm 139 - Disclosure - Summary of Significant Accounting Policies - Changes in the Allowance for Doubtful Accounts and the Amounts Charged to Bad Debt Expense (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesChangesInTheAllowanceForDoubtfulAccountsAndTheAmountsChargedToBadDebtExpense Summary of Significant Accounting Policies - Changes in the Allowance for Doubtful Accounts and the Amounts Charged to Bad Debt Expense (Detail) Details 38 false false R39.htm 140 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyAndEquipment Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Detail) Details 39 false false R40.htm 141 - Disclosure - Shareholders' Equity - Additional Information (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureShareholdersEquityAdditionalInformation Shareholders' Equity - Additional Information (Detail) Details 40 false false R41.htm 142 - Disclosure - Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureEarningsPerShareComputationOfBasicAndDilutedEarningsPerShare Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Detail) Details 41 false false R42.htm 143 - Disclosure - Earnings Per Share - Additional Information (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureEarningsPerShareAdditionalInformation Earnings Per Share - Additional Information (Detail) Details 42 false false R43.htm 144 - Disclosure - Marketable Securities - Fair Value of Available for Sale Marketable Securities (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureMarketableSecuritiesFairValueOfAvailableForSaleMarketableSecurities Marketable Securities - Fair Value of Available for Sale Marketable Securities (Detail) Details 43 false false R44.htm 145 - Disclosure - Business Combinations - Additional Information (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformation Business Combinations - Additional Information (Detail) Details 44 false false R45.htm 146 - Disclosure - Business Combinations - Summary of Purchase Price (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureBusinessCombinationsSummaryOfPurchasePrice Business Combinations - Summary of Purchase Price (Detail) Details 45 false false R46.htm 147 - Disclosure - Business Combinations - Summary of Preliminary Fair Value of Assets Acquired and Liabilities Assumed (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureBusinessCombinationsSummaryOfPreliminaryFairValueOfAssetsAcquiredAndLiabilitiesAssumed Business Combinations - Summary of Preliminary Fair Value of Assets Acquired and Liabilities Assumed (Detail) Details 46 false false R47.htm 148 - Disclosure - Business Combinations - Components of Identifiable Intangible Assets and Estimated Useful Lives (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureBusinessCombinationsComponentsOfIdentifiableIntangibleAssetsAndEstimatedUsefulLives Business Combinations - Components of Identifiable Intangible Assets and Estimated Useful Lives (Detail) Details 47 false false R48.htm 149 - Disclosure - Business Combinations - Summary of Unaudited Proforma Financial Information (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureBusinessCombinationsSummaryOfUnauditedProformaFinancialInformation Business Combinations - Summary of Unaudited Proforma Financial Information (Detail) Details 48 false false R49.htm 150 - Disclosure - Property and Equipment - Summary of Property and Equipment (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipment Property and Equipment - Summary of Property and Equipment (Detail) Details 49 false false R50.htm 151 - Disclosure - Property and Equipment - Additional Information (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation Property and Equipment - Additional Information (Detail) Details 50 false false R51.htm 152 - Disclosure - Goodwill - Changes in Carrying Amount of Goodwill (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureGoodwillChangesInCarryingAmountOfGoodwill Goodwill - Changes in Carrying Amount of Goodwill (Detail) Details 51 false false R52.htm 153 - Disclosure - Goodwill - Additional Information (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureGoodwillAdditionalInformation Goodwill - Additional Information (Detail) Details 52 false false R53.htm 154 - Disclosure - Intangible Assets - Additional Information (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformation Intangible Assets - Additional Information (Detail) Details 53 false false R54.htm 155 - Disclosure - Intangible Assets - Identifiable Intangible Assets (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureIntangibleAssetsIdentifiableIntangibleAssets Intangible Assets - Identifiable Intangible Assets (Detail) Details 54 false false R55.htm 156 - Disclosure - Intangible Assets - Expected Annual Amortization Expense (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureIntangibleAssetsExpectedAnnualAmortizationExpense Intangible Assets - Expected Annual Amortization Expense (Detail) Details 55 false false R56.htm 157 - Disclosure - Business Segments - Business Segment Information Based on Net Revenues and Operating Income (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureBusinessSegmentsBusinessSegmentInformationBasedOnNetRevenuesAndOperatingIncome Business Segments - Business Segment Information Based on Net Revenues and Operating Income (Detail) Details 56 false false R57.htm 158 - Disclosure - Business Segments - Business Segment Information Based on Assets (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureBusinessSegmentsBusinessSegmentInformationBasedOnAssets Business Segments - Business Segment Information Based on Assets (Detail) Details 57 false false R58.htm 159 - Disclosure - Income Taxes - Summary of Provision (Benefit) for Income Taxes (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxes Income Taxes - Summary of Provision (Benefit) for Income Taxes (Detail) Details 58 false false R59.htm 160 - Disclosure - Income Taxes - Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to the Provision for Income Taxes (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtTheStatutoryFederalIncomeTaxRateToTheProvisionForIncomeTaxes Income Taxes - Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to the Provision for Income Taxes (Detail) Details 59 false false R60.htm 161 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation Income Taxes - Additional Information (Detail) Details 60 false false R61.htm 162 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Liability for Gross Unrecognized Tax Benefits (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheBeginningAndEndingLiabilityForGrossUnrecognizedTaxBenefits Income Taxes - Reconciliation of the Beginning and Ending Liability for Gross Unrecognized Tax Benefits (Detail) Details 61 false false R62.htm 163 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Deferred Tax Liabilities (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilities Income Taxes - Significant Components of Deferred Tax Assets and Deferred Tax Liabilities (Detail) Details 62 false false R63.htm 164 - Disclosure - Stock Based Compensation - Additional Information (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation Stock Based Compensation - Additional Information (Detail) Details 63 false false R64.htm 165 - Disclosure - Stock Based Compensation - Summary of Activity and Various Other Information Relative to Stock Options (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityAndVariousOtherInformationRelativeToStockOptions Stock Based Compensation - Summary of Activity and Various Other Information Relative to Stock Options (Detail) Details 64 false false R65.htm 166 - Disclosure - Stock Based Compensation - Other Information Relative to Option Activity (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureStockBasedCompensationOtherInformationRelativeToOptionActivity Stock Based Compensation - Other Information Relative to Option Activity (Detail) Details 65 false false R66.htm 167 - Disclosure - Stock Based Compensation - Summary of Activity Relative to RSU's (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelativeToRSUs Stock Based Compensation - Summary of Activity Relative to RSU's (Detail) Details 66 false false R67.htm 168 - Disclosure - Stock Based Compensation - Stock Based Compensation Expense Recorded in Consolidated Statements of Income (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseRecordedInConsolidatedStatementsOfIncome Stock Based Compensation - Stock Based Compensation Expense Recorded in Consolidated Statements of Income (Detail) Details 67 false false R68.htm 169 - Disclosure - Employee Benefit Plan - Additional Information (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation Employee Benefit Plan - Additional Information (Detail) Details 68 false false R69.htm 170 - Disclosure - Debt - Additional Information (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureDebtAdditionalInformation Debt - Additional Information (Detail) Details 69 false false R70.htm 171 - Disclosure - Leases - Additional Information (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureLeasesAdditionalInformation Leases - Additional Information (Detail) Details 70 false false R71.htm 172 - Disclosure - Leases - Future Rental Payment Commitments under Non-Cancelable Operating Leases (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureLeasesFutureRentalPaymentCommitmentsUnderNonCancelableOperatingLeases Leases - Future Rental Payment Commitments under Non-Cancelable Operating Leases (Detail) Details 71 false false R72.htm 173 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation Related Party Transactions - Additional Information (Detail) Details 72 false false R73.htm 174 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation Subsequent Events - Additional Information (Detail) Details 73 false false All Reports Book All Reports hstm-20151231.xml hstm-20151231.xsd hstm-20151231_cal.xml hstm-20151231_def.xml hstm-20151231_lab.xml hstm-20151231_pre.xml true true ZIP 95 0001193125-16-481909-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-16-481909-xbrl.zip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

-@6B*\'!_%!7UT&]=A M*P,HY9BO:*W'.OD<*N=H2[2%8,4#F-;".W/7_03!MG' MUH4$2JF#4+#JNK7GOT(D9:6D"ZA&SE8J&N@=:DJVOY^DME*[G8Y&=97:[?07 M*JW4;J?GCZ=W-XIH=+P+;->1.NK_C..]F@7;?:,]L!/0*,9W%MJ%L(M[9T': M<:RO!@F[1KO&6NRCY_KDM-\AV!]N?M_"OWV4G2V!2/T6H:ZC-_[$WOC1]SUZ MD@?%%'82D)/L9KX3)+#=[_^1XBV!JWR;A'9B"W346P/D4%*LW]F[XD>Q8B#B M(XW^VDOPU];F7]9)V]IU],R.GEFSG(ZC9W;TS$I4%Y"^:D>GHSK\+MWCJ I& MH4O^ GR,HQ]M]*.-?C23_&B=3CC;Q5D9I:SQ%-#1DS^7X2@3Q4?$(&2]FZPC M=F+F=^LC<48GHV@],>*+7CCO*'Y.-QLGVDV7V848D_,A\YHRM8G[,HG^)(L/YR^>GQ^^?8HH-ZO M%B&V!#OKY*L!>3?NA(;0P>.>%N%"1ZP>6CD0FA N]AJN*X$Y:%8*YAR'MIM( MN^'%.W1M-Y9*HB9ZJ-MN:>D(F]B=8;L91A(\ 9R&KA]OCD!^&+M<^VF2+-:( MK+ 4[M3=X0Z=P\I;A-!B+\GK%^%',<, $:^YHF[7Y(7)QZ \L:!!;IGZV?'3 M_)#P_?#-"5Q:?(J"@0W"@S)EDU+0VN^WQD:3@Z;C-PQ"*7MF8>+]/8V3S*(B MQ_]1;X,X:[^QD22'U%$,XA3^< O[$LO.7JW?.0H5:K;[J%R)H$O?3*.:)8)? M?8MVT[#.Z=DI-9A)"32CYB4"Z?%M;[M77+W&VL6Y>YX::^F?)2?^WEVI0]N\ M0R[0'0-M7X,(%O0JP+]GYT$Q/?$C:-=.#)2^^+M9&,>8'H3?;2R=[HK]N;>_ M1&Z=*-K!C+PYD1=/?-B& #=O)BHA3N^P[FT"^) MO^8'Q[7:.5F%D[,+NOK$$R5K2*3'<%2U)^%Y MNCR\8IZP\P*2=K*3,R)W_XP>K#+9P"_*9#RCZ!6[Z''^S+S)>+UTD$TSJ813_L69QOSCNZFT"XNY(S=PX* M(6C"ZTG@W<&^\L,LJI:>+LYLKRUEM+0J_D<:X=C#+L&(N1MYO71PTJI'339A M&M#D!%8/=Q.+[7?"U+[O1'4_B!([0\:J:59,$L]8X9 Y$YP]O)4)H&# M%#MQW2BM#,4'?/49T2 $%FLG^25,?>]QLP7%^WZY1"ZQ9K*#/#H.9H1[H]4N MU^K9.+*$V9[7Q[,!'J6^LR32/5B?+'=W4XV.[$55EU N;V$=RV=-M#BFDVIQ M7;03FVM0M'5A2=AWVV+4!0,D[(ISZHB9>I-OMT"HW)=DVQ8,/]BO+W8L4B43V*69,T,< M6H^E"UH_;>$4=4PHF1#56K'+-"B!3&MD:H6+718;"5Q:(E\J5.RRR71"Y?MC M5.PRKG1"Y8=C5(8VDYB3PWE8=6BQ1C=HA8. 5(@.O/O (UZ'THOU$$8_1:#) M4Q3^L=*0PA@EN2"D\Z7\UVN3:"^-6K QXM0G+C?RS[J]+1?9,PN1A3!:%+(88/6RPA.R%L@R>XS2M8AT/6*V%4( MA;L;P5NF28ERDCIO"6?FW(F":B #P_[D(%WBE@/2\!DGL!@1/K][@-HR%YUC% MIPS%C#C)HM@]_1MB4V0L/8707IB_),O7A-Q+ JA@E MUH>,P.OLRYY1- (N$P:MW!HIAP>4L\6)XQ-=\3E<)G!N"TR/W'#F\/Y3&'IO MV/?S0%0G6)&POT*(+7Z28EYDO+/@_O"_5:%P-*XY:%0ZUV/P)02],DBBT/>1 M-UDN,Y^3Y!87&<\<[J64#DH_<[B916CKX/(,DINWP[X6E>K38*H4T6YYB1A] MI2M;TT5/C'&+=&^[_T(%LJU:M*TYHP,NR0Y*NJT)ILI0/C2^VYIUJ@PPAM7/ MUBQ49=A1_2.VYJ(J0TZL^H"=X9&]P2M<5_WR2F4>O3A3G)B%5J2R2,\IE*(W M;)F'L5^>Z%DM+K;-@ *5K,G-]LIDI\'SV(AG>SZ*0ER/3$BV%S13B)V(2\'V M-#J%< I9IFU/J>J%9WO$7+]\JXNZM;NF835%P87YF$F&UK+%Q],E:9T;6+3U MN$?L>NA48LVQR,])Z/YV9+8TYI5"H@.Z9,NVFU>+BYWBBQ+LK,.Q-B%6DP5\ MA5&_O]E&!Y6W:XR6]^_(34E-IRG<\BYBO^K#ZJ&%@W"S(2\MPR(OI+]L+<2% M7\E["*.'-"$Q^7&<,D* Y,?1XH3>;^OILK[2Y\@GVX X(W(_Q0O9"S-GEQD^ M>?[V?H-J>0]RL_7#'2JK0;=O?Y!@B3@+TFMFPR,4Q[%15 M"$I]1RM:%2'L]U^I[750_]EY)]4[F10WVRAYY:PH&GKOX\PLEY\H,)GY2EB$ ML!L0W-^U6^^ MJZC**'^2TJ0F"[+J8Q+"D0)EQM Q[HHK]'BDEV$L ]_PY$ZQ8]CI,?+.K_\):$.(#Z.$/1&'L)H5HD2L.1$] WA>4P'F9_0'V8'-3 MTKGM.)P!O'\%:36>/W]E[Q]F'RUO:KIKY*4^*L ]-I=$$=GSV1%[LZO:%,=N MKLBWO-NL?GPMZ/!HII&<_<_/,-NP/'/A@:9+*?W$66&4!RL]!K ETFS^I\D: M18NU$Q1"]T\P!'&QYMRIQD_V\W9A6W6K.V0=?'J8Z938A?C/F;9>+J=,7W]P M<$1B@JB'IQYBM.'^PF?UY8C5_:L;_&-"R?AGM2J?#BOVJUIAU8A<\0O"JS4QH[VBR%FA.2+* ERIY&DO8N5-'7^!H@WS^CXQ)>>(^#1-XL3) MRD<*\GD]$.)=*#%RSU/EYR8 M:A:G[(XZHT1:?>Z-AXH'.4QLKTJOQNGZL%8-NWF'(S^-%A9?D[;JV?_@FCH;IQ+L6SUXMI>Y&7 .U-CV;:^& M,\P$= @5M[UZSH KO; _VEX9Q["SHH^?P?::/&9.52 M=FB8V>H>56E[I:)A\.X>D=ZOXM&EXGVBW*INE97&R3EM@F&_ND[C+"E+I+.] M(-1 DI5 1('M):'.368]C"OO578*-):7\+)FJ$NFHNVUJ 9 N$LFJ^TEJH8Y M:D1+L?2K9G6IZ/8+/.Q6%.OB,=>1.&1[+:XA([(9]I_#S-(J>NE"-::>,-," MMRM<+U1,5[1\&65+*HB']HD967ON.=ULG&@W74[D< M$1NV\H4%]2V.HWV:5]Q D-&_=^;H#7JC'G]G1$OB.[\:FG\NSH<&"43TZR.R M WW=U%5+-7(T1==*@!@"8K5$G"G.1\*M'J3ER#A+K%O$8AU8RY)QEE@WI6H= M,$M08%X=DIJQLR2U6_61UH$L*R:A7J+ME>"VS?%/G"@QVQ-BWE100Y(LS7,; M8 8Z'"O=DMS.ZNU5XU9ZJ_G4]EPY\Z:AU2;;+0]NW ^JS3W]LMSR:_@^&*>B MOX?1]@0V\R9!V+C5*]=M%%5/H^':GB!GX/1(&C!MSY(S7KH&+1>"7CCWE$;.&-[IMY DS%09/#I$OJ,C)BG MA\7GV)6!]&-@O+[ ^%D4N@AY,2DN(.._X_!.ZVTU5*-5)".\IIK$2T M^?-7+1F+K:_A'-P1S38Z+L51?,Q)'M]1+L]RR]]1[B)J<,M13%:K* L\:-YU M-?N&:B%1!4EGI=AP&=Y7:]'V5/,Q!58B3+P1!Y;4S!E[!XM-WUO"4L39-2_C M"^6G8LZ\92]+GUVSLZ\ .TPNI/3W1W0'_+ZIN7S]^3/O6)$@;9P3X^;$NIW2 M-/*>'/F#S]N,K7G+7I:^LYJ=I\/RF:I@K08V$H\>1?Z4):HR/C6^HCYZ9?C> MLO$5=2,>-J6\$FOO$Z7C*[':IT#9?7^:_OV3%)CSG::!&Q""DH%C/*$=N>@]84&SFT" MI6VSX].[9DV@7,B,[74*SFWVI#QN_6H8C#*,ML!,V^L:#.F,Z?)@V."E"Z?'9\%#.C_(_;C7D:^O(TA)X<+U8=_&NZ/'SZ/6.*YW97_14=2/V$ M A!6?#BZ)]X&!YA,&LF(*O8<<\V+]=7!57X.[D_&IV(&&#E6K!X&<< ,0B3C89;9^N"\JRIRAG4>BE;G*'7I$?;LE76E<(NZW>G" VJ) K<#U<7&CEP# KEY!.&7.IV;Y:8G<#1\,2)\0P/?$\G)-8J]*GI1H? M4!20623NAI>4D$'H*TB."!,1RBB-=O5&DTV8!E0S7;]!E9@'2M#CSW (;]+- M9(7N?;S"+]B'I;((9TZ48!=O,U<+H:[-;B _B!+:BZ_E&V>._I%BV!:+\*;X MN(\>PJCZ- !'YZ#K4$KXJ 5^.]G_IB\Q]C#,.L7.*]I+QY$KR=%>W.RP$&TM M!-<5PL[[P5;%IP.0J@[\BZG;=H=>$F.N:2)JS>&$8-HZ#QII\5'"2L#)@^-F MAQO#R='24#^]3)=&:U,MGE58F-4RY7E,VQOKHKN*?+EUHFA'; ML09+113\/ M^86$W<(R/XMP0&X@7X@;:F<(<-=-!ZP/RB(7E(0V\^'ZY M1*2 )GI^<[;< U*DIQ+!]PDE<-5-E_F9 1?SLC@VZ"Y*7A<=2!-UO:2( FFC MB6X:!>X=:G-3:+]-(R+UW811%+[!87?K;.&79"?!#W4(4WBL7G(B,:FT>N0B M/=7LUI8//08@!A/[5OF'9_P[NDO1(IRX)/0-*'A #HF3;MW,_48T99X> SB2 M4)R0X_$.@6* ,PE=8KYH(QC)8>W]XZXLUH6)%6]/:F4/\U2(F_IE@HM^%F@Q.B>3P@5$V%!'=BX^G@OM@<3%V@V48+ ME;E5DTUEHXV6.O,DZ8(A4%>_:Z..7?.^UD)/G?YM$;7B+.@@?@+>LM^HDZ 6&MS$W4TE!G= _=JM4(^&SU8=@>%\ORW#23 M/)DWF/7/MC*=176@& J/[6N)9T/FP=2TL%PB6FTVIGWX1MLM:_O;U4+&JV9< M!LL[:FM$4&>XVCK072>VQ@$IA>_(*V-[.H02U.BV7-M3(X3A4^)DLSUA0LEB MI+NS>M6[LPD^%?X-VZO.J5^+=>>Q[27?>HI^]* RVZNM*5EV@EZN7K7/;,?2 M_A)CTO PW#BGJQ-V)EB)FO\KX#KH%V=1ZH!A4^/9<2\D@54*(;J=KL3IHHQN M5)QJ/OL2F.L1F%:G58G/]R,^=$=Y"=(/(TC\^]#^QX2.0H*.SI[C*A<6(]%T MV=>Q.(A#J^0=.Q5?'AK->+<]&M=VJAC,H"/FH7LICD1.@%/E/V3$R51[RDZ[ MIBA&W(RS"B@[C4>T>"2:^'^U1'1BBGLEI"=IJ]Q: Z3,6O[K%+7D#' M"<05+I:7SW\B+LS8F%(1!3GLL@ 'C70$94ZWB$0;!*N([?*0$K<^ <'Q"T]7Y:N)OY)HLB]A<.L$+O+)Z7. MWKBQA#=6CG190JEP8MREM$POT=X&0TOX;.1$M^K[# M0&;S&Z:1&G[W QG-[P*^JF:":R.9S?%;J(;?-];'."D&K':_6!SNK@ZUV"UL?XZP0M4I6LSZ6615J]1O2 M^@AF5:#UC4\.024_$UM"\5 2J?V[6T1.$ -RF+RB:HHQSMJW*-<8+>_?D9L2 M1\%TN<0N8I>.9/50DDU?F8](V6+8)2AP=Y/ HZX11@GRSF,IXZ1X?_5K@+,X MRCQVDD9J>V,EM'Q)R0Q5STO$99L?14KAGJ@?OL(?OX M,6!6:3S9Y[75UIFC;1JY:T+_<80]#15^1VU/&?2]N]N?P)3:>19:1#/Y=A'K;3:-=UJ_\<[YV M&DBEUQY#N;7=+"JO[#0S4(\O<-N%EE[J$PT\'O36YUP.C>J3GF0HS;9H\OP: M^D=*POI>B5QBC VZ=N(^!JZ?>J2NV)ZXF8.]Q^#6V>+$\=D67.EQM+QDE,F' MY"X. Y@&ID&OO>U8L7RL!3Z4[:9XI?I@X<6L>M3,/@98H&91N(JEX#:W #:F7N[O:T!5/,BQJG- M#:"=Z8YH:VH"S9SZ_I36AE#.KO%/;:]3G6!*7 WCLKP@:KU)8"RE0)?>1$HI M6&I6$Y(4&_F7[9O0]E7#DVX8KAJZW&J[OZ8_:(TQYSR1KH%8JPAU81M1 MIC29O79604PXA[WUM>V$<:()^M87N>N(D"9#O!D8L2HNT?6N2SNG6RL*<>PO MIXL'T.+2^1(F*%Z$#SAP A<[_OYXCI_Q*L!+[#I!0AXH2+-0M5GH8Q=##_CN MC4\")G3D&1R1P[$Z,3IHL82((4LQBXAUUKGM^//3V'>":%A>,Z3O1BS_,&[( M#O1[KRA*<$Q>M GC),Z(VO%V(J^7EE0E)UY/ H_\'Y&O7QV?K" Q?L3ZJDGZ M61/-Z#'X*0R]-^S[CYNM@R.RVA2A MGAF*LM!",49XO?0%LY 3"$[3SRA9A]YC\ H[>%.=0\S8%DY7'3P]P$'TL^.G MZ#-R2-Q4]LB-P+DFWU\K=]/E7FZI!:LSITRLKPZNRFL$EM,C2'M!%BP^B6,D M>I%*#*"#O^IZG$9W.-Z&L>-/ET]AL'K"K\B3X;334%IX#D#B1@OG79 O6G,] MX7+1;R@A5K!GY*:@N6#$WEJ,#CKH_X+>:O)^!#I/"N),;9>+S8GT,#IX!;JV MH!3L9C[1UH(L@6=;'=H\'H6[ZTE?)MDR9%G%B\CQ$-"7I2,5LQ)7OY-\D3=2 MS?(AC.["]"59IG[9BKERE7Y"B:9"OA@D_F[BA=L$3K3]"@3]//"W^#8\POKF>!$BG76P1?GOOH:O(!&0 Z$_0W' MG,[.P^G@_6L,6MQ]G."-DU!+,APT.B,'A=C)8WL@E1AHOI2Z'U>'59WO9&,F5).:.[%?"TS;06/:^"BD[ M7U640ZJ[S%WA:.<#<7UOR".[1_4#H&NL0FW4+EBA7:=[E/D<<.(&"E=PC3H! M)TJ_@FK4 CH&,500C@I!EQC)"K^AU8*S3(?+LL;'9+B.KWB5-KC\S'L*0:N* MIT$Q&<&J;M C_\O-E.LSI)(P3JJAXFN,EJE/=$=-5;W6<4C6C1-C%Z2I.^RG"?*$](ZNHYW+ANR,UL5NUYJ?ZS&X0R]$/J_B M[7*9H8JZ(RXRD.0=')"X%6*9S]R+ADBG-5X*3H[H9^]\B0'TY&P/-%=<--1^ M3N=I(K]&FJZ5H69@/( 40ZI/W+#]&*HNV-L M.4G*)AV'/=]CI3^B%WM\W*0Q#E V_Q*4+B:'T\@S;"RM(I@.L+)CT_:B$5V%7V'9Z71%) R3@JD!+X:HIE3Z. (BOY]1 M)2;%U6VI(73N6>&9$TI*''77KKM6GP9[(7NW\XZU<9^.NS.)RPQA0ZY01L)R M12%G2\J-H;/RN_A-RNJAY,)Q<7N33J6X\UY@B 0/OBTZ ]^S[/>K4+0C+N6CLYXLY[F9@U9MN2'-"%T M;D@)[-^S17+_3E*]D91'2MY8GO\5Q],Q>^GTX5X&29O[&M$&B+? MM]##39*C]]#ZH+*,I9?116\V&W M+O=4%A:=&Q0@N% E39#R(^I%H'QW!:@L0IP;P>.2W,N-IKD[+V)JC#YS-GE!@:= M6I\PR2]UDCGB:L]!==SH?:>N)Q"4476>%FI61N.%PKX87ZP>VQ,Y?:KN>+P< M272;K1_N$'I&T2MV4?L[%:3NN;LW\Y?9RC,$RS9G3T*C4OP]):7O*_(H]'@> MSO=C5CXY?[8CGA!)&'8MORB^TO'UKI=V!N8(%C-V8;5G#'P-,"SP-R?RA# : MZBLF(B6]@!0.;-?UK0)IVQ5]=:@/<$[:;A@X_9*7/H9M-S$,.07*):>+M5/, M "VSJ%G6)LH8-&.K8.'SP6Z:Q^.K=3._KU;23 ][BA:-CH M,V.?R[:JY35F:7:?<8 WZ69.9M,OM:V',-J'/.2:D'F=AR 4I1"%?H9080\&'( M(\5[=XO( 97=S6S.AFQO&GF<'_3QQJ.;9,V[ZBL];,.)) YV*WZW/Z M$J-_I/#/^U?ML6:'Q/ 2-FG-]41\TX 4(]Z,C<:;@6;<+)5CS=OI+Q\)L<2# M!/_Q_P%02P$"% ,4 " "'@%I(<<4PF!TZ 0"4X T $0 M@ $ :'-T;2TR,#$U,3(S,2YX;6Q02P$"% ,4 " "'@%I(A#9"<@ 4 M "7UP $0 @ %,.@$ :'-T;2TR,#$U,3(S,2YX&UL4$L! A0#% @ AX!:2 HJOQ@N, ME # M !4 ( !?6@! &AS=&TM,C Q-3$R,S%?9&5F+GAM;%!+ 0(4 M Q0 ( (> 6DC\+%81XI$ #!+" 5 " =Z8 0!H&UL4$L%!@ 0 & 8 B@$ #UZ @ $! end